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Summary 
The hepatitis C virus (HCV) is highly prevalent among people who inject drugs (PWID) in 
Scotland and the large majority of new HCV infections occurring in Scotland are within 
this population group. Harm reduction interventions, mainly sterile injecting equipment 
provision (IEP) and opioid substitution treatment (OST), to prevent the transmission of 
blood-borne viruses among PWID, were implemented in Scotland in the late 1980s/early 
1990s. More recently, government policy initiatives, particularly the Hepatitis C Action 
Plan for Scotland, have stipulated the scale-up of these interventions. The overarching aim 
of this thesis was to investigate the impact of harm reduction interventions on the 
transmission of HCV among PWID in Scotland. Five secondary objectives were addressed 
in order to fulfil the main aim: (i) to review the international literature on the effectiveness 
of IEP and OST in preventing HCV transmission; (ii) to determine the association between 
self-reported sharing of needles/syringes and incident/prevalent HCV infection; (iii) to 
determine the association between sharing non-needle/syringe injecting paraphernalia and 
incident HCV infection; (iv) to determine the incidence of HCV among PWID in Scotland; 
and (v) to determine the association between self-reported uptake of IEP/OST and incident 
HCV infection.  
To address the first thesis objective, a systematic review of the literature was undertaken to 
identify existing international research evidence (published up to March 2007) for the 
effectiveness of harm reduction interventions. While HCV was the main outcome of 
interest, HIV and injecting risk behaviour (IRB) were also considered. A review of reviews 
approach identified: insufficient evidence that sterile needle and syringe provision (NSP) 
was effective in preventing HCV transmission; tentative evidence that NSP was effective 
in preventing HIV transmission; sufficient evidence to support the effectiveness of NSP in 
reducing self-reported IRB; and little to no evidence on needle/syringe vending machines, 
outreach NSP or the provision of other injecting paraphernalia (spoons, filters, water) in 
relation to any of the outcomes. With regard to OST, the findings were: insufficient 
evidence to show that OST has an impact on HCV transmission; sufficient evidence to 
support the effectiveness of continuous OST in reducing HIV transmission; and sufficient 
evidence to support the effectiveness of OST in reducing IRB by reducing the frequency of 
injection, the sharing of injecting equipment and injecting risk scores. An update to the 
review of reviews was undertaken to include literature published through March 2011, and 
found that little changed as a result of additional published reviews: in the main, the 
evidence statement for the effectiveness of OST with regard to HCV was upgraded from 
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insufficient to tentative. The finding of weaker evidence with regard to biological 
outcomes (e.g. HCV, HIV), as compared with behavioural outcomes, indicated that low 
levels of IRB may be insufficient to reduce high levels of transmission, particularly for 
HCV. 
The subsequent chapter aimed to address the second thesis objective, by summarising, and 
exploring factors that explained the variation in, the measure of association between self-
reported sharing of needles/syringes and HCV prevalence/incidence among PWID. A 
systematic review and meta-analysis were undertaken to identify and combine the results 
of European studies of HCV prevalence (or incidence) among those who reported 
ever/never (or recent/non-recent) sharing of needles/syringes. Among the 16 cross-
sectional studies and four longitudinal studies identified, the pooled prevalence of HCV 
was 59% among PWID who reported never sharing needles/syringes and the pooled 
incidence of HCV was 11% among PWID who reported not recently sharing 
needles/syringes. Random effects meta-analysis generated a pooled odds ratio (OR) of 3.3 
(95% confidence interval [CI] 2.4-4.6), comparing HCV infection among those who ever 
(or recently) shared needles/syringes relative to those who reported never (or not recently) 
sharing. Differences in pooled ORs were found when studies were stratified by recruitment 
setting (prison vs. drug treatment sites), recruitment method (outreach vs. non-outreach), 
sample HCV prevalence and sample mean/median time since onset of injecting. High 
incidence/prevalence rates among those who did not report sharing needles/syringes during 
the risk period may be a result of a combination of unmeasured risk factors (such as 
sharing non-needle/syringe injecting paraphernalia) and reporting bias. Study design and 
population were found to be modifiers of the size and strength of association between HCV 
and needle/syringe-sharing.  
To address the third thesis objective, the risk of HCV associated with sharing injecting 
paraphernalia (spoons, filters and water) was investigated using data from the 2008-09 and 
2010 sweeps in a series of national cross-sectional surveys of PWID in Scotland, 
collectively called the Needle Exchange Surveillance Initiative (NESI). Logistic regression 
was used to examine the association between recent HCV infection (anti-HCV negative 
and HCV-RNA positive individuals) and self-reported measures of injecting equipment 
sharing in the six months preceding interview. Twelve percent of the sample reported 
sharing needles/syringes and 40% reported sharing paraphernalia in the previous six 
months. The adjusted odds ratios (AORs) for sharing needles/syringes (with or without 
paraphernalia) and sharing only paraphernalia in the last six months were 6.7 (95% CI 2.6-
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17.1) and 3.0 (95% CI 1.2-7.5), respectively. Among those who reported not sharing 
needles/syringes, sharing spoons and sharing filters were significantly associated with 
recent HCV infection (AOR 3.1, 95% CI 1.3-7.8 and 3.1, 95% CI 1.3-7.5, respectively); 
sharing water was not. This cross-sectional approach to the analysis of the association 
between sharing paraphernalia and incident HCV infection demonstrated consistent results 
with previous longitudinal studies. The prevalence of paraphernalia-sharing in the study 
population was high, potentially representing a significant source of HCV transmission.  
Addressing the fourth and fifth thesis objectives, a method to determine the incidence of 
HCV among PWID using a cross-sectional design was applied, and the associations 
between self-reported uptake of harm reduction interventions (OST and IEP) and recent 
HCV infection were examined. This was undertaken on data from the first sweep (2008-
09) of NESI. Twenty-four recent HCV infections (as defined above) were detected, 
yielding incidence rate estimates ranging from 10.8-21.9 per 100 person-years. After 
adjustment for confounders, those with high needle/syringe coverage had reduced odds of 
recent infection (AOR 0.32, 95% CI 0.10-1.00, p=0.050). In the Greater Glasgow and 
Clyde region only, there were reduced odds of recent infection among those currently 
receiving OST, relative to those on OST in the last six months but not currently (AOR 
0.04, 95% CI 0.001-1.07, p=0.055). The effect of combined uptake of OST and high 
needle/syringe coverage was only significant in unadjusted analyses (OR 0.34, 95% CI 
0.12-0.97, p=0.043; AOR 0.48, 95% CI 0.16-1.48, p=0.203).   
The final analysis chapter built on the previous chapter investigating the association 
between uptake of harm reduction interventions and recent HCV infection, by using data 
from three sweeps of the NESI survey, undertaken in 2008-09, 2010 and 2011-12. A 
framework to triangulate different types of evidence – ‘group-level/ecological’ and 
‘individual-level’ – was applied. Data on service provision (injecting equipment provision 
and methadone dispensation) were also collated and analysed. Ecological analyses 
examined changes in intervention provision, self-reported intervention uptake, self-
reported risk behaviour and HCV incidence; individual-level analyses investigated 
relationships within the pooled survey data. The approach to deriving estimates for 
incidence, and associated uncertainty ranges, was modified from that applied to the first 
sweep of NESI. A decline in HCV incidence, per 100 person-years, from 13.6 (95% CI 
8.1-20.1) in 2008-09 to 7.3 (95% CI 3.0-12.9) in 2011-12 was observed, a period during 
which increases in the coverage of OST and IEP, and decreases in the frequency of 
injecting and sharing of injecting equipment, were also seen. Individual-level evidence 
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demonstrated that combined OST and high coverage of needles/syringes were associated 
with reduced risk of recent HCV in analyses that were unweighted (AOR 0.29, 95% CI 
0.11-0.74) and weighted for frequency of injecting (AORw 0.05, 95% CI 0.01-0.18). There 
was no additional effect found for high paraphernalia coverage. The combination of harm 
reduction interventions may have averted an estimated 1,400 new HCV infections and 
1,000 new chronic infections between 2008 and 2012.  
The body of work in this thesis represents a novel contribution to the evidence base: it was 
the first large-scale, national application of a method designed to determine incidence of 
HCV using a cross-sectional design, and the first study to apply a framework to triangulate 
the evidence from different designs in order to investigate the association between harm 
reduction interventions and HCV transmission. This thesis does not propose to be able to 
establish a definitive causal link between IEP/OST and the prevention of HCV 
transmission. It does, however, provide sufficiently plausible evidence that the scale-up of 
a combination of harm reduction interventions in Scotland between 2008 and 2012 
contributed to the reduction in HCV incidence observed. Components of the thesis have 
already influenced existing policy and practice in Scotland and internationally. Regarding 
future policy in this area, the evidence generated and presented here supports, at least, the 
maintenance of the HCV prevention investment in Scotland, and certainly the 
consideration of further scale-up.  
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1 Introduction and Background 
1.1 Background to the hepatitis C virus (HCV) 
In the 1970s, it was recognised, among blood transfusion recipients, that a distinct 
infectious agent was causing hepatitis above and beyond what was attributable to the 
known hepatitis viruses at the time (A and B); it was initially called ‘non-A, non-B 
hepatitis’ (Seeff, 2009). In 1989, the cause of this non-A, non-B hepatitis was identified, 
cloned and named the hepatitis C virus (HCV) (Choo et al., 1989; Kuo et al., 1989).  
1.1.1 The virus 
HCV is a member of the family Flaviridae, comprising viruses whose genomes (genetic 
material) consist of ribonucleic acid (RNA) (Ohno and Lau, 1996; Simmonds, Mutimer, 
and Follett, 1998). During the process of viral replication (i.e. generating copies of the viral 
genome and packaging these into new viruses), RNA viruses typically incorporate many 
errors (Holland, 1998); this high mutation rate of the HCV genome results in the extensive 
genetic variability observed in HCV quasispecies (populations of viruses that have 
variability in their genomes but are genetically related) (Argentini et al., 2009; Farci, 2011; 
Ferrari et al., 1999). The genetic variation in HCV has resulted in the virus being classified 
into different genotypes, 1 through 6, although the latter are further divided into numerous 
subtypes (Simmonds et al., 2005; Simmonds, Mutimer, and Follett, 1998).  
1.1.2 Modes of transmission 
HCV is most commonly transmitted through percutaneous exposure to infected blood 
(Lavanchy, 2011). Exposures may include injection drug use (i.e. sharing 
needles/syringes), receiving blood or blood products, accidental needle-stick injury and the 
use of unsterile instruments for activities that break the skin (e.g. medical/dental 
procedures, tattooing) (Anonymous, 1999a).  
Studies have, however, identified cases that do not report any of the above risk factors 
(Ackerman, Ackerman, and Paltiel, 2000). Household or sexual transmission have been 
proposed as potential routes of infection, although their respective contributions have been 
debated, and they are likely to be relatively rare with respect to the transmission routes 
above. Household transmission is thought to occur through the sharing of personal items 
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such as razors or toothbrushes, which may become contaminated with small amounts of 
blood. The plausibility of this route has been demonstrated – for example, hepatitis C viral 
RNA (HCV-RNA) contamination of the toothbrushes of infected individuals has been 
shown – and epidemiological studies have indicated an increased risk among non-sexual 
household contacts of HCV-infected persons (Lock et al., 2006). Similarly, the plausibility 
of sexual transmission of HCV has been confirmed by the detection of HCV-RNA in the 
semen of HCV-infected men; although this has not been consistently verified (Debono et 
al., 2000; Leruez-Ville et al., 2000). Epidemiological studies of sexual transmission have 
generally demonstrated no increased risk among discordant heterosexual couples, but an 
increased risk of transmission among human immunodeficiency virus (HIV) co-infected 
individuals, particularly men who have sex with men (MSM) (Tohme and Holmberg, 
2010).  
Finally, vertical (mother-to-child) transmission is possible, but also rare; although, 
similarly, the risk of transmission increases when the mother is HCV-HIV co-infected 
(Conte et al., 2001).  
1.1.3 Disease progression 
1.1.3.1 Acute infection 
The early stages of HCV infection are generally asymptomatic: acute infection with HCV 
only produces symptoms in approximately 5% of cases, which may include jaundice, 
fatigue, anorexia and nausea. Acute infection can, very rarely, result in fulminant liver 
failure (Simmonds, Mutimer, and Follett, 1998). 
A proportion of newly-infected individuals will spontaneously clear HCV: a review of 
longitudinal studies of acute HCV estimated a mean clearance rate of 26% (Micallef, 
Kaldor, and Dore, 2006). Studies have, however, reported a wide range of clearance rates; 
the variation in rates of resolution has been shown to be associated with the study 
population and methodology (Amin et al., 2007; Seeff, 2009). For example, higher rates of 
spontaneous resolution have been reported among children and women (Amin et al., 2007; 
Seeff, 2009). The period of viraemia (the presence of virus in the bloodstream) among 
those who spontaneously resolve infection has been shown to be short-lived; nevertheless, 
there is some indication of increased liver-related morbidity in this group relative to the 
general population (Innes et al., 2011). The median time to spontaneous viral clearance has 
been reported to be approximately four months (Grebely et al., 2014).   
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1.1.3.2 Chronic infection 
The individuals with viral persistence are considered to have chronic HCV infection and 
are at risk of progressive liver disease including cirrhosis, decompensated cirrhosis and 
hepatocellular carcinoma (Alter and Seeff, 2000; Seeff, 2009). Studies of the natural 
history of HCV infection have documented diverse rates of the development of these long-
term outcomes, primarily due to different patient populations, study designs and durations 
of follow-up (Seeff, 2009). One of the largest reviews/meta-analyses of chronic HCV 
infection involved 111 studies and estimated that 16% (95% confidence interval [CI] 14%-
19%) of individuals develop cirrhosis within 20 years of infection, although this figure was 
7% (95% CI 4%-12%) for studies undertaken in non-clinical settings (Thein et al., 2008). 
Among persons with HCV infection and cirrhosis, the development of hepatocellular 
carcinoma has been estimated at 1-8% per year (Fassio, 2010). Host, viral and 
environmental factors can contribute to the variation in disease progression: factors include 
age at the time of infection, gender, race, co-infection with HIV or hepatitis B virus 
(HBV), HCV genotype and alcohol consumption (El-Serag, 2012; Seeff, 2009).  
Studies of deaths among HCV mono-infected persons have found that they have two to 
five times the risk of liver-related mortality as compared with non-infected persons, after 
adjustment for the confounding effects of alcohol and drug-related deaths (Grebely and 
Dore, 2011). 
1.1.4 Immunology and diagnostics 
One of the major serologic markers for HCV infection is the presence of HCV antibodies 
(anti-HCV). The presence of anti-HCV indicates that an individual has mounted an 
immune response to the HCV virus (i.e. has been exposed to HCV), but it does not confirm 
whether an infection is current or resolved (Table 1-1). The first test to detect anti-HCV 
became available in 1991 (Choo et al., 1989; Kuo et al., 1989). The current, most widely-
used tests are third-generation enzyme-linked immunoassays (EIAs) (Pawlotsky, 1999). 
Immunoblot asssays were previously used for confirmatory testing, but are now not 
considered useful given the high sensitivity and specificity of the EIAs (Seme et al., 2005). 
Nucleic acid amplification testing can be used to detect the presence of HCV-RNA (Busch 
et al., 2000). Polymerase chain reaction (PCR) assays are most commonly used for this 
purpose (Pawlotsky, 1999). The detection of HCV-RNA indicates that an individual has a 
current infection; thus, in combination with anti-HCV, an individual’s HCV-RNA status 
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can help to determine whether he/she is not infected, has a resolved infection, has a current 
infection, or has recently been infected (Table 1-1).  
HCV-RNA is usually detectable within a few weeks of first exposure to the virus. By 
contrast, seroconversion (the formation of antibodies) generally does not occur until 
several weeks, or even months, after infection (Busch et al., 2000). The resulting interval, 
when the virus is present but antibodies have not yet been formed, has been called the ‘pre-
seroconversion window period’ (Page-Shafer et al., 2008). Several studies have measured 
the duration of this window period (Table 1-2) with estimates in human subjects ranging 
from 28 to 84 days (approximately one to three months); however, the largest studies (n > 
50) have estimated a mean duration of 51 to 56 days (Glynn et al., 2005; Page-Shafer et al., 
2008).  
HCV antigen testing detects the circulating core HCV viral protein (antigen) and is 
sometimes used as a lower-cost alternative for nucleic acid amplification testing, although 
it has a lower sensitivity (Seme et al., 2005).  
1.1.5 Treatment 
The standard treatment for HCV infection over the last decade has been pegylated 
interferon and ribavirin, which achieves sustained viral response (SVR) rates (i.e. viral 
clearance rates) of up to 80% in patients with genotypes 2 and 3, and up to approximately 
50% in patients with genotype 1 (Pawlotsky, 2013). Further research on the HCV life cycle 
has fostered the development of a class of drugs called direct-acting antivirals (Pawlotsky, 
2013). Two of these, boceprevir and telaprevir, have been approved for use in treating 
HCV genotype 1 patients and have been shown in clinical trials to improve the SVR rates 
in this group (Pawlotsky, 2013; Welsch et al., 2012).  
Historically, many people who inject drugs (PWID) have not been considered for treatment 
owing to perceptions that they will not adhere to treatment regimens and the risk of re-
infection following treatment for those who continue to inject (Cox and Thomas, 2013). A 
systematic review and meta-analysis examined studies of treatment among people who use 
drugs, more than half of whom were injectors, and found good adherence rates, as well as a 
low rate of re-infection (Aspinall et al., 2013). Current guidelines recommend that efforts 
should be made to treat PWID (Anonymous, 2002) and recommendations for the 
management of PWID with HCV have recently been published (Robaeys et al., 2013) 
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1.1.6 Vaccine 
Although there are vaccines under development, there is currently no vaccine available to 
protect against infection with HCV (Roohvand and Kossari, 2012). Chimpanzee models 
have been used to study immunity to HCV, and have demonstrated that immunity can 
follow from both infection and vaccination (Cox and Thomas, 2013). Some follow-up 
studies of PWID have shown higher rates of re-infection among those who were previously 
infected as compared to never infected PWID, but comparatively higher rates of viral 
clearance (Corson et al., 2011) – as well as a lower magnitude and shorter duration of 
viraemia – among the former compared with the latter (Cox and Thomas, 2013). These 
findings suggest that, while immunity might not be sterilising, it may protect against 
chronic infection (Cox and Thomas, 2013). The first clinical trial of an HCV vaccine 
among PWID began in 2012 with the aims of assessing safety and effectiveness – the latter 
in terms of reduced incidence of chronic HCV infection among uninfected PWID, as 
compared to placebo (Cox and Thomas, 2013). 
1.2 Global epidemiology of HCV infection 
1.2.1 Prevalence of HCV 
Previous published estimates of the number of individuals infected with HCV globally 
have ranged from 130 million to 170 million, corresponding to approximately 2% to 3% of 
the global population (Anonymous, 2004; World Health Organization, 1997; World Health 
Organization, 2011). More recently, a systematic review and meta-analysis estimated that, 
in 2005, the world-wide prevalence of anti-HCV was 2.8% (95% uncertainty interval 2.6-
3.1%), corresponding to 185 million people (Mohd et al., 2013). Prevalence rates vary 
regionally, ranging from less than 1.5% in, for example, North America to greater than 
3.5% in North Africa and the Middle East. Western Europe, as a region, is estimated to fall 
within the moderate prevalence range (1.5 to 3.5%), with an anti-HCV prevalence of 2.4% 
(uncertainty interval 2.2-2.7%), corresponding to 10 million people estimated to have 
antibodies to HCV (Mohd et al., 2013). 
There is also substantial regional variation in HCV prevalence across the countries within 
Western Europe: <1% in countries such as France, Germany, Norway, Sweden and the 
United Kingdom; 1 to 2% in Portugal, Switzerland and Poland; 2 to 3% in Spain; and >3% 
in Italy and Romania (Cornberg et al., 2011). The regional variation is likely caused by 
historical variation in the relative contribution of risk factors for HCV (Cornberg et al., 
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2011). For example, in Germany, Norway, Sweden and the United Kingdom, injecting 
drug use accounts for the majority of prevalent infections (Jarvis et al., 2005); by contrast, 
Italy has a large burden of HCV infection associated with the multi-use syringes that were 
used to deliver therapeutic injections (e.g. vitamins) in the 1960s and 1970s (Cornberg et 
al., 2011). 
In most industrialised countries, a large proportion of transmission was historically 
attributable to contaminated blood and blood products; however, with the advent of the 
screening test for anti-HCV, this route of transmission has virtually been eliminated 
(Lavanchy, 2011). Injecting drug use increased in the 1970s and 1980s (Geraghty, 2011; 
Kaya et al., 2004; Robertson and Richardson, 2007), and is now the main risk factor for 
HCV infection in these countries.  
A recent systematic review identified and synthesised international studies of HCV 
prevalence among PWID and found a central prevalence estimate of 67%, corresponding 
to an estimated 10 million anti-HCV positive PWID globally (range 6 million to 15.2 
million). While there was a large range of reported rates across countries, prevalence rates 
among PWID of over 50%, over 60% and over 80% were reported in 49, 37 and 12 
countries, respectively (out of 77 countries with eligible reports) (Nelson et al., 2011). At 
the time of the latter review, there were an estimated 16 million PWID at risk of HCV 
infection worldwide (Mathers et al., 2008); however, more recent estimates put this figure 
at 14 million PWID worldwide (range 11.2 to 22.0 million) (United Nations Office on 
Drugs and Crime, 2013). 
1.2.2 Incidence of HCV 
HCV incidence has been less widely reported than HCV prevalence because it is more 
difficult to measure: given that acute HCV infection is usually asymptomatic, new 
infections are generally not notified and counted. The direct measurement of incidence has 
generally focused on risk groups such as PWID and MSM, and has involved follow-up to 
ascertain seroconversion (Lavanchy, 2011). In contrast to HCV prevalence, no pooled 
global estimate of incidence among non-incarcerated PWID has been reported; however, a 
number of studies have reported incidence rates among selected local PWID populations. 
A review (comprising studies published to December 2006) (Hagan et al., 2008) identified 
10 studies that reported a median cumulative incidence of 20.7% (interquartile range: 
11.57-29.81) among PWID in the community. A more recent review and meta-analysis of 
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HCV in prisons found a summary incidence rate of 16.4 per 100 person-years (95% CI 0.8-
32.1) among prisoners with a history of injecting (Larney et al., 2013).  
1.3 Epidemiology of HCV infection in Scotland 
1.3.1 Diagnosed cases 
By the end of 2012, more than 33,000 cases of anti-HCV positivity had been diagnosed in 
Scotland (14% of whom are known to have died as of 31 December 2011), representing 
approximately 0.8% of the Scottish population aged 15 to 59. Ninety percent of the HCV-
diagnosed individuals, for whom a risk factor is recorded, reported having injected drugs 
(Health Protection Scotland, 2012). Because of the generally long asymptomatic period 
after acquisition of HCV infection, there is often a long delay between the date of infection 
and date of diagnosis; consequently, many individuals in Scotland remain undiagnosed. 
There are an estimated 50,000 living individuals thought to be chronically infected with 
HCV in Scotland (Hutchinson et al., 2006). 
1.3.2 Prevalence of HCV 
Seroprevalence surveys have been undertaken in various population groups in Scotland. 
The prevalence of anti-HCV among groups surveyed in the 1990s and early 2000s (and the 
year surveyed and geographical region) are as follows: women giving birth 0.3-0.4% 
(2000, Scotland), blood donors 0.008% (2003, Scotland), healthcare workers 0.28% (1996, 
Glasgow) and MSM attending genitourinary medicine clinics 0.6% (1996-1997, Scotland). 
Slightly higher prevalence rates have been detected among renal dialysis patients (3.9%), 
non-injector inmates (3.5-4.0%) and children surveyed at a dental school (3%) (Hutchinson 
et al., 2006); but the highest rates have been, and continue to be, observed among PWID.  
HCV prevalence among PWID in Scotland has been derived from a programme of 
unlinked anonymous testing (UAT) for HCV of residual sera from PWID who had 
undergone named HIV testing (Hutchinson et al., 2002). This programme was undertaken 
in the four largest National Health Service (NHS) Board areas in Scotland – Greater 
Glasgow and Clyde (formerly Greater Glasgow)1, Lothian, Tayside and Grampian. These 
four areas contain the major cities in Scotland of Glasgow, Edinburgh, Dundee and 
                                                 
1The former Argyll and Clyde NHS Board was dissolved in 2006 and the Clyde portion was 
allocated to the Greater Glasgow NHS Board. Thus, figures up to, and including, 2006 pertain to 
the Greater Glasgow NHS Board and figures from 2007 onward pertain to the Greater Glasgow 
and Clyde NHS Board.  
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Aberdeen, respectively. Figures 1-1 and 1-2 illustrate the changes in HCV prevalence over 
time among all PWID tested and among those aged <25 years, respectively; the data are 
also presented in Table 1-3. While the UAT system did not permit the elucidation of 
current or former injecting status, those in the younger age group were more likely to be 
current injectors, and any infections in this group were more likely to be relatively new 
infections. In 1990, anti-HCV prevalence rates of 91% and 69% were detected among 
PWID aged <25 in Glasgow and Lothian, respectively, and in Tayside in 1993, 57% 
prevalence was detected among <25s. Prevalence of HCV was estimated to have declined 
substantially by 1997 in Glasgow (43%) and Lothian (13%), likely indicative of a decline 
in HCV incidence (Goldberg et al., 2001). Between 1997 and 2000, there were no 
significant changes in HCV prevalence in any of the four NHS Boards among <25s 
(Hutchinson et al., 2002). There was a significant reduction among <25s in Tayside 
between 1999 and 2009, but non-significant reductions in the other three NHS Boards over 
this period (Health Protection Agency, 2011a). Latterly (1999 to 2009 approximately), 
significant reductions in HCV prevalence among all PWID were seen in Lothian and 
Tayside, but not in Greater Glasgow and Clyde or Grampian (Health Protection Agency, 
2011a).  
Further to the above prevalence estimates, cross-sectional community-wide surveys of 
PWID have been conducted in Glasgow since the early nineties (Taylor et al., 2000). 
Participants provided voluntary saliva samples, which were tested for the presence of anti-
HCV. Prevalence rates detected in these surveys have generally been lower than those 
reported from the UAT system, although the surveys have involved more selected PWID 
populations. These demonstrated a decline in HCV prevalence from 79% in 1990 to 66% 
in 1996 (Hutchinson et al., 2006). 
1.3.3 Incidence of HCV 
The prevalence of anti-HCV is useful to determine the extent of the problem; however, 
since a prevalent infection could have been acquired at any time in the past, prevalence 
does not provide information about the current levels of transmission. Although numerous 
studies have been undertaken to establish the prevalence of HCV infection in Scotland, the 
incidence of infection is less well described. Given the very low prevalence rates of HCV 
in non-PWID population groups, incidence studies have focused on infections likely to 
have been acquired by means of injecting drug use. Published measures of HCV incidence 
in the United Kingdom are presented in Table 1-4. Incidence rates from community studies 
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in Greater Glasgow ranged from 21.1 to 29.0 per 100 person-years, at various time points 
between 1990 and 2000. Studies undertaken in prison settings in Scotland revealed 
incidence rates ranging from 11.9 to 21.0 per 100 person-years. Very high HCV incidence 
rates have been detected in other parts of the United Kingdom: 41.8 per 100 person-years 
in London in 2001-2002 and 38 to 47 per 100 person-years in Bristol in 2006. In contrast, 
much lower rates were reported in Wales, Leeds and Birmingham (5.9, 7.6 and 5.2 per 100 
person-years, respectively) more recently. The most up-to-date estimates of the incidence 
of HCV among PWID in Scotland will be presented later in this thesis. 
1.3.4 Size of the injecting population 
Log-linear modelling of capture-recapture data was first applied in Greater Glasgow to 
estimate the number of PWID in Glasgow (who were currently injecting) in 1990 (Frischer 
et al., 1993). The capture-recapture approach involves the extraction of records (including 
identifier information) on PWID from available data sources, the matching of these 
records, and the analysis of the overlap between the data sources using log-linear 
modelling. This approach was later applied to generate estimates for all of Scotland for 
2000, 2003, 2006 and 2009 (Table 1-5). Although the CIs for most of the estimates overlap 
and therefore one cannot be certain, the trend in the central estimate suggests a decline 
between 2000 and 2003, an increase between 2003 and 2006 and a decline again by 2009. 
The most recent figures put the size of the injecting population at approximately 15,000 to 
16,000 individuals (Overstall et al., 2014).  
1.4 Preventing HCV among people who inject drugs 
Harm reduction is generally defined as the policies, programmes, services and actions that 
work to reduce the health (and other) harms that are associated with the use of drugs 
(Newcombe, 1992). The main harm reduction interventions are generally considered to be 
sterile injecting equipment provision (IEP) and opioid substitution treatment (OST). While 
the focus of this thesis is primarily HCV, it is recognised that harm reduction interventions 
have a role in preventing not only other blood-borne viruses (BBVs) – for example, HIV 
and HBV – but also bacterial infections.  
1.4.1 Injecting equipment provision services 
IEP services are a critical component of harm reduction interventions to reduce the 
transmission of BBVs among PWID. Traditionally, these services involved the distribution 
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of sterile needles/syringes in exchange for used ones, hence the term ‘needle exchange’. 
The terminology has evolved over time, reflecting the changing nature of the service. An 
alternative name – needle and syringe provision (NSP) – was introduced, more recently, to 
indicate that the return of used needles/syringes is not necessarily a pre-requisite for the 
provision of new sterile needles/syringes. In turn, NSP has been replaced by IEP, reflecting 
that these services often provide injecting equipment other than needles/syringes, which 
may include such items as spoons (also called cookers or containers), filters, water 
ampoules and citric acid (collectively referred to as injecting paraphernalia). IEP will be 
used throughout this thesis to refer to these services. The settings for these services can 
vary – from fixed-site specialist services, to pharmacies, to vending machines. Other 
approaches may involve outreach provision of sterile injecting equipment through, for 
example, mobile vans.  
Injecting paraphernalia may consist of such items as spoons (on which to heat and/or 
prepare drugs), filters (to remove particles when drawing drugs up into a syringe), water 
(to rinse syringes or mix with drugs) and citric acid (to dissolve drugs). Most IEP services 
provide advice on safer injecting practices and an assessment of client needs; some will 
also offer access to a range of other resources including (either on-site or through referral) 
BBV testing, wound care and access to other health and social care services.  
IEP services may also distribute non-injection drug use equipment (for smoking or snorting 
drugs); this type of equipment is out of the scope of this thesis, because of the undefined 
risk of transmission of HCV from sharing this type of equipment2. 
1.4.2 Opioid substitution treatment 
OST refers to the treatment of opioid addiction through the administration of 
pharmacological agents (usually legal opioids), which eliminate or reduce withdrawal 
symptoms but cause minimal intoxication. Although opioid substitutes may be used to 
assist in detoxification, OST generally corresponds to ‘maintenance’, whereby an 
individual is stabilised on a dosage for a given length of time. Methadone is the most 
commonly used drug for maintenance, followed by buprenorphine (White, 2011). OST is 
usually administered orally under medical supervision.  
                                                 
2Although HCV transmission through sharing equipment for smoking/snorting is biologically 
plausible (Aaron et al., 2008; Fischer et al., 2008), and the sharing of smoking/snorting 
implements have been associated with increased risk of HCV in epidemiological studies 
(Macias et al., 2008; Tortu et al., 2004), it is likely to be a much less important source of HCV 
transmission as compared with injecting equipment.  
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Although the primary goal of OST is to reduce, or ideally eliminate, illegal opioid use 
among those treated, it is recognised that OST plays a role in the prevention of BBVs by 
reducing the frequency of injecting (whether complete cessation is achieved or not), and 
thus reducing the opportunity for sharing needles/syringes or other equipment.  
1.4.3 Other prevention interventions 
Other interventions that have the potential to reduce the transmission of HCV among 
PWID include: information, education and counselling; HCV testing/screening (knowledge 
of HCV status); drug consumption rooms; antiviral treatment for HCV infection; 
promoting non-injecting routes of drug administration; preventing transitions into injecting 
drug use; and bleach disinfection of needles/syringes. These interventions are not 
considered within this thesis.  
1.4.4 History of harm reduction interventions in Scotland 
The recreational injecting of the 1970s and 1980s gave HCV an efficient means of 
transmission: the virus had unknowingly been circulating among PWID populations during 
this time (Gore et al., 1998; Hutchinson et al., 2006). As stated above, when the test to 
detect antibodies to HCV became available in 1991, prevalence rates of HCV of greater 
than 90% were detected among regional PWID populations in Scotland (Goldberg et al., 
2001).  
IEP was initially introduced in Scotland as a response to the HIV epidemic among PWID 
in the late 1980s/early 1990s, when prevalence rates of HIV reached as high as 50% in 
PWID populations in the east of Scotland (Robertson et al., 1986; Ronald, Robertson, and 
Roberts, 1992). By the mid-1990s, HIV transmission was largely under control in this 
population group (McIntyre et al., 2001); in contrast, high prevalence rates of HCV 
persisted (Goldberg et al., 2001; Goldberg, Cameron, and McMenamin, 1998). Thus, 
although the early motivation for establishing harm reduction interventions in Scotland 
was HIV, the evolution of these interventions has, in more recent times, been driven by the 
desire to curb HCV transmission. 
The first pilot needle exchange in Scotland was established in Glasgow in 1987 (Gruer, 
Cameron, and Elliott, 1993). Historical figures for the number of sterile needles/syringes 
distributed are available only for Glasgow, because of their being reported in a peer-
reviewed publication (Gruer, Cameron, and Elliott, 1993) and in Greater Glasgow NHS 
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Board AIDS Control Act reports (Greater Glasgow Health Board, 1997). These illustrate 
an increase from 2,600 to over one million needles/syringes distributed between 1988 and 
2007 (Figure 1-3). Needle/syringe distribution figures have been routinely reported at a 
national level from 2007/08 onwards, and will be presented later in this thesis. Reporting 
on the numbers of other items of injecting paraphernalia distributed began in 2008/09. 
Oral methadone has been, and continues to be, the most commonly prescribed opioid 
substitute in Scotland. The timing of the establishment of schemes to provide methadone to 
PWID varied across NHS Boards, but generally began in the late 1980s/early 1990s 
(Greenwood, 1990). A scheme in Glasgow – involving general practitioners, pharmacists 
and a specialised drug problem service – was established in 1994, although individual 
practitioners were dispensing methadone earlier than that (Gruer et al., 1997). The number 
of methadone mixture prescriptions dispensed in Scotland has been reported since 1995, 
and has increased from approximately 130,000 to nearly 500,000 prescriptions dispensed 
annually (Figure 1-4). Although the number of individuals receiving methadone in 
Scotland has not been routinely reported, we can infer that this number has increased over 
time, assuming that prescription practices have not changed drastically. One prescription 
corresponds to multiple dispensations (i.e. occasions on which methadone is dispensed to 
the prescription-holder) and the number of dispensations per prescription has remained 
consistent (at approximately 12) between 1998 and 2010. In contrast, the average dose per 
dispensation has increased from 68mg to 97mg over the same period, indicating that on 
average higher doses are being prescribed to stabilise patients (Information Services 
Division, 2012a). 
1.5 Policy context  
The Scottish Government became aware of the public health problem posed by HCV as a 
result of a number of factors leading up to, and culminating in, the Hepatitis C Action Plan 
for Scotland: prevalence surveys and laboratory reports of diagnoses that established the 
extent of infection (Goldberg, Cameron, and McMenamin, 1998; Hutchinson et al., 2002; 
McLeod et al., 2006); a needs assessment undertaken in 1999 (Howie et al., 2000) that 
made recommendations for improvements in HCV services; and awareness-raising by non-
statutory organisations such as the UK Hepatitis C Trust. The Action Plan, however, was 
the first major policy initiative to include funding attached to the recommendations.  
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1.5.1 The Hepatitis C Action Plan for Scotland (2006-2011) 
In 2006, the Scottish Executive released Phase I of the Hepatitis C Action Plan for 
Scotland (Goldberg et al., 2008; Scottish Executive Health Department, 2006). The aims of 
the plan were: to prevent the spread of HCV, particularly among PWID; to diagnose HCV-
infected persons, particularly those who would most benefit from treatment; and to ensure 
that those infected receive optimal treatment, care and support. The first phase was 
undertaken during September 2006 to March 2008, and involved establishing a governance 
structure to oversee this phase and gathering evidence to inform proposals and actions for 
the development of HCV services during Phase II. Three working groups were formed, 
corresponding to the areas of (i) prevention, (ii) testing, treatment, care and support and 
(iii) education, training and awareness-raising. Using evidence gathered by means of 
systematic reviews of the literature and reviews of existing Scottish services, among other 
methods, the working groups developed ‘issues’ and corresponding ‘actions’.  
In relation to IEP, the Prevention Working Group derived the following issues: (i) that 
there are widespread variations in the provision and uptake of injection equipment by 
PWID across Scotland, (ii) that, apart from guidelines on the number of sets of 
needles/syringes that can be given to PWID, comprehensive National Guidelines for the 
provision of injecting equipment do not exist and (iii) that the re-use/sharing of injection 
equipment among PWID is still highly prevalent and HCV transmission among PWID 
throughout Scotland is very common. The resulting actions to address these issues were 
published in Phase II of the Action Plan, to be undertaken during the period May 2008 – 
March 2011 (Scottish Government, 2008a). The actions on prevention mainly relate to the 
prevention of HCV through IEP, reflecting the fact that PWID constitute the large majority 
of infected individuals, and that the main purpose of IEP is to prevent BBV transmission 
(unlike, for example, OST). The Phase II actions relevant to IEP are:  
Action 14: “National Guidelines for services providing injection equipment to IDUs 
[injecting drug users] will be developed”; and  
Action 15: “Services providing injection equipment (needles/syringes and other injection 
paraphernalia) will be improved in accordance with the Guidelines referred to in action 14 
above. Improvements will be made in terms of the i) quantity (increasing access to and 
uptake of equipment through innovative, including outreach, approaches) ii) quality (e.g. 
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the colour coding of equipment to avoid sharing) and, iii) nature (e.g. the provision of 
equipment other than needles/syringes), of provision”.   
A total of £36.7 million was allocated to the 14 NHS Boards in Scotland as part of the 
Action Plan, £8 million of which was for the development of prevention services (Scottish 
Government, 2008a).  
1.5.2 Guidelines for services providing injecting equipment in 
Scotland 
The National Needle Exchange Guidelines (Action 14 of the Hepatitis C Action Plan for 
Scotland) were first released as interim guidelines in 2009 before official publication in 
2010 (Scottish Government, 2010). The guidelines consist of 17 recommendations and are 
organised into three sections: developing an IEP programme; increasing distribution of 
injecting equipment; and improving the effectiveness and consistency of IEP services. The 
recommendations are summarised in Table 1-6.  
1.5.3 The Sexual Health and Blood Borne Virus Framework (2011-
2015) 
Building on the HCV Action Plan and other relevant policies, the Scottish Government’s 
Sexual Health and Blood Borne Virus Framework merges HCV with three other policy 
areas – sexual health, HIV and HBV (Scottish Government, 2011). Although broader in 
scope and focused on outcomes, rather than processes, the Framework nevertheless aims to 
continue the work of the Action Plan in relation to prevention of HCV among PWID. The 
Framework outcome that is relevant to HCV prevention is: 
Outcome 1: “Fewer newly acquired blood borne virus and sexually transmitted 
infections”.  
1.5.4 Legal framework for injecting equipment provision in 
Scotland  
In Scotland (and indeed in the United Kingdom (Stimson, 1988)), there has generally been 
an acceptance of the public health benefits of IEP by policymakers and a greater tolerance 
for these services among the general public, as compared with some countries – for 
example, the United States of America – where many services have had to operate illegally 
and no central funding for IEP was provided (Anonymous, 1999b; Paone et al., 1999). 
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Nevertheless, in Scotland, there were initially restrictions on IEP services. Prior to 2002, 
there were strict limits on the number of needles/syringes that could be distributed from 
IEP services: an individual was allowed to receive five sets on the first visit, up to 15 sets 
at visits thereafter (subject to the return of the same number of sets) and up to 30 sets if 
collecting equipment for someone else or in the case of public holidays (Taylor et al., 
2005). The Lord Advocate reviewed these guidelines and, in December 2002, these limits 
were increased to 20 sets on the first visit, 60 sets on visits thereafter (as previously, 
subject to returns) and 120 sets for holiday periods.  
Another relevant legal decision with implications for IEP services was the decision to 
allow the provision of sterile paraphernalia. Prior to 2003, providing non-needle/syringe 
injecting equipment to PWID was prohibited by the UK Misuse of Drugs Act. In 
recognition of the potential risk of HCV transmission from sharing these items, their 
provision became legal in August 2003.  
1.5.5 The Road to Recovery (2008–) 
The Road to Recovery: A New Approach to Tackling Scotland’s Drug Problem – the 
Scottish Government’s drug and alcohol strategy – was launched in 2008. While the focus 
of the Action Plan was limited to IEP, the latter policy had the potential to impact on the 
delivery of OST in Scotland (Scottish Government, 2008b). The Road To Recovery sets 
out a programme of reform to tackle Scotland’s drug problem, placing recovery from drug 
use as the central theme. The strategy encompasses a wide range of policy areas including 
law enforcement and protection of children and families, but the most relevant to this 
thesis is the chapter ‘Promoting Recovery’, which sets out aspirations for service 
providers, and the chapter ‘Making it Work’, which outlines more specific action for 
implementation.  
The former chapter is informed by two reports published by the Scottish Advisory 
Committee on Drug Misuse (Scottish Advisory Commitee on Drug Misuse Essential Care 
Working Group, 2008; Scottish Advisory Commitee on Drug Misuse Methadone Project 
Group, 2007) and advocates the need to extend and integrate existing services to support 
recovery, the key roles of general practice and pharmacy, the need for person-centred care 
and the importance of carers and families. The latter chapter outlines action (that had 
already commenced) to set up the Delivery Reform Group, whose remit includes: 
developing an outcomes-based framework for assessing and managing local performance; 
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developing a statement of the strategic functions that need to be carried out at a local level 
in order to deliver the strategy; and developing accountability arrangements between 
central and local government.  
The Government’s approach to ‘Preventing Drug Use’ (Chapter 2 in the strategy) may also 
indirectly impact on the provision of OST services in Scotland by preventing/reducing 
drug use, thereby reducing demand for treatment. While the approach to addressing the 
underlying causes of drug use (for example, their economic strategy and their early years 
intervention policy) may prevent drug use in the longer term, other initiatives to address 
the proximate factors associated with drug use (for example, substance misuse education 
within the school curriculum) may have a more immediate impact on rates of drug use and, 
potentially, injecting drug use. 
1.6 Aims and objectives of this thesis 
The Scottish Government policies – the HCV Action Plan, the Sexual Health and Blood 
Borne Virus Framework and the Road to Recovery – imply the possibility of significant 
changes in harm reduction services. Reflecting the opportunity to examine the impact of 
harm reduction interventions contemporaneous with this period of potential change, the 
primary aim of this thesis is therefore to investigate the impact of IEP and OST on the 
transmission of HCV among PWID in Scotland.  
The objectives of this thesis are: 
i. To review the international literature on the effectiveness of IEP and OST in 
preventing HCV transmission among PWID;  
ii. To determine the association between self-reported sharing of needles/syringes and 
incident/prevalent HCV infection among PWID; 
iii. To determine the association between sharing non-needle/syringe injecting 
paraphernalia and incident HCV infection among PWID in Scotland;  
iv. To determine the incidence of HCV among PWID in Scotland; and 
v. To determine the association between self-reported uptake of harm reduction 
interventions (IEP and OST) and incident HCV infection among PWID in Scotland.  
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1.7 Structure of this thesis 
This thesis will consist of five main chapters. Each chapter is essentially a ‘stand-alone’ 
piece of work; however, a common narrative links them, as they all contribute to the 
overall thesis aim of examining the impact of IEP and OST on the transmission of HCV 
among PWID in Scotland. Chapter 2, addressing the first objective, sets the scene by 
reviewing the international literature to establish the state of existing evidence for the 
effectiveness of these interventions in preventing HCV among PWID. Chapter 3 addresses 
the second objective, and consists of a systematic review and meta-analysis to quantify the 
association between self-reported sharing of needles/syringes and incident and prevalent 
HCV infection. Chapter 4, addressing the third objective, investigates the association 
between sharing injecting paraphernalia (i.e. spoons, filters and water) and recent 
(incident) HCV infection using data from national cross-sectional surveys of PWID 
undertaken in Scotland. To answer the fourth and fifth objectives, Chapter 5 also uses the 
cross-sectional survey data to determine the incidence of HCV, and to examine the 
association between self-reported uptake of harm reduction interventions and recent HCV 
infection. Chapter 6 builds on and refines the analysis conducted in Chapter 5, using 
additional data from subsequent surveys in the same series. Finally, Chapter 7 summarises 
the thesis findings, derives conclusions on the body of evidence and makes 
recommendations for policy and research.  
1.8 Epidemiological study designs for examining the 
impact of harm reduction interventions 
Epidemiological studies can be classified by whether they are attempting to answer 
questions of aetiology or effectiveness (Reeves et al., 2011). Chapters 3 and 4 will address 
aetiological questions (i.e. are needles/syringes and paraphernalia associated with HCV 
transmission) whereas Chapters 2, 5 and 6 will address questions of effectiveness (i.e. are 
harm reduction interventions effective in preventing HCV transmission).  
Regardless of the above, the central aim of epidemiological studies is usually to establish a 
causal relationship between the exposure (in the case of aetiology) or intervention (in the 
case of effectiveness) and the outcome of interest. The hierarchy of epidemiological study 
designs for determining causation is well accepted, with the randomised controlled trial 
(RCT) representing the ‘gold standard’ (Academy of Medical Sciences, 2007). There has 
been much discourse in the literature about the applicability of this design hierarchy to the 
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public health context, given that these types of studies were initially developed to 
investigate biomedical interventions: for example, clinical trials of new medicines 
(Barreto, 2005). Although RCTs have been advocated for evaluating public health 
interventions (Macintyre, 2011), they may not be appropriate, or possible, for a number of 
reasons including: (i) that the intervention is already well established; (ii) that the 
intervention has been shown to be efficacious but its effectiveness has not been 
demonstrated; and/or (iii) that there are ethical issues with conducting an experimental 
study where the intervention is withheld from a control group.  
The interventions under study here share many of these characteristics. For example, NSP 
has been widely implemented in Scotland for some time (see section 1.4.4). The efficacy 
of NSP essentially does not need to be demonstrated, since it is known that using a sterile 
needle/syringe for a given injection will not transmit a BBV (it is likely because of this 
perceived efficacy that NSP was implemented before there was evidence to demonstrate its 
effectiveness)3. Thus, since it is already widespread and efficacious, it is generally 
accepted that it would be unethical to introduce experimental conditions where a control 
group was denied access to sterile needles/syringes (Lurie, 1997).  
In contrast, pre-Action Plan, the provision of sterile injecting paraphernalia was not 
assumed to be efficacious (primarily because the evidence for sharing paraphernalia as a 
risk factor for HCV was weak at the time), nor was its distribution widespread in Scotland 
(although some NHS Boards were already distributing it). One randomised study design 
that has been increasingly applied to public health interventions is the cluster-randomised 
trial, whereby clusters of individuals (e.g. schools, hospitals, communities) are randomised 
to receive/not receive the intervention (Donner and Klar, 2004). This type of design would 
theoretically have been an option to investigate the impact of providing sterile 
paraphernalia by randomising NHS Boards to distribute (or not) paraphernalia via their IEP 
services (and also would have reduced the likelihood that the distinction between exposed 
and unexposed groups would be diluted by individuals obtaining paraphernalia from 
others, as might occur in an individually randomised study). However, this was not seen to 
be feasible in relation to evaluating the impact of the Action Plan, since the distribution of 
paraphernalia was explicitly recommended in the National Needle Exchange Guidelines 
                                                 
3Using the analogy of assessing a vaccine, the efficacy measures whether the vaccine has the 
intended effect on individuals under ‘ideal conditions’, whereas the effectiveness measures the 
‘real-world’ situation with regard to whether it produces the intended effect when an 
immunisation programme is delivered to a population (Barreto, 2005).  
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and since NHS Boards, not researchers, had control over the implementation of these 
guidelines.  
Thus, in cases where experimental studies are not practicable, observational study designs 
must be relied upon to investigate these associations. Much discussion has focused on this 
issue, i.e. if randomised studies cannot be undertaken, but observational studies are seen as 
less valid, then how is an evidence base generated for many public health interventions 
(Black, 1996; Kirkwood, 2004; Lurie, 1997; Medical Research Council, 2009; Victora, 
Habicht, and Bryce, 2004)?  
A common theme that has emerged, as this area of evaluation develops, is the value of an 
approach that combines evidence from diverse study designs to support causal inferences. 
For example, the Medical Research Council states that, if non-experimental methods are 
used, “wherever possible, evidence should be combined from different sources that do not 
contain the same weaknesses” (Medical Research Council, 2009). Others have similarly 
recommended a strategy involving several evaluative elements with different designs 
(Academy of Medical Sciences, 2007; Kirkwood et al., 1997; Lurie, 1997; Medical 
Research Council, 2011). Such evaluations have successfully been undertaken to 
investigate the impact of other public health interventions, for example the Scottish 
smoking ban (Pell et al., 2008).  
An additional theme that has emerged is the importance of understanding the processes 
that lead from the intervention(s) to the outcome(s): this has sometimes been referred to as 
a ‘theory of change’. Traditional epidemiological studies have usually focused solely on 
outcomes, but these types of designs can be limited in producing explanations if failure to 
implement the intervention properly results in the intervention not producing the expected 
change(s) in the outcome(s). The Medical Research Council recommends undertaking a 
process evaluation since it “…can be used to assess fidelity and quality of implementation, 
clarify causal mechanisms, and identify contextual factors associated with variation in 
outcomes” (Craig et al., 2008). Examples of studies that have elucidated (or plan to 
elucidate) the processes between interventions and outcomes include RCTs with embedded 
process evaluations (Medical Research Council, 2009) and the planned evaluation of 
Scotland’s Alcohol Strategy (Beeston et al., 2011), the latter of which adopts a theory of 
change approach.  
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These topics are being explored here because the overall aim of this thesis is to investigate 
the impact of IEP and OST on the transmission of HCV among PWID in Scotland. The 
approach applied in Chapter 6 of this thesis (and utilising/building on data and analyses 
undertaken in prior chapters), borrows from the above themes and is described further in 
the chapter.  
1.9 Publications arising from this thesis  
Publications arising from the thesis chapters are as follows:  
Chapter 2: Palmateer, N., Kimber, J., Hickman, M., Hutchinson, S., Rhodes, T. and 
Goldberg, D., 2010. Evidence for the effectiveness of sterile injecting equipment provision 
in preventing hepatitis C and human immunodeficiency virus transmission among injecting 
drug users: a review of reviews. Addiction, 105(59), pp.844-859.  
Chapter 3: Palmateer, N. E., Hutchinson, S. J., Innes, H., Schnier, C., Wu, O., Goldberg, D. 
J. and Hickman, M., 2013. Review and meta-analysis of the association between self-
reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among 
people who inject drugs in Europe. Int J Drug Policy, 24(2), pp.85-100.   
Chapter 4: Palmateer, N., Hutchinson, S., McAllister, G., Munro, A., Cameron, S., 
Goldberg, D., and Taylor, A., 2014. Risk of transmission associated with sharing drug 
injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-
sectional survey data. J Viral Hepat, 21(1), pp.25-32.  
Chapter 5: Allen, E. J., Palmateer, N. E., Hutchinson, S. J., Cameron, S., Goldberg, D. J. 
and Taylor, A., 2012. Association between harm reduction intervention uptake and recent 
hepatitis C infection among people who inject drugs attending sites that provide sterile 
injecting equipment in Scotland. Int J Drug Policy, 23(5), pp.346-52.   
Chapter 6: Palmateer, N.E., Taylor, A., Goldberg, D.J., Munro, A., Aitken, C., Shepherd, 
S.J., McAllister, G. and Hutchinson, S.J. Rapid decline in HCV incidence among people 
who inject drugs associated with national scale-up in coverage of sterile injecting 
equipment and opiate substitution therapy. PLOS ONE, under review. 
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Figure 1-1. Prevalence of anti-HCV among PWID who had a named HIV test by NHS Board area, 
1989-2009 
GG&C: Greater Glasgow and Clyde 
Diamonds represent the central prevalence estimates and the vertical bars represent the 95% CIs. 
Estimates have been staggered slightly along the x-axis for ease of viewing.  
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Figure 1-2. Prevalence of anti-HCV among PWID aged <25 years who had a named HIV test by 
NHS Board area, 1989-2009 
GG&C: Greater Glasgow and Clyde 
Diamonds represent the central prevalence estimates and the vertical bars represent the 95% CIs. 
Latter years have been grouped to reduce the size of the CIs (Glasgow 2006 & 2007 and 2008 & 
2009; and 2007-2009 for Grampian and Tayside). Estimates have been staggered slightly away 
from the calendar year for ease of viewing. 
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Figure 1-3. Number of sterile needles/syringes distributed per year, Greater Glasgow, 1988 to 2007 
Figures to 2006 are for Greater Glasgow NHS Board; figures from 2007 onward also include the 
Clyde area of the former Argyll and Clyde NHS Board, following its dissolution. Data are from Gruer 
et al. (1993), AIDS Control Act Reports (Greater Glasgow Health Board, 1997) and ISD 
(Information Services Division, 2009). For 1993 onward, years refer to financial years, e.g. 1993 
represents the 1993/94 financial year.  
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Figure 1-4. Number of methadone mixture prescriptions dispensed in Scotland, 1995-2007 
Data from Drug Misuse Statistics Scotland (Information Services Division, 2012a). Years refer to 
financial years, e.g. 1994 represents the 1994/95 financial year.  
Chapter 1  42 
 
 
Table 1-1. Interpretation of HCV serologic test results 
  Anti-HCVa 
  Negative Positive 
HCV-RNAa Negative 
Not infected 
(susceptible) Resolved/past infection 
 
Positive ‘Window period’ (recent) infection Current infection 
aAssumes no false positive or negative test results and no fluctuations in viraemia 
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Table 1-2. Duration of HCV pre-seroconversion window period in published studies 
Reference Mean 95% CI Range 
Population 
studied 
Sample 
size 
Farci et al., 1991  78 days (11.2 wks) - 77-84 days 
Blood transfusion 
recipients 5 
Farci et al., 1992  88.2 days (12.6 wks) - 40-189 days Chimpanzees 6 
Glynn et al., 2005  56.3 days 44.8-67.8 75% within 30-65 Plasma donors 77 
Netski et al., 
2005  42 days - 28-63 days 
People who inject 
drugs 8 
Page-Shafer et 
al., 2008  50.9 days 46.1-55.8 - Plasma donors 58 
 
 
  
   
 
 
 
Table 1-3. Prevalence of anti-HCV among PWID who had a named HIV test by NHS Board area, 1989-2009 
 
  Greater Glasgow Grampian Lothian Tayside 
 
 Aged <25 All Aged <25 All Aged <25 All Aged <25 All 
1990 % (95% CI) 91 (85-95) 89 (85-93) - - 69 (65-74)a 76 (73-78)a - - 
1993 % (95% CI) - - - - - - 57 (42-71) 70 (62-78) 
1995 % (95% CI) 59 (49-68) 77 (72-81) - - 31 (23-41) 58 (52-63) - - 
1996 % (95% CI) 61 (50-70) 80 (75-84) 28 (20-37) 38 (31-44) 17 (11-25) 44 (38-49) 42 (33-51)a 64 (59-68)a 
1997 % (95% CI) 43 (34-51) 68 (64-73) - - 13 (8-21) 40 (35-46) 45 (29-63) 65 (58-73) 
1999 % (95% CI) 41 (34-48)a 62 (58-66)a 29 (24-36) 38 (33-42) 17 (11-25) 36 (31-41) 35 (23-50) 53 (44-60) 
2002/2003a % (95% CI) 42 (34-50) 64 (60-67) 26 (18-33) 34 (29-40) 9 (4-14) 34 (30-38) 28 (17-39) 43 (36-50) 
2006 % (95% CI) 51 (35-67) 67 (62-71) - - - - - - 
2007 % (95% CI) 36 (21-54) 72 (68-77) 34 (22-47) 41 (35-48) 9 (5-17) 25 (22-29) 15 (5-32) 33 (25-43) 
2008 % (95% CI) 35 (21-52) 63 (58-68) 19 (10-32) 50 (44-55) 13 (7-20) 24 (21-28) 25 (15-37) 32 (26-39) 
2009 % (95% CI) 21 (5-51) 52 (46-58) 21 (12-33) 41 (35-46) 11 (6-17) 27 (24-30) 19 (12-27) 31 (27-36) 
This table has been modified and updated from Hutchinson et al. (2002). 
aFor Greater Glasgow, 1999 samples were taken in 1999/2000; for Lothian, 1990 samples were taken 1989/1990; and for Tayside, 1996 samples were taken in 
1995/1996. In these instances, and for all areas in 2002/2003, it was not possible to separate the anti-HCV results of the specimens into the appropriate calendar 
years. 
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Table 1-4. Published estimates of HCV incidence in the United Kingdom, in approximate chronological order 
Region Method Setting/ recruitment  
Sample 
type Inclusion criteria Year(s) 
No. of 
PWID  
No. 
of 
SCs 
Exposure/ 
follow-up 
time 
Incidence per 
100 PY 
(95%CI) 
Greater Glasgow Using HCV prevalence and date 
of commencement of injectinga  
Community surveys Saliva Injected in last two 
months 
1990-
1993 
550 356 1264.8 28.1 
(25.3-31.2) 
Greater Glasgow Unlinked anonymous testing 
among PWID with two or more 
specimens 
Stored serum 
specimens originally 
collected for HIV testing 
Serum People who had ever 
injected  
1993-
1998 
31 11 38.8 28.4 
(15.7-51.2) 
Greater Glasgow Using HCV prevalence and date 
of commencement of injectinga  
Community surveys Saliva Injected in last two 
months 
1994, 
1996 
173 79 373.8 21.1 
(16.9-26.3) 
Greater Glasgow, 
Grampian, Lanarkshire, 
Forth Valley 
Documentation of SC (date of 
SC defined as endpoint of 
follow-up)  
Prison Saliva Inmates who began 
injecting in 1992-1996 
1994-
1996 
114 42 203.5 21.0 (14-28) 
Greater Glasgow Using HCV prevalence and date 
of commencement of injectinga  
Community surveys Saliva Injected in last six 
months 
1999 283 130 523.2 24.8 
(20.9-29.5) 
Lanarkshire Documentation of SC  Prison Saliva Prisoners who ever 
injected  
1999-
2000 
69 4 33.5 11.9 
(4.5-31.8) 
Greater Glasgow Using HCV prevalence and date 
of commencement of injectinga  
Community surveys Saliva Injected in last six 
months 
2001-
2002 
385 228 785.9 29.0 
(25.5-33.0) 
London (Judd et al., 
2005a) 
Documentation of SC  Community prospective 
cohort study  
Saliva Injected in last four 
weeks and <30 years old 
or <six years injecting 
2001-
2002 
151 53  Not stated 41.8 (31.9-54.7) 
Wales (Craine et al., 
2009) 
Documentation of SC  Community prospective 
cohort study  
DBS Injected in last four 
weeks   
2004-
2006 
286 17 287.33  5.9 (3.4-9.5) 
Bristol (Hope et al., 
2011) 
Extrapolation of incidence from 
those in pre-SC window period 
Community survey (RDS) DBS Injected in last four 
weeks 
2006 115 14b N/A  38-47c 
Leeds (Turner et al., 
2011) 
Extrapolation of incidence from 
those in pre-SC window period 
Community survey (RDS) DBS Injected in last four 
weeks 
2008 120 2b  N/A 7.6 
Birmingham (Turner et 
al., 2011) 
Extrapolation of incidence from 
those in pre-SC window period 
Community survey (RDS) DBS Injected in last four 
weeks 
2009 310  2b N/A 5.2 
This table has been modified and updated from Roy et al. (2007b). 
DBS: dried blood spot; PY: person-years; RDS: respondent-driven sampling; SC: seroconversion 
aAssuming that HCV has been acquired since onset of injecting and taking the midpoint of the exposure period (i.e. the time elapsed since onset of injecting) as the 
date of acquisition of infection 
bNumber of recent infections (anti-HCV negative and HCV-RNA positive)  
c95% CIs were not calculated: the range of incidence rates is generated from the range in the estimated duration of the window period  
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Table 1-5. Estimates of the size of the injecting population, Scotland, 2000-2009 
Year 
Central 
estimate 95% CI Reference Data sources and censoring Sources 
2000 22,805 15,835 - 43,030 Hay et al., 2001 4 data sources GP reports to SDMD, agency reports to SDMD, social enquiry reports, HCV 
diagnoses 
2003 18,737 17,731 - 20,289 Hay et al., 2005 4 data sources  SDMD, social enquiry reports, HCV diagnoses, hospital records 
  16,700 14,300 - 20,900 Overstall et al., 2014 4 data sources, censoring SDMD, social enquiry reports, HCV diagnoses, hospital records 
  16,500 14,200 - 20,800 Overstall et al., 2014 3 data sources SDMD, social enquiry reports, hospital records 
2006 23,933 21,655 - 27,143 Hay et al., 2009 4 data sources  SDMD, social enquiry reports, HCV diagnoses, hospital records 
  22,900 16,300 - 27,00 Overstall et al., 2014 4 data sources, censoring SDMD, social enquiry reports, HCV diagnoses, hospital records 
  24,000 19,500 - 29,700 Overstall et al., 2014 3 data sources SDMD, social enquiry reports, hospital records 
2009 15,200 11,500 - 18,600 Overstall et al., 2014 4 data sources, censoring SDMD, social enquiry reports, HCV diagnoses, hospital records 
  16,000 11,500 - 19,400 Overstall et al., 2014 3 data sources SDMD, social enquiry reports, hospital records 
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Table 1-6. National Needle Exchange Guidelines recommendations 
Recommendation Summary of recommendation 
1: Planning and developing IEP services In planning and developing services that provide injecting 
equipment, NHS Boards, together with local partners, 
should undertake a number of tasks (needs assessment, 
stakeholder consultation, advertise and promote IEP 
services) to ensure that services are able to meet the needs 
of their clients effectively 
2: Choosing appropriate models of delivery NHS Boards and other service commissioners should 
ensure that a range of IEP services are provided using 
models of delivery appropriate to their injecting 
populations and the geography in their locality, based on 
an assessment of local needs 
3: Meeting the needs of sub-populations of injectors In deciding which models of service provision to use, 
service commissioners and service providers should give 
special consideration to the specific needs of sub-
populations of injectors (new injectors, women, sex 
workers, homeless injectors, steroid users, minority ethnic 
groups, people enrolled in drug treatment programmes, 
people in custody) 
4: Opening times There should be out-of-hours and weekend access within 
each NHS Board area corresponding to the needs of local 
injecting populations 
5: Provide one needle per injection IEP services should provide, free of charge, as many 
needles as an individual client requires, within the limits of 
the Lord Advocate's Guidance 
6: Provide other non-needle drug injecting equipment IEP services should provide, free of charge: acidifiers, 
cookers, filters, water for injections and pre-injection 
swabs. These items should be supplied in sufficient 
quantities to enable the use of one item per each injection 
7: Secondary distribution If a client states he/she is supplying injecting equipment to 
others, it is acceptable to provide supplies for the purpose 
of secondary distribution 
8: Provide methods for syringe identification A method of equipment identification should be made 
available to clients who inject in the company of other 
injectors in order that they can identify their own 
equipment and avoid accidental sharing 
9: Training of IEP service staff All individuals involved in the distribution of injecting 
equipment should receive appropriate training prior to 
providing a service or during induction 
10: Identifying and responding to the individual client's 
needs 
All clients attending a service for the first time should be 
asked how often they inject, what they are injecting, how 
often they visit the IEP service and whether they are 
collecting supplies for anyone else 
11: Service user education When providing needles and injecting equipment, IEP 
services should educate clients about: washing their hands 
with soap and water before injecting, the correct use of 
each item of injecting equipment, the risks of sharing 
injecting equipment and the correct methods of disposing 
of used injecting equipment 
12: Getting client feedback All IEP service providers should put in place mechanisms 
for identifying and responding to client feedback at regular 
intervals - at least annually 
13: Monitoring, evaluation and audit IEP services should have systems for monitoring, 
evaluation and audit to enable on-going needs assessment 
at a local level 
14: BBV testing and vaccination for IEP clients IEP services should encourage clients to be tested annually 
for HCV. In addition, wherever possible, all IEP services 
should make available vaccination and testing on-site 
15: Improving integration between IEP services and other 
services 
All IEP services should be able to signpost or formally 
refer clients to treatment for drug misuse. In addition, IEP 
services should be able to signpost or formally refer clients 
to other broader health and social support services 
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Table 1-6 (continued).  
16: Ensuring the safe disposal of used injecting equipment As part of wider risk assessment procedures, NHS Boards 
should ensure that all services in their area have robust 
policies and procedures in place in relation to the safe 
disposal of used injecting equipment 
17: Hepatitis B vaccination for staff  NHS Boards should work together with employers to 
facilitate vaccination for Hepatitis B, free of charge, for all 
staff who are responsible for delivering an IEP service 
This table has been adapted from the Scottish National Injecting Equipment Provision Guidelines 
(Scottish Government, 2010). 
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2 Evidence for the effectiveness of sterile 
injecting equipment provision and opioid 
substitution treatment in preventing HCV 
transmission among people who inject drugs: a 
review of reviews 
2.1 Background 
This chapter aims to address the first objective of the thesis, which is to review the 
international literature on the effectiveness of IEP and OST in preventing HCV 
transmission among PWID. This chapter forms part of a larger piece of work that 
examined other harm reduction interventions, in addition to IEP and OST: 
information/education/counselling and outreach; knowledge of HCV status; HCV antiviral 
treatment; use of drug consumption rooms; promotion of non-injecting routes of drug 
administration; structural interventions; and provision of bleach for disinfection of 
needles/syringes (Palmateer et al., 2009). This larger review also considered evidence for 
the impact of interventions in specific settings (prisons), and in specific populations (young 
PWID), and considered the cost-effectiveness of interventions. The section set out below 
(2.2) relates solely to IEP interventions. As detailed in the Author’s Declaration, because 
another individual contributed substantially to the section on OST, it is included as an 
appendix (Appendix A). The latter is summarised in section 2.3. The remaining 
interventions are outwith the scope of this thesis and are therefore not included. 
2.2 Injecting equipment provision  
2.2.1 Introduction  
Since the inception of ‘needle exchanges’ in resource-rich countries, numerous studies of 
their impact on BBVs have been undertaken. As a result, there is an ample body of 
literature consisting not only of primary studies, but also of reviews. Therefore, rather than 
a review of the primary literature, this chapter presents a review of the secondary literature, 
i.e. a ‘review of reviews’4. This approach – developed as a response to the increasing 
number of reviews of effectiveness of public health interventions in the literature (Kelly et 
                                                 
4
 It is recognised that this methodological area has been further developed since the work for this 
chapter was undertaken and this type of meta-review is now called an ‘overview of reviews’. 
Recent developments in the methodology and updated results are discussed in section 2.4.  
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al., 2002) – provides a more efficient way of summarising the body of evidence for an 
intervention.  
IEP services potentially comprise a range of separate interventions and were thus divided 
into the following categories based on the setting and items provided: fixed-site specialist 
NSP, alternative modes of NSP (pharmacies, vending machines and outreach) and the 
provision of (non-needle/syringe) injecting paraphernalia. Although the main outcome of 
interest was HCV, the scope was widened to include HIV and injecting risk behaviour 
(IRB). These additional outcomes were included because (i) it was hypothesised that there 
would be a potential paucity of studies looking at HCV specifically, (ii) there are notable 
parallels between HIV and HCV in that both are transmitted via blood-to-blood contact 
and both have had high prevalence rates recorded among populations of PWID and (iii) 
IRB is on the ‘causal pathway’ between the interventions and outcomes (i.e. a reduction in 
IRB needs to be achieved in order to affect BBV transmission). An additional objective of 
this chapter was to identify gaps and inconsistencies in the evidence base to inform further 
analysis. 
2.2.2 Methods 
2.2.2.1 Inclusion and exclusion criteria 
Systematic reviews, syntheses, or meta-analyses looking at the effectiveness of injecting 
equipment interventions in relation to the prevention of HCV, HIV, or IRB among PWID 
were considered for inclusion. The relevant interventions were: (i) NSP, (ii) alternative 
modes of NSP via pharmacies, vending machines, or outreach and (iii) the provision of 
sterile injecting paraphernalia. The outcomes considered were HCV prevalence or 
incidence, HIV prevalence or incidence and self-reported IRB. IRB was considered to 
include the borrowing, lending, or reuse of needles/syringes or paraphernalia. Papers that 
only considered the sexual transmission of HCV or HIV were excluded, as were papers 
that did not report their literature review methods. The literature search was limited to 
English language reviews only. 
2.2.2.2 Search strategy 
The following electronic databases were searched: CINAHL, Cochrane Library, EMBASE, 
IBSS, MEDLINE and PsycINFO; the search terms used are presented in Appendix B. The 
publications of key international agencies were also searched: the European Monitoring 
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Centre on Drugs and Drug Addiction, the National Institute on Drug Abuse, the US 
Institute of Medicine, the United Nations Office on Drugs and Crime Prevention and the 
World Health Organization. All databases were searched from 1980 to March 2007, with 
the exception of CINAHL, which was searched from 1982 to March 2007.  
At the screening stage it became apparent that the relevant reviews from the 1980s and 
1990s had been superseded by more recent reviews; consequently, the period was 
restricted to 2000 onwards. The reviews that were published earlier than 2000 were 
checked to see whether their exclusion would influence the findings. There were eight 
review papers excluded because they were published earlier than 2000 (Brettle, 1991; Des 
Jarlais and Friedman, 1998; Friedman and Des Jarlais, 1991; Heimer, 1998; Paone et al., 
1995; Vlahov and Junge, 1998; Watters, 1996; Wong, 1995), which were revisited and 
examined for references relating to the interventions and outcomes of interest. From these 
eight reviews, 23 relevant published primary papers were identified. Eighteen (Bruneau et 
al., 1997; Des Jarlais et al., 1994; Des Jarlais et al., 1995; Des Jarlais et al., 1996; 
Donoghoe et al., 1989; Groseclose et al., 1995; Hagan et al., 1991; Hagan et al., 1995; Hart 
et al., 1989; Hartgers et al., 1989; Heimer et al., 1993; Hurley, Jolley, and Kaldor, 1997; 
Kaplan, 1994; Kaplan and Heimer, 1994; Ljungberg et al., 1991; Strathdee et al., 1997; van 
Ameijden et al., 1992; Watters et al., 1994) out of the 23 papers were covered by the post-
2000 reviews that were ultimately selected (including three that duplicated data from 
papers that were covered). Of the remaining five, four would not have been relevant for 
various reasons: one was related to methadone treatment (Metzger et al., 1993); one was a 
mathematical modelling study (Lurie and Drucker, 1997); one was a statistical 
methodology paper (Kaplan and Heimer, 1992b); and for one, the full text was unable to 
be retrieved (Wodak and Gold, 1986). The one missed article related to HIV as an outcome 
and would not have changed the conclusions (Des Jarlais et al., 1998). 
2.2.2.3 Review selection  
The identified abstracts were screened and evaluated by two reviewers to determine 
whether the paper met the inclusion criteria. If there was disagreement between the two 
reviewers regarding the relevance of an abstract, the full paper was retrieved for further 
evaluation. The two reviewers independently screened the full papers to determine 
eligibility for inclusion; in the event of lack of concordance, a decision was reached by 
discussing the points of disagreement.  
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2.2.2.4 Critical appraisal 
The selected reviews were critically appraised using a tool based on that developed by the 
Health Development Agency (Table 2-1), which considers the strength of the methods 
used to identify the relevant literature, the appraisal of the primary literature, the quality of 
methodological analysis (in the case of meta-analyses) and the appropriateness of the 
conclusions (Kelly et al., 2002). The papers were then categorised as one of the following: 
(i) to be included as data where the whole of the review is judged to be of high quality; (ii) 
to be included as data where only part of the review is judged to be of high quality; or (iii) 
to be included only as potential background or contextual material (Kelly et al., 2002). 
Papers categorised as (i) or (ii) were included as high-quality (‘core’) reviews and the 
remaining papers were retained as ‘supplementary’ reviews, not considered to be of 
sufficient quality to rely on the authors’ conclusions but viewed as potentially providing 
complementary information on the effectiveness of the interventions. Meta-analyses were 
not necessarily assigned a higher score than other types of reviews; reviews had to satisfy 
the majority of the critical appraisal criteria in order to be classed as a core review. 
2.2.2.5 Data extraction and synthesis 
From each review, information was extracted on the reviewers’ assessment of the evidence 
and the number, design and findings of relevant primary studies. Information on primary 
studies was extracted from the reviews; in the case where reviews reported discrepant 
study findings, the primary studies were consulted.  
The level of evidence in support of (or discounting) the effect of an intervention was 
classified as: ‘sufficient’; ‘tentative’; ‘insufficient’; or ‘no’ evidence from reviews. These 
were derived using a framework (Table 2-2) based on the quality of the reviews, the 
reviewers’ conclusions and the designs/findings of the primary studies included in the 
reviews (Ellis et al., 2003). With regard to study design, a summary of the typical 
epidemiological study designs and the ‘weight of evidence’ that was attributed to them, for 
the purposes of this review of reviews, is presented in Table 2-3. While RCTs were 
considered to be the most robust study design, longitudinal cohort and case-control designs 
were considered to be less robust, whereas ecological, serial cross-sectional and cross-
sectional designs were considered to the weakest. While it is recognised that the potential 
to make inferences about cause-effect relationships in case-control studies is the same as in 
cross-sectional analysis if the outcome is prevalent cases of disease, the case-control 
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studies included in the evidence base were verified and all found to examine incident cases 
of disease (thus the outcome can be assumed to have followed the exposure in time). 
2.2.3 Results 
The literature search generated 1083 references after exclusion of duplicates (Figure 2-1). 
Abstracts were reviewed and 976 were excluded, leaving 43 papers related to injecting 
equipment interventions to be screened. Full screening eliminated a further 25, leaving 18 
for critical appraisal. Of the 18 papers, three were judged to be core reviews and the 
remainder were retained as supplementary reviews. Five (three core and two 
supplementary) were drawn upon for evidence (Table 2-4). A critical appraisal summary 
for the supplementary reviews not included in the evidence base is given in Appendix C.  
The findings of the reviews (and primary studies) are presented below (and in Table 2-5) 
for each intervention and outcome. With regard to the results of primary studies, a 
‘positive’ finding refers to an observed reduction in the stated outcome (e.g. HCV 
prevalence) associated with the intervention, a ‘negative’ finding refers to an increase in 
the outcome associated with the intervention and ‘no association’ refers to no statistically 
significant association between the outcome and intervention. Where a review reported a 
study finding as positive or negative, it was assumed that the result was statistically 
significant at the 5% level even if this was not explicitly stated; where a review reported 
‘no association’, it was assumed that this indicated a non-statistically significant result. 
2.2.3.1 Needle and syringe provision  
2.2.3.1.1 Effects on HCV Incidence/Prevalence 
Three core reviews (Gibson, Flynn, and Perales, 2001; Tilson et al., 2007; Wodak and 
Cooney, 2004) and one supplementary review (Wright and Tompkins, 2006) considered 
the impact of NSP on HCV incidence or prevalence. The core reviews primarily focused 
on HIV outcomes and, therefore, may not have identified all of the relevant HCV-related 
literature: Wodak and Cooney referred to only one HCV study (Hagan et al., 1995), Tilson 
et al. identified six (Des Jarlais et al., 2005b; Hagan et al., 1995; Hagan and Thiede, 2000; 
Mansson et al., 2000; Sarkar et al., 2003; Taylor et al., 2000) and Gibson et al. included 
three (Hagan et al., 1995; Hagan et al., 1999; Lamden et al., 1998). None of these reviews 
examined HCV in any depth, and only Tilson et al. drew conclusions, stating there was 
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moderate evidence that “HIV prevention programs that include NSP” have less of an 
impact on HCV transmission than on HIV transmission. 
The three core reviews covered seven primary studies between them and the 
supplementary review, which focused exclusively on HCV outcomes, included an 
additional nine relevant papers (Goldberg et al., 2001; Goldberg, Cameron, and 
McMenamin, 1998; Hernandez-Aguado et al., 2001; Hutchinson et al., 2002; MacDonald 
et al., 2000; Patrick et al., 2001; Smyth, Keenan, and O'Connor, 1999; Somaini et al., 
2000; van Ameijden et al., 1993), although three of them present duplicate data (Goldberg 
et al., 2001; Goldberg, Cameron, and McMenamin, 1998; Hutchinson et al., 2002) (Table 
2-6). There were seven primary studies with positive findings, but these mainly involved 
weaker designs. The stronger study designs (cohorts) mainly showed either no association 
or negative findings between NSP and HCV seroconversion. Given an absence of clear 
statements from the core reviews, and inconsistent evidence from the primary studies 
identified by the reviews, it was concluded that the level of evidence is insufficient (Table 
2-5). 
2.2.3.1.2 Effects on HIV Incidence/Prevalence 
Three core reviews examined HIV prevalence/incidence, covering 16 primary studies 
between them. The findings of these studies are summarised in Table 2-7. Tilson et al. 
identified four prospective cohort studies (Bruneau et al., 1997; Mansson et al., 2000; 
Schechter et al., 1999; Strathdee et al., 1997), two case-control studies (Patrick et al., 1997; 
van Ameijden et al., 1992), three ecological studies (Des Jarlais et al., 2005b; Hurley, 
Jolley, and Kaldor, 1997; MacDonald et al., 2003) and two serial cross-sectional studies 
(Des Jarlais et al., 2005a; Hammett et al., 2006); others (Coutinho, 2005; Des Jarlais et al., 
1995) that did not form part of their evidence base, were also included in their discussion. 
They highlighted the findings of two prospective cohort studies conducted in Montreal and 
Vancouver (Bruneau et al., 1997; Strathdee et al., 1997) that reported higher incidence of 
HIV seroconversion among needle exchange attenders, but acknowledged that a number of 
factors could have contributed to, or accounted for, these results, including: that high-risk 
individuals are more likely to use needle exchange (selection bias) and the availability of 
clean injecting equipment through sources other than needle exchange (dilution bias). They 
also made reference to four ecological studies demonstrating declining HIV 
prevalence/incidence in the context of needle/syringe programme provision or expansion 
(Des Jarlais et al., 1995; Des Jarlais et al., 2005b; Hurley, Jolley, and Kaldor, 1997; 
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MacDonald et al., 2003). Tilson et al. concluded that “the evidence of the effectiveness of 
NSE [needle and syringe exchange] in reducing HIV prevalence is considered modest, 
based on the weakness of these study designs.”  
Wodak and Cooney stated “there is compelling evidence that increasing the availability 
and utilization of sterile injecting equipment by IDU [injecting drug users] reduces HIV 
infection substantially.” This review, however, did not consider separately the effects of 
NSP on HIV transmission vs. IRB: possibly, the evidence of effectiveness of NSP in 
reducing IRB had a bearing on conclusions drawn with respect to HIV. Of the 38 studies 
they reviewed, 10 were relevant to HIV (Bruneau et al., 1997; Des Jarlais et al., 1996; 
Heimer et al., 1993; Hurley, Jolley, and Kaldor, 1997; Ljungberg et al., 1991; MacDonald 
et al., 2003; Monterroso et al., 2000; Patrick et al., 1997; Schechter et al., 1999; Strathdee 
et al., 1997); five had positive findings (Des Jarlais et al., 1996; Heimer et al., 1993; 
Hurley, Jolley, and Kaldor, 1997; Ljungberg et al., 1991; MacDonald et al., 2003), two had 
negative findings (Bruneau et al., 1997; Strathdee et al., 1997) and three did not find an 
association (Monterroso et al., 2000; Patrick et al., 1997; Schechter et al., 1999). Four of 
the five positive findings were generated by studies with weaker designs (Heimer et al., 
1993; Hurley, Jolley, and Kaldor, 1997; Ljungberg et al., 1991; MacDonald et al., 2003).  
Gibson et al. reviewed studies published up until 1999; all were covered in the later 
reviews discussed above. Particular consideration of potential bias was given for the 
studies with negative results, but not for those with protective findings. They concluded 
that there is “substantial evidence that syringe exchange programs are effective in 
preventing HIV risk behaviour and HIV seroconversion among IDU [injecting drug 
users]”. However, as above, their conclusions were apparently inconsistent with the HIV 
studies reviewed: two studies showed an increased risk of HIV infection associated with 
NSP (Bruneau et al., 1997; Strathdee et al., 1997), one showed a protective effect of NSP 
(Des Jarlais et al., 1996) and three showed no association (Patrick et al., 1997; Schechter et 
al., 1999; van Ameijden et al., 1992).  
Reflecting on the findings of the primary studies (Table 2-5; Table 2-7), the most rigorous 
(cohort and case-control) provided conflicting evidence. The conclusions of Tilson et al. 
are consistent with the equivocal results from cohort and case-control studies; furthermore, 
this review undertook the most rigorous evaluation of the primary studies and was the only 
review to consider HIV incidence/prevalence as a separate outcome. Thus, on the basis of a 
tentative statement from one core review, supported by consistent evidence from less 
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robust primary studies, it was concluded that there is tentative review-level evidence to 
support the effectiveness of NSP in reducing HIV transmission. 
2.2.3.1.3 Effects on self-reported injecting risk behaviour 
Self-reported IRB has been studied more frequently than biological outcomes (HCV and 
HIV), and this is reflected in the numbers of primary studies (43 in total) identified by the 
three core reviews (Table 2-8).  
Tilson et al. identified 25 studies (Bluthenthal et al., 2000; Cox et al., 2000; Des Jarlais et 
al., 2000; Gibson et al., 2002; Hagan et al., 1993; Hagan and Thiede, 2000; Hammett et al., 
2006; Hart et al., 1989; Hartgers et al., 1992; Huo et al., 2005; Keene et al., 1993; Klee et 
al., 1991; Longshore, Bluthenthal, and Stein, 2001; Monterroso et al., 2000; Ouellet, Huo, 
and Bailey, 2004; Schoenbaum, Hartel, and Gourevitch, 1996; van Ameijden and 
Coutinho, 1998; van Ameijden, van den Hoek, and Coutinho, 1994; van den Hoek, van 
Haastrecht, and Coutinho, 1989; Vazirian et al., 2005; Vertefeuille et al., 2000; Vlahov et 
al., 1997; Watters et al., 1994; Wood et al., 2002; Wood et al., 2003), 14 of which were 
longitudinal cohorts, and demonstrated reductions in self-reported needle-sharing (lending 
or borrowing needles/syringes) (Bluthenthal et al., 2000; Cox et al., 2000; Gibson et al., 
2002; Hagan and Thiede, 2000; Hart et al., 1989; Huo et al., 2005; Monterroso et al., 2000; 
Ouellet, Huo, and Bailey, 2004; Schoenbaum, Hartel, and Gourevitch, 1996; van Ameijden 
and Coutinho, 1998; van den Hoek, van Haastrecht, and Coutinho, 1989; Vertefeuille et 
al., 2000; Vlahov et al., 1997; Wood et al., 2002). They concluded that there was moderate 
evidence to show that “multi-component HIV prevention programs that include needle and 
syringe exchange” are associated with a reduction in self-reported sharing of needles and 
syringes. 
Wodak and Cooney identified 28 primary studies of IRB (needle/syringe borrowing, 
lending, or reuse); among these, there were 24 positive (Bluthenthal et al., 1998; 
Bluthenthal et al., 2000; Cox et al., 2000; Des Jarlais et al., 1994; Donoghoe et al., 1989; 
Frischer and Elliott, 1993; Gibson et al., 2002; Gleghorn, Wright-De Aguero, and Flynn, 
1998; Guydish et al., 1995; Guydish et al., 1998; Hartgers et al., 1989; Heimer et al., 1998; 
Keene et al., 1993; Monterroso et al., 2000; Oliver et al., 1994; Paone et al., 1994; Peak et 
al., 1995; Power and Nozhkina, 2002; Schoenbaum, Hartel, and Gourevitch, 1996; Singer 
et al., 1997; van Ameijden and Coutinho, 1998; van Ameijden, van den Hoek, and 
Coutinho, 1994; Vlahov et al., 1997; Watters et al., 1994), one negative (Klee et al., 1991), 
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one indeterminate result (Klee and Morris, 1995) and two showing no association 
(Donoghoe, Dolan, and Stimson, 1992; Hartgers et al., 1992). The reviewers did not 
formulate any conclusions specifically regarding IRB. 
The 23 studies identified by Gibson et al. were covered by the other two core reviews 
(Bluthenthal et al., 1998; Des Jarlais et al., 1994; Donoghoe et al., 1989; Donoghoe, Dolan, 
and Stimson, 1992; Frischer and Elliott, 1993; Guydish et al., 1995; Guydish et al., 1998; 
Hartgers et al., 1989; Hartgers et al., 1992; Keene et al., 1993; Klee et al., 1991; Klee and 
Morris, 1995; Oliver et al., 1994; Paone et al., 1994; Peak et al., 1995; Schoenbaum, 
Hartel, and Gourevitch, 1996; Singer et al., 1997; van Ameijden and Coutinho, 1998; van 
Ameijden, van den Hoek, and Coutinho, 1994; Vlahov et al., 1997; Watters et al., 1994), 
with the exception of two (Broadhead, van Hulst, and Heckathorn, 1999); (Hagan, Des 
Jarlais, and Friedman, 1994). Both studies were suggestive of a protective effect of NSP: 
Broadhead, van Hulst, and Heckathorn (1999) noted an increase in the reported reuse and 
sharing of syringes after the closure of a needle exchange, and Hagan, Des Jarlais, and 
Friedman (1994) observed a decline in the proportion borrowing used syringes among 
needle exchange attendees (pre vs. post-intervention comparison). The authors concluded 
that there is substantial evidence that NSP is effective in preventing HIV risk behaviour 
among PWID. 
Table 2-5 lists the types of studies included within the three core reviews: out of 43 
studies, 39 were positive and 20 of these were cohort studies. Thus, based on consistent 
evidence across multiple robust studies, as well as moderate to strong statements of 
evidence in support of an effect of NSP on IRB from two core reviews, it was concluded 
that there is sufficient review-level evidence to support the effectiveness of NSP in 
reducing self-reported IRB.  
2.2.3.2 Pharmacy access to needles/syringes 
2.2.3.2.1 Effects on HCV Incidence/Prevalence 
No reviews were identified that examined the effects of pharmacy access to 
needles/syringes on HCV incidence or prevalence.  
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2.2.3.2.2 Effects on HIV Incidence/Prevalence 
One core review examined the effectiveness of pharmacy access to needles/syringes in 
reducing HIV prevalence (Wodak and Cooney, 2004): two relevant studies were identified 
(Table 2-9). The first, a serial cross-sectional study conducted in the UK, observed declines 
in HIV prevalence coinciding with a period of increased access to needles/syringes through 
pharmacies and needle exchanges (Hunter et al., 1995). The second, a cross-sectional 
survey, found a lower HIV prevalence in diabetic PWID, who had ready access to sterile 
syringes through pharmacies, compared with non-diabetic PWID (Nelson et al., 1991). 
They also referred to two studies as evidence of “replication of findings”: Des Jarlais et al. 
(1995) found that pharmacy exchange was a common characteristic of cities that had 
maintained HIV prevalence rates of less than 5% over the previous five years, and De 
Jong, Tsagarelli, and Schouten (1999) observed a low HIV infection rate in Georgia, where 
syringes were readily available in pharmacies.  
Wodak and Cooney concluded that “there is reasonable evidence that pharmacy 
availability of sterile injecting equipment does provide specific benefits in addition to those 
derived from NSPs.” Despite a tentative statement of effectiveness from a core review, the 
evidence is based on a small number of primary studies with weak designs, and was 
therefore considered to be insufficient.  
2.2.3.2.3 Effects on self-reported injecting risk behaviour 
Tilson et al. and Wodak and Cooney examined seven studies of the effects of pharmacy 
access to needles/syringes on IRB (Table 2-10). Tilson et al. identified two studies (both 
serial cross-sectional) that compared IRB before and after liberalisation of the laws 
permitting syringe sale from pharmacies in New York and Connecticut (Groseclose et al., 
1995; Pouget et al., 2005): both found that reports of syringe-sharing among PWID 
declined. The authors concluded: “…A few studies have examined the impact on drug-
related HIV risk, and found suggestive evidence of a reduction.” Wodak and Cooney 
reported the results of a further five cross-sectional studies (Calsyn et al., 1991; Gleghorn 
et al., 1995; Ingold and Ingold, 1989; Nelson et al., 1991; Richard, Mosier, and Atkinson, 
2002): all findings were positive. Given consistent evidence from less robust studies 
identified within two core reviews, it was concluded that the level of evidence is tentative. 
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2.2.3.3 Needle/syringe vending machines 
2.2.3.3.1 Effects on HCV Incidence/Prevalence  
No reviews were identified that examined the effects of vending machines on HCV 
transmission.  
2.2.3.3.2 Effects on HIV Incidence/Prevalence 
One core review (Wodak and Cooney, 2004) reported the results of a cross-sectional study 
of PWID (Obadia et al., 1999), which found that primary users of vending machines were 
less likely to be HIV positive, although this was not significant after adjustment. Although 
the authors stated that “access to sterile needles and syringes from community pharmacies 
and syringe vending machines was shown in all nine studies to be effective in reducing risk 
behaviour and HIV seroprevalence”, this conclusion was based on one study of vending 
machines with a weak design and it was therefore concluded that there was insufficient 
evidence.  
2.2.3.3.3 Effects on self-reported injecting risk behaviour 
Tilson et al. and Wodak and Cooney both mentioned a cross-sectional pilot study of 
vending machines in a German prison (Heinemann and Gross, 2001), although their 
reporting of the study results differs. Wodak and Cooney reported that significant 
decreases in needle-sharing subsequent to the introduction of the programme were found, 
whereas Tilson et al. stated that this study showed that PWID will use vending machines as 
a source of sterile needles/syringes. Other studies discussed by these reviews looked at the 
characteristics of vending machine users and the acceptability of machines. Tilson et al. 
concluded that there was insufficient evidence of the effectiveness of vending machines in 
reducing HIV risk; the conclusions of Wodak and Cooney are as above, for HIV.  
A supplementary review, published after the date the literature search was undertaken, was 
identified (Islam and Conigrave, 2007). This review cited a paper summarising experiences 
with vending machines in prison (Stover and Nelles, 2003): the reviewers stated that 
machines in Germany and Switzerland reduced syringe-sharing significantly, although the 
study designs were not reported. 
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Given the above conflicting statements from the core reviews and the fact that that there is 
only one primary study with a weak design and insufficient detail regarding a second 
paper, it was concluded that there is insufficient evidence. 
2.2.3.4 Outreach needle/syringe provision 
2.2.3.4.1 Effects on HCV Incidence/Prevalence, HIV Incidence/Prevalence 
and self-reported injecting risk behaviour 
No reviews were identified that examined the effects of outreach needle/syringe provision 
in relation to any of the outcomes.  
2.2.3.5 Provision of sterile drug injecting paraphernalia 
2.2.3.5.1 Effects on HCV Incidence/Prevalence and HIV Incidence/prevalence 
No reviews were identified that examined injecting paraphernalia provision in relation to 
HCV or HIV outcomes. 
2.2.3.5.2 Effects on self-reported injecting risk behaviour 
Tilson et al. identified four relevant studies (Table 2-11): a cohort study (Ouellet, Huo, and 
Bailey, 2004) and a cross-sectional study (Longshore, Bluthenthal, and Stein, 2001) both 
found that the provision of paraphernalia was associated with declines in paraphernalia-
sharing, whereas two other cohort studies (Hagan and Thiede, 2000; Huo et al., 2005) 
found no association between use of needle exchange (which presumably provided 
paraphernalia, although this was not explicitly stated) and reductions in paraphernalia-
sharing. Given the lack of a statement of evidence from a core review, and inconsistent 
evidence from a small number of studies, it was concluded that the level of evidence is 
insufficient.  
2.2.4 Discussion 
There was insufficient evidence from these reviews to conclude that NSP is effective in 
preventing HCV transmission among PWID. The body of evidence was slightly more 
robust in relation to HIV prevention (i.e. a larger number of studies and more with positive 
findings); however, discrepancies were noted between core reviews – in the studies they 
identified, their reports of study designs and findings and the conclusions they drew from 
their respective bodies of evidence – and it was possible only to conclude that the evidence 
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for the effectiveness of NSP in preventing HIV transmission is tentative. Another finding 
of this review of reviews is that ecological studies have suggested more consistently a 
positive impact of NSP on HCV and HIV than individual-level observational studies. In 
contrast to the findings pertaining to biological outcomes (HCV and HIV), there was 
sufficient evidence to demonstrate that NSP is effective in reducing self-reported IRB. 
There was also tentative evidence to suggest that pharmacy provision, in addition to 
dedicated NSP, is effective in reducing such behaviour. With regard to the remaining 
interventions (vending machines, outreach NSP, provision of injecting paraphernalia), 
there was no or insufficient review-level evidence either to support or to discount their 
effectiveness in relation to any of the outcomes.  
The findings highlight an absence of reviews that have been undertaken for many of the 
interventions considered here; for some (vending machines, outreach, provision of 
injecting paraphernalia), this probably reflects a lack of primary studies. For NSP and 
HCV, no high quality (core) reviews have addressed this association specifically, although 
at least 14 studies had been published to December 2002. For NSP and HIV, at least 16 
primary studies examined this association, but previous reviews (Gibson, Flynn, and 
Perales, 2001; Wodak and Cooney, 2004) seem to have overstated the evidence in their 
assessment of these studies (Amundsen, 2007). In general, reviews gave more 
consideration to issues of bias and limitations in studies with negative findings than in 
studies with positive (protective) findings, and thus may have ascribed less importance to 
negative findings when synthesising the evidence. 
It is important, however, to emphasise that the conclusions of insufficient/tentative 
evidence do not equate to evidence for lack of effectiveness for these interventions: these 
findings may, in part, be attributable to limitations of the primary studies. One of the 
criticisms of studies investigating NSP effectiveness in preventing BBVs is that they do 
not measure accurately the coverage or intensity of the intervention delivered (i.e. the 
amount of injecting equipment distributed) (Lurie, 1997). Many of the NSP sites studied 
had strict limits on the numbers of needles/syringes that could be distributed at any one 
visit and, therefore, were likely not providing adequate amounts for clients’ needs. Thus, 
residual sharing, even among PWID who access NSP sites regularly, is likely to occur. 
Modelling studies have predicted reductions in HIV and HCV as NSP coverage is 
increased or as IRB decreases (Kretzschmar and Wiessing, 1998; Vickerman, Hickman, 
and Judd, 2007); however, the optimal level of coverage required to reduce HIV and HCV 
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transmission is unknown and will depend on the local context, including the baseline 
prevalence of HCV/HIV, levels of IRB and injecting networks.  
Further consideration of the limitations of the primary studies helps to explain the finding 
of a discrepancy between the results of ecological studies and individual-level studies 
(cohort and case-control). Individual-level, non-randomised studies of PWID are difficult 
to design and execute, and thus highly susceptible to bias. In cohort studies, for example, 
two groups, such as NSP site attenders and non-attenders, are usually compared with 
respect to the outcome. This measurement of the exposure to the intervention has generally 
been limited because: (i) these groups are ‘self-selecting’ and thus may be inherently 
different with respect to characteristics, including injecting risk, that can influence the 
outcome (Lurie, 1997) and (ii) the distinction between exposed and unexposed groups is 
often inadequate (for example, unexposed individuals may have access to clean 
needles/syringes from other sources or exposed individuals may still be engaging in 
injecting risk despite high uptake of NSP), potentially diluting the effect size (Gibson, 
Flynn, and Perales, 2001). Ecological studies, by contrast, are more likely to report a 
positive association: because one cannot isolate the effects of a single intervention nor 
control for confounding factors in an ecological study, such studies may in fact be 
measuring the impact of several interventions and/or other factors. This is consistent with a 
recent study that found no independent effect of either NSP or methadone maintenance 
treatment, but that those participating in both services had a reduced incidence of HIV and 
HCV (Van Den Berg et al., 2007).  
All of the evidence for NSP effectiveness is based on observational study designs, i.e. 
exposure to NSP has not been randomised. Observational studies, as discussed above, are 
generally at risk of confounding and selection bias. However, it is logistically and ethically 
difficult to conduct a randomised trial for interventions such as NSP, which have face 
validity and have already been widely introduced (Lurie, 1997). It has been suggested that 
community randomised trials, comparing a basic package of services with an enhanced 
package, are a feasible alternative study design. These trials would randomise participants 
on a group basis, rather than an individual basis, thereby avoiding some of the biases 
associated with observational designs (Tilson et al., 2007).  
Another methodological issue is that the primary studies might not have been adequately 
powered to detect an impact of NSP. Few of the reviews addressed this issue in their 
reporting of the studies and, therefore, it was usually unclear whether equivocal findings 
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were due to a lack of power or truly represented no association. Others (Bastos and 
Strathdee, 2000) have suggested reasons why evaluations of NSP have not been 
conclusive, contending that evaluations have not taken into account the numerous 
contextual factors, for example, NSP infrastructure and policies and local environmental 
conditions, that may influence their effectiveness.  
The reliance on self-reported risk behaviour is a problem for epidemiological studies 
examining the effectiveness of harm reduction interventions. Although it has been 
suggested that self-reported behaviour by heroin users and PWID can be reliable (Darke, 
1998; Goldstein et al., 1995), it is uncertain whether this reliability applies to all 
behaviours. Limitations of self-reported injecting risk may explain the finding of greater 
strength of evidence for behavioural measures than for biological measures. First, 
differential reporting of risk behaviour between exposed and unexposed groups could bias 
measures of the effectiveness of NSP; for example, if PWID exposed to NSP are more 
sensitised to the risks of sharing and more reluctant to report this behaviour than 
unexposed individuals. Secondly, some modelling studies (Vickerman et al., 2006) have 
suggested that the association between IRB and HIV/HCV transmission does not follow a 
dose-response relationship; rather, a reduction in injecting risk has to surpass a threshold 
level before changes in HIV/HCV transmission are observed. Consequently, a change in 
IRB may have no impact on HIV/HCV incidence, thereby limiting the usefulness of IRB 
as a proxy measure for the effectiveness of an intervention.  
A limitation of the review of reviews methodology is that it is unknown whether gaps in 
the evidence might be filled by recent primary research. To verify this, a search of the 
primary English language literature was undertaken, which identified several recent cohort 
studies of NSP and HCV/HIV (Hagan, Thiede, and Des Jarlais, 2004; Roy et al., 2007a; 
Van Den Berg et al., 2007; Wood et al., 2007). Although these studies generally presented 
improvements upon previous research in terms of larger sample sizes, careful adjustment 
for potential confounders and improved measurements of NSP uptake, none found an 
independent effect of NSP on HCV or HIV seroconversion. The conclusions drawn here 
are supported by a more recent review undertaken for the National Institute for Health and 
Care Excellence (Jones et al., 2008).  
Another limitation of the methodology is the reliance on the reviewers’ accounts of the 
designs and findings of the primary studies. In considering the primary evidence, study 
design was used as a proxy for study quality; however, other factors – for example, sample 
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size and recruitment strategy – affect the integrity of a study’s results. The likelihood of 
having missed primary studies is a possibility for HCV, which the core reviews did not set 
out specifically to examine. To compensate for this, the studies identified by a 
supplementary review that focused on HCV as an outcome were included. With regard to 
HIV and IRB, three core reviews examined these outcomes as their primary objective and, 
given the large number of studies identified for each outcome and the large overlap 
between the studies identified by each review, it is likely that the key primary studies for 
the years searched have been captured. 
Countries face a challenge in reducing, or maintaining low, prevalence of BBVs among 
PWID and good quality research is fundamental to formulating policy on the development 
of public health interventions. The findings of this review do not justify closing or 
hindering the introduction of NSP, given that the evidence remains strong regarding self-
reported IRB and given that there is no evidence of negative consequences from the 
reviews examined here. A step change in evaluations of harm reduction interventions is 
recommended so that future evaluations: (i) focus on biological outcomes rather than 
behavioural outcomes and are powered to detect changes in HCV incidence; (ii) consider 
complete packages of harm reduction interventions rather than single interventions; (iii) 
are randomised where possible (preferably at the community level); and (iv) compare 
additional interventions or increased coverage/intensity of interventions with current 
availability. 
2.3 Opioid substitution treatment  
2.3.1 Summary of findings with regard to HCV, HIV and IRB 
The extended version of this section can be found in Appendix A. Three core reviews 
(Gowing et al., 2004; Sorensen and Copeland, 2000; Tilson et al., 2007) and one 
supplementary review (Wright and Tompkins, 2006) that examined OST and any of the 
outcomes were identified.  
The relationship between OST and HCV was examined by only one supplementary review 
(Wright and Tompkins, 2006). Of the five studies identified by that review (four cohort, 
one nested case-control), all had neutral findings (i.e. none found any statistically 
significant difference in the risk of HCV among those who were receiving OST vs. those 
who were not, nor observed declines in HCV over time associated with OST) although the 
definition of OST varied between studies (Crofts et al., 1997; Rezza et al., 1996; Selvey, 
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Denton, and Plant, 1997; Thiede, Hagan, and Murrill, 2000; van Ameijden et al., 1993). 
Since the Wright and Tompkins review was published, however, an additional six relevant 
cohort studies were identified (Craine et al., 2009; Dolan et al., 2003; Dolan et al., 2005; 
Hallinan et al., 2004; Maher et al., 2006; Miller et al., 2004), three of which found a lower 
incidence of HCV among those on uninterrupted or longer-term OST (Craine et al., 2009; 
Dolan et al., 2005; Miller et al., 2004). Nevertheless, a conclusion of insufficient evidence 
was arrived at, given the absence of a statement from a core review and the predominantly 
equivocal findings from a large number of robust studies: three positive findings all 
generated from cohort studies, but eight studies of various designs (one RCT, six cohort 
and one case-control) showing no association.  
The three core reviews (Gowing et al., 2004; Sorensen and Copeland, 2000; Tilson et al., 
2007) covered eight primary studies of the association between OST and HIV, consisting 
of two RCTs, four cohort studies, one case-control study and one cross-sectional study 
(Dolan et al., 2003; Hartel and Schoenbaum, 1998; Metzger et al., 1993; Moss et al., 1994; 
Novick et al., 1990; Rhoades et al., 1998; Serpelloni et al., 1994; Williams et al., 1992). 
Four of these studies found a positive association, i.e. a reduced risk of HIV infection 
associated with a higher dosage of, or continuous, OST. One retrospective study did not 
observe any HIV seroconversions in a cohort of patients on OST. The remaining two 
studies, both RCTs, did not find any HIV seroconversions in either of the treatment or 
control arms, but this was potentially due to a short follow-up period and low baseline 
prevalence of HIV. Thus, based on consistent evidence from multiple robust studies, as 
well as moderate to strong statements of evidence in support of an effect of OST from 
three core reviews, there was considered to be sufficient review-level evidence to support 
the effectiveness of OST in preventing HIV transmission. Nevertheless, it is of note that 
two of the reviews gave the following caution about the ‘self-selected’ samples: since 
participants were not randomly allocated to exposed (OST) and unexposed (no OST, 
discontinuous OST, or short-term OST) groups (with the exception of the RCTs), 
systematic differences between the groups – other than the exposure – may account for the 
differences in HIV seroconversion.  
With regard to studies of OST and IRB, the measurement of IRB in these studies could 
generally be classified into three categories: prevalence and frequency of injection, sharing 
of injecting equipment and scores of drug-related risk.  
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Twenty studies, of varying design, looked at self-reported prevalence and/or frequency of 
injecting and all found statistically significant decreases in these behaviours (Abbott et al., 
1998; Baker et al., 1995; Ball et al., 1988; Batki et al., 1989; Brooner et al., 1998; 
Camacho et al., 1996; Chatham et al., 1999; Dolan et al., 2003; Gossop et al., 2000; 
Greenfield, Bigelow, and Brooner, 1995; Iguchi, 1998; King et al., 2000; Kwiatkowski and 
Booth, 2001; Magura et al., 1991; Meandzija et al., 1994; Saxon, Calsyn, and Jackson, 
1994; Shore et al., 1996; Simpson et al., 1995; Stark et al., 1996b; Strang et al., 2000). The 
three reviews also presented 14 studies showing significant decreases in self-reported 
sharing of injecting equipment (Camacho et al., 1996; Caplehorn and Ross, 1995; Chatham 
et al., 1999; Dolan et al., 2003; Gossop et al., 2000; Greenfield, Bigelow, and Brooner, 
1995; Grella et al., 1996; Klee et al., 1991; Longshore et al., 1993; Magura et al., 1991; 
Margolin et al., 2003; Rhoades et al., 1998; Saxon, Calsyn, and Jackson, 1994; Stark et al., 
1996b) and three studies that found no difference (Baker et al., 1995; Calsyn et al., 1991; 
King et al., 2000). These study designs were a mix of pre- vs. post-OST comparisons, 
comparisons of treatment vs. non-treatment samples and longitudinal in-treatment samples 
comparing retention in OST vs. drop-out. 
Finally, five studies (Abbott et al., 1998; Avants et al., 1998; Baker et al., 1995; Chatham 
et al., 1999; Sees et al., 2000) examined drug-related HIV risk behaviour scores using 
various validated tools: three found significant decreases in the scores before and after 
OST, one found a non-significant reduction in risk scores between a methadone 
maintenance and methadone detoxification group and one found reduced risk scores in a 
cohort of individuals currently receiving OST, as opposed to those who were previously or 
never on OST.  
The conclusions of the reviews, based on evidence from one RCT and numerous 
observational studies, led to the statement that the evidence was sufficient to support the 
effectiveness of OST in reducing injecting frequency, the sharing of injecting equipment 
and injecting risk scores. 
2.3.2 Discussion 
The evidence from reviews was insufficient to conclude that OST has an impact in 
reducing HCV incidence; however, there was sufficient review-level evidence that OST is 
effective in reducing HIV incidence and self-reported IRB. The findings for OST thus echo 
those for IEP: limited evidence for an impact on HCV, more evidence for an impact on 
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HIV and the most evidence for an impact on IRB (with regard to the conclusions of the 
reviews and the number and robustness of studies).  
As with IEP, a conclusion of insufficient or tentative evidence (in this case, in relation to 
HCV) does not necessarily equate to evidence for lack of effectiveness, as the strength of 
evidence is highly correlated with aspects of study quality. The early studies of the 
association between OST and HCV – which tended to have short follow-up times and 
‘crude’ definitions of OST – did not provide evidence for an impact. By contrast, later 
studies, which included improved classification of exposure groups – based on dosage, 
continuity of treatment and length of treatment – mostly demonstrated reduced HCV 
incidence associated with OST uptake. Thus, the choice of outcome measure used can 
greatly affect the findings.  
Although the studies of OST discussed here have also been mostly observational, five 
RCTs were undertaken: one examining HIV (Dolan et al., 2003), one examining HIV and 
IRB (Rhoades et al., 1998) and three examining IRB (Avants et al., 1998; Margolin et al., 
2003; Strang et al., 2000). All of the studies that looked at IRB as the outcome had positive 
findings, whereas the studies of HIV found no association. It is notable, however, that the 
latter two RCTs potentially did not allow sufficient follow-up time, or have enough 
participants, to observe any HIV seroconversions. 
As with IEP, there is greater strength of evidence for HIV, as compared with HCV. This is 
likely a result of two factors: (i) the smaller body of literature with respect to HCV and (ii) 
the different nature of the two viruses and their epidemics within injecting populations. 
Regarding the latter, the higher prevalence of HCV in many injecting populations, 
combined with its higher infectivity relative to HIV (Bell, 1997; Centers for Disease 
Control and Prevention, 1998), means that each sharing event carries a higher probability 
of HCV infection than HIV infection. Consequently, there is a need to achieve a greater 
reduction in IRB to reduce HCV transmission: the reduced levels of IRB detected in 
studies of IEP and OST may therefore translate into a reduction in HIV, but not HCV.  
Several of the reviews included here emphasise that it is often difficult to study the effects 
of a single intervention in isolation from other interventions that may have been delivered 
concurrently. This is a limiting feature of many of the study designs that have been used to 
investigate the effectiveness of harm reduction interventions, particularly ecological study 
designs. On the other hand, Tilson et al. (2007) stressed that particular harm reduction 
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interventions may be effective as components of an overall harm reduction programme, 
rather than alone. A study of the combined effects of OST and NSP, which found reduced 
incidence of HCV among those who reported uptake of both OST and NSP (but no 
significant effects of either intervention alone), provides support for this assertion (Van 
Den Berg et al., 2007).  
Given the parallels between the evidence bases for the effectiveness of IEP and OST, the 
same recommendations as stated in section 2.2.4 apply here: give preference to biological 
rather than behavioural outcomes, consider complete packages of harm reduction 
interventions rather than single interventions, randomise interventions where possible, and 
compare additional interventions or increased coverage/intensity of interventions with 
current availability. 
2.4 Update on review of reviews since original work was 
undertaken 
2.4.1 Updated findings 
As part of a separate programme of work, the review of reviews was updated to include 
reviews published through March 2011 (European Centre for Disease Prevention and 
Control and European Monitoring Centre for Drugs and Drug Addiction, 2011a; European 
Centre for Disease Prevention and Control and European Monitoring Centre for Drugs and 
Drug Addiction, 2011b; Macarthur et al., 2014). The changes in evidence statements 
between the original and the updated review of reviews, as well as details of the additional 
reviews and studies contributing to the evidence base, are presented in Table 2-12. Despite 
updating the evidence base by four years, only four evidence statements were changed as a 
result of the additional literature identified. In some cases (e.g. NSP and HCV, pharmacy 
NSP and HIV/IRB), additional evidence was insufficient to alter the original evidence 
statement. By contrast, the evidence statement for the effectiveness of outreach NSP with 
respect to HIV was upgraded from none to insufficient, as was the evidence statement for 
injecting paraphernalia with respect to HCV. Additionally, the evidence statement for the 
effectiveness of injecting paraphernalia with regard to IRB was upgraded from insufficient 
to tentative; as was the evidence for OST with regard to HCV. 
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2.4.2 Comment on methodology  
At the time of undertaking the original work for this chapter, there were relatively limited 
resources in development to guide a review of reviews process (Kelly et al., 2002) – 
particularly with respect to grading the reviews and synthesising the evidence to derive 
conclusions. Since then, the Cochrane Collaboration has developed guidance on this 
methodology, which is now referred to as an ‘overview of reviews’ (Becker and Oxman, 
2011). However, this methodology is primarily designed to provide overviews of Cochrane 
Intervention Reviews and would not necessarily have been a suitable methodology to apply 
here. The Cochrane Overview method does not specifically recommend a critical appraisal 
tool for assessing review quality but suggests that some checklists are available; however, 
these instruments would not have been largely applicable since they are designed for 
systematic reviews of randomised studies. A tool for reviews of non-randomised studies is 
not currently available, but is under development (AMSTAR, 2012). The Cochrane 
Handbook also does not explicitly provide any particular guidance with regard to 
mediating between the evidence in the reviews and deriving conclusions. This lack of 
guidance is perhaps because they are unlikely to have encountered discrepancies between 
different reviews’ conclusions, or been unsure of the reviews’ quality assessments of the 
primary studies, given that Cochrane Overviews are intended to: (i) summarise reviews 
addressing the effects of two or more interventions for a single health problem (not 
multiple reviews addressing the same intervention, as here) and (ii) summarise Cochrane 
Intervention Reviews (and can therefore be assured of the rigour with which these were 
undertaken).  
In summary, much of the development work in this ‘meta-review’ area has been focused 
on systematic reviews or meta-analyses of studies that are generally more robust than the 
studies that have been undertaken to investigate harm reduction interventions and, 
consequently, a Cochrane Overview of reviews would likely not have been recommended 
to address the objectives in Chapter 2. Despite the acknowledged limitations, the 
methodology applied in Chapter 2 was sufficiently rigorous, systematic and appropriate for 
the purposes of this thesis (Ellis et al., 2003; Kelly et al., 2002). 
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Abstracts and titles identifieda  (n 
= 1230) 
 
Remaining abstracts (excluding 
duplicates) screened by two 
reviewers (n = 1083) 
 
Remaining full text reviews retrieved  
(n = 107; 43 related to injecting 
equipment provision and 64 related to 
other interventions ) 
 
Duplicates excluded 
(n = 147) 
 
Abstracts excluded as not relevant 
(n=976): 
• Did not examine the selected 
interventions and/or outcomes; 
and/or 
• Not a systematic, meta-analytic or 
narrative review  
Papers excluded as not  relevant (n=25):  
• Published pre-2000 (n=8) 
• Not a review of the literature  (n=5) 
• Did not address evidence of effectiveness of 
interventions (n=2) 
• Did not examine selected  outcomes or 
interventions (n=2) 
• Reviews of cost effectiveness (n=3) 
• Restricted to prison setting (n=5) 
 
Core reviews (n=3) 
 
Supplementary reviews (n=15) 
Cochrane – 60 
Cinahl – 105 
Embase – 508 
Medline – 368 
PsycInfo & IBSS – 
160 
43 reviews related to injecting 
equipment provision screened by two 
reviewers 
 
Remaining reviews critically 
appraised by two reviewers (n=18) 
 
2 drawn upon for 
supplementary evidenceb 
14 not utilised in this review because 
interventions/outcomes were covered 
by one or more  core review(s) 
 
 
Figure 2-1. Papers identified in the review of reviews 
aIn addition to reviews of injecting equipment provision interventions, the initial search also included 
reviews of the following interventions: opioid substitution treatment; information, education, 
counselling and outreach; HCV testing and knowledge of HCV status; drug consumption rooms; 
treatment for HCV infection; promotion of non-injecting routes of administration; structural 
interventions; and bleach disinfection of needles/syringes.  
bOne review (Islam and Conigrave, 2007) was identified after the search was carried out 
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Table 2-1. Critical appraisal criteria for reviews 
Does the paper have a clearly focused aim or research question?  
Study identification 
Are details given of: 
Databases and years searched  
Grey literature searched  
Search terms used 
Inclusion criteria used 
What materials were excluded  
Critical appraisal 
Do the authors address the quality (rigour) of the included studies?  
Data presentation 
Are sufficient data from individual studies included to mediate between data and interpretation/conclusions? 
Synthesis and interpretation 
Does the review make clear what steps have been taken to deal with potential bias? 
Do the authors consider whether the results could be due to chance (p-values and confidence intervals)? 
Do the authors acknowledge any other limitations to the research, including weakness in their own approach?  
Has more than one assessor been involved? 
For meta-analyses: 
Are the studies addressing similar research questions?  
Are the studies sufficiently similar in design?  
Are the results similar from study to study (test of heterogeneity)?  
Are the reasons for any variation in the results discussed?  
Modified from Kelly et al. (2002) 
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Table 2-2. Framework for deriving evidence statements from reviews 
Evidence statement Level of evidence 
Sufficient evidence from reviews to either support or 
discount the effectiveness of an intervention 
• Clear statement from one or more core reviews 
based on multiple robust studies, or 
• Consistent evidence across multiple robust studies 
within one or more core reviews, in the absence of 
a clear and consistent statement in the review(s) 
Tentative evidence from reviews to either support or 
discount the effectiveness of an intervention 
• A tentative statement from one or more core 
reviews based on consistent evidence from a small 
number of robust studies or multiple weaker 
studies, or 
• Consistent evidence from a small number of robust 
studies or multiple weaker studies within one or 
more core reviews, in the absence of a clear and 
consistent statement in the review(s), or 
• Conflicting evidence from one or more core 
reviews, with the stronger evidence weighted 
towards one side (either supporting or discounting 
effectiveness) and a plausible reason for the 
conflict, or  
• Consistent evidence from multiple robust studies 
within one or more supplementary reviews, in the 
absence of a core review 
Insufficient evidence from reviews to either support 
or discount the effectiveness of an intervention 
• A statement of insufficient evidence from a core 
review, or 
• Insufficient evidence to either support or discount 
the effectiveness of an intervention (either 
because there is too little evidence or the evidence 
is too weak), in the absence of a clear and 
consistent statement of evidence from (a) core 
review(s), or 
• Anything less than consistent evidence from 
multiple robust studies within one or more 
supplementary reviews 
No evidence • No core or supplementary reviews of the topic 
identified, possibly due to a lack of primary 
studies 
Modified from Ellis et al. (2003) 
  
 
Table 2-3. Summary of study designs used to assess effectiveness of harm reduction interventions 
Study design Type Description 
Weight 
of 
evidence Example 
Establishes 
temporal 
sequencea Main limitations 
Strength of causal 
interpretations 
Randomised 
controlled trial 
Experimental Researchers control which 
individuals are exposed to the 
intervention by random 
assignment; individuals are 
then followed over time to see 
who develops the outcome  
Very 
robust 
Dolan et al. (2003) 
randomly assigned 
participants to receiving 
methadone or a waitlist 
control group; groups were 
followed up and HIV 
incidence was compared 
Yes Often not feasible to 
undertake an RCT to 
evaluate harm reduction 
interventions 
Strongest – 
randomisation should 
theoretically eliminate 
selection bias  
Cohort (with 
non-
randomised 
control group) 
Observational Individuals with and without 
the exposure (i.e. exposed vs. 
not exposed to a harm reduction 
intervention) are followed over 
time and compared to see if 
they develop the outcome  
Robust Bruneau et al. (1997) 
followed users and non-
users of NSP sites and 
compared HIV incidence 
between the two groups 
Yes High probability of 
selection bias; loss to 
follow-up 
Potentially limited by 
systematic differences in 
the comparison groups 
Cohort (pre vs. 
post-
intervention 
comparison) 
 Observational The outcome is compared, in a 
single group of individuals, 
before and after (and sometimes 
during) the implementation of 
an intervention 
Robust Vlahov et al. (1997) 
interviewed a sample of 
PWID who enrolled at an 
NSP site at baseline, two 
weeks and six months later 
and compared IRB 
between these times 
Yes Loss to follow-up; risk of 
confounding by changes 
over time in factors 
(other than the 
intervention) that may 
impact the outcome of 
interest 
Limited by lack of a 
comparison group – 
other factors could be 
causing and/or 
contributing to the 
association 
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Table 2-3 (continued).  
Study 
design Type Description 
Weight 
of 
evidence Example 
Establishes 
temporal 
sequencea Main limitations 
Strength of causal 
interpretations 
Case-
control 
Observational Individuals who have the 
outcome (cases) are 
identified and their past 
exposure to the intervention 
is compared with that of 
patients who do not have the 
outcome (controls) 
Robust Hagan et al. (1995) compared 
prior use of syringe exchange 
between HCV-infected PWID 
(cases) and non-infected PWID 
(controls) 
Yes Information on the exposure is 
usually ascertained 
retrospectively, therefore there 
is a risk of inaccuracy and 
recall bias (if controls recall 
exposure differently from 
cases)  
Potentially limited by 
sources of bias  
Ecological Observational The exposure and outcome 
variables are measured at the 
population or community-
level 
Weaker MacDonald et al. (2003) 
compared HIV prevalence over 
time in cities with and without 
NSP 
Usually High risk of confounding by 
changes over time in factors 
(other than the intervention) 
that may impact the outcome 
of interest 
Highly limited – other 
factors could be 
causing and/or 
contributing to the 
association 
Serial 
cross-
sectional 
Observational The prevalence (or 
incidence) of the exposure 
and outcome are measured 
at multiple points in time in 
comparable samples drawn 
from the same population 
Weaker van Ameijden et al. (1992) 
compared IRB among different 
samples of PWID recruited 
(from the same sites) in 
successive years: 1986, 1987, 
1988, 1989/90 and 1991/92 
Yes High risk of confounding by 
changes over time in factors 
(other than the intervention) 
that may impact the outcome 
of interest 
Highly limited – other 
factors could be 
causing and/or 
contributing to the 
association 
Cross-
sectional 
Observational The prevalence of the 
exposure and outcome are 
measured (and the 
association between them is 
usually determined) at one 
particular point in time  
Weaker Longshore, Bluthenthal, and 
Stein (2001) tested the 
correlation between the 
frequency of attendance at NSP 
sites and injecting-risk 
behaviour among a sample of 
IDUs interviewed on a single 
occasion 
No High risk of confounding by 
other factors; cannot know 
whether exposure precedes 
outcome 
Highly limited – due 
to lack of time 
dimension  
aBetween exposure and outcome 
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Table 2-4. Summary of reviews of injecting equipment interventions included in the review of reviews 
Author and 
date 
Title Inclusion criteria/terms of reference Dates 
covered 
Interventions covered Critical 
assessment 
No. 
studiesa 
Gibson et al., 
2001  
Effectiveness of syringe exchange 
programs in reducing HIV risk behaviour 
and HIV seroconversion among injecting 
drug users 
Published studies of the effectiveness of syringe exchange 
programs in reducing HIV risk behaviour and HIV 
seroconversion among PWID, regardless of design. Also 
included studies that examined effects of syringe exchange on 
HBV and HCV seroconversion 
1989 to 
end 1999 
NSP Core review 3 HCV 
6 HIV 
23 self-
reported 
IRB 
Islam and 
Conigrave, 
2007  
Assessing the role of syringe dispensing 
machines and mobile van outlets in 
reaching hard-to-reach and high-risk groups 
of injecting drug users (IDUs): a review 
To examine the available evidence for the 
effectiveness of syringe dispensing machines and mobile 
van or bus-based NSP in making services accessible to 
hard-to-reach and high-risk groups of PWID. 
Not 
specified 
Vending machines Supplementary 
review 
1 self-
reported 
IRB 
Tilson et al., 
2007  
Preventing HIV infection among injecting 
drug users in high-risk countries: an 
assessment of the evidence 
 
Published and unpublished literature on the effectiveness of 
HIV prevention interventions (drug dependence treatment, 
sterile needle and syringe access and outreach and education 
programs) for PWID 
1980 to 
Jan 2006 
NSP, pharmacy NSP, 
vending machines, 
provision of injecting 
paraphernalia 
Core review 6 HCV 
12 HIV 
24 self-
reported 
IRB 
Wodak and 
Cooney, 2004  
Effectiveness of sterile needle and syringe 
programming in reducing HIV/AIDS 
among injecting drug users 
 
To evaluate evidence on the effectiveness of sterile needle and 
syringe programming (including other injecting paraphernalia) 
for HIV prevention among PWID in different contexts 
1989 to 
2002 
NSP, pharmacy NSP, 
vending machines 
Core review 1 HCV 
10 HIV 
28 self-
reported 
IRB 
Wright and 
Tompkins, 
2006  
A review of the evidence for the 
effectiveness of primary prevention 
interventions for Hepatitis C among 
injecting drug users 
Intervention or observational studies describing a primary 
prevention intervention targeting injecting drug using 
populations with the outcome to reduce either the prevalence or 
incidence of hepatitis C infection 
Up to end 
2002 
NSP  Supplementary 
review 
9 HCV 
aNumber of primary studies in the review, listed by outcome 
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Table 2-5. Summary of evidence used in the derivation of evidence statements for each intervention (a) NSP, (b) pharmacy NSP, (c) vending machines, (d) outreach 
NSP and (e) provision of injecting paraphernalia and each outcome (HCV, HIV and self-reported IRB) 
Outcome Gibson et al. (2001) Tilson et al. (2007) Wodak and Cooney (2004) Primary studiesa Evidence statement 
(a) Needle and syringe provision (NSP) 
HCV No statement of evidence Tentative statement of 
evidence discounting the 
effects of NSP 
No statement of evidence Inconsistent evidence; 14 studies: 
7 positive (1 CC, 1 EC, 2 SCS, 3 
CS) 
2 negative (2 COH) 
5 no association (2 COH, 2 SCS, 
1 CS) 
Insufficient evidence to 
either support or discount the 
effectiveness of NSP 
HIV Clear statement of evidence in 
support of NSP, but conflicting 
with the primary studies reviewed 
Tentative statement of 
evidence in support of NSP 
Clear statement of evidence in 
support of NSP, but conflicting 
with the primary studies 
reviewed 
Consistent evidence from 
multiple weaker studies; 16 
studies: 
10 positive (2 COH, 4 EC, 2 
SCS, 2 CS) 
2 negative (2 COH) 
4 no association (2 COH, 2 CC) 
Tentative evidence to support 
the effectiveness of NSP 
Self-reported IRB Clear statement of evidence in 
support of NSP based on 
consistent evidence from multiple 
robust studies 
Clear statement of evidence in 
support of NSP 
No statement of evidence Consistent evidence from 
multiple robust studies; 43 
studies: 
39 positive (20 COH, 1 EC, 7 
SCS, 11 CS) 
1 negative (1 CS) 
3 no association (1 COH, 2 CS) 
Sufficient evidence to 
support the effectiveness of 
NSP 
(b) Pharmacy NSP 
HCV         No evidence 
HIV     Tentative statement of 
evidence in support of 
pharmacy NSP providing 
benefits in addition to 
dedicated NSP, but conflicting 
with the primary studies 
reviewed 
Insufficient evidence from few 
studies with weak designs; 2 
studies:  
2 positive (1 SCS, 1 CS)  
0 negative 
0 no association 
Insufficient evidence 
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Table 2-5 (continued). 
Outcome Gibson et al. (2001) Tilson et al. (2007) Wodak and Cooney (2004) Primary studiesa Evidence statement 
Self-reported IRB   Tentative statement of 
evidence in support of 
pharmacy NSP, based on 
consistent evidence from a 
small number of weak studies 
Tentative statement of 
evidence in support of 
pharmacy NSP providing 
benefits in addition to 
dedicated NSP, based on 
consistent evidence from 
multiple weaker studies 
Consistent evidence from 
multiple weaker studies; 7 
studies 
7 positive (2 SCS and 5 CS) 
0 negative 
0 no association  
Tentative evidence 
 
(c) Needle/syringe vending machines 
HCV         No evidence 
HIV   No statement of evidence Statement of evidence in 
support of vending machines, 
but conflicting with the 
primary studies reviewed 
Insufficient evidence; 1 study: 
0 positive 
0 negative 
1 no association (1 CS) 
Insufficient evidence 
Self-reported IRB   Statement of insufficient 
evidence 
Statement of evidence in 
support of vending machines, 
but conflicting with the 
primary studies reviewed 
Insufficient evidence; 1 study: 
1 positive (1 CS) 
0 negative 
0 no association  
Insufficient evidence 
(d) Outreach NSP 
HCV         No evidence 
HIV         No evidence 
Self-reported IRB         No evidence 
(e) Provision of injecting paraphernalia 
HCV         No evidence 
HIV         No evidence 
Self-reported IRB   No statement of evidence   Inconsistent evidence from a 
small number of studies; 4 
studies:  
2 positive (1 COH, 1 CS) 
0 negative 
2 no association (2 COH)  
Insufficient evidence 
COH: cohort; CC: case-control; EC: ecological; SCS: serial cross-sectional; CS: cross-sectional 
aFindings of primary studies were extracted from reviews. A positive finding refers to a reduction in the stated outcome associated with the intervention; a negative 
finding refers to an increase in the outcome associated with the intervention and ‘No association’ refers to no change in the outcome, or a change that did not reach 
statistical significance, associated with the intervention. Where a review reported a study finding as positive or negative, it was assumed that the result was statistically 
significant even if this was not explicitly stated. 
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Table 2-6. Summary of results of primary studies of the effectiveness of NSP with respect to HCV 
prevalence/incidence outcomes, by study design 
Design Author and 
yeara 
Findingb Overall 
findingc 
Gibson et al. 
(2001) 
Tilson et al. 
(2007) 
Wodak and 
Cooney 
(2004) 
Wright and 
Tompkins 
(2006) 
Case-control Hagan et al., 
1995  
Positive Positive Positive Positive Positive 
Cohort Hagan and 
Thiede, 2000  
 N/Ad   N/A 
Cohort Hagan et al., 
1999  
No association   No association No association 
Cohort Mansson et 
al., 2000  
 Negative  Negative Negative 
Cohort Patrick et al., 
2001  
   Negative Negative 
Cohort  Van 
Ameijden, 
1993  
   No association No association 
Cross-
sectional 
Lamden et al., 
1998  
No association    No association 
Cross-
sectional 
Smyth, 
Keenan, and 
O’Connor, 
1999  
   Positive Positive 
Cross-
sectional 
Somaini et al., 
2000  
   Positive Positive 
Cross-
sectional 
Taylor et al., 
2000  
 Positive  Positive Positive 
Ecological Des Jarlais et 
al., 2005b 
 Positive (in 
appendices, 
not in text) 
  Positive 
Serial cross-
sectional 
Goldberg et 
al. 2001; 
Goldberg, 
Cameron, and 
McMenamin, 
1998; 
Hutchinson et 
al. 2002  
   Positive Positive 
Serial cross-
sectional 
Hernandez-
Aguado et al., 
2001  
   No association No association 
Serial cross-
sectional 
MacDonald et 
al., 2000  
   Positive Positive 
Serial cross-
sectional 
Sarkar et al., 
2003  
 No association   No association 
aStudies are those identified by Gibson et al. (2001), Tilson et al. (2007), Wodak and Cooney 
(2004) and Wright and Tompkins (2006) 
bA positive finding refers to a reduction in the stated outcome associated with the intervention, a 
negative finding refers to an increase in the outcome associated with the intervention and ‘no 
association’ refers to no statistically significant association between the intervention and outcome 
cOverall finding based on consensus between the reviews; primary studies were verified where 
discrepant findings were reported  
dStudy reports self-reported IRB outcomes only 
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Table 2-7. Summary of results of primary studies of the effectiveness of NSP with respect to HIV 
prevalence/incidence outcomes, by study design 
Study design Author and 
yeara 
Findingb Overall findingc 
Gibson et al. 
(2001) 
Tilson et al. 
(2007) 
Wodak and 
Cooney (2004) 
Case-control Patrick et al., 
1997 
No association No association No association No association 
Case-control van Ameijden et 
al., 1992 
No association No association  No association 
Cohort and 
nested case-
control 
Bruneau et al., 
1997 
Negative Negative Negative Negative 
Cohort (Meta-
analysis to 
combine HIV 
incidence data 
from three 
prospective 
cohort studies) 
Des Jarlais et al., 
1996 
Positive  Positive Positive 
Cohort Mansson et al., 
2000 
 Positive  Positive 
Cohort Monterroso et al., 
2000 
  No associationd No association 
Cohort Schechter et al., 
1999 
No association Negative No association No association 
Cohort Strathdee et al., 
1997 
Negative Negative Negative Negative 
Cross-sectional: 
random sample 
of syringes 
returned to an 
NSP 
Heimer et al., 
1993  
  Positive Positive 
Cross-sectional  Ljungberg et al., 
1991 
  Positive Positive 
Ecological Des Jarlais et al., 
1995  
 Positive  Positive 
Ecological Des Jarlais et al., 
2005b  
 Positive  Positive 
Ecological Hurley, Jolley, 
and Kaldor, 1997  
 Positive Positive Positive 
Ecological MacDonald et 
al., 2003e 
 Positive Positive Positive 
Serial cross-
sectional 
Des Jarlais et al., 
2005a  
 Positive  Positive 
Serial cross-
sectional 
Hammett et al., 
2006  
 Positive  Positive 
aStudies are those identified by Tilson et al. (2007) and Wodak and Cooney (2004); Coutinho 
(2005) is excluded from this table because insufficient information regarding the study was 
provided by Tilson et al. 
bA positive finding refers to a reduction in the stated outcome associated with the intervention, a 
negative finding refers to an increase in the outcome associated with the intervention and ‘no 
association’ refers to no statistically significant association between the intervention and outcome 
cOverall finding based on consensus between the reviews; primary studies were verified where 
reviews reported discrepant findings 
dAlthough listed as a study with a positive finding in their review, Wodak and Cooney also state that 
the result was not statistically significant  
eAlso reported as Health Outcomes International 
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Table 2-8. Summary of results of primary studies of the effectiveness of NSP with respect to self-
reported IRB outcomes, by study design 
Study design Author and 
yeara 
Findingb Overall findingc 
Gibson et al. 
(2001) 
Tilson et al. 
(2007) 
Wodak and 
Cooney (2004) 
Cohort Bluthenthal et al., 
2000 
 Positive Positive Positive 
Cohort Cox et al., 2000   Positive Positive Positive 
Cohort Donoghoe et al., 
1989 
Positive  Positive Positive 
Cohort Gibson et al., 
2002  
 Positive Positive Positive 
Cohort Hagan and 
Thiede, 2000  
 Positive  Positive 
Cohort Hagan, Des 
Jarlais, and 
Friedman, 1994 
Positive   Positive 
Cohort Hart et al., 1989   Positive  Positive 
Cohort Hartgers et al., 
1992  
No association No association No association No association 
Cohort Huo et al., 2005   Positive  Positive 
Cohort Monterroso et al., 
2000  
 Positive Positive Positive 
Cohort Oliver et al., 
1994  
Positive  Positive Positive 
Cohort Ouellet, Huo, and 
Bailey, 2004  
 Positive  Positive 
Cohort Schoenbaum, 
Hartel, and 
Gourevitch, 1996 
Positive Positive Positive Positive 
Cohort van Ameijden 
and Coutinho, 
1998  
Positive Positive No association Positive 
Cohort van den Hoek, 
van Haastrecht, 
and Coutinho, 
1989  
 Positive  Positive 
Cohort Vertefeuille et 
al., 2000  
 Positive  Positive 
Cohort Vlahov et al., 
1997  
Positive Positive Positive Positive 
Cohort Wood et al., 
2002  
 Positive  Positive 
Cohort Wood et al., 
2003  
 Positive  Positive 
Cohort 
(retrospective) 
Heimer et al., 
1998  
  Positive Positive 
Cohort 
retrospective) 
Paone et al., 
1994  
Positive  Positive Positive 
Cross-sectional Bluthenthal et al., 
1998  
Positive  Positive Positive 
Cross-sectional Donoghoe, Dolan 
and Stimson, 
1992 
No association  No association No association 
Cross-sectional Frischer and 
Elliott, 1993  
Positive  Positive Positive 
Cross-sectional Gleghorn, 
Wright-De 
Aguero, and 
Flynn, 1998 
  Positive Positive 
Cross-sectional Guydish et al., 
1995  
Positive  Positive Positive 
Cross-sectional Guydish et al., 
1998  
Positive  Positive Positive 
Cross-sectional Hagan et al., 
1993  
 Positive  Positive 
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Table 2-8 (continued). 
Study design Author and 
yeara 
Findingb Overall findingc 
Gibson et al.  Tilson et al.  Wodak and 
Cooney 
Cross-sectional Hartgers et al., 
1989 
Positive  Positive Positive 
Cross-sectional Keene et al., 
1993  
Positive Positive Positive Positive 
Cross-sectional Klee and Morris, 
1995  
Indeterminate  Indeterminate Indeterminate 
Cross-sectional Klee et al., 1991 Negative Negative Negative Negative 
Cross-sectional Longshore, 
Bluthenthal, and 
Stein, 2001 
 Positive  Positive 
Cross-sectional Power and 
Nozhkina, 2002 
  Positive Positive 
Cross-sectional Vazirian et al., 
2005  
 Positive  Positive 
Ecological Des Jarlais et al., 
2000  
 Positive  Positive 
Serial cross-
sectional 
Broadhead, van 
Hulst, and 
Heckathorn, 
1999 
Positive   Positive 
Serial cross-
sectional 
Des Jarlais et al., 
1994  
Positive  Positive Positive 
Serial cross-
sectional 
Hammett et al., 
2006  
 Positive  Positive 
Serial cross-
sectional 
Peak et al., 1995  Positive  Positive Positive 
Serial cross-
sectional 
Singer et al., 
1997  
Positive  Positive Positive 
Serial cross-
sectional 
van Ameijden, 
van den Hoek, 
and Coutinho, 
1994 
Positive Positive Negative Positive 
Serial cross-
sectional 
Watters et al., 
1994  
Positive Positive Positive Positive 
aStudies are those identified by Gibson et al. (2001), Tilson et al. (2007) and Wodak and Cooney 
(2004); van Haastrecht et al. (1996), Kaplan (1991), Kaplan et al. (1994) and Kaplan and Heimer 
(1995) are excluded from this table because they examined other outcomes (mortality, syringe 
return rates) 
bA positive finding refers to a reduction in the stated outcome associated with the intervention, a 
negative finding refers to an increase in the outcome associated with the intervention and ‘no 
association’ refers to no statistically significant association between the intervention and outcome  
cOverall finding based on consensus between the reviews; primary studies were verified where 
reviews reported discrepant findings 
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Table 2-9. Results of primary studies of the effectiveness of pharmacy access to needles/syringes 
with respect to HIV prevalence/incidence outcomes, by study design 
Study design Author and yeara Findingb  
Cross-sectional Nelson et al., 1991  Positive 
Serial cross-sectional Hunter et al., 1995  Positive 
aStudies are those identified by Wodak and Cooney (2004) 
bA positive finding refers to a reduction in the stated outcome associated with the intervention, a 
negative finding refers to an increase in the outcome associated with the intervention and ‘no 
association’ refers to no statistically significant association between the intervention and outcome 
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Table 2-10. Summary of results of primary studies of the effectiveness of pharmacy access to 
needles/syringes with respect to self-reported IRB outcomes, by study design 
Study design Author and yeara Findingb Overall findingc 
Tilson et al. (2007) Wodak and Cooney 
(2004) 
Cross-sectional Calsyn et al., 1991  Positive Positive 
Cross-sectional Gleghorn et al., 1995  Positive Positive 
Cross-sectional Ingold and Ingold, 
1989  
 Positive Positive 
Cross-sectional Nelson et al., 1991   Positive Positive 
Cross-sectional Richard, Mosier and 
Atkinson, 2002  
 Positive Positive 
Serial cross-sectional Groseclose et al., 
1995  
Positive Positive Positive 
Serial cross-sectional Pouget et al., 2005  Positive  Positive 
aStudies are those identified by Tilson et al. (2007) and Wodak and Cooney (2004) 
bA positive finding refers to a reduction in the stated outcome associated with the intervention, a 
negative finding refers to an increase in the outcome associated with the intervention and ‘no 
association’ refers to no statistically significant association between the intervention and outcome 
cOverall finding based on consensus between the reviews; primary studies were verified where 
reviews reported discrepant findings 
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Table 2-11. Summary of results of primary studies of the effectiveness of providing sterile drug 
injecting paraphernalia with respect to self-reported IRB outcomes, by study design   
Study design Author and yeara Findingb  
Cohort Hagan and Thiede, 2000  No association 
Cohort Huo et al., 2005  No association 
Cohort Ouellet, Huo, and Bailey, 2004  Positive 
Cross-sectional Longshore, Bluthenthal, and Stein, 
2001  
Positive 
aStudies are those identified by Tilson et al. (2007) 
bA positive finding refers to a reduction in the stated outcome associated with the intervention, a 
negative finding refers to an increase in the outcome associated with the intervention and ‘no 
association’ refers to no statistically significant association between the intervention and outcome 
  
 
 
Table 2-12. Additional evidence identified and updated evidence statements for the review of reviews of the effectiveness of interventions in preventing IRB and 
HCV/HIV transmission among PWID 
Intervention Outcome Original evidence statement Additional evidence identified Updated evidence statementa 
NSP HCV Insufficient evidence  Two additional supplementary reviews (Hong and Li, 
2009; Nacopoulos, Lewtas, and Ousterhout, 2010) 
covering three additional studies (Holtzman et al., 2009; 
Neaigus et al., 2008; Wu et al., 2007) 
No change 
 HIV Tentative evidence  None No change 
 IRB Sufficient evidence  None No change 
Pharmacy 
NSP 
HCV No evidence None No change 
HIV Insufficient evidence One additional core review (Jones et al., 2010) covering 
two additional studies (Miller et al., 2002a; Singer et al., 
1997) 
No change 
 IRB Tentative evidence One additional core review (Jones et al., 2010) covering 
six additional studies (Bluthenthal et al., 2004; Fisher et 
al., 2003; Khoshnood et al., 2000; Obadia et al., 1999; 
Rhodes et al., 2004; Singer et al., 1997) 
No change 
Needle/ 
syringe 
vending 
machines 
HCV No evidence None No change 
HIV Insufficient evidence One additional core review (Jones et al., 2010) covering 
no additional studies 
No change 
 IRB Insufficient evidence One additional core review (Jones et al., 2010) covering 
one additional study (Obadia et al., 1999); one additional 
supplementary review (Islam, Wodak, and Conigrave, 
2008) covering one additional study (Islam et al., 2008) 
No change 
Mobile vans 
(outreach 
NSP) 
HCV No evidence None No change 
HIV No evidence One additional core review (Jones et al., 2010) covering 
one additional study (Miller et al., 2002b) 
Insufficient evidence 
IRB No evidence None No change 
 
  
85
 
  
 
 
Table 2-12 (continued).  
Intervention Outcome Original evidence 
statement 
Additional evidence identified Updated evidence statementa 
Sterile 
injecting 
paraphernalia 
HCV No evidence  One additional core review (Gillies et al., 2010) covering one additional study (Morissette et 
al., 2007) 
Insufficient evidence 
HIV No evidence  None No change 
 IRB Insufficient evidence One additional core review 
(Gillies et al., 2010) covering 11 additional studies (Bluthenthal et al., 1998; Colon et al., 
2009; Guydish et al., 1998; Heimer et al., 2002; Huo and Ouellet, 2007; Kipke et al., 1997; 
Morissette et al., 2007; Sears et al., 2001; Sears, Weltzien, and Guydish, 2001; Stoltz et al., 
2007; Vlahov et al., 1997)  
Tentative evidence 
OST HCV Insufficient evidence One additional supplementary review (European Centre for Disease Prevention and Control 
and European Monitoring Centre for Drugs and Drug Addiction, 2011b) covering an 
additional study (Van Den Berg et al., 2007) and a meta-analysis/pooled analysis (Turner et 
al., 2011) 
Tentative evidence  
 HIV Sufficient evidence None No change 
 IRB Sufficient evidence None No change 
aEvidence statements as described in MacArthur et al. (2014) 
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3 Systematic review and meta-analysis of the 
association between self-reported sharing of 
needles/syringes and HCV prevalence and 
incidence among people who inject drugs in 
Europe  
3.1 Introduction 
The previous chapter reviewed the association between sterile NSP, among other 
interventions, and self-reported IRB, HIV and HCV; one of the findings was sufficient 
evidence of an impact of NSP on self-reported IRB. Given that IRB is on the ‘causal 
pathway’ between NSP and HIV/HCV (i.e. IRB must first be reduced in order to affect 
BBV transmission; Box 3-1), one might expect also to have seen evidence for an impact on 
HIV and HCV; however, this was not the case. While several potential reasons for the lack 
of evidence for biological outcomes were proposed in Chapter 2 (e.g. few primary studies, 
crude measures of NSP uptake, selection bias), this observed discrepancy between the 
evidence for behavioural outcomes (i.e. self-reported IRB) and the evidence for biological 
outcomes (i.e. HIV, HCV) may suggest that reductions in self-reported IRB do not 
necessarily translate into reductions in HCV/HIV transmission. Thus, as illustrated in Box 
3-1, there is evidence for relationship (a), but there is still uncertainty regarding 
relationship (b). Insight may therefore be gained by examining further the relationship 
indicated by (b). 
 
The specific relationship that will be addressed in this chapter is the association between 
sharing needles/syringes and HCV. Many studies have investigated the association 
between sharing needles/syringes and HCV, usually with the aim of examining risk factors 
for HCV incidence or prevalence. Despite the relatively large body of literature, only one 
study has reviewed/meta-analysed studies of this association (Pouget, Hagan, and Des 
Jarlais, 2012). The lack of reviews/meta-analyses may be because it seems obvious that 
needle/syringe-sharing should be associated with HCV. While this is true, studies of 
Sterile 
needle/syringe 
provision (NSP) 
Injecting risk 
behaviour 
(IRB)  
Blood-borne 
virus  (BBV) 
transmission 
(a) (b) 
Box 3-1. Schematic diagram of impact of NSP  
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incident and prevalent HCV have reported substantially different effect sizes for this 
association, as well as surprisingly high rates of infection among those who report not 
sharing needles/syringes (Denis et al., 2000; Judd et al., 2005b; Rezza et al., 1996). 
Additionally, the aim of the previous review/meta-analysis was to establish the risk of 
HCV associated with needle/syringe-sharing and so included only studies reporting HCV 
incidence (Pouget, Hagan, and Des Jarlais, 2012). In contrast, given the aforementioned 
range of effect sizes across studies, a pooled estimate of the magnitude of association 
(including both studies of incidence and prevalence) is of interest in itself. Furthermore, 
exploration of the potential reasons for the variation and/or inconsistencies – including the 
high rates of HCV among those who report not sharing at all – may yield important 
insights.  
This chapter therefore aims to: (i) review the literature for studies that have reported a 
measure of the association between self-reported sharing of needles/syringes and HCV; (ii) 
summarise the size of this association; (iii) explore potential factors that account for the 
variation in the size of this association between studies; and (iv) consider potential 
explanations for apparent inconsistencies. Investigating this relationship may help to 
ascertain the relative contribution of needle/syringe-sharing to HCV transmission and to 
define issues with its measurement, thus informing prevention strategies and future 
research.  
3.2 Methods 
3.2.1 Study identification 
This systematic review and meta-analysis builds on an earlier systematic review of the 
literature, undertaken to identify studies of HCV prevalence and incidence among PWID in 
the European Union (Roy et al., 2002). The Roy et al. review identified studies, published 
between January 1990 (shortly after HCV was first identified (Choo et al., 1989)) and 
December 2000, through a computerised search of MEDLINE and EMBASE and from the 
bibliographies of retrieved articles. To update this review, two additional literature 
searches (Box 3-2) were undertaken of the same electronic databases to identify studies 
reporting the association between self-reported sharing of needles/syringes and either (i) 
HCV prevalence or (ii) HCV incidence, published between January 2001 and September 
2011. The reference lists of selected published reviews related to HCV were also searched 
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(Hagan et al., 2007; Hagan, Pouget, and Des Jarlais, 2011; Lelutiu-Weinberger et al., 2009; 
Palmateer et al., 2010). 
 
3.2.2 Inclusion/exclusion criteria 
Eligible studies reported either (i) HCV prevalence (or incidence) among PWID who 
reported ever and never (or recent and non-recent) sharing of needles/syringes or (ii) an 
association between HCV prevalence (or incidence) and ever (or recently) having shared 
needles/syringes among PWID. HCV infection was defined as the detection of an HCV 
marker using a serological or saliva test. Ideally, sharing would have been defined as 
receptive needle/syringe-sharing (i.e. using a needle/syringe that had previously been used 
by someone else) rather than distributive sharing (i.e. passing on a used needle/syringe to 
someone else); however, most studies did not provide a definition of needle/syringe-
sharing and therefore no restrictions were placed on studies in relation to this criterion. 
Studies were excluded if they: (i) did not present sufficient data to quantify the association 
between HCV prevalence or incidence and sharing needles/syringes; (ii) did not present the 
risk of HCV infection separately from other infections (e.g. HIV, HBV); (iii) did not 
distinguish needles/syringes from other injecting paraphernalia; (iv) involved antiviral 
Box 3-2. Terms used in the two literature searches 
 
(i) Prevalence studies  
1. exp Hepatitis C/ or (hepatitis c or HCV).mp. 
2. (intravenous drug use$ or inject$ drug use$ or drug addict$ or drug 
abuse$ or drug misuse$).mp. 
3. risk behavio?r.mp. or (shar$ and (needle$ or syringe$ or inject$ 
equipment or inject$ paraphernalia)).mp. or (shar$ and (needle$ or 
syringe$ or inject$ equipment or inject$ paraphernalia)).tw. or (risk 
factor$).ti,ab. 
4. ($prevalen$ or $positiv$).mp. 
5. 1 and 2 and 3 and 4 
 
(ii) Incidence studies 
1. exp Hepatitis C/ or (hepatitis c or HCV).mp. 
2. (intravenous drug use$ or inject$ drug use$ or drug addict$ or drug 
abuse$ or drug misuse$).mp. 
3. risk behavio?r.mp. or (shar$ and (needle$ or syringe$ or inject$ 
equipment or inject$ paraphernalia)).mp. or (shar$ and (needle$ or 
syringe$ or inject$ equipment or inject$ paraphernalia)).tw. or (risk 
factor$).ti,ab. 
4. ($inciden$ or $conver$).mp. 
5. 1 and 2 and 3 and 4 
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treatment for HCV infection; or (v) were based on self-reported HCV status. Studies were 
restricted to those conducted in countries of the European Union. Where two or more 
papers were generated from the same study, the paper that presented an analysis of the 
largest sample size was retained. Non-English language publications were considered for 
inclusion.  
3.2.3 Study selection and data extraction 
The abstracts retrieved in the literature searches described above were screened by two 
reviewers for potential relevance; full text papers for the selected abstracts were obtained 
and further screened by at least two reviewers. The following information was extracted, 
where available, from each paper: study dates; geographical area; recruitment site(s); 
sample size; mean and/or median age; proportion male; time since onset of injecting; 
method of ascertainment of needle/syringe-sharing (eg. interview, self-complete 
questionnaire, etc.); measurement of HCV infection (eg. saliva or serum test and test used); 
proportion reporting sharing injecting paraphernalia (filters, spoons and/or water); overall 
HCV prevalence (at baseline for cohort studies); number of HCV-positives (or 
seroconverters) and HCV-negatives (or non-seroconverters) who did and did not report 
sharing needles/syringes; unadjusted/adjusted odds ratios (ORs), risk ratios (RRs), or 
incident rate ratios (IRRs); and covariates that were adjusted for. Additionally, for cohort 
studies, information on numbers of participants followed up and lost to follow-up, mean 
length of follow-up, frequency of study visits and overall incidence was collected.  
3.2.4 Quality assessment 
The approach to assessing the quality of studies focussed on assessing the ‘risk of bias and 
precision’ of studies. Relevant items from a previously developed tool (Viswanathan and 
Berkman, 2012) were used to create two proformas (Appendix D) – one for cross-sectional 
and one for cohort studies. Items (common to both study designs) were grouped into the 
following categories: sample definition and selection (non-response rate, choice of 
comparison group, representativeness of sample), measurement of exposure and outcome 
(validity and reliability of tools, consistency of application), analysis (adjustment for 
confounding and effect modification, appropriateness of statistical methods) and sample 
size. An additional category – follow-up – was included for cohort studies, which 
considered the adequacy of follow-up time, the attrition rate and differences in attrition 
between comparison groups. For each item in the proforma, a study was categorised as 
either high, moderate or low, with ‘high’ indicating high risk of bias or poor precision. If a 
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study did not provide any information to address a particular item, the item was assigned a 
high risk of bias by default. Studies were then assigned an overall category of 
high/moderate/low, based on their respective proportions of these items.  
3.2.5 Data synthesis and analysis 
ORs and RRs of HCV infection associated with categories of exposure (needle/syringe-
sharing), and their standard errors, were generated from the raw data in each paper. Where 
a paper presented the OR and 95% CIs, but not the underlying data, the following 
calculation was used to derive an estimate of the standard error of the log OR:  
	 = 	 − 			21.96  
where SE is the standard error, UCL is the upper 95% confidence limit and LCL is the 
lower 95% confidence limit.  
Meta-analysis, based on the random effects model, was conducted to generate a pooled 
estimate of the association between needle/syringe-sharing and HCV prevalence/incidence. 
Statistical heterogeneity among the studies was assessed using the chi-square test for 
homogeneity and the extent of inconsistency between the study findings was examined 
using the I2 statistic. The latter measures the proportion of the total variation in the study 
estimates that is attributable to heterogeneity, with values greater than 50% corresponding 
to substantial heterogeneity (Higgins and Thompson, 2002). Sensitivity analyses were 
undertaken to examine the influence on the summary effect measure of varying the 
outcome measurement scale (i.e. OR or RR), using the adjusted odds ratio (AOR) instead 
of unadjusted and excluding studies at high risk of bias. To examine the role of selected 
study-level characteristics (for example, recruitment setting) on heterogeneity, meta-
regression and stratified analyses were explored. There were insufficient studies to 
generate meaningful results from multivariable meta-regression and therefore only 
univariable analyses were carried out. Publication bias was assessed by constructing a 
funnel plot and examining it for asymmetry (Sterne et al., 2011). Statistical analyses were 
performed in Stata version 9.2. 
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3.3 Results 
A total of 1,047 abstracts and 128 full text papers were reviewed, yielding 16 cross-
sectional studies (Cook et al., 2001; Denis et al., 2000; Galeazzi et al., 1995; Girardi et al., 
1990; Hedouin and Gosset, 1998; Holbach et al., 1998; Huntington et al., 2010; Judd et al., 
2005b; Malliori et al., 1998; Mathei et al., 2005; Sanchez, 1998; Serfaty et al., 1997; 
Sherriff and Mayon-White, 2003; Stark et al., 1995; Stark et al., 1996a; Taylor et al., 2008) 
and four longitudinal cohort studies (Craine et al., 2009; Foley and Abou-Saleh, 2009; 
Rezza et al., 1996; Van Den Berg et al., 2007) for the prevalence and incidence 
components of the review, respectively (Figure 3-1). One of the studies classified as cross-
sectional was, in fact, a cohort study; however, the paper presented the relevant HCV 
prevalence data for the baseline visit of the study cohort and is therefore considered to 
have a cross-sectional design for the purposes of this meta-analysis (Galeazzi et al., 1995). 
Eight studies were carried out between 1989 and 1995 (Denis et al., 2000; Galeazzi et al., 
1995; Girardi et al., 1990; Malliori et al., 1998; Rezza et al., 1996; Sanchez, 1998; Stark et 
al., 1995; Stark et al., 1996a), five in the latter half of the 1990s (Cook et al., 2001; 
Hedouin and Gosset, 1998; Holbach et al., 1998; Mathei et al., 2005; Taylor et al., 2008) 
and four during the early 2000s (Craine et al., 2009; Huntington et al., 2010; Judd et al., 
2005b; Sherriff and Mayon-White, 2003). One study spanned two decades (Van Den Berg 
et al., 2007) and two did not report the study dates (Foley and Abou-Saleh, 2009; Serfaty et 
al., 1997). 
3.3.1 Characteristics of the cross-sectional studies 
The 16 studies included in the prevalence component of the review were carried out in 
seven western European countries and ranged in size from 56 to 720 participants (Table 3-
1). The majority recruited participants at drug treatment sites (n=9). Twelve studies used 
an interviewer-administered questionnaire to ascertain information about IRB, two studies 
used a self-completed questionnaire and two studies did not specify how this information 
was obtained. All studies defined prevalent HCV as the presence of HCV antibodies; four 
studies used a saliva test and the remaining used a serum test.  
Overall HCV prevalence ranged from 45% to 90% (Table 3-2) and the proportion of the 
sample who reported ever sharing needles/syringes ranged from 41% to 93%. Among 
PWID who reported ever and never sharing needles/syringes, prevalence of HCV ranged 
from 48% to 94% and 33% to 82%, respectively. The pooled prevalence of HCV was 59% 
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among PWID who reported never sharing needles/syringes. Fifteen studies reported 
unadjusted ORs (Huntington et al. reported only an AOR) of the association between ever 
sharing needles/syringes and prevalent HCV infection, ranging from 1.2 to 13.5; twelve of 
these associations were significant at the 5% level. Seven studies reported AORs, which 
ranged from 1.0 to 5.9, five of which were significant at the 5% level.  
3.3.2 Characteristics of the longitudinal cohort studies 
The studies retrieved in the incidence component of the review were conducted in the UK, 
Italy and the Netherlands (Table 3-1) and had effective sample sizes of 286, 62, 106 and 
168 (Table 3-3). Three of these studies detected incidence rates of HCV ranging from 5.9 
to 28.6 per 100 person-years. The fourth study (Van Den Berg et al., 2007) did not report 
an overall incidence rate, since follow-up occurred over a period of 20 years; rather, it 
reported a decline in incidence from 27.5 per 100 person-years in the late 1980s to around 
2 per 100 person-years more recently. One study (Craine et al., 2009) that assessed risk 
behaviour during the year preceding the follow-up interview reported a needle/syringe-
sharing rate of 20%. Two studies examined risk behaviour in the preceding six months and 
reported needle/syringe-sharing rates of 2% (Rezza et al., 1996) and 27% (Foley and 
Abou-Saleh, 2009). The pooled incidence of HCV was 11% among PWID who reported 
not sharing needles/syringes during the risk period. Unadjusted ORs of the association 
between recent needle/syringe-sharing and incident HCV infection ranged from 2.3 to 4.3, 
only one of which was significant at the 5% level. Only one cohort study reported an AOR 
of 3.7 (not statistically significant).  
3.3.3 Meta-analysis 
Meta-analysis of unadjusted ORs generated a random effects pooled OR of 3.34 (95% CI 
2.42-4.62), comparing HCV infection among those who ever (or recently) shared 
needles/syringes relative to those who reported never (or non-recent) sharing. There was 
substantial heterogeneity and inconsistency between the study effect sizes (χ2=66.1, 
p<0.001 and I2=72.8%). A forest plot of the individual unadjusted ORs and the pooled OR 
is presented in Figure 3-2.  
3.3.4 Sensitivity analysis 
Table 3-4 presents the results of a sensitivity analysis comparing the effects of analysis 
scale (further stratified by study design), adjustment for confounding and risk of bias on 
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the pooled effect size. The pooled OR was very similar across study designs (cross-
sectional and longitudinal), indicating that the pooled OR was robust to variation in this 
study characteristic. The pooled RR for longitudinal studies (2.70, 95% CI 1.78-4.10) was 
similar to the pooled OR for these studies (3.43, 95% CI 1.95-6.05). The sensitivity 
analysis also revealed that the effect size was relatively robust to adjustment for 
confounding (OR 3.34, 95% CI 2.42-4.62 vs. AOR 3.46, 95% CI 1.77-6.76) and to 
exclusion of studies at high risk of bias (OR 3.34, 95% CI 2.42-4.62 vs. OR 3.46, 95% CI 
2.34-5.14).  
3.3.5 Stratified analysis and meta-regression 
Because a large proportion of the variability was likely a result of between-study 
heterogeneity, stratified analysis and meta-regression were carried out to investigate the 
effects of selected study characteristics. A number of study characteristics were significant 
(p<0.05) in univariable meta-regression (Table 3-5). Studies that recruited participants in 
prison had a pooled OR of 5.92 (95% CI 2.83-12.40) vs. 2.72 (95% 1.97-3.76) among 
studies that recruited from drug treatment settings (p=0.038). Studies that employed 
outreach methods had a lower pooled OR than those that did not (1.53, 95% CI 1.20-1.95 
vs. 3.93, 95% CI 2.94-5.27, p=0.004). The linearity of continuous variables (time since 
onset of injecting and HCV prevalence) were verified by plotting these study-level 
variables against the respective study log ORs (Figures 3-3 and 3-4). Studies with a higher 
sample mean/median time since onset of injecting generally had lower ORs (ratio of ORs 
0.86, 95% CI 0.78-0.95, p=0.003, for each one year increase in the mean/median). Higher 
sample HCV prevalence was associated with increased odds of HCV infection, giving a 
ratio of ORs of 1.02 (95% CI 1.00-1.03, p=0.037) per percentage point increase in 
prevalence. Adjusted meta-regression analysis was attempted, but results were not 
meaningful because there were insufficient studies, and are therefore not shown.  
3.3.6 Funnel plot 
A funnel plot, plotting the unadjusted log OR vs. its standard error for each study, is 
presented in Figure 3-5. This figure demonstrates an asymmetrical shape, with most studies 
having relatively low standard errors (i.e. a narrow spread on the vertical axis), with a few 
exceptions, and relatively wide range (on the horizontal axis) of effect sizes among those 
with low standard errors. No statistical tests for funnel plot asymmetry were performed 
because of the small number of studies and the substantial between-study heterogeneity 
(Sterne et al., 2011). 
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3.4 Discussion 
This meta-analysis generated a pooled OR of greater than three, comparing the odds of 
HCV infection among PWID who report sharing needles/syringes with PWID who report 
not sharing needles/syringes. This study is the first pooled association between 
prevalent/incident HCV infection and needle/syringe-sharing. A previous study has used 
meta-analysis to investigate the association between needle/syringe-sharing and incident 
HCV (Pouget, Hagan, and Des Jarlais, 2012). That study reported a pooled RR of 1.97 
(95% CI 1.57-2.49) associated with needle/syringe-sharing, which is lower than the 
estimated RR of 2.7 for incidence studies derived here (although it should be noted that 
this estimate is based on only four studies). Differences between the pooled risk estimates 
could be due to several factors relating to local injecting populations, such as population 
HCV prevalence and/or injecting networks (Aitken et al., 2004; Burt, Thiede, and Hagan, 
2009). 
The results also highlight the high rates of HCV infection among individuals who do not 
report needle/syringe-sharing, with incidence rates of up to 19% and prevalence rates of up 
to 82% among those who reported having not recently or never shared needles/syringes, 
respectively. It is possible that other risk factors, not measured in the studies included in 
this review, could account for some of the HCV infection among those reporting not 
sharing, such as sexual contact with HCV-infected individuals, needle-stick injury and 
tattooing. Sexual contact and needle-stick injuries are plausible but unlikely to account for 
much of the HCV burden in the PWID population (Judd et al., 2005b; Tohme and 
Holmberg, 2010). Some infections may be attributable to tattooing with unsterile 
equipment, which has been documented among PWID, occurring particularly in prisons 
(Hellard, Aitken, and Hocking, 2007; Tohme and Holmberg, 2012; Vescio et al., 2008). 
Other behaviours that are more likely to explain some of the HCV infection among those 
who reported not sharing needles/syringes include sharing injecting paraphernalia (e.g. 
spoons, filters, water), backloading/frontloading (i.e. using a pre-used syringe to prepare 
and distribute drugs) and accidental sharing. The latter has been observed in situations 
where PWID cohabit or inject together (Taylor et al., 2004), and there is evidence to 
suggest that backloading/frontloading may be a common practice (Thiede et al., 2007). The 
potential for HCV transmission due to sharing injecting paraphernalia is significant, given 
that these are highly prevalent behaviours among PWID (ranging from 47% to 83% in the 
studies included here); however, only three of the included studies adjusted for this (Denis 
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et al., 2000; Holbach et al., 1998; Rezza et al., 1996) and only eight studies reported the 
proportion of their sample that engaged in these behaviours.  
It is unlikely, however, that the unmeasured behaviours discussed above would entirely 
account for the substantial levels of infection among those reporting not sharing 
needles/syringes. A larger, perhaps more intractable, problem is that of misclassification of 
risk. Studies of IRB inevitably rely on self-reported measures. Numerous studies have 
examined the reliability of self-report of risk behaviours among PWID (De Irala et al., 
1996; Goldstein et al., 1995; Petry, 2001), but few have assessed their validity (Darke et 
al., 1991). An individual’s responses may be subject to social desirability bias (i.e. 
underreporting of stigmatised behaviours), which could result in a dilution of the effect 
sizes if an individual who has engaged in risk behaviour (and is HCV-positive) does not 
disclose this information. The extent of underreporting is unknown but will be related to a 
respondent’s willingness to disclose sensitive information, and will thus depend on the 
setting, the interviewer and the questionnaire used. Differential bias could also exist: for 
example, if individuals are more likely to report sharing injecting paraphernalia (as this 
type of sharing is less stigmatised than needle/syringe-sharing), the result could be an 
overestimate of the risk associated with this type of behaviour. Qualitative studies have 
found a discrepancy in self-reported sharing, with repeated and longer interviews finding a 
much greater level of sharing than reported in the first instance or to short quantitative 
surveys (Craine et al., 2004). A comprehensive qualitative review may provide greater 
insight into misclassification of sharing behaviour.  
There was strong evidence of between-study heterogeneity, for which an explanation was 
sought by examining differences in study-level variables. Although the analysis lacked 
statistical power to undertake a multivariable meta-regression, univariable analysis 
suggested that study-level characteristics – recruitment setting, recruitment method, 
baseline HCV prevalence of the study sample and mean/median time since onset of 
injecting of the study sample – were potential modifiers of the pooled association between 
needle/syringe-sharing and HCV prevalence/incidence. Studies that recruited participants 
in prison generally showed larger effect sizes compared with studies that recruited 
participants in drug treatment settings, which may reflect that individuals who have been 
incarcerated tend to engage in riskier behaviour, both inside and outside prison (Carvell 
and Hart, 1990; Jurgens, Ball, and Verster, 2009).  
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By contrast, studies that recruited at drug treatment sites generally had lower ORs of the 
association between needle/syringe-sharing and HCV. It could be hypothesised that 
undertaking studies in settings that are linked to treatment for drug misuse (and particularly 
where the individual undertaking the interview is involved in the respondent’s treatment) 
may be subject to social desirability bias. Studies that recruited respondents using outreach 
methods (defined as any method to recruit outwith fixed-site services, e.g. street 
recruitment) had a lower pooled OR than studies that did not. A possible explanation for 
this observation could be that these methods generally target young and high risk PWID; 
these individuals are more likely to have recently commenced injecting and are therefore 
less likely to be infected, but probably still engaging in high levels of risk behaviour, 
thereby diluting the strength of association between HCV and needle/syringe-sharing. That 
studies with a higher baseline prevalence have larger ORs also intuitively makes sense: in 
populations with a larger pool of infection, each injecting event would carry a higher risk 
of infection, therefore strengthening the association between HCV and needle/syringe-
sharing. The finding of generally lower ORs among studies with increasing sample 
mean/median time since onset of injecting may be due to recall bias – i.e. if long-term 
injectors have more difficulty remembering their behaviour, as the recall period is longer. 
Another possibility is that, for long-term injectors, the cumulative effect of other 
unmeasured exposures over time (for example, sharing injecting paraphernalia, tattooing, 
etc) has diluted the strength of effect between needle/syringe-sharing and HCV. 
Publication bias is one potential explanation for the funnel plot asymmetry observed in this 
meta-analysis; however, publication bias is less likely to be the case here because most of 
these studies were simply aiming to identify risk factors for HCV infection, rather than to 
examine needle/syringe-sharing and HCV specifically, and would therefore not necessarily 
have a vested interest in demonstrating a significant association with needle/syringe-
sharing. Furthermore, by including non-English language studies (n=4), the potential for 
publication bias has been reduced even more. Additionally, although studies might have 
selectively reported adjusted outcomes (i.e. not reported the adjusted effect size if 
needle/syringe-sharing was not significant in a multivariate model), any impact of this 
selectivity will have been reduced because unadjusted effect sizes were also used (and 
most studies investigating risk factors for HCV infection will have examined 
needle/syringe-sharing). The influence of study-level characteristics (not shown) on the 
funnel plot were investigated, but no clear picture of any ‘subgroups’ of studies with 
asymmetry emerged. It is therefore likely that true heterogeneity in the effect size between 
studies is the most likely reason for the asymmetry. Finally, chance is another potential 
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reason for funnel plot asymmetry and is plausible in this case since there were relatively 
few studies.  
Limitations of the methodology include the low power of meta-regression. Although a 
number of characteristics were statistically significant in univariable analysis, there was an 
insufficient number of studies to undertake multivariable analysis. Heterogeneity was 
explored at the study level by examining the effect of aggregate study characteristics on the 
pooled OR; sub-group analyses would have been preferable, but it was not possible to 
undertake these as the necessary data could not be extracted from the studies. Similarly, it 
would have been informative to explore a dose-response relationship between 
needle/syringe-sharing and HCV infection (i.e. the risk or odds of HCV by different 
frequencies of needle/syringe-sharing) but the majority of studies did not present an 
exposure gradient.  
In this systematic review/meta-analysis, cross-sectional studies (of HCV prevalence), as 
well as longitudinal studies (of HCV incidence), were included. It is generally recognised 
that cross-sectional studies are limited with respect to measuring current risk of HCV 
transmission, since a prevalent HCV infection could have occurred at any time in the past. 
They were included here, however, as one of the objectives was to explore the correlation 
between HCV prevalence and self-reported needle/syringe-sharing (including the 
prevalence of HCV among those who reported never sharing needles/syringes), given a 
previous anecdotal observation that the latter varied between studies. It should also be 
noted that the RR and OR – although these were combined in the meta-analysis – do not 
measure the same thing. However, the sensitivity analyses showed that they were 
sufficiently similar to combine and, furthermore, the aim was not to measure a risk of 
infection per se.  
Limitations of the studies themselves must also be considered, as individual study effect 
sizes that are biased will result in a biased pooled effect estimate. All of the studies 
included in this review were observational in nature (i.e. not randomised), therefore the 
association between needle/syringe-sharing and HCV infection may be subject to 
confounding by measured or unmeasured variables. Many of the studies either did not 
undertake adjusted analyses or did not include needle/syringe-sharing in the adjusted 
model(s), although the latter could be because they did not set out specifically to 
investigate the association between needle/syringe-sharing and HCV. However, sensitivity 
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analyses indicated that the pooled effect size did not differ substantially whether AORs or 
unadjusted ORs were used. 
The included studies dated as far back as 1989; since then, there has been a general decline 
in IRB reported in many countries, which is generally accepted to be a result of 
introduction and expansion of harm reduction services (Palmateer et al., 2010). However, 
this decline should not affect the association between needle/syringe-sharing and HCV 
infection, provided that there have been no trends in reporting of risk behaviour over time. 
The finding that the year of study start did not impact on the pooled OR would seem to 
support the latter.  
These findings may have implications for the use of IRB as a proxy for risk of BBV 
transmission. This inconsistency between self-reported IRB and BBV transmission has 
been seen in previous investigations of harm reduction interventions: for example, studies 
of NSP have found that provision of sterile needles/syringes has an impact on IRB, but not 
necessarily on HIV or HCV transmission (Palmateer et al., 2010). Therefore, if possible, 
the use of a biological measure is recommended if it is the actual outcome of interest. It 
will nevertheless remain important and desirable, in some studies, to measure IRB. Steps 
can be taken to reduce underreporting; for example, computer-assisted self-interviewing 
has been shown in some studies to yield a higher level of disclosure of sensitive behaviours 
(Des Jarlais et al., 1999a; Perlis et al., 2004) and may thus increase validity. In the study 
design phase, it is also very important to consider how other factors – for example, the 
privacy afforded by the setting and the impartiality of the interviewer – could influence the 
measurement of behaviours. Studies should also measure other risk factors for HCV – e.g. 
sharing non-needle/syringe paraphernalia, in addition to needle/syringe-sharing – as it is 
potentially the cumulative effect of these behaviours that accounts for most HCV 
transmission. Additionally, studies should define precisely what they mean by sharing: 
questions to elicit risk behaviour should distinguish between the receipt of used items of 
equipment and the passing on of used items of equipment.  
In conclusion, the results suggest a higher risk of HCV infection among PWID who 
reported sharing needles/syringes relative to those who did not. Nevertheless, there were 
very high incidence/prevalence rates among those who did not report sharing 
needles/syringes during the risk period, which may be a result of a combination of 
unmeasured risk factors and reporting bias. Study design and population may be important 
modifiers of the size and strength of association between HCV and needle/syringe-sharing. 
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These findings have implications for the use of self-reported sharing of needles/syringes as 
a proxy for HCV risk. 
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Figure 3-1. Papers identified in the systematic review of the association between self-reported 
sharing of needles/syringes and HCV prevalence/incidence among PWID in Europe 
aNote that although the prevalence and incidence components of the review were carried out 
separately, the numbers are combined here for brevity. The excluded papers may therefore contain 
some duplicates; however, the reasons for exclusion are presented for the respective components 
of the review. 
  
1,655 references identified 
through literature search: 
691 Medline 
925 Embase 
39 identified from other 
published reviews  
 
1,047 abstracts reviewed 
by two reviewers 
608 duplicate 
references 
128 full papers 
reviewed by two 
reviewers 
919 abstracts 
excluded 
 20 HCV papers 
included (16 HCV 
prevalence and 4 
HCV incidence) 
116 papers excludeda:  
• 27 did not report needle/syringe-sharing data 
• 25 outwith Europe 
• 10 did not associate HCV with sharing 
• 9 data not shown 
• 7 correlated HCV prevalence with recent sharing 
behaviour 
• 7 only looked at IV drug use (y/n) as risk factor 
• 6 did not consider needles/syringes separately from 
other injecting equipment 
• 4 did not present HCV incidence (for incidence 
component) 
• 3 sexual risk behaviour 
• 2 did not present prevalence (for prevalence 
component of review) 
• 2 did not present sharing rates for non-
seroconverters (for incidence component) 
• 3 duplicate data in other papers 
• 2 did not test for HCV 
• 2 included non-PWID 
• 1 cohort following seronegatives only 
• 1 paper retracted 
• 1 unpublished manuscript 
• 1 followed PWID on treatment 
• 1 did not include HCV negatives 
• 1 editorial 
• 1 unable to translate 
98 papers identified 
through previous 
literature review 
scanned for relevance 
by two reviewers 
8 12 
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Figure 3-2. Forest plot of unadjusted ORs of the association between needle/syringe-sharing and 
HCV infection among PWID and the random effects (DerSimonian and Laird) pooled estimate.  
The size of the boxes represents the weight assigned to each study. The overall effect size 
estimate is indicated by a diamond, with the 95% CIs being indicated by its width.  
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Figure 3-3. Plot of sample mean/median time since onset of injecting vs. the log OR for studies 
reporting this information (n=8) from the systematic review and meta-analysis of the association 
between self-reported sharing of needles/syringes and HCV prevalence/incidence among PWID in 
Europe 
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Figure 3-4. Plot of sample HCV prevalence vs. the log OR for studies reporting this information 
(n=19) from the systematic review and meta-analysis of the association between self-reported 
sharing of needles/syringes and HCV prevalence/incidence among PWID in Europe 
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Figure 3-5. Funnel plot of the unadjusted 
OR for each of the included studies (n=19)
association between self
among PWID in Europe
 
OR (on the log scale) versus the standard error of the log 
 from the systematic review and meta
-reported sharing of needles/syringes and HCV prevalence/
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Table 3-1. Description of studies included in the systematic review and meta-analysis of the association between self-reported sharing of needles/syringes and HCV 
prevalence/incidence among PWID in Europe 
Reference Design  Setting Study population Assessment of exposure Assessment of outcome Study limitations Risk of 
biasa 
Cook et 
al., 2001  
Cross-
sectional 
Manchester and Wirral, UK; 
1997-1999; recruitment at 
community drug teams, drug 
dependency units, 
rehabilitation centres, 
agency-based syringe 
exchange schemes, outreach 
Convenience sample of those 
attending drugs agencies for the 
first time or specifically to request 
a test. Snowballing was also used 
to recruit 60 people. 360 completed 
questionnaires; 341 with HCV 
blood results.  
72% male; mean age by 
recruitment group: 31.3 years at 
treatment sites; 29.1 at needle 
exchange; 30.0 self-presenters; and 
28.6 not in contact with services. 
‘Direct sharing’ not defined 
but this is presumed to refer 
to sharing of N/S; assessed 
via self-administered 
questionnaire 
Anti-HCV positivity 
assessed through repeat 
reactive serum samples 
(all positives confirmed 
with second ELISA; 
remaining inconclusive 
samples tested with 
RIBA and PCR) 
• No information on 
refusal rate (non-
participation) 
• Self-complete 
questionnaire may reduce 
accuracy  
• Sharing N/S not included 
in adjusted analyses 
 
Low 
Craine et 
al., 2009  
Longitudinal 
cohort 
South Wales, UK; 2004-
2006; recruitment at 
treatment services, NSP, 
homeless hostels 
Convenience sample of 700 current 
PWID (had injected in past year) at 
baseline – 516 of whom were 
seronegative; 286 seronegatives 
followed-up.  
71% male; mean age 28.5 years.  
N/S sharing (not explicitly 
defined) in the year since 
baseline assessed via 
interviewer-administered 
questionnaire 
HCV seroconversion, 
defined as someone who 
was HCV seronegative 
at baseline and 
seropositive at follow-up 
(one year later) 
• Those lost to follow-up 
less likely to be on OST 
at baseline  
• Adjusted model included 
N/S sharing and any 
equipment sharing 
(which includes N/S) 
• Analysis included those 
who did not inject during 
follow-up (25/286) and 
therefore not at risk 
 
Low 
Denis et 
al., 2000  
Cross-
sectional 
Charleroi, Belgium; 1995; 
recruitment at nine GP 
practices and a residential 
detoxification clinic for drug 
users 
Convenience sample of past or 
current heroin users; 329 heroin 
users recruited, of which 244 were 
PWID.  
73% male; mean age 26.3 years.  
Ever/never sharing N/S 
assessed via interview 
Anti-HCV positivity in 
serum assessed through 
2nd or 3rd generation 
MEIA or ELISA; RIBA 
for confirmation 
• PWID in treatment only 
• Questionnaire 
administered by GP – 
could result in 
underreporting of risk 
behaviour 
• No information on 
refusal rate 
 
Moderate 
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Table 3-1 (continued). 
Reference Design  Setting Study population Assessment of exposure Assessment of outcome Study limitations Risk 
of 
biasa 
Foley and 
Abou-
Saleh, 2009  
Longitudinal cohort London and Surrey, 
UK; dates not reported; 
recruitment at drug 
treatment centres 
95 HCV seronegative PWID who 
had injected in the last six months, 
were aged 18-70 and had an ICD-
10 diagnosis of mental and 
behavioural disorder due to the use 
of drugs. 62 individuals completed 
12-month follow-up.  
74% male; mean age 32 years. 
Standardised self-completed 
questionnaire; N/S sharing 
refers to previous six 
months and is defined as 
‘accepting used needles 
and/or syringes’ 
HCV seroconversion 
defined as testing 
positive to anti-HCV in 
serum by the 12-month 
follow-up date; 
laboratory test not 
specified 
• No adjusted analyses 
• 35% of sample lost to 
follow-up; no comparison 
of these with those 
retained in study 
• Small sample size 
• Risk behaviour is 
assessed for the six 
months prior to baseline 
interview, but period 
during which infection 
could have been acquired 
is 12 months after 
baseline interview 
• Analysis included those 
who did not inject during 
follow-up and therefore 
not at risk 
High 
Galeazzi et 
al., 1995  
Longitudinal cohort 
(but only presents 
relevant data at 
baseline, therefore 
classified here as 
cross-sectional) 
Veneto, Italy; 1992-
1993; recruitment at 
drug dependence 
treatment centre in a 
hospital covering an 
area of about 138,000 
inhabitants 
Convenience sample of 227 PWID.  
83% male; mean age 28 years. 
Interview with physician 
(no details of questionnaire 
given); definition of N/S 
sharing not given  
Anti-HCV positivity in 
serum assessed through 
2nd generation ELISA; 
not specified whether 
confirmatory testing 
undertaken   
• No adjusted analyses 
• If interviewing physician 
is involved in 
respondent’s treatment, 
could bias responses 
• No information on 
sharing injecting 
paraphernalia 
• N/S sharing not defined   
• No information on 
refusal rate (non-
participation) 
High 
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Table 3-1 (continued). 
Reference Design  Setting Study population Assessment of exposure Assessment of outcome Study limitations Risk of 
biasa 
Girardi et al., 
1990  
Cross-
sectional 
Rome, Italy; 1989; 
recruitment at methadone 
treatment programme in a 
public assistance centre 
Random sample of 80 IV heroin 
users attending the programme. 
71% male; mean age 29.5 years. 
Questionnaire – not clear if 
self or interviewer-
administered; syringe 
sharing categorised as 
‘never’, ‘sometimes’, or 
‘often’ 
Anti-HCV positivity in 
serum assessed through 
repeated reactivity to 
ELISA 
• No adjusted analyses 
• No information on 
sharing injecting 
paraphernalia 
• N/S sharing not defined 
• No information on 
refusal rate (non-
participation) 
• Small sample size (in 
particular, small number 
of never sharers) 
High 
Hedouin and 
Gosset, 1998  
Cross-
sectional 
Loos-lez-Lille prison, France; 
1995-1996; recruitment in 
prison 
Convenience sample of 806 
entering into prison during the 
period of study, 241 of whom were 
PWID.  
91% male; mean age 22.5 years. 
Interview by prison doctors; 
N/S sharing defined as 
‘exchange of injection 
material (needles and 
syringes) at least once in the 
past’ 
Anti-HCV positivity in 
serum assessed through 
repeated reactivity to 3rd 
generation ELISA 
• No adjusted analyses 
• Interview by prison 
doctors may have biased 
responses 
• No information on 
sharing injecting 
paraphernalia 
• No information on 
refusal rate (non-
participation) 
 
Moderate 
Holbach et 
al., 1998  
Cross-
sectional 
Lohr, Germany; 1995-1997; 
recruitment at psychiatric 
hospital 
Convenience sample of 120 
individuals who had taken drugs 
intravenously in the past. 
87% male; median age 24.5 years.  
Standardised interview 
using questionnaire; N/S 
sharing not defined.  
Anti-HCV or HCV-RNA 
positivity in serum 
assessed via ELISA/PCR  
• No information on 
refusal rate (non-
participation) 
• Recruitment at 
psychiatric hospital may 
have under-represented 
high risk users 
• Small sample size 
 
Moderate 
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Table 3-1 (continued). 
Reference Design  Setting Study population Assessment of exposure Assessment of outcome Study limitations Risk of 
biasa 
Huntington 
et al., 2010  
Cross-
sectional 
Catalonia, Spain; 2006; 
recruitment in the community 
296 individuals who had injected 
drugs in the last six months. 
78% male; 32% aged≤30 years. 
Standardised questionnaire; 
sharing defined as ever 
having injected with used 
syringes 
Anti-HCV positivity in 
saliva; test 
used/confirmation not 
specified 
• No information on 
sharing injecting 
paraphernalia 
• No information on 
refusal rate (non-
participation) 
• Laboratory methods not 
specified 
• Sampling method not 
explicitly described 
• Oral fluid instead of 
serum 
 
Moderate 
Judd et al., 
2005  
Cross-
sectional 
London and Glasgow, UK; 
2001-2002; recruitment at 
drug treatment agencies, 
syringe exchanges and street 
setting 
Convenience sample of 720 
individuals who had begun 
injecting since January 1996 and 
had injected in the previous four 
weeks. 
70% male; 37% aged <25 years. 
Interviewer-administered 
questionnaire; sharing 
defined as having ever 
injecting with a previously 
used N/S 
Anti-HCV positivity in 
saliva assessed using 
ELISA 
• No information on 
refusal rate (non-
participation) 
• Oral fluid instead of 
serum 
• Only presents recent 
sharing of injecting 
paraphernalia 
 
Low 
Malliori et 
al., 1998  
Cross-
sectional 
Athens and Patra, Greece; 
1994-1995; recruitment in 
prison 
Prisoners convicted of/awaiting 
trial for drug-related offences who 
reported use of narcotic drugs 
(intravenous/mouth/nose/smoking) 
either currently or in the past, 375 
of whom were PWID. 
90% male; mean age 35 years. 
Interviewer-administered 
questionnaire; exposure 
defined as ‘ever shared 
needles’ 
Anti-HCV in serum, 
assessed via 2nd 
generation EIA 
• No information on 
refusal rate (non-
participation)  
• No information on 
sharing injecting 
paraphernalia 
 
Low 
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Table 3-1 (continued). 
Reference Design  Setting Study population Assessment of exposure Assessment of outcome Study limitations Risk of 
biasa 
Mathei et 
al., 2005  
Cross-
sectional 
Antwerp and Limburg, 
Belgium; 1999-2000; 
recruitment from patients 
attending a methadone 
programme at medico-social 
centres for drug users 
Convenience sample of 310 drug 
users (out of 479 eligible who were 
approached); 225 PWID.  
67% male; mean age of 33.0 and 
34.5 years among participants from 
Limburg and Antwerp, 
respectively. 
Standardised interview; 
exposure simply stated as 
‘N/S sharing’ 
Anti-HCV positivity in 
serum, assessed via 3rd 
generation EIA with 
confirmation by RIBA. 
Where RIBA was 
indeterminate, HCV-
RNA testing was done.  
• Interview by health 
personnel could have 
biased responses 
• Recruitment of PWID in 
treatment only, may 
under-represent high risk 
users 
• N/S sharing not entered 
into adjusted model 
Moderate 
Rezza et 
al., 1996  
Longitudinal 
cohort 
Naples, Italy; 1991-1993; 
recruitment from three drug 
treatment centres 
746 PWID were eligible; 713 had 
data on HCV available. Among the 
263 anti-HCV negative PWID, 106 
completed follow-up. 
97% male; 79% aged≤28 years. 
Interviewer-administered 
questionnaire at baseline 
and 6-monthly intervals; 
exposure simply defined as 
‘needle-sharing’ and 
referred to the six month 
period preceding interview 
Anti-HCV seropositivity 
assessed by EIA and 
confirmed by RIBA. 
• High loss to follow-up 
rate; no comparison 
provided of those 
followed up vs. not 
High 
Sanchez et 
al., 1998  
Cross-
sectional 
Northeast Spain; 1994-1995; 
recruitment from seven 
prisons 
All persons entering prison who 
remained for seven days or more; 
included 557 PWID.  
85% male, mean age 
approximately 30 years.  
Questionnaire administered 
by health personnel; 
exposure was ‘syringe 
sharing’ 
Anti-HCV seropositivity 
assessed by EIA; 
positives confirmed by 
INNO-LIA 
• No information on 
sharing injecting 
paraphernalia 
• No information on 
refusal rate (non-
participation) 
• No adjusted analyses 
• Unclear if health 
personnel were affiliated 
to prisons – in which case 
responses could have 
been biased 
• Demographic 
information only 
presented for entire 
sample and not PWID 
subset 
Moderate 
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Table 3-1 (continued). 
Reference Design  Setting Study population Assessment of exposure Assessment of outcome Study limitations Risk of 
biasa 
Serfaty et 
al., 1997  
Cross-
sectional 
Newcastle UK; study dates not 
reported; recruitment in a 
regional drug and alcohol clinic 
Eligible patients had a DSM-IV 
diagnosis of drug 
dependency/abuse and were either 
regular opioid users, receiving an 
opioid prescription, or had a 
history of past injecting. 202 
patients were recruited; 194 with a 
history of injecting. 99 provided a 
blood sample for testing (2 of these 
had no history of injecting).  
65% male; mean age 32.9 and 30.0 
years among HCV positives and 
negatives, respectively. 
Does not state how 
exposure data were 
collected or definition of 
‘needle sharing’.  
Anti-HCV seropositivity 
assessed by 2nd 
generation ELISA and 
confirmed by RIBA 
• Methods of ascertaining 
exposure not described 
• Sample includes two who 
had never injected 
• Analysis only adjusted 
for age 
• No information on 
sharing injecting 
paraphernalia 
 
 
Moderate 
Sheriff and 
Mayon-
White, 2003  
Cross-
sectional 
Oxford, UK; 2002; recruitment 
from sheltered accommodation 
and medical centre for 
homeless people  
Convenience sample of 98 
homeless individuals attending the 
recruitment sites, 56 of whom were 
past or current PWID. 
90% male, mean age 30 years. 
Interviewer-administered 
questionnaire; exposure 
simply stated as ‘sharing 
needles’ 
Anti-HCV positivity in 
saliva (test not specified) 
• No information on 
refusal rate (non-
participation) 
• No adjusted analyses 
• Laboratory tests not 
specified 
• Oral fluid instead of 
serum 
• Demographic 
information only 
presented for entire 
sample and not PWID 
subset 
High 
Stark et al., 
1995  
Cross-
sectional 
Berlin, Germany; 1992-1993; 
recruitment at two drug 
treatment centres, an infectious 
disease hospital and a 
‘storefront agency’ that 
provided syringe exchange 
Sample of 405 individuals who had 
injected in the last three months.  
71% male; median age 29. 
Interviewer-administered 
questionnaire; exposure 
simply stated as ‘syringe 
sharing’ 
Anti-HCV seropositivity 
in serum assessed with 
2nd generation ELISA 
• No information on 
sharing injecting 
paraphernalia 
• Adjusted analyses did not 
include N/S sharing 
• N/S sharing not defined 
Low 
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Table 3-1 (continued).  
Reference Design  Setting Study population Assessment of exposure Assessment of outcome Study limitations Risk of 
biasa 
Stark et al., 
1996  
Cross-
sectional 
Berlin, Germany; 1994; 
recruitment at a treatment 
centre and ‘storefront 
agencies’ 
Convenience sample of 324 PWID. 
74% male; mean age 30.4 years. 
Interviewer-administered 
questionnaire; exposure 
simply stated as “needle-
sharing” 
Anti-HCV seropositivity 
in serum assessed with 
2nd generation ELISA 
• No information on 
sharing injecting 
paraphernalia 
• Adjusted analyses did not 
include N/S sharing 
• N/S sharing not defined 
 
Low 
Taylor et al., 
2008  
Cross-
sectional 
Glasgow, UK; 1999; 
recruitment at a drop-in 
centre for sex workers 
All women attending the centre 
during a four week period were 
approached (223); 114 agreed to 
participate; 99 had ever injected 
drugs, of which 89 had sufficient 
saliva sample.  
0% male; mean age 26 years. 
Self-completed 
questionnaire; exposure 
stated as ‘ever shared 
needles for injecting’ 
Anti-HCV in saliva 
assessed using modified 
ELISA (85% sensitivity 
and 100% specificity) 
• Oral fluid instead of 
serum and low sensitivity 
of antibody test 
• No information on 
sharing injecting 
paraphernalia 
 
 
Moderate 
van den 
Berg et al., 
2007  
Longitudinal 
cohort 
Amsterdam, Netherlands; 
1985-2005; recruitment 
from drug treatment 
centres, STD clinics and 
via word of mouth 
Among 1640 DU enrolled, 1259 
had at least two visits; 952 were 
ever injectors, of whom 168 were 
HCV seronegative.  
67% male; median age 29 years. 
Standardised questionnaire 
at baseline and at 4 to 6-
month visits (questions refer 
to the previous six months 
at baseline and the time 
since last visit at follow-up 
visits) 
Seroconversion defined 
as anti-HCV 
seropositivity detected 
by 3rd generation ELISA 
(in previous 
seronegatives); date of 
seroconversion was 
taken to be the midpoint 
between last 
seronegative and first 
seropositive visit  
• Adjusted analyses did not 
include N/S sharing 
• No information on non-
participation or loss-to-
follow-up 
 
High 
ELISA: enzyme-linked immunosorbent assay; N/S: needle(s)/syringe(s); RIBA: recombinant immunoblot assay 
aSee the methods for a description of the risk of bias approach; ‘high’ refers to high risk of bias and/or poor precision  
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 Table 3-2. Key findings of the cross-sectional (HCV prevalence) studies from the systematic review and meta-analysis of the association between self-reported sharing 
of needles/syringes and HCV prevalence/incidence among PWID in Europe 
Study Sample sizea 
Overall HCV 
prevalence 
HCV prevalence among 
those ever shared N/S 
HCV prevalence 
among those never 
shared N/S 
Unadjusted OR 
(95% CI)b AOR (95% CI)c Variables adjusted for 
Cook et al., 2001  341 53.1 NR NR 1.8 (1.2-2.8)* NR N/A 
Denis et al., 2000  236 78.3 90.2% (138/153)  54.2% (45/83) 7.8 (3.7-16.5)* 5.9 (2.4-14.2)* “Cotton” sharing 
Galeazzi et al., 1995  227 75.3 80.2% (146/182) 55.6% (25/45)  3.2 (1.5-6.8)* NR N/A 
Girardi et al., 1990  80 67.5 70.2% (52/74) 33.3% (2/6) 4.7 (0.6-54.6) NR N/A 
Hedouin and Gosset, 1998  241 80.1 92.2% (153/166) 46.7% (35/75) 13.5 (6.2-30.1)* NR N/A 
Holbach et al., 1998  108 65.8 83.9% (52/62) 50% (23/46) 5.2 (2.0-14.1)* 5.2 (1.4-18.9)* Age, total number of injections, borrowed 
syringes, borrowed spoons, intimate contact 
with risk person 
Huntington et al., 2010  296 80.1 NR NR NR 3.1 (1.6-5.9)* Front/backloading, age, drugs injected most 
frequently 
Judd et al., 2005  720 45.7 48.4% (221/457) 40.8% (104/255) 1.4 (1.0-1.9) 1.0 (0.7-1.5) Duration of injecting, frequency of injecting 
in last six months, no. of drugs mainly 
injected, cocaine and crack use, ever 
needlestick injury, ever in prison, 
recruitment setting and city of study 
Malliori et al., 1998  355 80.6 89.2% (215/241) 62.3% (71/114) 5.0 (2.8-9.1)* 5.5 (2.7-10.9)* Age, gender, no. of imprisonments, duration 
of injecting, injecting in prison  
Mathei et al., 2005  225 79.1 84.4% (136/161) 65.6% (42/64) 2.8 (1.4-5.9)* NR N/A 
Sanchez et al., 1998  551 89.6 94.0% (328/349) 82.2% (166/202) 3.4 (1.9-6.3)* NR N/A 
Serfaty et al., 1997  99 67.7 73.2% (60/82) 41.2% (7/17) 3.9 (1.2-13.5)* 2.8 (0.99-7.95)d Age 
Sheriff and Mayon-White, 
2003  
56 44.6 47.8% (11/23) 42.4% (14/33) 1.2 (0.4-4.1) NR N/A 
Stark et al., 1995  394 82.5 85.7% (264/308) 72.1% (62/86) 2.3 (1.2-4.2)* NR N/A 
Stark et al., 1996  324 85.5 88.3% (203/230) 78.7% (74/94) 2.0 (1.0-4.0)* NR N/A 
Taylor et al., 2008  87 68.5 85.1% (40/47) 47.5% (19/40) 6.3 (2.1-20.4)* 5.8 (2.0-16.5)* Number of times in prison 
NR: not reported; N/S: needle(s)/syringe(s) 
* p<0.05. 
aSample size used in analysis 
bAs reported in paper if no HCV prevalence among sharers/non-sharers reported; otherwise calculated from 2x2 data presented in paper, with exact CIs 
cAs reported in paper 
dCIs for AORs calculated from the standard error of the log OR, which was presented in the paper 
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 Table 3-3. Key findings of the cohort (HCV incidence) studies from the systematic review and meta-analysis of the association between self-reported sharing of 
needles/syringes and HCV prevalence/incidence among PWID in Europe 
Study Na 
HCV 
prevalencea 
Effective 
Nb SC PY 
HCV 
Incidence 
% seroconverted 
among those with 
recentc N/S 
sharing 
% seroconverted 
among those with 
no recentc N/S 
sharing 
Unadjusted OR 
(95% CI)d 
Unadjusted 
RR (95% CI) 
AOR (95% 
CI)e Variables adjusted for 
Craine et 
al., 2009  
700 26.3% 286 17 287.33 5.9/100 
PY 
10.5% (6/57) 4.8% (11/229) 2.3 (0.7-7.2) 2.2 (0.8-5.7) NR N/A 
Foley and 
Abou-
Saleh, 
2009 
291 29.2% 62 8 NR 9.1/100 
PY 
23.5% (4/17) 8.9% (4/45) 3.2 (0.5-19.2) 2.6 (0.7-9.4) NR N/A 
Rezza et 
al., 1996  
716 63.1% 106 21 73.4 28.6/100 
PY 
50.0% (1/2) 19.2% (20/104) 4.2 (0.05-333.5) 2.6 (0.6-11.0) 3.7 (0.1-
129.1) 
Age, years injecting, injecting 
outside Naples, daily use of 
heroin, injecting cocaine, 
sharing of paraphernalia, 
PWID sexual partner, >1 
sexual partners, methadone 
(all variables refer to last six 
months) 
van den 
Berg et 
al., 2007 
952 82.2% 168 58 NR NR 42.1% (16 SC/38 
PY)f 
 14.4 % (23 SC/159 
PY)f 
4.3 (1.8-10.0)*,g 2.9 (1.7-4.9)g NR N/A 
N/A: not applicable; NR: not reported; N/S: needle(s)/syringe(s); PY: person-years; SC: seroconversions. 
* p<0.05. 
aSample size at baseline, i.e. before exclusion of anti-HCV positives 
bSample size used in analysis 
cSee Table 3-1 for definitions of recent sharing in the respective studies  
dCalculated from data presented in paper 
eAs reported in paper 
fIncidence rates of HCV seroconversion per person-years of observation 
gOR and RR were calculated by taking the person-years of observation as a proxy for the number of individuals at risk 
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Table 3-4. Results of sensitivity analysis comparing pooled effect measures of the association between needle/syringe-sharing and prevalent/incident HCV infection 
Study or model characteristic 
No. of 
studiesa 
Pooled 
effect sizeb 95% CI 
Test of overall 
effect Test for heterogeneity I2 
Analysis scale All studies OR 19 3.34 2.42 4.62 Z=7.35, p<0.001 Χ2=66.1 (d.f.=18), p<0.001 72.8% 
 
Cross-sectional OR 15 3.36 2.33 4.85 Z=6.50, p<0.001 Χ2=64.5 (d.f.=14), p<0.001 78.3% 
 
Longitudinal OR 4 3.43 1.95 6.05 Z=4.27, p<0.001 Χ2=0.9 (d.f.=3), p=0.830 0.0% 
 
Longitudinal RR 4 2.70 1.78 4.10 Z=4.67, p<0.001 Χ2=0.3 (d.f.=3), p=0.966 0.0% 
Adjustment for 
confounding 
All studies OR 19 3.34 2.42 4.62 Z=7.35, p<0.001 Χ2=66.1 (d.f.=18), p<0.001 72.8% 
Studies reporting adjusted ORs AOR 8 3.46 1.77 6.76 Z=3.63, p<0.001 Χ2=35.4 (d.f.=7), p<0.001 80.2% 
Risk of bias All studies OR 19 3.34 2.42 4.62 Z=7.35, p<0.001 Χ2=66.1 (d.f.=18), p<0.001 72.8% 
 Studies with low/moderate risk of bias OR 13 3.46 2.34 5.14 Z=6.18, p<0.001 Χ2=61.9 (d.f.=12), p<0.001 80.6% 
aUnadjusted analyses are based on 19 studies since Huntington et al. (2010) did not present an unadjusted effect size 
bCalculated using random effects (DerSimonian and Laird) 
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Table 3-5. Results of stratified analyses and meta-regression of study variables on the association between needle/syringe-sharing and HCV prevalence/incidence 
 
 
No. of studies Stratified pooled ORs (95% CI) Test for heterogeneity 
 Univariable meta-regression 
Study characteristics 
 
I2 Ratio of ORs (95% CI) p-value 
Study region  S and E Europe 5 3.93 (2.81-5.50) Χ2=1.3 (d.f.=4), p=0.856 0.0% Ref  
 N Europe 14 3.21 (2.16-4.78) Χ2=59.0 (d.f.=13), p<0.001 78.0% 0.81 (0.39-1.68) 0.571 
Year of study start  1995-2006 9 3.40 (1.91-6.04) Χ2=55.8 (d.f.=8), p<0.001 85.7% Ref  
 1985-1994 8 3.24 (2.52-4.16) Χ2=6.5 (d.f.=7), p=0.486 0.0% 0.99 (0.50-1.94) 0.974 
Recruitment setting Drug treatment 13 2.72 (1.97-3.76) Χ2=30.1 (d.f.=12), p=0.003 60.1% Ref  
 Prison 3 5.92 (2.83-12.40) Χ2=8.7 (d.f.=2), p=0.013 77.1% 2.13 (1.04-4.36) 0.038 
 Other 3 3.53 (1.36-9.20) Χ2=5.6 (d.f.=2), p=0.060 64.4% 1.30 (0.56-3.03) 0.536 
Recruitment method Non-outreach 16 3.93 (2.94-5.27) Χ2=30.2 (d.f.=15), p=0.011 50.4% Ref  
 Outreacha 3 1.53 (1.20-1.95) Χ2=1.7 (d.f.=2), p=0.435 0.0% 0.42 (0.23-0.76) 0.004 
Current or past injectorsb Current only 5 2.24 (1.38-3.63) Χ2=9.5 (d.f.=4), p=0.051 57.7% Ref  
 
Current and past 11 4.15 (2.69-6.40) Χ2=35.0 (d.f.=10), p<0.001 71.4% 1.79 (0.90-3.56) 0.098 
Mean or median time since onset of injecting of sample (continuous) 8    0.86 (0.78-0.95) 0.003 
Proportion of sample that are male <72% 8 2.80 (1.82-4.31) Χ2=18.3 (d.f.=7), p=0.011 61.8% Ref  
 ≥72% 10 3.76 (2.30-6.17) Χ2=36.5 (d.f.=9), p<0.001 75.3% 1.31 (0.69-2.51) 0.408 
Baseline HCV prevalence of sample (continuous) 19    1.02 (1.00-1.03) 0.037 
Risk behaviour questionnaire type Interviewer-led 13 3.31 (2.19-4.99) Χ2=57.7 (d.f.=12), p<0.001 79.2% Ref  
Self-administered 3 2.98 (1.25-7.13) Χ2=5.3 (d.f.=2), p=0.072 62.0% 0.90 (0.35-2.30) 0.825 
HCV test 
Serum 16 3.67 (2.72-4.95) Χ2=36.2 (d.f.=15), p=0.002 58.5% Ref 
 
 
Oral fluid 3 2.08 (0.82-5.22) Χ2=8.2 (d.f.=2), p=0.017 75.6% 0.54 (0.25-1.15) 0.107 
aDefined as any method to recruit individuals outside of services, e.g. street recruitment 
bWhere a current injector is someone who has injected recently; the definition of recently varies by study 
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4 Risk of transmission associated with sharing 
drug injecting paraphernalia: analysis of recent 
HCV infection using cross-sectional survey data 
4.1 Introduction 
In Chapter 3, it was concluded that the observed high incidence/prevalence rates among 
those who did not report sharing needles/syringes during the relevant risk period were 
likely a result of a combination of unmeasured risk factors and reporting bias. One of the 
unmeasured risk factors that may explain some of the HCV infection is sharing injecting 
paraphernalia. As described previously, the preparation of drugs for injection also involves 
several other items of equipment: spoons – on which the drugs are dissolved and heated – 
and filters – through which the drugs are drawn up into a needle/syringe (for removing 
particles). Water is also used to make a drug solution and/or to flush out a needle/syringe 
after injecting. These additional items are henceforth collectively referred to as injecting 
paraphernalia. 
The evidence that direct percutaneous exposure to contaminated blood from a 
needle/syringe transmits HCV is generated from studies of needle-stick injuries in 
healthcare settings (Gerberding, 1995; Tomkins et al., 2012; Yazdanpanah et al., 2005). 
There is thus evidence that sharing needles/syringes in the recreational drug injecting 
setting has the potential to transmit HCV, although the actual risk of transmission would 
differ from the former setting based on a number of factors, such as the quantity of blood 
inoculated and the viral load. There is no equivalent evidence to demonstrate conclusively 
that sharing paraphernalia can transmit HCV infection. However, paraphernalia items may 
become contaminated with HCV in several ways, for example: if an individual draws up 
drug solution from a spoon and/or through a filter with a used needle/syringe (and these 
items are subsequently shared); or if someone flushes out his/her used needle/syringe with 
water (that is subsequently reused by someone else for flushing or for mixing with drugs) 
(Taylor et al., 2004).  
Epidemiological studies have sought to quantify the risk of HCV transmission associated 
with sharing paraphernalia. Two previous reviews/meta-analyses have synthesised the 
evidence for the association between paraphernalia-sharing and incident HCV among 
PWID (De et al., 2008; Pouget, Hagan, and Des Jarlais, 2012), the latter of which 
concluded that there was an increased risk. These reviews included only two studies from 
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Europe (Lucidarme et al., 2004; Rezza et al., 1996), both of which were conducted more 
than a decade ago and neither of which specifically aimed to study paraphernalia-sharing. 
Furthermore, while the prevalence of paraphernalia-sharing has been fairly well described 
in the United States (Hagan et al., 2001; Hagan et al., 2010; Hahn et al., 2002; Kapadia et 
al., 2002; Roy et al., 2007a; Thorpe et al., 2002), these behaviours have not been 
extensively examined among PWID in Europe (Folch et al., 2012; Health Protection 
Agency, 2011b; University of the West of Scotland, Health Protection Scotland, and West 
of Scotland Specialist Virology Centre, 2010). Given the risk of HCV from paraphernalia-
sharing observed in other studies (Pouget, Hagan, and Des Jarlais, 2012), this issue merits 
investigation in a European context.  
This chapter therefore aims to address the third thesis objective of determining the 
association between sharing injecting paraphernalia and incident HCV infection among 
PWID in Scotland. As part of the Hepatitis C Action Plan for Scotland and the Sexual 
Health and Blood Borne Virus Framework (see sections 1.5.1 and 1.5.3), national cross-
sectional surveys to monitor risk behaviour and HCV among Scottish PWID were 
implemented. Here, data from these surveys are used to examine the prevalence of sharing 
paraphernalia, and to examine the associations between incident HCV infection and (i) 
sharing needles/syringes (with or without paraphernalia) or paraphernalia only and (ii) 
sharing spoons, filters or water among those who report not sharing needles/syringes. This 
is the first study to apply a cross-sectional approach to the analysis of the relationship 
between paraphernalia-sharing and incident HCV. 
4.2 Methods 
4.2.1 Data collection  
The Needle Exchange Surveillance Initiative (NESI) is a voluntary anonymous cross-
sectional survey of PWID undertaken across mainland Scotland. Three sweeps of this 
survey have been undertaken to date: in 2008-09 (recruitment during June 2008 through 
June 2009), in 2010 (recruitment during January through November 2010) and in 2011-12 
(recruitment during March 2011 through March 2012).  
Participants were recruited from agencies and pharmacies that provide sterile injecting 
equipment, although many of these sites also provide other harm reduction interventions, 
such as OST. The number of sites at which recruitment was conducted exceeded 100 in 
each survey sweep, comprising more than 40% of all IEP services in Scotland (Information 
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Services Division, 2012c). Within logistical constraints (service manager agreement and a 
private room where the interviews could take place), services were selected to be broadly 
geographically representative.  
The inclusion criteria for participation in the study were (i) having injected drugs at least 
once in the past and (ii) not having participated in the study during the current survey 
sweep. Current injectors (defined as having injected in the last six months) were 
oversampled, if necessary, so that the proportion of the sample comprised by this group 
was at least 75% in each recruitment area. Trained interviewers conducted the recruitment 
and interviewing of participants. The recruitment strategy simply involved approaching all 
potentially eligible individuals, although this was not always possible if the interviewer 
was occupied with an interviewee. If someone met the inclusion criteria, the purpose of the 
study and study procedures were explained to him/her and his/her consent was obtained. 
For those who were unwilling to participate, the reason for refusal, approximate age and 
gender of each person were recorded. After obtaining informed consent, the interviewer 
administered a questionnaire based on a longer questionnaire that has been employed in 
community surveys of PWID in Glasgow since the early 1990s (Taylor et al., 2001). The 
questions were designed to elicit information on socio-demographics, injection history, 
drug use practices, imprisonment, uptake of healthcare and harm reduction services and 
testing history for HCV. The same set of core questions were asked in all three surveys 
(2008-09, 2010 and 2011-12); with certain supplementary questions applied in some of the 
surveys (the 2011-12 questionnaire is attached in Appendix E). Forename and surname 
initial, date of birth, gender and first part of postcode were the only items of potentially 
identifying information collected.  
Participants were also asked to provide a blood spot sample for HCV testing: capillary 
blood from a participant’s finger was obtained by means of a single-use disposable lancet 
and then spotted onto Whatman Protein Saver cards. Individuals who completed the 
questionnaire were provided with a £5 voucher. So that the results of serological testing 
remained anonymous, a participant’s dried blood spot (DBS) was linked to his/her 
questionnaire via a unique study number. Ethical approval for this research was obtained 
from the West of Scotland Research Ethics Service. 
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4.2.2 Laboratory methods 
The DBSs on the absorbent cards were extracted and tested in a modification of the Ortho 
Save 3.0 EIA (Judd et al., 2003). Samples with optical densities of <0.4, 0.4-0.79 and ≥0.8 
were classified as negative, weak reactive and positive for anti-HCV, respectively. HCV-
RNA testing was undertaken on anti-HCV negative samples using an ‘in house’ PCR 
assay: the bioMerieux extraction protocol for DBSs on the Easymag and a real-time PCR 
(Bennett et al., 2012). The assay detects to 1000 IU/ml in DBSs. The testing was carried 
out in pools of five; samples in positive pools were then tested individually. 
4.2.3 Analysis 
The analysis presented in this chapter involves the NESI 2008-09 and 2010 surveys. 
4.2.3.1 Outcome measure 
The measure of incident HCV infection used here exploits the features of the immune 
response to the virus. As described in section 1.1.4, in the very early stages of HCV 
infection, individuals have high levels of viraemia prior to developing antibodies 
(seroconverting); this has been referred to as the viraemic pre-seroconversion window 
period and has been estimated to be of relatively short duration (Page-Shafer et al., 2008). 
Individuals who are anti-HCV negative and HCV-RNA positive have therefore acquired 
their infection recently. This outcome (anti-HCV negative and HCV-RNA positive) is 
henceforth referred to as recent HCV infection. 
4.2.3.2 Measures of exposure 
The exposures of interest were sharing needles/syringes and/or paraphernalia in the last six 
months. This information was elicited by the following questions: “how many times have 
you injected with a needle/syringe that had already been used by someone else?’; “have 
you used spoons or containers for mixing which had previously been used by someone 
else?”; “have you used filters or cottons which had previously been used by someone 
else?”; and “have you prepared drugs or rinsed your works with water that had already 
been used by someone else?” 
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4.2.3.3 Statistical analysis 
Duplicate interviews (i.e. from individuals who participated more than once in either 
survey year or across both survey years) were identified based on initials, gender, date of 
birth and NHS Board of interview and were removed.  
Two analyses were undertaken. In the first, a variable was created combining the 
exposures into the following categories: ‘did not share in the last six months’, ‘shared 
needles/syringes with or without paraphernalia’, or ‘shared paraphernalia only’. The 
second analysis was limited to those who had not shared needles/syringes in the last six 
months, and examined the sharing of each item of paraphernalia individually. Analyses 
were restricted to anti-HCV negatives who reported injecting in the past six months. The 
association between the measures of exposure and recent infection was examined using 
logistic regression: univariable associations were initially determined; multivariable 
models were then built by entering suspected confounders and considering their 
contribution to the model. The confounding variables considered were: homelessness in the 
last six months (yes/no), stimulant injection in the last six months (yes/no), frequency of 
injection in the last six months (less than daily/daily or more frequently), time since onset 
of injecting (<5 years/≥5 years) and excessive alcohol consumption in a typical week 
during the past year (yes/no; where excessive is defined as >21 units per week for men and 
>14 units per week for women). Analyses were undertaken in SPSS version 17. 
4.3 Results 
A combined total of 5,355 unique respondents participated in the surveys, of whom 4,138 
(77%) had reported injecting in the last six months (Figure 4-1). Of those with sufficient 
DBS samples for testing, 2,168 (53%) were found to be positive for anti-HCV. Among the 
1,839 antibody negatives with sufficient sample for testing, 35 (1.9%) tested positive for 
HCV-RNA and were classified as recent infections. 
Among the antibody negatives, 12% reported sharing needles/syringes and 40% reported 
sharing any paraphernalia in the last six months. The majority of those who reported 
sharing needles/syringes also reported having shared paraphernalia: 26 respondents 
reported sharing needles/syringes only (1.4% of the sample, Figure 4-2). In the last six 
months, 35% of the sample reported sharing spoons, 26% reported sharing filters and 26% 
reported sharing water. There were very large overlaps between these behaviours (Figure 
4-3).  
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Table 4-1 presents characteristics of the study sample, according to self-reported sharing in 
the last six months. The proportions reporting sharing needles/syringes (with or without 
other paraphernalia) and paraphernalia only were significantly lower in 2010 (10% and 
26%, respectively) than in 2008/09 (15% and 33%, respectively). Significantly more 
females than males reported sharing needles/syringes (with or without paraphernalia) and 
paraphernalia only. The mean age of those who reported sharing needles/syringes (with or 
without paraphernalia) was lower (29.4) than the mean age of those who reported sharing 
paraphernalia only (31.5) and not sharing (32.6). A higher proportion of those who had 
been homeless in the last six months, who had commenced injecting within the last five 
years, who had injected stimulants, who had injected more than daily in the last six months 
and who had consumed excessive alcohol, reported sharing both needles/syringes (with or 
without paraphernalia) and paraphernalia only.  
The group that reported sharing needles/syringes with or without paraphernalia 
experienced the highest proportion of recent HCV infections (5.7%) as compared with 
those who reported sharing paraphernalia only (2.6%) or not sharing in the last six months 
(0.7%) (Table 4-2a). In univariable analyses, relative to those who had not shared any 
injecting equipment in the last six months, those who had shared needles/syringes with or 
without paraphernalia had the highest odds of recent infection (OR 9.1, 95% CI 3.6-23.0), 
followed by those who shared paraphernalia only (OR 4.0, 95% CI 1.6-9.9). The OR for 
needles/syringes with or without paraphernalia-sharing was lower after adjustment (AOR 
6.7, 95% CI 2.6-17.1), as was the OR for sharing paraphernalia only (AOR 3.0, 95% CI 
1.2-7.5). Unadjusted RRs for sharing needles/syringes with or without paraphernalia and 
sharing paraphernalia, relative to not sharing, were also calculated for comparison with the 
unadjusted ORs: they were very similar (RR 8.6, 95% CI 3.5-21.3 and RR 3.9, 95% CI 
1.6-9.6, respectively). 
The associations between sharing individual paraphernalia items and recent HCV infection 
among those who reported not sharing needles/syringes are given in Table 4-2b. Sharing 
spoons and sharing filters in the last six months were both significantly associated with 
recent infection in multivariable analyses (AOR 3.1, 95% CI 1.3-7.8 and AOR 3.1, 95% CI 
1.3-7.5, respectively). Sharing water was not significantly associated with recent infection 
(AOR 1.2, 95% CI 0.5-3.3).  
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4.4 Discussion 
This analysis showed that PWID who reported sharing needles/syringes (with or without 
paraphernalia) and sharing paraphernalia (only) had approximately seven and three times, 
respectively, the odds of recent HCV infection of those who did not share in the last six 
months. Although it was not possible to isolate the risk associated with needle/syringe-
sharing due to too few participants reporting solely this behaviour, the fact that the 
majority of individuals who reported sharing needles/syringes also reported sharing 
paraphernalia suggests that the risk from the latter could be higher than the OR of three 
that was observed.  
The effect size for sharing paraphernalia is consistent, if slightly higher, than effect sizes 
reported in previous studies (Hagan et al., 2010; Hahn et al., 2002; Lucidarme et al., 2004; 
Rezza et al., 1996; Roy et al., 2007a). These studies reported RRs ranging from 1.1 to 2.7, 
although the CIs for most of these included the estimate derived here. In addition, previous 
studies found a significant association with water (Kapadia et al., 2002; Maher et al., 2006; 
Thorpe et al., 2002), which was not replicated in this analysis. It is of note that ORs, rather 
than RRs, were presented here; however, RRs in univariable analyses were also calculated 
and these were comparable to the ORs. 
In the sample presented in this study (NESI 2008-09 and 2010 combined), 7% reported 
sharing needles/syringes in the previous month, which is relatively low in comparison with 
other countries with comparable IEP services: 17% of PWID surveyed at specialist 
services in England, Wales and Northern Ireland in 2011 (Health Protection Agency, 2012) 
and 16% of PWID surveyed at IEP sites in Australia in 2011 (Iversen and Maher, 2012). In 
contrast, 30% of the NESI study population reported sharing paraphernalia in the last 
month; the comparable figures for England, Wales and Northern Ireland and Australia are 
20% and 16%, respectively. The risk associated with paraphernalia-sharing determined in 
this analysis, combined with the high prevalence of this behaviour among Scottish PWID, 
means that it could potentially account for a substantial number of new HCV infections in 
this population. Previous studies have suggested that the proportion of infections 
attributable to paraphernalia-sharing could be in the region of 19% to 51% (Hagan et al., 
2010). 
During the Hepatitis C Action Plan for Scotland, there were approximately six-fold and 
four-fold increases in the provision of filters and spoons, respectively, between 2008/09 
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and 2009/10 (financial years) (Information Services Division, 2012c; Scottish 
Government, 2008a). Given these increases, the finding that the prevalence of sharing 
paraphernalia was significantly lower in 2010 than in 2008-09 is notable. Further NESI 
surveys will provide data to determine trends in this risk behaviour (see Chapter 6). 
This study is the first to examine the association between paraphernalia-sharing and recent 
HCV infection using a cross-sectional design. This study design is generally considered 
inferior to a longitudinal design since the former usually cannot measure incident infection, 
a limitation that was overcome with the approach to detecting recent infections. Another 
frequently cited limitation of cross-sectional studies is that it is not known whether the 
exposure precedes the outcome. This limitation may apply here, as injecting equipment 
sharing (the exposure) relates to the six months prior to interview and it is not known 
exactly when in that six-month interval the behaviour occurred. However, this uncertainty 
presents no disadvantage in comparison with longitudinal studies of risk behaviour and 
BBVs, for which establishing the temporal association can also be a problem: these studies 
often follow up individuals at six-month intervals – the infection could have been acquired 
at any time during the interval and the exact timing of the risk behaviour is similarly not 
known. Although cross-sectional studies may be subject to sampling bias, they avoid bias 
from participant attrition that can arise in longitudinal cohort designs (DiFranceisco et al., 
1998; Maher et al., 2006). Previous studies of paraphernalia-sharing and incident HCV 
have lost substantial numbers of participants to follow-up (De et al., 2008; Hagan et al., 
2001; Hagan et al., 2010; Hahn et al., 2002; Maher et al., 2006), and although a description 
of dropouts was not always provided, in some cases they tended to engage in riskier 
behaviour than those who remained in the study (Maher et al., 2006). The result could be 
an underestimate of the association between sharing paraphernalia and incident infection.  
To determine the independent effects of paraphernalia-sharing with regard to incident 
HCV, it is important to adjust for needle/syringe-sharing. Although many previous studies 
adjusted for needle/syringe-sharing, not all have done so (Brunton et al., 2000; Kapadia et 
al., 2002; Roy et al., 2007a). Furthermore, few studies have undertaken a stratified analysis 
(i.e. restricted the analysis to individuals who did not share needles/syringes) (Hagan et al., 
2001; Lucidarme et al., 2004), as was done here, which can be a more reliable method of 
eliminating confounding from needle/syringe-sharing than simply adjusting for it in a 
multivariate model (Cook and Goldman, 1988).  
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In the study population, there were large overlaps between sharing of different 
paraphernalia items and thus the models examining individual items could not be adjusted 
for the other items. It therefore cannot be stated that the effect size associated with sharing 
filters is independent of sharing spoons or water, and vice versa. Despite this limitation, an 
association between recent HCV infection and sharing water was not detected. A few 
epidemiological studies have detected significant associations between sharing water (for 
rinsing) and HCV transmission (Kapadia et al., 2002; Maher et al., 2006; Thorpe et al., 
2002), and a recent laboratory study demonstrated that HCV can survive for up to three 
weeks in bottled drinking water and remain infective (depending on the initial dose) 
(Doerrbecker et al., 2013). Water can become contaminated when it is used to flush/rinse 
out a syringe; it poses a transmission risk when it is subsequently reused by someone else 
for making a drug solution or rinsing out a needle/syringe (which is then used for 
injection). Twenty-six percent of the sample reported sharing water in the last six months, 
but it is not known which of the two behaviours (making a drug solution or rinsing out a 
needle/syringe) this refers to. It is plausible that the sharing of water for mixing is less 
risky, because a small volume of water is used, and the subsequent heating of the drug 
solution may deactivate some of the virus (Doerrbecker et al., 2011). The concentration of 
virus in the contaminated flush/rinse water may be correlated with the volume of residual 
blood left in the syringe after an injection, corresponding to the syringe’s ‘dead space’ 
(Zule and Bobashev, 2009). The relative proportion of high/low dead space syringes used 
by the study population might therefore influence the transmission risk associated with 
water sharing. The NESI study did not collect information on syringe type, therefore it was 
not possible to examine this risk factor. 
Limitations of this study include the use of self-reported measures of exposure. Evidence 
from studies that have compared computer-assisted self-interviewing with interviewer-
administered questionnaires suggests that PWID underreport ‘sensitive’ behaviours, such 
as sharing needles/syringes and other equipment (Des Jarlais et al., 1999b; Metzger et al., 
2000). Although there may be a degree of underreporting, the NESI surveys have taken 
steps to reduce this underreporting, including: employing independent, trained 
interviewers, undertaking the interviews in a private area and collecting the information 
anonymously. Corroboration of the behavioural data collected in the NESI surveys is 
provided by the strength of the association between sharing needles/syringes and recent 
infection seen here, which is larger than previous studies in which inconsistencies have 
been observed (Palmateer et al., 2013), and by the dose-response relationship that was 
observed between risk behaviour and recent HCV infection, such as increasing odds of 
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recent infection corresponding with increasing reported frequency of needle/syringe-
sharing (e.g. ORs of 3.9 and 5.4 among those who shared once/twice and ≥3 times, 
respectively, in the last six months, relative to those who reported not sharing).  
The pre-seroconversion window period for detection of recent HCV infection – with an 
estimated mean duration of six to eight weeks (Glynn et al., 2005; Netski et al., 2005; 
Page-Shafer et al., 2008) – has implications for this study. The studies that generated these 
window-period estimates mostly involved plasma donors as study subjects and therefore 
the validity of the estimates for PWID is less certain. Many factors can influence the 
duration of this acute phase of infection, including demographics and exposure frequency 
(Page-Shafer et al., 2008). However, the accuracy of the actual duration of the window 
period is perhaps less important in this study, where the aim is not to estimate incidence 
per se. Nevertheless, the short duration of the window period means that the outcome is 
rare: in this study, the 35 recent infections limited the statistical power.  
Misclassification of the outcome must also be considered. A small number of recent 
infections may have been false positives in the case of delayed seroconversion among 
immunocompromised persons (i.e. chronic infections that are misclassified as recent) 
(Thomson et al., 2009). Similarly, because of fluctuating viraemia among a small 
proportion of acutely infected individuals, a recent infection could have been misclassified 
as being HCV-RNA negative during a low viraemic phase (Page-Shafer et al., 2008; 
Thomson, Smith, and Klenerman, 2011). Both of these sources of misclassification could 
result in a biased estimate of the association between the exposure and outcome. While re-
infections among individuals who had previously cleared the virus would ideally be 
included in the outcome, they would not be captured by the measure of incident infection 
used here, because of the presence of antibodies from previous exposure to HCV among 
these individuals. This type of misclassification could result in a dilution of the exposure-
outcome association as these individuals would likely be positive for the exposure (sharing 
injecting equipment) but negative for the outcome. Finally, a further source of 
misclassification could be the laboratory tests to detect anti-HCV and HCV-RNA in DBSs. 
Although these tests have high sensitivities (99% and 100%, respectively) and specificities 
(100% and 96%, respectively) (Bennett et al., 2012; Judd et al., 2003), there is nevertheless 
the possibility of false antibody negatives and false RNA positives.  
There is the possibility that other unmeasured risk factors (for example, tattooing) may 
account for some of the risk of HCV infection. There may also be a role for other items 
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used in the injecting process (for example, swabs) in the transmission of HCV, but no 
information on the sharing or reuse of items was collected, other than the ones presented 
here (Thibault et al., 2011). It is also notable that the ORs presented here are not related to 
a ‘per event’ risk, since no information on the frequency of paraphernalia-sharing was 
available; however, an attempt was made to address this issue by adjusting for variables 
related to frequency of injecting in the models.   
In conclusion, this analysis has demonstrated that a cross-sectional design generates results 
that are similar to those from longitudinal studies of the association between sharing 
injecting paraphernalia and incident HCV infection. This study is the first European study 
to examine this association, and confirms that, as has been observed in other western 
countries (Pouget, Hagan, and Des Jarlais, 2012), the prevalence of paraphernalia-sharing 
is high and represents significant potential for HCV transmission among PWID. 
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Figure 4-1. Flowchart of respondents in the 2008-09 and 2010 surveys of PWID recruited from IEP 
sites across Scotland and laboratory results of anti-HCV and HCV-RNA testing 
aInjected in the last six months. 
  
2,744 respondents 
(2008/09 survey) 
3,315 respondents 
(2010 survey) 
6,059 total 
respondents 
704 duplicates 
removed 
5,355 (88%) unique 
respondents 
1,914 (47%) anti-
HCV negative 
2,168 (53%) anti-
HCV positive 
56 refused DBS or 
insufficient sample 
35 (1.9%) HCV-
RNA positive 
1,804 (98.1%) HCV-
RNA negative 
75 insufficient 
sample 
4,138 (77%) current 
injectorsa 
1,217 former 
injectors removed 
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Figure 4-2. Venn diagram of overlap between self-reported sharing of needles/syringes and 
paraphernalia in the last six months among 1,821 anti-HCV negative PWID recruited from IEP sites 
in Scotland in 2008-09 and 2010 (excludes 18 missing responses) 
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Figure 4-3. Venn diagram of overlap between self-reported sharing of paraphernalia items in the 
last six months among 1,829 anti-HCV negative PWID recruited from IEP sites in Scotland in 2008-
09 and 2010 (excludes 10 missing responses) 
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Table 4-1. Characteristics of 1,820 anti-HCV negative PWID recruited from IEP sites in Scotland in 
2008-09 and 2010, by self-reported sharing behaviour in the last six months 
 Characteristic Categories N 
% who shared 
N/S (+/- 
paraphernalia)  
% who shared 
paraphernalia 
only  
% who did not 
share  p-valuea 
Survey year 2008-09 921 15% 34% 52% 
<0.001 2010 899 10% 26% 64% 
Gender (7 NR) Male 1347 11% 28% 61% 
<0.001 Female 466 17% 34% 49% 
Age Mean (SD) 1825 29.4 (6.9) 31.5 (7.0) 32.6 (6.8) <0.001 
Homeless in the last 
six months (2 NR) 
No 1384 11% 27% 62% 
<0.001 Yes 434 18% 38% 44% 
Time since onset of 
injecting (5 NR) 
<5 years 781 14% 33% 53% 0.001 
≥5 years 1034 11% 28% 61% 
Injected stimulants in 
the last six months 
No 1610 12% 29% 60% 
<0.001 Yes 210 20% 38% 43% 
Frequency of injecting 
in last six months 
<daily 786 8% 25% 67% 
<0.001 
≥daily 1034 16% 33% 51% 
Excessive alcohol 
consumption (8 NR)b 
No 1410 11% 29% 61% 
<0.001 Yes 402 18% 34% 47% 
NR: non-response; N/S: needle(s)/syringe(s); SD: standard deviation 
ap-value for age was calculated using one-way ANOVA; p-values for all other variables were 
calculated using Chi-square test 
bRefers to consumption in an average week during the last year where excessive is defined as >14 
units/wk for women and >21 units/wk for men 
  
  
Table 4-2. Logistic regression analyses of the association between sharing injecting equipment and recent HCV infection among anti-HCV negative PWID recruited 
from IEP sites in Scotland in 2008-09 and 2010 
 
 
 
No. anti-HCV 
negatives (N) 
No. recent 
infections (n) % (n/N) 
Univariable Multivariablea 
  OR 95% CI p-value AOR 95% CI p-value 
(a) Combined sharing variable (last six months)        
       (n=1,813)  
No sharing in last six months 1051 7 0.7 1   1   
Needles/syringes +/- paraphernalia 227 13 5.7 9.06 3.57-22.98 <0.001 6.65 2.58-17.13 <0.001 
Paraphernalia only 542 14 2.6 3.96 1.59-9.86 0.003 2.95 1.16-7.48 0.023 
          
(b) Individual sharing variables (restricted to those who did not report N/S sharing in last six months)    
        (n=1,594)  
Shared spoons in the last 
six months 
No 1146 8 0.7 1   1   
Yes 455 13 2.9 4.18 1.72-10.16 0.002 3.14 1.26-7.80 0.014 
           
           (n=1,593)  
Shared filters in the last 
six months 
No 1294 11 0.9 1   1   
Yes 306 10 3.3 3.94 1.66-9.37 0.002 3.07 1.26-7.49 0.013 
           
  
      (n=1,587)  
Shared water in the last 
six monthsb 
No 1290 15 1.2 1   1   
Yes 304 6 2.0 1.71 0.66-4.45 0.270 1.21 0.45-3.26 0.702 
N/S: needle(s)/syringe(s) 
aAdjusted for homelessness in last six months, stimulant injection in last six months and time since onset of injecting 
bRefers to sharing water for flushing N/S or mixing with drugs  
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5 Measuring HCV incidence and determining the 
association between self-reported harm 
reduction intervention uptake and recent HCV 
infection 
5.1 Introduction 
The Scottish Government’s Hepatitis C Action Plan for Scotland (section 1.5.1) 
recognised: (i) the need for augmentation of harm reduction interventions (principally IEP) 
to prevent HCV transmission and (ii) that monitoring of HCV transmission among PWID 
is essential to establish the impact of increases/changes in interventions. The monitoring of 
HCV among PWID in Scotland, and indeed in other countries, has often involved 
measuring the prevalence of anti-HCV – an indicator of past infection (Hutchinson et al., 
2002; Roy et al., 2007b). Although examining long-term trends in HCV prevalence can 
inform on the effectiveness of interventions, measures of incidence of HCV are much more 
useful in determining short term impact. The traditional method of measuring incidence of 
HCV has been to establish seroconversion (i.e. development of antibodies to HCV) 
through follow-up and repeat testing of a cohort of individuals. This approach can, 
however, be logistically difficult (compared with other observational study designs) and 
suffers from attrition of participants over the course of follow-up, which can lead to bias 
(Mann, 2003).  
In Scotland, the only study of HCV incidence applying a prospective approach was 
undertaken in a prison (Champion et al., 2004). A retrospective cohort approach, whereby 
the residual blood from PWID who had presented for at least two voluntary HIV tests was 
tested for anti-HCV, has also been applied (Roy et al., 2001). While the latter approach is 
relatively inexpensive and easy to undertake, disadvantages may include that: (i) the 
retrospective nature of the study is not useful if one is wanting to determine current 
incidence rates, (ii) the potentially long periods between last negative and first positive 
antibody test can make it difficult to estimate the exact date of seroconversion, (iii) many 
years of data can be required to generate a sufficient sample size and (iv) the sampling 
frame may not be representative of PWID at risk of HCV acquisition.  
Another ‘indirect’ method of measuring HCV incidence that has been utilised in Scotland 
involved using, as a proxy for incidence, HCV prevalence among PWID who had recently 
commenced injecting. This approach assumes the date of seroconversion occurred midway 
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through their exposure period, which began at the commencement of injecting (Roy et al., 
2007b). This approach also has obvious limitations, including the inaccuracy of the 
estimated date of seroconversion. It is also notable that all of the incidence estimates 
discussed here have been restricted to regional populations within Scotland (Roy et al., 
2007b). 
A measure of incident infection not only provides information about the rate of acquisition 
of new infections, but it is also essential for the evaluation of the effectiveness of 
interventions to prevent HCV. As determined in Chapter 2, the foremost harm reduction 
interventions – OST and IEP – have been shown to reduce self-reported IRB, but there was 
a dearth of evidence with respect to their impact on HCV transmission among PWID (at 
the time of undertaking this analysis) (Palmateer et al., 2010). As discussed in Chapter 2, 
rather than being an indication of the ineffectiveness of these interventions, the lack of 
evidence may result from limitations of the studies that had been conducted, such as 
employing ecological study designs and using crude measures of intervention uptake (for 
example, users vs. non-users of IEP services). Furthermore, few studies had measured the 
‘coverage’ or intensity of interventions (e.g. the amount of injecting equipment distributed) 
(Lurie, 1997; Turner et al., 2011; Van Den Berg et al., 2007).  
This chapter therefore aims to address the fourth and fifth thesis objectives, which are to 
measure the incidence of HCV and to determine the association between the (self-reported) 
uptake of harm reduction interventions and incident HCV infection among PWID in 
Scotland. The analyses in this chapter are based on a series of cross-sectional Scotland-
wide surveys of PWID. At the time of conducting this analysis, it represented the first 
large-scale, national application of a novel method designed to determine incidence of 
HCV using a cross-sectional design (Hope et al., 2011; Page-Shafer et al., 2008).  
5.2 Methods 
5.2.1 Data collection and laboratory methods 
The analysis in this chapter is based on data from NESI; the data collection and laboratory 
methods for the series of surveys have been described in greater detail in Chapter 4 (see 
sections 4.2.1 and 4.2.2).  
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5.2.2 Analysis 
At the time of analysis, only the 2008-09 data were available and therefore this chapter 
relates to the analysis of this survey sweep. Chapter 6 presents an analysis of all three 
survey sweeps. 
5.2.2.1 Outcome measure 
The outcome of interest in this analysis is recent HCV infection. Recent infections were 
defined in Chapter 4 as individuals who were anti-HCV negative and HCV-RNA positive 
on DBS testing. 
5.2.2.2 Intervention measures 
The harm reduction interventions considered were IEP and OST. Although it will be 
referred to as OST, it should be noted that, for the purposes of the NESI study, this 
abbreviation designates methadone maintenance, which is the most commonly prescribed 
opioid substitute in Scotland. (In the 2008-09 NESI survey, methadone accounted for 97% 
of the respondents who reported receiving pharmacological treatment for opioid addiction 
in the last six months.)  
Variables representing two types of IEP coverage were generated: needle/syringe coverage 
and injecting paraphernalia coverage were determined by dividing the reported number of 
obtained sterile needles/syringes and items of paraphernalia (i.e. spoons, filters or water 
ampoules), respectively, by the self-reported number of injecting events in the previous six 
months. The distribution of the latter variables was examined and, given a very large 
proportion of individuals who reported receiving at least one needle/syringe for every 
injection (i.e. 100% coverage), it was suspected that respondents may have over-reported 
the numbers of needles/syringes obtained. The threshold separating high and low 
needle/syringe coverage was therefore set at 200% (i.e. two needles/syringes for every 
injection).  
Because the 2008-09 survey contained no questions to ascertain methadone dosage, 
individuals were simply categorised according to whether they were currently receiving 
OST, had received OST in the last six months (but were not currently receiving it), or had 
not received OST in the last six months.  
Chapter 5  136 
 
A combined measure of intervention coverage was created with categories low, medium 
and high: the combinations of needle/syringe coverage and OST that were used to create 
these categories are listed in Box 5-1. Respondents who were not receiving OST and had 
not injected in the last six months were excluded.  
 
5.2.2.3 Statistical analyses 
5.2.2.3.1 Calculation of HCV incidence 
A measure of incidence can be derived from the number of recent infections by 
multiplying them by a factor proportional to the duration of the window-period state (Hope 
et al., 2011; Page-Shafer et al., 2008). The following calculation was used to generate an 
estimate of incidence:  
( )
( )nTnN
nT
I
365)(
365
+−
=
  
where I is the incidence, T is the estimated duration of the viraemic pre-seroconversion 
window period, n is the number of recent infections and N is the number of susceptibles 
(i.e. anti-HCV negative individuals) (Hope et al., 2011). Estimates of the duration of the 
pre-seroconversion window period (28 to 65 days) were obtained from the published 
literature. The window-period estimates used here were derived from the two largest 
studies (Glynn et al., 2005; Page-Shafer et al., 2008), as well as the only study of this kind 
involving PWID (Netski et al., 2005). These three studies presented different measures of 
spread of the window-period data: one presented a 95% CI, one presented an overall range 
and one presented a range capturing 75% of the data (Glynn et al., 2005; Netski et al., 
2005; Page-Shafer et al., 2008). To be conservative, the smallest lower bound (28 days) 
Box 5-1. Categories of needle/syringe coverage and OST used to create combined 
intervention coverage 
    Needle/syringe coverage 
    <200% >=200% 
Did not inject in last 
six months 
OST Currently 
Medium  
(n=267) 
High 
(n=275) 
High 
(n=183) 
  
In the last six months 
(not currently) 
Low 
(n=21) 
Medium 
(n=12) 
 High 
(n=0) 
  
Not in the last six 
months 
Low 
(n=218) 
Medium 
(n=140) 
 Excluded 
(n=24) 
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and the largest upper bound (65 days) were chosen from the latter reported ranges. Ninety-
five percent CIs around the incidence estimates were not calculated as the uncertainty in 
the window period duration generated a wide range of potential values. 
5.2.2.3.2 Association between harm reduction intervention uptake and recent HCV 
infection 
Respondents who participated in the study more than once (duplicates) were identified in 
the database using initials, date of birth, gender and NHS Board of interview: either the 
first interview, or the interview with valid laboratory results, was retained for analysis. Out 
of a total of 2,749 respondents, 115 duplicates were identified (Figure 5-1). Anti-HCV 
weak reactives (representing only 2.7% of those with DBS results) were treated as anti-
HCV positive.  
Logistic regression was undertaken to examine associations between recent HCV infection 
and self-reported uptake of harm reduction interventions (OST and IEP). The reference 
group for comparison consisted of anti-HCV negative, HCV-RNA negative individuals. 
Associations between other variables and recent HCV infection were also explored. 
Univariable associations between each variable and recent infection were examined in turn. 
Multivariable models were subsequently built by including known or suspected 
confounders of the relationship between OST/IEP and recent HCV infection; IRB variables 
and injecting frequency variables were not considered because they are on the causal 
pathway. Where there was a theoretical reason to suspect potential effect modification 
between two variables, the presence of interactions was assessed by entering interaction 
terms into the model individually and examining the p-values (based on the Wald test), as 
well as the effect sizes when the analysis was stratified by the effect modifier. 
Additionally, sensitivity analyses were undertaken to assess the robustness of the final 
model(s) to: (i) the exclusion of unexpected results (incident infections who reported not 
injecting in the last six months) and (ii) restriction to current PWID (i.e. those who had 
injected in the last six months). All analyses were undertaken in SPSS version 14. 
5.3 Results 
A total of 2,629 respondents completed the questionnaire; comprising 63% of potentially 
eligible clients that were approached. Non-participants were slightly younger than 
participants (mean of 29 vs. 34 years); however, both participants and non-participants had 
the same gender distribution (72% male).  
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Among the 2,555 respondents who provided a sufficient DBS, 1,367 (54%) were anti-HCV 
positive (including weak reactives) (Figure 5-1). Twenty-four of the 1,140 anti-HCV 
negatives (with sufficient sample) were found to be positive for HCV-RNA. This 
generated incidence rate estimates ranging from 10.8 to 21.9 per 100 person-years, 
corresponding to viraemic pre-seroconversion window period estimates of 28 to 65 days.  
In univariable analyses (Table 5-1), the following variables were found to be significantly 
associated with increased odds of recent HCV infection: homelessness in the last six 
months, imprisonment in the last six months and excessive alcohol consumption. The 
following factors were significantly associated with reduced odds of recent HCV infection: 
age >30 years, receipt of prescribed OST, ≥200% needle/syringe coverage (where sterile 
needles/syringes had been obtained from IEP services or from other people) and high 
coverage of combined interventions. Longer time since onset of injecting (≥5 years) was 
also associated with reduced risk and was marginally statistically significant (p=0.059). 
Table 5-2 presents two alternative adjusted models: (i) with OST and IEP entered as 
separate variables in the model and (ii) with a combined measure of OST and IEP. In 
model (i), those who had ≥200% needle/syringe coverage had a nearly 70% reduction in 
odds of recent HCV (AOR 0.3, 95% CI 0.1-1.0), relative to those with <200% coverage, 
after adjustment for region, gender, homelessness, imprisonment, time since onset of 
injecting and excessive alcohol consumption. The results were also suggestive of reduction 
in risk among both those on OST currently and those not on OST in the last six months, 
relative to the baseline group of those who had been on OST in the last six months, 
although neither association was statistically significant.  
In model (ii), the reduced risk of recent infection among those with high coverage, as 
compared with low coverage, observed in univariable analysis (OR 0.3, 95% CI 0.1-1.0) 
was no longer statistically significant after adjustment (AOR 0.5, 95% CI 0.2-1.5, 
p=0.203).  
Suspected interactions between variables were investigated and there was some evidence 
that geographical region modifies the effect of OST. Table 5-3 shows the AORs for OST, 
stratified by region: in Greater Glasgow and Clyde there were marginally significant 
(p=0.055) reduced odds of recent HCV infection among those currently on OST, relative to 
those who had been prescribed OST in the last six months but not currently (AOR 0.04, 
95% CI 0.001-1.1). This association was not seen in other Scottish regions.  
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Sensitivity analyses were undertaken to examine the robustness of the main effects model 
(Table 5-2, model (i)). The effect sizes were robust to the exclusion of those who had not 
injected in the last six months and the four incident infections who had not injected in the 
last six months. There was a loss of precision; however, this was expected because of the 
corresponding reduction in sample size.  
5.4 Discussion 
This analysis generated an estimated HCV incidence rate of 11 to 22 per 100 person-years 
in this population of Scottish PWID. This is higher than a recently reported incidence rate 
of 5.9 per 100 person-years among a cohort of PWID in Wales (Craine et al., 2009) but 
lower than rates (38 to 47 per 100 person-years) reported in England (Hope et al., 2011; 
Judd et al., 2005a). These variations may be attributable to differences in risk behaviour 
among regional injecting populations and/or study designs/recruitment approaches. Two of 
these studies employed prospective cohort designs (Craine et al., 2009; Judd et al., 2005a) 
and one recruited participants using respondent-driven sampling (RDS) (Hope et al., 2011). 
Notably, the RDS study may have overestimated HCV incidence due to detection of a 
transmission cluster; the authors note that exclusion of this cluster would result in an 
incidence rate of 18 to 25 per 100 person-years. Historically, regional incidence rate 
estimates among PWID in Scotland have ranged from 10 to 29 per 100 person-years 
(McDonald et al., 2012; Roy et al., 2007b). However, whereas the foregoing estimates 
were generally confined geographically, the estimate generated in this chapter applies to all 
of mainland Scotland.  
A subset (Greater Glasgow and Clyde region) of the data presented here was included in a 
previous analysis that examined the effect of harm reduction interventions by pooling data 
from UK studies (Turner et al., 2011). Turner et al. demonstrated an independent effect of 
needle/syringe provision on incident HCV infection, a finding for which this analysis 
provides further evidence using data collected from across mainland Scotland. These 
studies are the first to observe a significant independent association between 
needle/syringe provision and recent HCV infection (European Centre for Disease 
Prevention and Control and European Monitoring Centre for Drugs and Drug Addiction, 
2011a; Palmateer et al., 2010); possible reasons are likely to be the larger sample sizes (for 
example, in comparison with Van Den Berg et al. (2007)) and the use of more sensitive 
measures of exposure to needle/syringe provision. Because cross-sectional studies are 
generally cheaper and easier to undertake than prospective cohort studies, this analysis was 
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able to achieve a large sample size through the application of a method to determine 
incidence using a cross-sectional design. This analysis is also the first to look at sterile 
needles/syringes obtained from both IEP services and from other PWID, which may have 
further increased the sensitivity of this measure of exposure (because PWID who obtain 
sufficient sterile needles/syringes from others may have otherwise been misclassified as 
having low coverage and resulted in a dilution of the exposure-outcome association). This 
observation is an important finding that suggests secondary distribution may play a role in 
preventing HCV transmission (Bryant and Hopwood, 2009; Lenton, Bevan, and Lamond, 
2006).   
In contrast to Turner et al., the analysis in this chapter did not find a significant 
independent effect of OST, nor a significant combined intervention effect, when 
considering Scotland overall. This discrepancy could be a result of statistical power: 
although this analysis had a larger sample size than that in the Turner et al. paper (by 
approximately 200), there were fewer recent infections (24 vs. 40) than in the Turner et al. 
paper. Nevertheless, as demonstrated by Turner et al. and confirmed in this analysis 
(although a different measure of OST was used here), current OST was associated with 
reduced odds of recent HCV infection in the Greater Glasgow and Clyde region. The 
finding that the reduced odds of those currently receiving OST, when compared to those 
who had received OST in the last six months (but not currently), suggests that individuals 
coming off opioid substitution are at increased risk of HCV infection. This pattern was not 
seen in the other Scottish regions: regional variations in the effectiveness of OST may 
reflect differences in local delivery policies and practices. However, it is of note that the 
NESI study applies the same design and questionnaire across all areas, whereas the Turner 
et al. study pooled data from studies which employed a mixture of different designs (RDS, 
cohort, cross-sectional) and questionnaires.  
No significant associations between the provision of filters or spoons and recent HCV 
infection were found: again, this lack of association is possibly attributable to insufficient 
statistical power. Additionally, this analysis was undertaken prior to the substantial 
changes in IEP services associated with the Hepatitis C Action Plan in Scotland, one of 
which was an approximately five-fold increase in the provision of filters and spoons 
between 2008/09 and 2009/10 (Information Services Division, 2011).  
Non-intervention variables that were found to be associated with recent HCV infection in 
these analyses (age, homelessness, imprisonment) are also consistent with previous studies 
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(Champion et al., 2004; Craine et al., 2009; Maher et al., 2006; Thorpe et al., 2002). There 
are no studies that have found an association between alcohol consumption and 
recent/incident HCV infection; however, previous studies have suggested a link between 
alcohol consumption and injecting risk behavior (Arasteh and Des Jarlais, 2009; Sander et 
al., 2010; Vidal-Trecan et al., 1998). The finding that those with shorter injecting histories 
(<5 years) had a higher odds of recent HCV infection, suggests that interventions targeted 
at new initiates to injecting may be important in reducing HCV incidence.  
The analysis presented in this chapter has a number of limitations. First, it was not 
specifically designed to examine OST as an intervention. The 2008-09 NESI survey did 
not collect information on methadone dosage from participants and, furthermore, 
methadone dosage remains a problematic measure of methadone coverage since an 
‘adequate’ dosage can vary greatly from person to person.  
Secondly, selection bias, which has been well documented in other studies of IEP 
programmes (Lurie, 1997; Palmateer et al., 2010), may be present here. Because 
recruitment was from sites that provide sterile injecting equipment (some of which will 
also dispense OST) rather than dedicated drug treatment sites, the NESI study is more 
likely to have sampled individuals who were receiving both OST and needles/syringes. 
The NESI survey will also have oversampled those on OST who continue to inject, since 
the proportion of non-current injectors (i.e. had not injected in the last six months) was 
confined to 25% of the sample. The survey may thus have been more likely to sample 
individuals receiving inadequate methadone dosages, because such individuals are likely 
getting injecting equipment in order to ‘top up’ with heroin; measures of OST 
effectiveness may therefore be underestimated. Recruitment at solely IEP sites may also 
bias the sample away from high risk injectors who are not in contact with services. 
Previous community-wide surveys undertaken in Glasgow showed that 90% of PWID 
recruited from street sites had visited IEP services in the past six months (Taylor et al., 
2000); however, exclusion of individuals not in contact with services may still lead to 
underestimation of the impact of interventions.  
Four recent infections among those who reported not injecting in the last six months were 
detected. Two of these four individuals reported receiving an HCV-positive result from a 
previous test. Possible reasons for this discrepancy could be false positive PCR results or 
false negative anti-HCV results. It is also plausible that the respondents were dishonest or 
incorrectly recalled their behaviour; however, other risk factors cannot be discounted, such 
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as tattooing, about which no information was collected in the questionnaire. Self-reported 
risk behaviour among PWID may be subject to social desirability or recall biases; however, 
it is unlikely to differ systematically between those who received/did not receive 
interventions or those with/without the outcome of interest. Respondents may have 
overestimated self-reported uptake of clean needles/syringes but the effect of this 
overestimation is likely to be non-differential. Thus, the 200% threshold is not meaningful 
in itself, except as an indicator of those with a higher ratio of clean needles/syringes to 
injections. However, it is recognised that the appropriate ratio of sterile needles/syringes to 
injections is important for policy-makers and injecting equipment providers, and therefore 
further work is required to elucidate this ratio.  
The approach to calculating incidence applied in this analysis is heavily dependent on 
accurate estimation of the duration of the pre-seroconversion window period, around which 
there is uncertainty (Glynn et al., 2005; Netski et al., 2005; Page-Shafer et al., 2008). 
Intervention uptake in the six months prior to interview was examined: because this time 
frame is longer than the upper estimates of the duration of the window period, this may 
contribute to some inaccuracy in the results.  
As stated in section 4.4, the laboratory test to detect antibodies to HCV on DBSs has been 
validated and has very high sensitivity and specificity (99% and 100%, respectively) (Judd 
et al., 2003); the respective values for the PCR test on DBSs are 100% and 96% (Bennett 
et al., 2012). Recent infections could have been missed if the sample was taken during a 
‘dip’ – a phase of undetectable viral load during a period of fluctuating viraemia that is 
observed, in some individuals, in the acute phase of HCV infection (Thomson, Smith, and 
Klenerman, 2011). Conversely, a small proportion of the recent infections might have been 
false positives. There is also a chance that chronic infections could have been misclassified 
as recent infections in the case of immunosuppressed individuals (for example, those 
infected with HIV (Thomson et al., 2009), who may have delayed seroconversion). Given 
the low HIV prevalence in the Scottish injecting population (Health Protection Scotland 
and University of the West of Scotland, 2008), this type of misclassification is unlikely to 
be a significant factor; however, other lifestyle factors may contribute to 
immunosuppression, including the use of opiates themselves (Vallejo, de Leon-Casasola, 
and Benyamin, 2004).   
In conclusion, this analysis utilised a method of generating incidence using a cross-
sectional design and demonstrated that high coverage of needles/syringes is associated 
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with a reduction in recent HCV infection among PWID in Scotland. Despite the large 
sample size, statistical power was nevertheless an issue, given that only 24 recent 
infections were detected among a sample of more than 1100 anti-HCV-negatives. 
Additional sweeps of this survey will increase the cumulative sample size (and therefore 
power to detect associations) and allow the examination of the impact of the increase in 
interventions delivered by the Hepatitis C Action Plan for Scotland.  
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Figure 5-1. Flowchart of respondents in the 2008-09 survey of PWID recruited from IEP sites 
across Scotland and laboratory results of anti-HCV and HCV-RNA testing 
aIncludes anti-HCV weak reactives 
 
 
  
Sample size 
2,749 
2,555 tested for 
anti-HCV 
1,367 (54%) anti-
HCV positivea 
1,188 (46%) anti-
HCV negative 
1,140 (96%) tested 
for HCV-RNA 
24 (2%)  
HCV-RNA positive 
48 insufficient 
or inhibitory  
1,116 (98%)  
HCV-RNA negative 
115 duplicate interviews 
5 incomplete questionnaires 
 
2,629 completed 
questionnaires 
74 refused or 
insufficient DBS 
  
Table 5-1. Descriptive characteristics of 1,140 anti-HCV negative PWID recruited from IEP sites across Scotland in 2008-09 and univariable logistic regression 
analyses of associations with recent HCV infection  
 
  No. anti-HCV 
negatives (N) 
No. recent 
infectionsa (n) % (n/N) 
Univariable 
Characteristic Categories OR 95% CI p-value 
Gender (5 NR) Male 835 17 2.0 1   
 Female 300 7 2.3 1.15 0.47-2.80 0.759 
Age 16-30 573 17 3.0 1   
 >30 567 7 1.2 0.41 0.17-0.99 0.048 
Region Greater Glasgow and Clyde 294 5 1.7 1   
 Elsewhere 846 19 2.2 1.33 0.49-3.59 0.576 
Homeless in last six months No 886 10 1.1 1   
Yes 254 14 5.5 5.11 2.24-11.65 <0.001 
Prison  
(2 NR) 
Never 641 9 1.4 1   
In the last six months 142 6 4.2 3.10 1.09-8.85 0.035 
In the past but not last six months 355 9 2.5 1.83 0.72-4.64 0.206 
Excessive alcohol consumption 
(last 12 months)b (6 NR) 
No 863 11 1.3 1   
Yes 271 13 4.8 3.90 1.73-8.82 0.001 
Time since onset of injecting  
(2 NR) 
<5 years 447 14 3.1 1   
≥5 years 691 10 1.4 0.45 0.20-1.03 0.059 
Stimulant injection in last six 
months 
No 1008 19 1.9 1   
Yes 132 5 3.8 2.05 0.75-5.58 0.161 
Received OST In the last six months (not currently) 33 3 9.1 1   
 Currently 725 13 1.8 0.18 0.05-0.68 0.011 
 Not in the last six months 382 8 2.1 0.21 0.05-0.85 0.028 
N/S coveragec,d <200% 506 16 3.2 1   
>200% 427 4 0.9 0.29 0.10-0.87 0.028 
Combined intervention coverage 
(N/S and OST)c,e 
Low 239 9 3.8 1   
Medium 419 8 1.9 0.50 0.19-1.31 0.157 
 High 458 6 1.3 0.34 0.12-0.97 0.043 
Filter coveragec,d <200% 804 19 2.4 1   
 ≥200% 129 1 0.8 0.35 0.05-2.65 0.307 
Spoon coveragec,d <200% 811 19 2.3 1   
 ≥200% 122 1 0.8 0.36 0.05-2.70 0.318 
NR: non-response; N/S: needle(s)/syringe(s) 
aAnti-HCV negative and HCV-RNA positive individuals 
bAs defined by UK Royal College of Physicians: >14 units/week for women and >21 units/week for men 
cSee methods for definitions of coverage 
dAmong individuals who reported injecting in the last six months 
eExcludes 24 respondents who reported not injecting and not receiving OST in last six months 
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Table 5-2. Multivariable logistic regression models examining the association between recent HCV infection and (i) OST and needle/syringe coverage as separate 
variables and (ii) combined OST and needle/syringe coverage among anti-HCV negative PWID recruited from IEP sites across Scotland in 2008-09 
   Univariable  Multivariablea 
   OR 95% CI p-value  AOR 95% CI p-value 
       (n=1,131)  
Model (i) Received OST In the last six months  1    1   
Currently 0.18 0.05-0.68 0.011  0.29 0.07-1.19 0.086 
 Not in the last six months 0.21 0.05-0.85 0.028  0.28 0.06-1.22 0.089 
          
 N/S coverageb <200% 1    1   
 >200% 0.29 0.10-0.87 0.028  0.32 0.10-1.00 0.050 
 Did not inject  0.60 0.20-1.83 0.372  1.30 0.38-4.43 0.674 
          
  
Combined intervention 
coverage (N/S coverage and 
OST)b 
     (n=1,107)  
Model (ii) Low 1    1   
Medium 0.50 0.19-1.31 0.157  0.50 0.18-1.35 0.170 
 High 0.34 0.12-0.97 0.043  0.48 0.16-1.48 0.203 
         
N/S: needle(s)/syringe(s) 
aAdjusted for region, gender, homelessness, imprisonment, time since onset of injecting and excessive alcohol consumption 
bSee methods for definitions of coverage 
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Table 5-3. Adjusted ORs for the association between interventions and recent HCV infection among anti-HCV negative PWID recruited from IEP sites across Scotland 
in 2008-09, stratified by effect modifying variables (n=1,131) 
   
   Multivariablea 
   N Recent HCV (n) Recent HCV (%) AOR 95% CI p-value 
Prescribed OST 
stratified by Scottish 
region 
GG&C Last six months 9 2 22.2 1   
 Currently 205 1 0.5 0.04 0.001-1.07 0.055 
 Not in the last six months 77 2 2.6 0.16 0.01-2.55 0.193 
        
Other Scottish regions Last six months 24 1 4.2 1   
Currently 515 12 2.3 0.73 0.08-6.64 0.777 
Not in the last six months 301 6 2.0 0.59 0.06-5.67 0.647 
         
GG&C: Greater Glasgow and Clyde 
aAdjusted for gender, homelessness, imprisonment, time since onset of injecting and excessive alcohol consumption  
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6 Scale-up of sterile injecting equipment and 
opioid substitution treatment among people who 
inject drugs in Scotland: evidence of impact on 
HCV transmission 
6.1 Introduction 
The review of the literature described in Chapter 2 highlighted that there is insufficient 
evidence demonstrating the effectiveness of certain harm reduction interventions – 
particularly IEP – on HCV transmission among PWID (Palmateer et al., 2010). This 
review was updated in 2011 (see section 2.4.1) and, although some of the evidence 
statements were strengthened in light of additional evidence, there was nonetheless only 
tentative evidence – at most – for the effectiveness of any of the interventions in 
preventing HCV transmission (Macarthur et al., 2014). These reviews also highlighted 
emerging evidence of a potentially synergistic impact of combined interventions, in that 
the combined effect may be greater than the impact of any of the interventions alone. Few 
studies have, however, examined the impact of combined harm reduction interventions 
(Turner et al., 2011; Van Den Berg et al., 2007) – including the analysis in Chapter 5 
(Allen et al., 2012) – and there remains a need to strengthen understanding of the 
effectiveness of OST and IEP, to inform public health policy (Smith-Spangler and Asch, 
2012; Vickerman et al., 2012). Furthermore, previous studies of the impact of IEP on HCV 
incidence have focused solely on sterile needle/syringe provision; no studies to date have 
directly examined the impact of providing injecting paraphernalia (primarily spoons and 
filters) in the prevention of HCV transmission (Gillies et al., 2010).  
The analysis in Chapter 5 found a significant association between sterile needle/syringe 
coverage and recent infection, but did not demonstrate an association with the other 
interventions (OST or paraphernalia). The absence of an association may have resulted 
from a lack of statistical power. The latter analysis utilised data from the first sweep (2008-
09) in a series of national cross-sectional surveys of PWID. This chapter examines the 
results of all three survey sweeps (2008-09, 2010 and 2011-12), presenting two 
advantages. First, these data allow the examination of trends in uptake of harm reduction 
interventions, risk behaviour and HCV incidence contemporaneous with a period of major 
service development in Scotland. Secondly, the pooling of these surveys helps to resolve 
sample size issues and generates the largest sample to have explored HCV transmission in 
relation to the combined effects of IEP and OST.  
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6.2 Methods 
In addressing the thesis objectives of determining HCV incidence and determining the 
association between uptake of harm reduction interventions and HCV transmission, this 
chapter builds on, and is informed by, the analysis in Chapter 5. Section 6.2.2.1 describes 
how these two approaches differ.  
6.2.1 Data collection and laboratory methods 
The data collection and laboratory methods for the NESI study have been described in 
detail in Chapter 4 (see sections 4.2.1 and 4.2.2). Briefly, PWID were recruited at sites that 
provide sterile injecting equipment (and usually other harm reduction interventions, such 
as methadone) across mainland Scotland in three cross-sectional surveys undertaken in 
2008-09, 2010 and 2011-12. People who had injected drugs in the past were eligible to 
participate, although the majority of participants were currently injecting (defined as 
having injected in the last six months). Individuals who consented to participate were 
asked to complete an interviewer-administered questionnaire and to provide a blood spot 
for laboratory testing for HCV markers.  
In addition to data from the NESI study, data on the provision of OST and IEP in Scotland 
were collated from routine reports published in the grey literature (Information Services 
Division, 2012b; Information Services Division, 2013; Public Health England et al., 2013). 
6.2.2 Analysis 
The hierarchy of epidemiological study designs in relation to the investigation of public 
health interventions was discussed in section 1.8. The difficulties in undertaking what 
would traditionally be considered ‘robust’ study designs to evaluate such interventions 
have been well documented. Indeed, the review of reviews (Chapter 2) found that most 
study designs that have been undertaken to investigate the impact of harm reduction 
interventions were non-randomised, with the exception of a few RCTs investigating OST. 
It is perhaps, then, unsurprising that a randomised evaluation of the impact of the scale-up 
of harm reduction interventions in Scotland was not feasible. Nevertheless, some common 
themes that have emerged from evaluations of public health interventions, in relation to 
causal attribution, are the need to understand processes/theories of change and the 
combination of evidence generated from different non-experimental study designs. The 
analytical approach applied in this chapter borrows from these themes.   
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First, drawing on the theme of theories of change, an analytical framework was produced 
to guide the analysis (Figure 6-1). Strictly speaking, a theory of change or process 
evaluation for these interventions might go even further back than provision, perhaps 
seeking to understand exactly how each of the elements of the National Needle Exchange 
Guidelines were implemented in the NHS Boards. For example, training of needle 
exchange staff, if well implemented, might influence uptake of interventions and risk 
behaviour of clients. It was not possible to undertake such an evaluation for the purposes of 
this thesis; however, this framework nevertheless highlights the comprehensive approach 
being taken here, given that previous analyses of the impact of NSP and OST have 
generally focussed on one or two associations (Turner et al., 2011; Van Den Berg et al., 
2007). The objective here was to describe each of the elements of the framework, as well 
as the relationships between them, in order to build an overall picture of the potential 
mechanisms between provision of interventions and HCV transmission. The framework is 
divided into interventions (boxes 1 to 3), intermediate determinants (boxes 4 to 9), 
outcome (box 10) and relationships (represented by letters A to M). The sources of 
evidence to populate the framework are indicated in Table 6-1: unless otherwise indicated, 
most of the evidence was derived from analysis of NESI data, described further below. All 
of the information was collated and summarised in a table, as a means of capturing the 
evidence for the framework.  
Secondly, in relation to combining evidence from different study designs, the approach 
taken here is similar to that proposed by Kirkwood et al. (1997), who advocate the use of 
three comparisons: (i) the pre- vs. post-intervention comparison, (ii) the intervention vs. 
control comparison and (iii) the (post-intervention) adopters vs. non-adopters comparison. 
The major difference here, as compared to the analyses of the association between harm 
reduction interventions and recent HCV in Chapter 5, is obviously the addition of two 
survey sweeps. This serial aspect permits the examination of time trends in the data and 
therefore enables a pre- vs. post-intervention comparison (henceforth referred to as an 
‘ecological’ or ‘group-level’ analysis). It was not possible to generate an intervention vs. 
control comparison; however, an adopters vs. non-adopters comparison was undertaken on 
the pooled data from all three surveys (henceforth referred to as the ‘individual-level’ 
analysis).  
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6.2.2.1 Outcome measure 
As previously described, recent infections were defined as individuals in the ‘viraemic pre-
seroconversion window period’, i.e. individuals who were anti-HCV negative and positive 
for HCV-RNA. Incidence was derived using the same formula applied in Chapter 5. The 
formula generates a rate per person-years of time and will be referred to as the ‘derived’ 
HCV incidence throughout this chapter. In Chapter 5, the uncertainty range surrounding 
the derived HCV incidence was generated by using the lower and upper pre-
seroconversion window period bounds reported in the literature. In this chapter, one of 
these estimates of the duration of the window period (mean 51 days) (Page-Shafer et al., 
2008), and its variance (56 days), was applied. Ninety-five percent CIs for the incidence 
rates were generated by: (i) sampling 1,000 values from each of the binomial and normal 
distributions relating to the number of recent infections and the window period, 
respectively; (ii) using the sampled values from (i) in the formula to generate a distribution 
for the incidence rates; and (iii) taking the 2.5th and 97.5th percentile values from (ii) to 
generate the lower and upper confidence limits. This process was undertaken for each 
survey year using R (2.8.1) statistical software. 
In order to validate the derived HCV incidence estimates, HCV prevalence among those 
who commenced injecting within the last 12 months was also examined, based on the 
assumption that HCV infection will have been acquired since initiation of injecting. 
6.2.2.2 Intervention measures 
Variables categorising participants into high and low ‘coverage’ of each injecting 
equipment item were created by dividing the self-reported number of items 
(needles/syringes, spoons, filters, or water ampoules) obtained in the last six months, by 
the self-reported number of injections undertaken in the last six months. The threshold for 
high coverage (≥200%) was chosen as described in Chapter 5. Further work was also done 
to examine the association between needle/syringe coverage and recent HCV infection. 
With the additional sample size afforded by the pooled dataset (2008 to 2012), it was 
possible to calculate the odds of recent HCV infection for a large number of needle/syringe 
coverage groups: the findings from this approach provided further support for the choice of 
200% as the threshold (results presented in Appendix F).   
The spoon and filter coverage variables were further combined into a single variable called 
paraphernalia coverage, such that those who reported high coverage of both spoons and 
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filters were classified as having high paraphernalia coverage, with the remaining falling 
into the low category. Water coverage was not considered in this chapter since self-
reported sharing of water (for mixing with drugs or rinsing needles/syringes) was not 
found to be associated with recent HCV infection in the analyses of NESI data described in 
Chapter 4.  
Participants were also categorised by whether they reported being on OST at the time of 
the survey (yes or no). These categories were different from the categories chosen in 
Chapter 5, but ensured a more even distribution of the sample across the categories. (The 
categories in Chapter 5 involved using the ‘in the last six months but not currently’ group 
as the comparator; however, there were only 84 people in this group5.) A simplified 
measure of OST was therefore preferable for increasing power when stratifying by 
additional variables and for combining OST with other interventions. Those who reported 
not injecting in the last six months and no uptake of any interventions were excluded from 
the analyses (n=157, 2.2% of the pooled sample).  
For the purposes of comparing trends over time at the group-level, an additional coverage 
measure was calculated by dividing published numbers of injecting equipment items 
distributed (Information Services Division, 2013) by estimates of the total number of 
injections annually among Scottish PWID (the latter generated by multiplying the 
estimated mean annual number of injections per PWID from NESI by estimates of the size 
of the injecting population (Overstall et al., 2014)).  
6.2.2.3 Group-level and ecological analysis 
Ecological analysis refers to the derivation of conclusions regarding the association 
between interventions and outcomes that occur contemporaneously, where the unit of 
analysis is the population rather than the individual (Coggon, Rose, and Barker, 2009). 
Here, the ecological analysis simply involved examining the group-level statistics and 
considering the plausibility of associations between them. For the associations between 
provision and uptake of interventions (relationships A, B and C in Figure 6-1), only 
ecological analysis is possible since provision, as measured here, is a group-level variable.  
                                                 
5
 The analyses in Chapter 5 were re-run on the pooled (2008  to 2012) dataset (see Appendix G): 
the updated multivariable analysis produced very similar effect sizes and essentially resolved 
the issue of lack of power, as evidenced by reduced p-values. 
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Group-level refers to the statistics (proportions or means) that describe the interventions, 
intermediate determinants and outcomes (i.e. the boxes in Figure 6-1), and any changes 
therein. The following were compared across the three surveys: (i) harm reduction 
intervention uptake, (ii) risk behaviour, (iii) HCV prevalence and (iv) HCV incidence. 
Statistical significance was assessed using either the Mantel-Haenszel test for trend (called 
the linear-by-linear association in SPSS output) for categorical variables or analysis of 
variance (ANOVA) for continuous variables. In the ecological analyses, ‘adequate’ 
coverage was defined as at least one sterile item per injection (i.e. ≥100%). With regard to 
risk behaviour, ‘sharing’ was defined as the use of an item of injecting equipment after it 
had previously been used by someone else.  
Respondents who had participated multiple times (duplicates) were identified using 
forename and surname initials, date of birth, gender and NHS Board of interview. The first 
interview was retained for analysis, unless more complete laboratory results were available 
from a subsequent interview. Duplicates were identified from within each survey (i.e. only 
individuals who participated more than once in a given survey were removed). There were 
115 (1.4%), 147 (1.8%) and 40 (0.5%) duplicates identified within the 2008-09, 2010 and 
2011-12 surveys, respectively. 
6.2.2.4 Individual-level analysis 
Individual-level analysis refers to the derivation of the associations between interventions 
and outcomes at the individual level, i.e. the intervention and outcome pair is known for 
each individual in the study sample. Analysis was conducted on the pooled dataset 
generated from combining the three surveys. Duplicates were identified using the criteria 
described above, except that individuals who participated more than once across the entire 
period, 2008 to 2012, were removed. Out of a total of 8,253 questionnaires, 5,966 (72%) 
were from individuals who participated only once across the period, with the remaining 
2,287 questionnaires corresponding to 1,022 individuals who had participated two or more 
times. As described above, the first interview was retained for analysis unless more 
complete laboratory results were available from a subsequent interview, leading to the 
exclusion of 1,265 (15%) out of the 8,253 questionnaires. However, given that this 
approach would generally result in the exclusion of more interviews undertaken in the later 
surveys (131 in 2008-09 as compared with 587 in 2010 and 547 in 2011-12), sensitivity 
analyses were undertaken to examine the effect of preferentially including interviews from 
the latter years (see section 6.2.2.5 for details of sensitivity analyses).  
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Logistic regression was used to investigate the associations D through M (Figure 6-1). 
Univariable analyses were undertaken to explore the associations between the dependent 
and independent variables in each relationship of interest (i.e. the respective associations 
between intervention uptake and risk behaviour, between risk behaviour and HCV and 
between intervention uptake and HCV). Confounding variables that were considered 
included survey year, gender, age, homelessness and stimulant injection (in the last six 
months), time since onset of injecting, imprisonment (ever) and alcohol consumption (last 
12 months). The general approach to model-building involved inclusion of the 
independent, dependent and all potential confounding variables in a model and 
subsequently removing confounding variables on the basis of having the largest p-value of 
the Wald statistic, until a model with only statistically significant variables was reached. 
Where it was felt that a variable should be included irrespective of statistical significance – 
for example, survey year – that variable was forced into the model(s). Logistic regression 
analyses were undertaken in SPSS version 21. 
For the investigation of the association between intervention uptake and HCV, five 
multivariable models were built to examine the association with recent HCV of (self-
reported): (i) needle/syringe coverage, (ii) paraphernalia coverage, (iii) OST, (iv) 
needle/syringe coverage and OST and (v) all three interventions combined. Weighted 
versions of the models were subsequently run in Stata version 9. Sampling weights 
(pweights in Stata) were set to be equal to the number of times that a respondent reported 
injecting in the six months prior to interview. Thus, observations from individuals who 
reported injecting more times counted more heavily in the analysis than those who reported 
injecting fewer times. All sampling weights were increased by one, such that individuals 
who reported not injecting in the last six months would be included in the analysis (with a 
weight equal to one). 
6.2.2.5 Sensitivity analysis 
A sensitivity analysis was undertaken to examine the effect of varying several parameters 
in the multivariable model examining combined needle/syringe coverage, paraphernalia 
coverage and OST (model (v) above). The aspects of the model that were varied were: (i) 
inclusion of continuous rather than categorical confounding variables or vice versa (for 
survey year and time since onset of injecting) and (ii) use of different criteria for the 
identification of duplicates (i.e. where a respondent participated multiples times across the 
surveys, the last interview was included).  
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6.2.2.6 New infections and infections averted 
The number of new chronic HCV infections was estimated for each calendar year from 
2008 to 2012 by combining the derived incidence rates with published estimates of the size 
of the PWID population (Overstall et al., 2014), estimates of anti-HCV prevalence from 
NESI and published estimates of the proportion of HCV-infected individuals who develop 
chronic infection (Micallef, Kaldor, and Dore, 2006). It was assumed that the size of the 
PWID population remained stable during this period. The method for generating a 
distribution of values for the incidence rates was described above. Additionally, posterior 
distributions for (i) the size of the PWID population, (ii) the proportion anti-HCV negative 
and (iii) the proportion that develop chronic infection, were generated. One thousand 
values were sampled from each of these distributions. The sampled values for the number 
of PWID were multiplied by those for the proportion anti-HCV negative, to generate a 
distribution for the number of susceptible PWID (i.e. number of anti-HCV negatives). The 
latter were then multiplied by the sampled incidence values and the sampled values for the 
proportion developing chronic infection, to generate a distribution (and 95% CIs, as also 
described above) for the number of new chronic HCV infections. An estimate of the 
number of HCV infections (all and chronic) potentially averted by harm reduction 
interventions over the period from 2008 to 2012 was calculated by subtracting the sum 
total of the calculated yearly estimates from that which would have been observed 
assuming the number of infections in 2008 had remained constant. 
6.3 Results 
Table 6-2 summarises the demographic characteristics of the study population by survey 
sweep. More than 2,000 participants were recruited in each sweep. Nearly three quarters of 
the sample were male and this proportion was consistent across the surveys. Significant 
differences in several variables were noted between the surveys: mean age increased from 
33.6 in 2008-09 to 35.3 in 2011-12 (p<0.001), as did mean time since onset of injecting, 
with respective figures of 10.5 and 11.6 years (p<0.001). The proportion of respondents 
who reported homelessness in the last six months decreased slightly from 27% to 22% 
(p<0.001), as did the proportion who reported injecting stimulants (23% to 15%, p<0.001). 
A summary of the evidence for each of the elements of the framework is provided in Table 
6-3, and discussed in more detail below.  
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6.3.1 Group-level analysis 
The major changes in provision of interventions (boxes 1, 2 and 3 in Figure 6-1) that took 
place over the period of study were increases in the provision of filters and spoons by six-
fold and four-fold, respectively, between 2008/09 and 2009/10 financial years (Table 6-4). 
By contrast, provision of needles/syringes remained approximately stable over the period, 
hovering at around 4.7 million distributed annually, albeit with minor relative fluctuations. 
The number of methadone prescriptions dispensed in Scotland increased only slightly up 
until 2010/11 and then declined by 4% in 2011/12. 
With regard to harm reduction intervention uptake (boxes 4 to 6 in Figure 6-1), the 
proportion who reported currently receiving OST increased from 50% to 64% (p<0.001) 
between 2008-09 and 2011-12 (Table 6-5). Despite the slight decline in the median number 
of sterile needles/syringes obtained (based on self-reported survey data), the proportion of 
individuals with adequate needle/syringe coverage was more or less stable (ranging from 
75% to 79%) because of simultaneous declines in the frequency of injecting. The 
proportion of individuals with adequate coverage of filters and spoons increased between 
2008-09 and 2011-12 (from 24% to 69% and from 20% to 70%, respectively, both 
p<0.001). Using the measure of IEP coverage based on service provision data, the 
proportion with adequate needle/syringe, filter and spoon coverage increased from 53% to 
74%, 4% to 40% and 6% to 39%, respectively. These changes were mostly attributable to 
declines in the frequency of injecting. 
The proportion of respondents reporting various risk behaviours in the last six months 
declined across the surveys (Table 6-5): injecting daily or more frequently (from 63% to 
49%, p<0.001), sharing needles/syringes (from 15% to 8%, p<0.001), reusing one’s own 
needles/syringes (64% to 45%, p<0.001), sharing spoons (42% to 20%, p<0.001), sharing 
filters (33% to 17%, p<0.001) and sharing water (31% to 21%, p<0.001).  
The results of laboratory analysis of DBS samples are presented in Table 6-6. Across all 
the surveys, a total of 53 recent infections were detected among 3,459 susceptible (i.e. anti-
HCV negative) individuals. The prevalence of anti-HCV ranged from 53% to 56% but did 
not differ significantly across the surveys. The proportion with recent HCV infection 
decreased from 2.1% (95% CI 1.4%-3.1%) in 2008-09 to 0.9% (95% CI 0.4%-1.7%) in 
2011-12 (X2 test for trend: p=0.02). The derived incidence rates per 100 person-years 
(among PWID, current) reduced from 13.6 (95% CI 8.1-20.1) in 2008-09, to 7.3 (3.0-12.9) 
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in 2011-12. HCV prevalence rates among those who commenced injecting within the last 
year were comparable to the derived incidence rates for the respective years (Figure 6-2), 
declining from 20.1% (95% CI 13.9%-27.6%) in 2008-09 to 8.2% (95% CI 3.4%-16.2%) 
(p=0.030).  
6.3.2 Individual-level analysis 
The individual-level associations between uptake of the interventions and IRB 
(relationships D, E and F) are presented in Tables 6-7, 6-8 and 6-9 and summarised in 
Table 6-3: high coverage (≥200%) of needles/syringes, spoons and filters was significantly 
associated with approximately 55%, 35% and 20% reductions, respectively, in the odds of 
having shared these items in the last six months. Currently being on OST was associated 
with a nearly 80% reduction in the odds of injecting daily or more frequently in the last six 
months (Table 6-10). 
With regard to the associations between sharing injecting equipment and recent HCV 
infection (relationships H and I), in Chapter 4 the odds of recent HCV infection were 
estimated to be seven-fold and three-fold for sharing needles/syringes and sharing 
paraphernalia in the last six months, respectively, as compared with no sharing. The 
analysis of the association between frequency of injecting and recent HCV infection 
(relationship J) is presented in Table 6-11: it was not statistically significant after 
adjustment for potential confounders (AOR 1.45, 95% CI 0.80-2.63, p=0.218). Because 
this association is an indirect one, i.e. the effect of injecting frequency on HCV 
transmission is mediated through sharing injecting equipment, the associations between 
frequency of injecting and sharing injecting equipment were also examined. This analysis 
showed that the risk of sharing either needles/syringes, spoons or filters was three times 
higher among those who injected daily or more frequently than among those who did not 
(Tables 6-12 to 6-14).  
Table 6-15 presents the univariable and multivariable analyses of the associations between 
uptake of harm reduction interventions and recent HCV infection (relationships K, L and 
M in Figure 6-1). The full models, including covariates, are included in Appendix H. The 
findings indicated that individuals with high needle/syringe or high paraphernalia coverage 
had lower proportions of recent HCV infection (0.9% and 0.7%, respectively) as compared 
with those on low coverage of these interventions (2.4% and 2.0%, respectively). 
Individuals on OST at the time of survey had a lower proportion recently infected (1.3%) 
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as compared with those not on OST (2.5%). The effect of the weighting was generally to 
amplify the differences in incidence between the high and low coverage groups.  
In multivariable unweighted analyses, both high needle/syringe and paraphernalia coverage 
were associated with reduced risk of recent HCV (AOR 0.39, 95% CI 0.19-0.83, p=0.014 
and AOR 0.39, 95% CI 0.14-1.12, p=0.081, respectively) relative to those with low 
coverage. In weighted analyses, both AORs moved farther away from null (weighted 
adjusted odds ratio [AORw] 0.14, 95% CI 0.04-0.48, p=0.002 for needle/syringe coverage 
and AORw 0.11, 95% CI 0.03-0.44, p=0.002 for paraphernalia coverage). Current OST, 
alone, was not statistically associated with recent infection in either unweighted or 
weighted analyses (AOR 0.63, 95% CI 0.35-1.12; and AORw 0.52, 95% CI 0.23-1.18, 
respectively).  
Model (iv) examined the combined effects of needle/syringe coverage and OST. With the 
exception of those who did not inject in the last six months (the last category), there was a 
general downward gradient in incidence with increasing coverage of interventions, and this 
trend was more apparent in the weighted incidence. In the unweighted analyses, those with 
high needle/syringe coverage had significantly lower odds of recent infection, whether also 
on OST or not (AOR 0.28, 95% CI 0.08-0.96 and AOR 0.29, 95% CI 0.11-0.74). This 
pattern was also true for the weighted analyses, although there was a slight difference 
between the effect sizes, with those on high needle/syringe coverage and current OST 
exhibiting a greater reduction in risk (AORw 0.05, 95% CI 0.01-0.18) as compared to those 
on high needle/syringe coverage and no OST (AORw 0.18, 95% CI 0.04-0.87).  
Model (v) further stratifies the results by intervention uptake. Figure 6-3 presents the 
unweighted and weighted proportions recently infected with HCV for the different strata. 
As above, a general downward trend in incidence with increasing coverage is seen, which 
is more pronounced in the weighted data. The highest incidence of HCV (3.5% unweighted 
and 3.9% weighted) was among the baseline group of those on the lowest coverage of all 
three interventions.  
Among PWID with low coverage of both needles/syringes and paraphernalia, the results 
were suggestive of a reduction in risk of approximately 40% for those on current OST (this 
can be also seen by the difference in the height of the two left-hand bars in Figures 6-3a 
and 6-3b); although, as before, it was not statistically significant after adjustment for 
covariates (AOR 0.55, 95% CI 0.27-1.11; AORw 0.58, 95% CI 0.25-1.34). There were no 
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recent infections in the ‘low needle/syringe, high para’ groups, due to very small numbers 
(approximately 50 in both groups combined), and therefore it was not possible to calculate 
ORs for these groups (and they are excluded from Figure 6-3 and Table 6-15). Moving 
from low to high needle/syringe coverage was associated with lower HCV incidence, 
although the larger difference was seen among those not on OST (3.5% to 1.0% 
unweighted; 3.9% to 0.8% weighted) as compared to those on OST (1.7% to 0.9% 
unweighted; 2.0% to 0.1% weighted).  
In unweighted analyses, those who were on the highest coverage of interventions (high 
coverage of needles/syringes, high coverage of paraphernalia and current OST) had 
significantly lower odds of recent infection relative to those on the lowest coverage of 
interventions (AOR 0.28, 95% CI 0.08-0.097, p=0.044). This effect size was not, however, 
substantially different from the group on high needle/syringe coverage and current OST, 
but low paraphernalia coverage (AOR 0.28, 95% CI 0.08-0.98, p=0.046). In weighted 
analyses, those who had high needle/syringe coverage and were on OST, regardless of 
paraphernalia coverage, had significantly lower odds of recent HCV (AORw 0.02, 95% CI 
0.01-0.09 and AORw 0.07, 95% CI 0.01-0.35 for those with low and high paraphernalia 
coverage, respectively). Similar to the unweighted analyses, there was no appreciable 
difference in magnitude between the latter two effect sizes, or between the effect sizes for 
those in the ‘high needle/syringe, low para, no OST’ group vs. the ‘high needle/syringe, 
high para, no OST’ group; this can also been seen from Figure 6-3b. 
6.3.3 Sensitivity analysis 
The results of the sensitivity analysis are shown in Table 6-16, and demonstrate that the 
combined multivariable (unweighted) model is relatively robust with respect to variation in 
the use of continuous or categorical variables for survey year and time since onset of 
injecting. Varying the criteria for defining duplicate records changed the effect sizes 
marginally, as well as the p-values.  
6.3.4 New infections and infections averted 
The estimated number of new infections per year declined from 1063 (95% CI 591-1682) 
in 2008 to 566 (95% CI 205-1039) in 2012 (Table 6-17). With regard to new chronic 
infections, these have potentially declined from 787 (95% CI 441-1248) in 2008 to 419 
(95% CI 152-774) in 2012. It is estimated that approximately 1,400 new infections and 
1,000 new chronic infections may have been averted during 2008-2012. 
Chapter 6  160 
 
6.4 Discussion 
In this analysis of data from a series of cross-sectional studies undertaken during a period 
of major developments in harm reduction services in Scotland, a decline in HCV incidence 
among Scottish PWID was observed. This finding is corroborated by a similar trend 
observed in prevalence of HCV among recent initiates to injecting, which can be 
considered a proxy for incidence. Several factors are likely to have contributed to the 
declining incidence of HCV: determining the contributions of individual interventions is 
the challenge.  
This analysis applied a framework approach in order to bring together evidence for all of 
the steps and relationships on the pathways from interventions to outcome. Considering 
first the ecological/group-level analysis: with regard to the provision of interventions, it 
would appear that the largest change was the increase in distribution of filters and spoons.  
The contemporaneous increase in the self-reported uptake of filters and spoons over the 
three surveys (both numbers of items and coverage) would appear to reflect this change in 
provision. Furthermore, the increases in uptake of paraphernalia were mirrored by 
significant declines in the self-reported sharing of these items over the period, as would be 
expected.  
By contrast, the finding of a decline in the self-reported numbers of sterile needles/syringes 
obtained by individuals is apparently inconsistent with the relatively stable numbers of 
needles/syringes distributed, as reported in national service-level data. Stratifying the data 
by NHS Board reveals that this downward movement is mainly restricted to the Greater 
Glasgow and Clyde NHS Board, but is reflected in the overall results because of the large 
proportion of the overall sample constituted by this NHS Board (~45%). Rather than 
indicating a real decline in the numbers of needles/syringes obtained per individual, this 
observation could be a result of differences in the sampling frame in Greater Glasgow and 
Clyde – for logistic reasons, different recruitment sites were used in 2008-09 as compared 
with the subsequent surveys.  
A further discrepancy lies between the numbers of needles/syringes and paraphernalia: 
while the self-reported data indicate that the uptake of paraphernalia is approximately the 
same as that of needles/syringes, the provision data show that the numbers of spoons and 
filters distributed annually remain substantially lower than the numbers of needles/syringes 
distributed. A potential explanation is that the NESI study population is biased toward 
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including individuals with a higher uptake of paraphernalia. This explanation is plausible 
because, again, such a large proportion of the study sample was recruited in Greater 
Glasgow and Clyde, where the service-level data do, in fact, indicate that spoons and filters 
are distributed in approximately equal quantities to needles/syringes (Information Services 
Division, 2013). Consequently, the proportion reporting high paraphernalia uptake in the 
NESI surveys may be an overestimate, but the observation of an upward trend is 
nevertheless valid.  
Interestingly, the decrease in self-reported numbers of needles/syringes obtained by 
respondents is mirrored by a decline in the frequency of injecting, such that the proportion 
of PWID reporting high needle/syringe coverage across the three surveys remained more 
or less stable. This observation suggests that the finding of a lower self-reported uptake of 
sterile needles/syringes is perhaps explained by a lower need for them. By contrast, the 
alternative measure of coverage (based on needle/syringe provision figures) showed an 
increase from approximately half to three quarters of PWID with adequate coverage. Given 
that this measure was based on stable numbers of needles/syringes distributed, it was again 
the declining frequency of injecting that caused the change (from a mean of approximately 
550 injections per PWID down to 400 in 2011-12). The observed reduction in reported 
needle/syringe-sharing is perhaps more consistent with increasing needle/syringe coverage. 
Otherwise, the decline in sharing might be explained by a potential improvement in the 
quantity/quality of education that is being provided during injecting equipment 
transactions, as recommended in the national guidelines (Scottish Government, 2010), 
leading to a greater awareness of the risks of injection. Thus, if PWID have usually been 
obtaining sufficient needles/syringes for their injections but not using all of them, coverage 
could feasibly stay the same while sharing goes down. A similar enigma was observed for 
water: self-reported sharing of water declined despite distribution of sterile water ampoules 
not having greatly increased. 
The increase in self-reported uptake of OST among survey participants also occurred 
contemporaneously with more or less stable dispensation of methadone prescriptions. 
Speculatively, if the PWID population had decreased, this might explain how stable levels 
of prescriptions could translate into an increase in the uptake of OST. The increased uptake 
of OST was further mirrored by a decrease in the self-reported frequency of injecting 
across the three surveys.  
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From an ecological perspective, there is thus a situation whereby data on the provision of 
interventions, uptake of interventions and corresponding risk behaviour usually, but not 
always, paint a consistent picture. So, while ecological analyses can give an overview of 
trends, they generally do not provide insight into the relationships and, moreover, can 
highlight discrepancies in the findings that need to be further investigated using individual-
level analyses.  
The crux of the individual-level analyses was the examination of the associations between 
self-reported uptake of interventions and recent HCV, with the analysis of the other 
relationships on the pathway providing explanatory context. In the results of the 
unweighted multivariable analyses for the three interventions independently, both 
needle/syringe and paraphernalia coverage were associated with reduced risk of recent 
HCV infection, although these models were not adjusted for the other respective 
interventions. Notably, these associations represent risks per individual, and individuals 
may have injected few or many times. Several of the associations that were not statistically 
significant in unweighted analyses became significant in weighted analyses, and indeed 
many of the effect sizes also changed, indicating that the frequency of injecting of 
individuals in particular intervention/outcome groups is potentially obscuring some of the 
intervention impact in the unweighted models. For example, the AOR for high 
needle/syringe coverage reduced from 0.39 to 0.14; the reason for this reduction was that 
those with low needle/syringe coverage – in particular, the incident infections – reported 
injecting more frequently, whereas those with high needle/syringe coverage – also the 
incident infections in particular – reported injecting less frequently. The weighting 
therefore had the effect of amplifying the difference in the proportion of recent infections 
between the low and high coverage groups, moving the effect size further from null. 
No significant association between uptake of OST, alone, and recent HCV was observed, 
in either unweighted or weighted analyses. It is possible that there was insufficient power 
to detect an effect – given that OST coverage is so high in this study population, the 
smaller sample in the lower coverage group reduces power, particularly when stratifying 
for other factors. A further consideration is that the association between OST and HCV is 
an indirect one, since OST affects frequency of injecting, which is not in itself a mode of 
HCV transmission (as is sharing needles/syringes). The theory is that higher OST uptake 
should reduce HCV risk, by reducing the frequency of injecting and, consequently, the 
probability of sharing injecting equipment. These analyses confirmed that OST was 
associated with a reduced frequency of injecting, and that lower frequency of injecting was 
Chapter 6  163 
 
associated with less sharing of all types of equipment. From the unadjusted proportions 
with recent infection, it appeared that OST had a larger effect among those on low 
coverage of needles/syringes and paraphernalia, which would be expected, given that the 
impact of injecting frequency on HCV transmission would be augmented if insufficient 
sterile equipment was being used.  
Despite there being no effect of OST alone, it was associated with recent HCV in 
combination with needles/syringes: being on OST and having high coverage of 
needles/syringes were associated with a greater reduction in risk of recent HCV (in 
weighted analyses, a 95% reduction in risk) as compared with either of the separate 
intervention effects, although the analysis was underpowered to demonstrate that the 
combined effect was statistically different from either independent effect. 
In the combined interventions model stratified for paraphernalia, there was little difference 
in effect size between the groups with low and high paraphernalia coverage when the other 
interventions were kept the same, indicating that the association between paraphernalia 
coverage and HCV is likely confounded by needle/syringe coverage. The lack of 
association between paraphernalia coverage and recent HCV might be explained by 
relationships between the intermediate determinants on the pathways between 
interventions and HCV: the individual-level analysis found that uptake of paraphernalia is 
associated with a lower reduction in sharing as compared with uptake of needles/syringes 
(i.e. although PWID are obtaining paraphernalia from services, they are not using all of it). 
This finding is consistent with the observation from the group-level analyses that sharing 
of spoons and filters still remains higher than that of needles/syringes, despite coverage of 
spoons/filters having potentially reached the same level as needle/syringe coverage. For 
example, evidence suggests that residual drug can be retained in the filter after injecting 
(Keijzer and Imbert, 2011), thereby potentially encouraging their reuse even when sterile 
ones are available.   
Further down the pathway, the evidence presented here suggests that there is potentially a 
lower risk (per individual) of HCV transmission associated with sharing paraphernalia (as 
compared with the risk associated with sharing needles/syringes), such that a reduction in 
sharing paraphernalia might have less of an effect on transmission as compared to a 
reduction in needle/syringe-sharing. Thus, these two elements – the weaker association 
between paraphernalia-uptake and paraphernalia-sharing, and the weaker association 
between paraphernalia-sharing and HCV transmission – may act to ‘dilute’ the association 
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between paraphernalia-uptake and recent HCV. In other words, providing sterile 
needles/syringes is likely more efficient in preventing HCV transmission than providing 
sterile paraphernalia.   
The findings regarding paraphernalia coverage do not necessarily mean that providing 
paraphernalia is ineffective with regard to preventing HCV transmission. To evaluate the 
impact of sterile paraphernalia, one would ideally compare the incidence rates between 
high and low paraphernalia coverage groups solely among those with low needle/syringe 
coverage. This comparison was not possible here because there were too few people in 
these groups, as a result of the fact that uptake of paraphernalia generally goes hand-in-
hand with uptake of needles/syringes. It is possible that these analyses are underpowered to 
detect an effect and that pooling further sweeps of NESI would enable this comparison 
with a larger sample size. A further consideration is that, for sharing paraphernalia to pose 
a risk of HCV transmission, it must first become contaminated with blood from a used 
needle/syringe. Thus, the risk from sharing paraphernalia is dependent on the rates of reuse 
or sharing of needles/syringes, both of which have declined over the period of study. 
Regardless, there have been no harms from distributing paraphernalia and, furthermore, 
sterile paraphernalia may have had an impact with regard to preventing bacterial 
infections: that sharing rates have gone down indicates that the injecting hygiene message 
is reaching PWID. If the rates of needle/syringe-sharing or reuse in Scotland were to rise, 
the availability of sterile paraphernalia might become more critical in preventing HCV 
transmission. 
6.4.1 Comparability of these results with other published findings 
Scotland is one of few countries in the world to have a surveillance system, with national 
coverage, that generates serial measures of HCV incidence. While one-off studies have 
been done to measure incidence in regional populations of PWID in the UK (Craine et al., 
2009; Hope et al., 2011; Judd et al., 2005a), it is not known whether the decline in HCV 
incidence observed here has been replicated elsewhere in the UK. Internationally, others 
have reported reductions in HCV incidence among PWID; however, these reductions have 
tended to be over very long periods of time (often decades), restricted to regional 
populations, involving smaller sample sizes than the sample size used in this chapter and/or 
involving lower coverage of interventions as compared with Scotland (Iversen et al., 2013; 
van den Berg et al., 2007). Furthermore, it is notable that the declines in HCV observed 
elsewhere occurred within the context of major shifts away from heroin and/or injecting 
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(de Vos et al., 2013; Iversen et al., 2013). Although this analysis observed a reduction in 
frequency of injecting (related to increased prescribed methadone), Scotland continues to 
have a large heroin-injecting population. Thus, other countries with persistent injecting 
populations can draw inferences on the potential impact of high coverage IEP and OST 
from these findings.  
The findings presented here regarding OST are in contrast to other reports in the literature, 
which have found a significant association between OST uptake and HCV. In a synthesis 
of UK data, Turner et al. (2011) found that receiving OST was associated with an 
approximately 60% reduction in odds of incident HCV (AOR 0.41, 95% CI 0.21–0.82). 
However, another meta-analysis of studies of OST and HCV incidence found a broadly 
similar result to the findings of this analysis, with a pooled RR of 0.60 (95% CI 0.35-1.03) 
(Hagan, Pouget, and Des Jarlais, 2011).  
Turner et al. also found that high needle/syringe coverage was associated with a reduced 
risk of recent HCV (AOR 0.48, 95% CI 0.25–0.93). This finding was very similar to the 
adjusted (unweighted) effect size reported in this analysis of 0.39 (95% CI 0.19-0.83). In 
contrast, the effect size for needles/syringes calculated by Hagan, Pouget, and Des Jarlais 
(2011) actually suggested an increased risk (pooled RR 1.62, 9% CI 1.04-2.52), as they 
found only one study (of a total of seven) that demonstrated a reduction in risk of HCV 
associated with needle/syringe use.  
Finally, Turner et al. determined that ‘full’ harm reduction (i.e. on OST plus high 
needle/syringe coverage) reduced the odds of new HCV infection by nearly 80% (AOR 
0.21, 95% CI 0.08–0.52), which is similar to the (unweighted) AOR for combined 
coverage of 0.29 (95% CI 0.11-0.74) derived in this chapter. Hagan, Pouget, and Des 
Jarlais (2011) derived a similar effect size of 0.25 (95% CI 0.07-0.83) for combined 
interventions, although this pooled RR was based on the meta-analysis of only two studies.  
6.4.2 Strengths and limitations  
Whereas most analyses take either an ecological or an individual-level approach, this 
analysis has attempted to consider both types of evidence in conjunction. Constructing a 
coherent narrative from the ecological data can be a puzzle in itself – particularly when 
trying to reconcile data from different sources, such as service provision and selected 
population samples. The limitations of drawing inferences solely from ecological analysis 
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are also apparent from this analysis: for example, one might assume – given the observed 
declines in all three types of risk behaviour (needle/syringe-sharing, paraphernalia-sharing 
and frequency of injecting) – that all three interventions played a significant role in 
contributing to the reduction in HCV incidence. On the other hand, considering just the 
individual-level evidence does not give an overview of trends in provision, uptake, risk 
behaviour and HCV incidence. Although these types of evidence will never provide the 
same level of confidence, with regard to a causal association between intervention(s) and 
outcome, as an RCT, the triangulation of evidence generated by different study designs is 
understood to increase confidence (Kirkwood et al., 1997). 
The difficulty with conducting ecological analyses is that that there is little certainty when 
attributing the changes in outcome to the intervention(s). Other contemporaneous 
interventions or factors could potentially have been responsible for some of the observed 
changes. In this study, the individual analyses provide validation for some of these 
associations. For example, that the uptake of interventions is associated with reduced risk 
behaviour at the individual-level, means one can therefore be more confident that the 
changes in risk behaviour observed across the surveys were a result of the provision of the 
interventions. There are nevertheless factors that were outwith the scope of these analyses 
that could have had an impact on HCV incidence; for example, HCV antiviral treatment. 
The number of PWID aged under 30 years (those who are most likely to be injecting) 
initiated onto HCV treatment has doubled from around 50 to 100 per year over the Action 
Plan period (Sharon Hutchinson, Glasgow Caledonian University, personal 
communication). Despite this increase, treatment rates remain low in this population group 
(in the order of 6 per 1,000 PWID annually, assuming a population of 16,000 active 
PWID) and so treatment, alone, is unlikely to account fully for the reduced HCV 
incidence. However, the potential impact of HCV treatment has been demonstrated in 
mathematical models (Martin et al., 2011; Martin et al., 2013a) and it is possible that, in 
combination with IEP and OST, it contributed to the reduction in HCV transmission 
observed here. 
Selection bias is an issue that always needs to be considered in non-randomised studies. 
The NESI studies recruited participants at services that provide sterile injecting equipment 
(and often dispense methadone as well); this approach may have excluded ‘high risk’ 
PWID who are not in contact with services. This potential exclusion might have resulted in 
an underestimate of HCV incidence (if one assumes that those not using services are at 
greater risk of HCV infection) and an underestimate of intervention impact (if one assumes 
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those not using services would have contributed to the group with recent infection and low 
coverage of interventions and thereby strengthened the effect size). However, a decline in 
incidence among those using services is nevertheless an important finding in itself, and is 
indicative that these services are having an impact among service users. There is also the 
issue of the comparability of the consecutive NESI surveys. While an attempt was made to 
maximise consistency in recruitment across surveys, it was not always possible to recruit 
from the same services year-on-year for logistical reasons.  
There are indications that the PWID population in Scotland is an ageing cohort: an increase 
in the average age and time since onset of injecting has been observed in the study sample 
over the years. One could postulate that older PWID are less likely to engage in risk 
behaviour and that this may explain some of the downward trends in risk behaviour and 
incidence. However, it is unlikely that the ageing population alone would be sufficient to 
explain the sharpness of the downward trends observed, and furthermore the finding of a 
declining prevalence among those who had commenced injecting within the previous year 
provides evidence that this decline in HCV is also occurring among newer PWID. 
One of the strengths of this analysis is the large sample size that was obtained by pooling 
data from three surveys. However, one result of large sample sizes is that relatively small 
changes can become statistically significant, as was the case with some of the variables 
examined in the group-level analyses. Nevertheless, despite the large sample size, only just 
over 50 recent infections were detected in the pooled analysis: thus, the opposite problem 
was the case with the individual-level analyses. The lack of statistical significance in some 
cases – particularly when examining interventions classified into multiple strata – may 
have been a result of lack of power. In a scenario of declining HCV incidence, increasingly 
large sample sizes will be required to detect increasingly small numbers of recent 
infections.  
The derived incidence estimates are reliant on an accurate figure for the duration of the 
pre-seroconversion window period, around which there is uncertainty (Glynn et al., 2005; 
Netski et al., 2005; Page-Shafer et al., 2008). This analysis will not have captured persons 
who had recently seroconverted at the time of interview; however, the incidence 
calculation used here takes this underestimation into account. The incidence estimates 
could nevertheless be underestimates, as re-infections would not have been detected: 
people who had already been infected in the past would have anti-HCV and would be 
classed as prevalent infections in this analysis. This may affect the individual-level 
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analysis, but the general trends observed in the group-level analyses are still valid, as one 
would expect any underestimation to apply equally to each survey year. The other issues in 
relation to potential misclassification of the outcome were described in the discussion 
sections of Chapters 4 and 5, and also apply here (false HCV-RNA positives, fluctuating 
viraemia during acute HCV infection and delayed seroconversion among 
immunocompromised individuals).  
In relation to OST, one of the limitations of this study is that it is not specifically designed 
to measure the impact of this intervention. Questions on methadone dosage have not been 
asked consistently across the survey years, and therefore it was not possible to examine the 
association between dosage and recent HCV; moreover, dosage itself is a problematic 
measure, as what constitutes an adequate dosage can vary greatly from person to person. 
At the provision level, the absence of available data on persons receiving methadone 
mixture meant that numbers of methadone mixture prescriptions were presented instead: 
these could be misleading because a single prescription can indicate that a single dose or 
multiple doses are to be dispensed at a given visit. However, assuming that prescribing 
practices have not changed drastically over the period of study, then the observed upward 
trend is still likely to be valid.  
Finally, the self-reported nature of the risk behaviours and uptake of harm reduction 
interventions is a limitation. While the self-reported data likely contains an element of 
inaccuracy because of difficulty with respondents’ ability to recall events, the consistency 
of the associations between self-reported behaviour and biological markers (both HCV 
prevalence and incidence) is high, lending credence to the validity of the data. 
6.5 Conclusions 
These data provide evidence of a downward trend in HCV incidence among PWID in 
Scotland. The two different approaches used in this analysis strengthen the inference that 
the changes in HCV incidence are attributable to harm reduction interventions – 
particularly high coverage of needles/syringes and OST combined. There is currently 
insufficient evidence to conclude that the increase in provision of paraphernalia 
contributed significantly to the decline in HCV incidence. Future monitoring of PWID will 
be required to establish whether the downward direction in HCV transmission among 
PWID in Scotland is sustained.  
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Figure 6-1. Analytical framework of potential associations between harm reduction interventions 
and HCV transmission 
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Figure 6-2. Prevalence (among recent onset injectors) and derived incidence of HCV among PWID 
recruited at IEP sites across Scotland, by survey  
The diamonds/circles represent the point estimates and the bars represent the upper and lower 
95% CIs. 
aanti-HCV prevalence among those who commenced injecting within the past 12 months 
bDetermined by applying the estimated pre-seroconversion window period durations to the 
observed number of anti-HCV negative and HCV-RNA positive individuals (see methods for 
details) 
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Figure 6-3. (a) Unweighted and (b) weighted proportions of PWID with markers of recent HCV 
infection, by harm reduction intervention coverage, using pooled data from surveys of PWID 
recruited at IEP sites across Scotland in 2008-09, 2010 and 2011-12  
95% CIs are indicated by the black bars.   
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Table 6-1. Sources of evidence to populate the analytical framework 
Item Reference to Fig.1 Source  
Changes in provision of 
interventions 
Boxes 1, 2, 3 Information Services Division 
Scotland (ISD) reports 
(Information Services Division, 
2012b; Information Services 
Division, 2013) 
Changes in uptake of 
interventions 
Boxes 4, 5, 6 NESI data (group-level analysis) 
Changes in injecting risk 
behaviour 
Boxes 7, 8, 9 NESI data (group-level analysis) 
Changes in outcome Box 10 NESI data (group-level analysis) 
Associations between provision 
and uptake of interventions 
Relationships A, B, C Ecological analysis of ISD reports 
and NESI data (group-level) 
Associations between uptake of 
interventions and risk behaviour 
Relationships D, E, F NESI data (individual-level 
analysis of pooled data)a 
Associations between risk 
behaviour and outcome 
Relationships H, I, J NESI data (individual-level 
analysis of pooled data); and 
evidence generated in Chapter 4 
using NESI data a 
Associations between uptake of 
interventions and outcome 
Relationships K, L, M NESI data (individual-level 
analysis of pooled data) a 
aWhere pooled data refer to the dataset generated by combining the 2008-09, 2010 and 2011-12 
survey data 
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Table 6-2. Demographic and other characteristics of PWID recruited at IEP sites across Scotland in 
2008-09, 2010 and 2011-12, by survey  
 2008-09 
(N=2,629) 
2010 
(N=3,168) 
2011-12 
(N=2,154) 
Χ
2
 test (trend) 
or ANOVA p-value 
Male gender 72% 72% 73% 0.086 0.770 
Mean age in years (SD) 33.6 (7.1) 34.6 (7.3) 35.3 (6.9) F=35.465 <0.001 
Aged <25 years 14% 12% 9% 37.000 <0.001 
Homeless in last six months 27% 22% 22% 21.370 <0.001 
Injected stimulants in last six monthsa 23% 13% 15% 45.416 <0.001 
Ever in prison 59% 61% 61% 2.213 0.137 
Excessive alcohol consumptionb (last 
12 months) 27% 24% 26% 0.572 0.449 
Mean time since onset of injecting in 
years (SD) 10.5 (7.4) 11.2 (7.7) 11.6 (7.4) F=15.247 <0.001 
Commenced injecting within the last 
five years 26% 24% 21% 11.970 0.001 
aAmong those who reported injecting in the last six months 
bDefined as >14 units/week for women and >21 units/week for men 
  
 
 
Table 6-3. Summary of evidence for the analytical framework 
Type of 
evidence 
Category Reference 
to Fig.6-1 
Description Needles/syringes OST Paraphernalia 
Group-
level 
Intervention 1, 2, 3 Changes in provision of 
intervention over time 
Minor fluctuations but relatively stable 
number of N/S distributed at approximately 
4.7 million annually (Table 6-4) 
More or less stable, if very slight increase, in 
number of methadone mixture prescriptions 
dispensed (Table 6-4) 
Several-fold increase in number of spoons and 
filters distributed, up to approximately 2.5 
million each annually (Table 6-4) 
Intermediate 
determinant 
4, 5, 6 Changes in uptake of 
intervention over time  
Decline in self-reported uptake of N/S but, 
given the concurrent declines in frequency of 
injecting, this translates into either a relatively 
stable or increasing proportion of PWID with 
adequate (≥100%) N/S coverage, depending 
on which measure of coverage is used (Table 
6-5) 
Increase in those reporting currently being on 
OST (Table 6-5) 
Increase in reported numbers of spoons and 
filters obtained, as well as increase in reported 
proportion with high filter and spoon 
coverage – reaching almost equal coverage to 
that of N/S (Table 6-5) 
Intermediate 
determinant 
7, 8, 9 Changes in risk behaviour 
over time 
Reduction in proportion who reported sharing 
N/S in last six months (Table 6-5) 
Decline in the proportion that reported 
injecting daily or more frequently in the last 
six months (Table 6-5) 
Decline, for both spoons and filters, in 
proportion who reported sharing in last six 
months (Table 6-5) 
Outcome 10 Changes in HCV incidence 
over time 
Decline in estimated HCV incidence between 2008-09 and 2011-12; validated by a parallel decline in the prevalence of anti-HCV among those 
who commenced injecting within the last 12 months (Table 6-6) 
Individual-
level 
Relationship D, E, F Association between uptake 
of intervention and risk 
behaviour 
Approx 55% reduction in the odds of having 
shared N/S in the last six months among those 
with high N/S coverage (Table 6-7) 
Nearly 80% reduction in the risk of injecting 
daily or more frequently in the last six months 
associated with current uptake of OST (Table 
6-10) 
~35% reduction in the odds of having shared 
spoons in the last six months among those 
with high spoon coverage. High filter 
coverage associated with ~20% reduction in 
odds of sharing filters (Tables 6-8 & 6-9) 
Relationship H, I, J Association between risk 
behaviour and HCV 
incidence 
Approx 7-fold increased risk of recent HCV 
infection associated with sharing N/S in the 
last six months (Chapter 4)a 
No direct association between frequency of 
injecting and recent HCV infection (Table 6-
11); but, injecting at least daily is associated 
with 3-fold increased risk of sharing (each of) 
N/S, spoons and filters (Tables 6-12 to 6-14) 
Approx 3-fold increased risk of recent HCV 
infection associated with sharing spoons or 
filters in the last six months (Chapter 4)a 
Relationship K, L, M Association between uptake 
of intervention and HCV 
incidence 
Strong association between high coverage N/S 
and recent HCV in unweighted analyses 
(AOR 0.4, 95% CI 0.2-0.8, p=0.01) and 
weighted analyses (AORw 0.1, 95% CI 0.04-
0.5, p=0.002) (Table 6-15, Appendix H) 
No evidence for an association between 
current OST and recent HCV, in either 
weighted or unweighted analyses (Table 6-15, 
Appendix H) 
High paraphernalia coverage associated with 
recent HCV in unweighted analyses (AOR 
0.4, 95% CI 0.1-1.1, p=0.08) but more so in 
weighted model (AORw 0.1, 95% CI 0.03-0.4, 
p=0.002) (Table 6-15, Appendix H) 
Evidence of a strong association between the combined effects of N/S & OST and a reduced risk of recent HCV (AOR 0.3, 95% CI 0.1-0.8, 
p=0.02; and AORw 0.05, 95% CI .01-0.19, p<0.001). Combined effects of N/S, OST, & paraphernalia (AOR 0.3, 95% CI 0.1-1.1, p=0.06 and 
AORw 0.07, 95% CI 0.01-0.4, p=0.002) are not substantially different from that of N/S and OST combined. (Table 6-15, Appendix H) 
N/S: needle(s)/syringe(s) 
aAs stated in Chapter 4, it was not possible to separate the effects of needles/syringes due to few individuals who reported sharing only needles/syringes. It is, 
however, assumed that the potential AOR for needles/syringes could be even higher than that detected for needles/syringes +/- paraphernalia. 
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Table 6-4. Numbers of items of injecting equipment distributed and methadone mixture prescriptions dispensed in Scotland, by financial year, 2008/09 to 2011/12 
 
  
2008/09 2009/10 2010/11 2011/12 
Factor 
increase 
between 
2008/09 and 
2009/10 
Factor increase 
between 
2009/10 and 
2010/11 
Factor increase 
between 
2010/11 and 
2011/12 
Injecting equipment 
items distributed 
Needles/syringesa 4,736,700 4,699,600 4,626,700 4,722,500 0.99 0.98 1.02 
Filters 355,872 2,224,259 2,500,147 2,534,289 6.25 1.12 1.01 
Water ampoules 62,229 77,352 71,575 68,984 1.24 0.93 0.96 
Spoons 508,515 2,142,740 2,438,381 2,527,480 4.21 1.14 1.04 
 
        
Methadone mixture prescriptions dispensed 493,767 510,063 534,674 515,897 1.03 1.05 0.96 
Modified from Injecting Equipment Provision in Scotland Survey 2011/12 (Information Services Division, 2013) and Drug Misuse Statistics Scotland 2011 (Information 
Services Division, 2012b) 
aFigures have been adjusted by the proportion of total services providing data for respective financial years 
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Table 6-5. Group-level analyses: risk behaviour and harm reduction intervention uptake among PWID recruited at IEP sites across Scotland in 2008-09, 2010 and 
2011-12, by survey 
    
2008-09 
(N=2,629) 
2010  
(N=3,168) 
2011-12 
(N=2,154) Χ2 test (trend) or ANOVA p-value 
(i) Intervention uptake (last six months)     
Proportion currently on OST  All PWIDa,b 50% 60% 64% 48.442 <0.001 
 PWID, currenta,b 49% 60% 64% 50.564 <0.001 
Median no. obtained in 
typical week in last six 
months 
Needles/syringes (SD)b  15 (25) 10 (17) 10 (18) 113.493 <0.001 
Filters (SD)b 0 (8) 8 (20) 10 (19) 794.167 <0.001 
 Spoons (SD)b 0 (5) 7.5 (19) 10 (18) 1026.638 <0.001 
Proportion with adequate 
coverage (≥100%) based on 
self-reported survey data 
Needle/syringe coverageb 75% 79% 77% 3.271 0.071 
Filter coverageb 24% 58% 69% 817.385 <0.001 
Spoon coverageb 20% 58% 70% 972.267 <0.001 
Proportion with adequate 
coverage (≥100%) based on 
service provision datac 
Needle/syringe coverage  53% 62% 74% - - 
Filter coverage 4% 34% 40% - - 
Spoon coverage 6% 33% 39% - - 
(ii) Risk behaviour (last six months)      
Injected at least dailyb 63% 54% 49% 73.712 <0.001 
Shared N/Sb 15% 11% 8% 51.497 <0.001 
Mean no. times shared N/S (SD)b 0.89 (4.0) 0.69 (4.2) 0.46 (4.0) F=5.357 0.005 
Mean no. times shared N/S among those who shared (SD)b 5.9 (8.7) 6.5 (11.4) 6.0 (13.0) F=0.209 0.812 
Reused own needle/syringeb 64% 59% 45% 131.952 <0.001 
Shared spoonsb 42% 33% 20% 217.652 <0.001 
Shared filtersb 33% 28% 17% 123.088 <0.001 
Shared waterb 31% 29% 21% 48.740 <0.001 
N/S: needle(s)/syringe(s) 
aAmong those who cited needle exchange as the reason for visit on day of recruitment 
bAmong those who reported injecting in the last six months 
cp-values have not been calculated for the second measure of IEP coverage – because of the large numbers, very small changes would be statistically significant 
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Table 6-6. Group-level analyses: HCV incidence/prevalence among PWID recruited at IEP sites across Scotland in 2008-09, 2010 and 2011-12, by survey 
 
 
2008-09 2010 2011-12 
Χ
2
 test 
(trend) p-value 
HCV prevalence        
HCV prevalencea   N 2,629 3,168 2,154   
% 
95% CI 
54% 
52-55% 
56% 
54-58% 
53% 
51-55% 0.004 0.951 
HCV incidence       
HCV prevalence among 
those injecting <1 year 
N 144 169 85   
% 
95% CI 
20.1% 
13.9-27.6% 
18.3% 
12.8-25.0% 
8.2% 
3.4-16.2% 4.711 0.030 
Proportion with recent HCV 
infection (all PWID)b 
N 1,140 1,323 996   
% 
95% CI 
2.1% 
1.4-3.1% 
1.5% 
0.9-2.3% 
0.9% 
0.4-1.7% 5.092 0.024 
Proportion with recent HCV 
infection (PWID, current)b,c 
N 933 1,024 831   
% 
95% CI 
2.1% 
1.2-3.3% 
1.5% 
0.8-2.4% 
1.1% 
0.5-2.0% 3.224 0.073 
Derived HCV incidence (all 
PWID)  
 
95% CI 
13.3  
8.4-19.8 
9.9  
5.5-14.8 
6.1  
2.5-11.1 - - 
Derived HCV incidence 
(PWID, current)c 
 
95% CI 
13.6  
8.1-20.1 
9.6  
5.1-15.5 
7.3  
3.0-12.9 - - 
aNumerator includes anti-HCV positives and weak reactives; the denominator is all PWID 
bWhere recent infection is defined as anti-HCV negative and HCV-RNA positive; the denominator is all anti-HCV negative PWID 
cAmong those who reported injecting in the last six months 
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Table 6-7. Univariable and multivariable models of the association between needle/syringe coverage and sharing needles/syringes (in the last six months) among 
PWID recruited at IEP sites across Scotland in 2008-09, 2010 and 2011-12 (pooled), including model covariates 
   No. who shared 
N/S (n) 
 Univariable Multivariable (n=5,409) 
  Total (N) % (n/N) OR 95% CI p-value AOR 95% CI p-value 
Needle/syringe coverage  
  
<100% 1274 227 18 1   1   
100-199% 1913 234 12 0.64 0.53-0.78 <0.001 0.64 0.52-0.79 <0.001 
  ≥200% 2264 195 9 0.44 0.35-0.53 <0.001 0.44 0.35-0.54 <0.001 
Survey 2008-09 2046 310 15 1   1   
  2010 2063 229 11 0.70 0.58-0.84 <0.001 0.77 0.64-0.93 0.008 
 2011-12 1379 120 9 0.53 0.43-0.67 <0.001 0.59 0.47-0.74 <0.001 
Gender Male 4035 453 11 1   1   
 Female 1430 201 14 1.29 1.08-1.55 0.005 1.35 1.12-1.63 0.002 
Homeless in last six months No  4067 425 10 1   1   Yes 1413 231 16 1.68 1.41-1.99 <0.001 1.34 1.12-1.61 0.002 
Injected stimulant in last six months No 4552 495 11 1   1   Yes 935 164 18 1.74 1.44-2.11 <0.001 1.58 1.29-1.94 <0.001 
Alcohol consumption in the last 12 
monthsa 
Not excessive 4047 414 10 1   1   
Excessive 1412 239 17 1.79 1.51-2.12 <0.001 1.68 1.40-2.01 <0.001 
Current OST No 1716 256 15 1   1   
Yes 3771 403 11 0.68 0.58-0.81 <0.001 0.80 0.67-0.96 0.014 
Age (years) <25 761 147 19 1   1   
 ≥25 4724 512 11 0.51 0.42-0.62 <0.001 0.59 0.47-0.73 <0.001 
N/S: needle(s)/syringe(s) 
Models are restricted to those who reported injecting in the last six months 
aExcessive is defined as >14 units/week for women and >21 units/week for men 
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Table 6-8. Univariable and multivariable models of the association between spoon coverage and sharing spoons (in the last six months) among PWID recruited at IEP 
sites across Scotland in 2008-09, 2010 and 2011-12 (pooled), including model covariates 
   No. who shared 
spoons (n) 
 Univariable Multivariable (n=5,419) 
  Total (N) % (n/N) OR 95% CI p-value AOR 95% CI p-value 
Spoon coverage  
  
<100% 2945 1165 40 1   1   
100-199% 1196 329 28 0.58 0.50-0.67 <0.001 0.72 0.62-0.85 <0.001 
  ≥200% 1320 326 25 0.50 0.43-0.58 <0.001 0.63 0.54-0.74 <0.001 
Survey 2008-09 2052 868 42 1   1   
  2010 2063 694 34 0.69 0.61-0.79 <0.001 0.87 0.76-1.00 0.055 
 2011-12 1380 266 19 0.33 0.28-0.38 <0.001 0.42 0.35-0.50 <0.001 
Gender Male 4035 1281 32 1   1   
 Female 1437 538 37 1.29 1.14-1.46 <0.001 1.35 1.18-1.55 <0.001 
Homeless in last six months No  4069 1217 30 1   1   Yes 1418 608 43 1.76 1.55-1.99 <0.001 1.50 1.32-1.72 <0.001 
Injected stimulant in last six months No 4557 1405 31 1   1   Yes 937 423 45 1.85 1.60-2.13 <0.001 1.63 1.40-1.90 <0.001 
Alcohol consumption in the last 12 monthsa Not excessive 4051 1190 29 1   1   Excessive 1415 628 44 1.92 1.69-2.17 <0.001 1.79 1.57-2.05 <0.001 
Current OST No 1717 636 37 1   1   
Yes 3777 1192 32 0.78 0.70-0.88 <0.001 0.90 0.79-1.02 0.094 
Age (years) <25 762 336 44 1   1   
  
≥25 4730 1491 32 0.58 0.50-0.68 <0.001 0.66 0.56-0.78 <0.001 
Models are restricted to those who reported injecting in the last six months 
aExcessive is defined as >14 units/week for women and >21 units/week for men 
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Table 6-9. Univariable and multivariable models of the association between filter coverage and sharing filters (in the last six months) among PWID recruited at IEP sites 
across Scotland in 2008-09, 2010 and 2011-12 (pooled), including model covariates 
   No. who shared 
filters (n) 
 Univariable Multivariable (n=5,413) 
  Total (N) % (n/N) OR 95% CI p-value AOR 95% CI p-value 
Filter coverage  
  
<100% 2882 871 30 1   1    
100-199% 1235 306 25 0.76 0.65-0.89 <0.001 0.90 0.76-1.06 0.211 
  ≥200% 1344 297 22 0.66 0.56-0.76 <0.001 0.81 0.69-0.95 0.011 
Survey 2008-09 2055 671 33 1     1     
  2010 2063 576 28 0.80 0.70-0.91 0.001 0.94 0.81-1.09 0.390 
 2011-12 1380 233 17 0.42 0.35-0.50 <0.001 0.50 0.42-0.60 <0.001 
Gender Male 4037 1036 26 1   1    
 Female 1438 434 30 1.25 1.10-1.43 0.001 1.40 1.21-1.62 <0.001 
Homeless in last six months No  4073 967 24 1     1     Yes 1417 511 36 1.81 1.59-2.06 <0.001 1.53 1.34-1.76 <0.001 
Injected stimulant in last six months No 4558 1124 25 1   1    Yes 939 356 38 1.87 1.61-2.16 <0.001 1.67 1.43-1.95 <0.001 
Imprisoned Never 2188 540 25 1     1     
 Ever 3302 938 28 1.21 1.07-1.37 0.002 1.21 1.06-1.38 0.006 
Alcohol consumption in the last 12 monthsa Not excessive 4052 958 24 1   1    Excessive 1417 511 36 1.82 1.60-2.08 <0.001 1.65 1.44-1.89 <0.001 
Current OST No 1718 529 31 1   1     
Yes 3779 951 25 0.76 0.67-0.86 <0.001 0.81 0.71-0.93 0.002 
Age (years) <25 763 258 34 1     1    
  
≥25 4732 1221 26 0.68 0.58-0.80 <0.001 0.79 0.66-0.94 0.008 
Models are restricted to those who reported injecting in the last six months 
aExcessive is defined as >14 units/week for women and >21 units/week for men 
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Table 6-10. Univariable and multivariable models of the association between OST and injecting daily or more frequently among PWID recruited at IEP sites across 
Scotland in 2008-09, 2010 and 2011-12 (pooled), including model covariates 
   No. injected at 
least daily (n) 
 Univariable Multivariable (n=6,776) 
  Total (N) % (n/N) OR 95% CI p-value AOR 95% CI p-value 
Current OST No 1724 1263 73 1     1     
Yes 5104 1869 37 0.21 0.19-0.24 <0.001 0.22 0.20-0.25 <0.001 
Survey 2008-09 2552 1295 51 1     1     
  2010 2666 1123 42 0.71 0.63-0.79 <0.001 0.84 0.74-0.94 0.003 
  2011-12 1611 715 44 0.78 0.68-0.88 <0.001 0.89 0.78-1.02 0.088 
Homeless in last six months No  5214 2209 42 1   1    Yes 1607 920 57 1.82 1.63-2.04 <0.001 1.50 1.33-1.69 <0.001 
Injected stimulant in last six 
months 
No 5887 2527 43 1     1     
Yes 941 606 64 2.41 2.09-2.78 <0.001 2.22 1.90-2.58 <0.001 
Imprisoned Never 2722 1181 43 1   1    
Ever 4094 1946 48 1.18 1.07-1.30 0.001 1.27 1.14-1.41 <0.001 
Age (years) <25 836 496 59 1     1     
  ≥25 5988 2636 44 0.54 0.47-0.63 <0.001 0.70 0.60-0.83 <0.001 
Models exclude individuals who reported not currently being on OST and also not injecting in the last six months 
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Table 6-11. Univariable and multivariable models of the association between frequency of injecting (in the last six months) and recent HCV infection among PWID 
recruited at IEP sites across Scotland in 2008-09, 2010 and 2011-12 (pooled) 
  
Total (N) 
No. recent HCV 
infections (n) % (n/N) 
Univariable Multivariable (n=2,999) 
  OR 95% CI  p-value AOR 95% CI p-value 
Injected daily or more frequently 
in the last six months 
No 1659 19 1.1 1     1    
Yes 1365 31 2.3 2.01 1.13-3.57 0.018 1.45 0.80-2.63 0.218 
Survey 2008-09 1116 23 2.1 1     1     
  2010 1130 19 1.7 0.81 0.44-1.50 0.507 0.92 0.49-1.72 0.795 
  2011-12 778 8 1.0 0.49 0.22-1.11 0.088 0.56 0.25-1.27 0.166 
Homeless in last six months 
 
No  2392 25 1.0 1    1    
Yes 629 25 4.0 3.92 2.24-6.87 <0.001 3.02 1.70-5.36 <0.001 
Injected stimulant in last six 
months 
No 2731 39 1.4 1     1     
Yes 293 11 3.8 2.69 1.36-5.32 0.004 2.26 1.11-4.58 0.024 
Time since onset of injecting 
 
<5 years 1186 32 2.7 1    1    
≥5 years 1826 18 1.0 0.36 0.20-0.64 0.001 0.39 0.22-0.71 0.002 
Alcohol consumption in last 12 
monthsa 
Not excessive 2383 31 1.3 1     1     
Excessive 631 19 3.0 2.36 1.32-4.20 0.004 1.93 1.07-3.50 0.030 
Models exclude individuals who reported not currently being on OST and also not injecting in the last six months 
aExcessive is defined as >14 units/week for women and >21 units/week for men 
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Table 6-12. Univariable and multivariable models of the association between frequency of injecting in the last six months and sharing needle/syringes in the last six 
months among PWID recruited at IEP sites across Scotland in 2008-09, 2010 and 2011-12 (pooled) 
   No. who shared 
N/S (n) 
 Univariable Multivariable (n=6,746) 
  Total (N) % (n/N) OR 95% CI p-value AOR 95% CI p-value 
Injected daily or more frequently 
in the last six months 
No 3687 180 4.9 1     1    
Yes 3119 479 15.4 3.54 2.96-4.23 <0.001 3.04 2.53-3.66 <0.001 
Survey 2008-09 2537 310 12.2 1     1     
  2010 2663 229 8.6 0.67 0.56-0.81 <0.001 0.80 0.66-0.97 0.020 
  2011-12 1606 120 7.5 0.58 0.47-0.72 <0.001 0.68 0.54-0.85 0.001 
Gender 
 
Male 4903 453 9.2 1    1    
Female 1879 201 10.7 1.18 0.99-1.40 0.069 1.21 1.01-1.46 0.042 
Homeless in last six months 
 
No  5197 425 8.2 1     1     
Yes 1601 231 14.4 1.89 1.60-2.25 <0.001 1.36 1.14-1.63 0.001 
Injected stimulant in last six 
months 
No 5870 495 8.4 1    1    
Yes 935 164 17.5 2.31 1.91-2.80 <0.001 1.75 1.42-2.14 <0.001 
Time since onset of injecting <5 years 1678 211 12.6 1     1     
 ≥5 years 5107 447 8.8 0.67 0.56-0.79 <0.001 0.80 0.66-0.98 0.031 
Alcohol consumption in last 12 
monthsa 
Not excessive 5057 414 8.2 1    1    
Excessive 1719 239 13.9 1.81 1.53-2.15 <0.001 1.75 1.46-2.09 <0.001 
Age (years) 
  
<25 833 147 17.6 1     1     
≥25 5968 512 8.6 0.44 0.36-0.54 <0.001 0.58 0.46-0.73 <0.001 
N/S: needle(s)/syringe(s) 
Models exclude individuals who reported not currently being on OST and also not injecting in the last six months 
aExcessive is defined as >14 units/week for women and >21 units/week for men 
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Table 6-13. Univariable and multivariable models of the association between frequency of injecting in the last six months and sharing spoons in the last six months 
among PWID recruited at IEP sites across Scotland in 2008-09, 2010 and 2011-12 (pooled) 
   No. who shared 
spoons (n) 
 Univariable Multivariable  
  Total (N) % (n/N) OR 95% CI p-value AOR 95% CI p-value 
Injected daily or more frequently 
in the last six months 
No 3845 612 15.9 1     1    
Yes 3125 1216 38.9 3.37 3.01-3.77 <0.001 3.02 2.68-3.39 <0.001 
Survey 2008-09 2603 868 33.3 1     1     
  2010 2724 694 25.5 0.68 0.61-0.77 <0.001 0.81 0.71-0.92 0.001 
  2011-12 1643 266 16.2 0.39 0.33-0.45 <0.001 0.42 0.35-0.49 <0.001 
Gender 
 
Male 5020 1281 25.5 1    1    
Female 1926 538 27.9 1.13 1.01-1.27 0.040 1.21 1.07-1.38 0.004 
Homeless in last six months 
 
No  5310 1217 22.9 1     1     
Yes 1652 608 36.8 1.96 1.74-2.21 <0.001 1.47 1.30-1.68 <0.001 
Injected stimulant in last six 
months 
No 6032 1405 23.3 1    1    
Yes 937 423 45.1 2.71 2.35-3.12 <0.001 2.11 1.80-2.46 <0.001 
Time since onset of injecting <5 years 1709 544 31.8 1     1     
 ≥5 years 5240 1279 24.4 0.69 0.61-0.78 <0.001 0.78 0.68-0.90 <0.001 
Alcohol consumption in last 12 
monthsa 
Not excessive 5167 1190 23.0 1    1    
Excessive 1773 628 35.4 1.83 1.63-2.06 <0.001 1.80 1.59-2.05 <0.001 
Age (years) 
  
<25 848 336 39.6 1     1     
≥25 6116 1491 24.4 0.49 0.42-0.57 <0.001 0.68 0.57-0.81 <0.001 
Models exclude individuals who reported not currently being on OST and also not injecting in the last six months 
aExcessive is defined as >14 units/week for women and >21 units/week for men 
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Table 6-14. Univariable and multivariable models of the association between frequency of injecting in the last six months and sharing filters in the last six months 
among PWID recruited at IEP sites across Scotland in 2008-09, 2010 and 2011-12 (pooled) 
   No. who shared 
filters (n) 
 Univariable Multivariable (n=6,772) 
  Total (N) % (n/N) OR 95% CI p-value AOR 95% CI p-value 
Injected daily or more frequently 
in the last six months 
No 3689 484 13.1 1     1    
Yes 3127 996 31.9 3.10 2.74-3.50 <0.001 2.77 2.44-3.14 <0.001 
Survey 2008-09 2546 671 26.4 1     1     
  2010 2663 576 21.6 0.77 0.68-0.88 <0.001 0.93 0.81-1.07 0.308 
  2011-12 1607 233 14.5 0.47 0.40-0.56 <0.001 0.54 0.45-0.64 <0.001 
Gender 
 
Male 4905 1036 21.1 1    1    
Female 1887 434 23.0 1.12 0.98-1.27 0.092 1.22 1.07-1.40 0.004 
Homeless in last six months 
 
No  5203 967 18.6 1     1     
Yes 1605 511 31.8 2.05 1.80-2.32 <0.001 1.59 1.39-1.82 <0.001 
Injected stimulant in last six 
months 
No 5876 1124 19.1 1    1    
Yes 939 356 37.9 2.58 2.23-2.99 <0.001 1.98 1.69-2.32 <0.001 
Alcohol consumption in last 12 
monthsa 
Not excessive 5062 958 18.9 1     1     
Excessive 1724 511 29.6 1.81 1.59-2.05 <0.001 1.68 1.47-1.92 <0.001 
Age (years) 
  
<25 835 258 30.9 1    1    
≥25 5976 1221 20.4 0.57 0.49-0.67 <0.001 0.72 0.61-0.86 <0.001 
Models exclude individuals who reported not currently being on OST and also not injecting in the last six months 
aExcessive is defined as >14 units/week for women and >21 units/week for men 
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Table 6-15. Individual-level analyses: unweighted and weighted models of the association between self-reported uptake of harm reduction interventions and recent 
HCV infection among PWID recruited at IEP sites across Scotland in 2008-09, 2010 and 2011-12 (pooled) 
   
Recent 
infection % 
Weighted 
recent 
infection % 
Univariable Multivariablea Weighted multivariablea 
Model Intervention Categories OR (95% CI) p-value AOR (95% CI) p-value AORw (95% CI) p-value 
       (n=2,481)  (n=2,481)  
(i) N/S coverageb Low  2.4 2.9 1  1  1  
 High 0.9 0.4 0.36 (0.17-0.75) 0.006 0.39 (0.19-0.83) 0.014 0.14 (0.04-0.48) 0.002 
           
       (n=2,481)  (n=2,481)  
(ii) Paraphernalia 
coverageb,c 
Low  2.0 2.7 1  1  1  
  High  0.7 0.2 0.33 (0.12-0.94) 0.037 0.39 (0.14-1.12) 0.081 0.11 (0.03-0.44) 0.002 
           
       (n=3,008)  (n=3,008)  
(iii) OST Not current 2.5 3.0 1  1  1  
   Current 1.3 1.3 0.51 (0.29-0.90) 0.020 0.63 (0.35-1.12) 0.111 0.52 (0.23-1.18) 0.119 
           
       (n=2,993)  (n=2,993)  
(iv) N/S coverage 
and OST 
combinedd 
Low N/S, no OST 3.4 3.8 1  1  1  
 Low N/S, OST 1.6 2.0 0.48 (0.24-0.95) 0.035 0.55 (0.27-1.11) 0.093 0.59 (0.26-1.35) 0.209 
 High N/S, no OST 0.9 0.7 0.26 (0.08-0.88) 0.030 0.28 (0.08-0.96) 0.043 0.18 (0.04-0.87) 0.034 
  High N/S, OST 0.8 0.1 0.24 (0.10-0.60) 0.002 0.29 (0.11-0.74) 0.009 0.05 (0.01-0.18) <0.001 
  Did not inject, OST 1.4 1.4 0.39 (0.17-0.94) 0.035 0.62 (0.24-1.59) 0.324 0.61 (0.21-1.80) 0.370 
           
        (n=2,992)   (n=2,992)  
(v) N/S coverage, 
paraphernalia 
coverage and 
OST combinedd 
Low N/S, low para, no OST 3.5 3.9 1   1  1  
 Low N/S, low para, OST 1.7 2.0 0.48 (0.24-0.96) 0.037 0.55 (0.27-1.11) 0.095 0.58 (0.25-1.34) 0.202 
 High N/S, low para, no OST 1.0 0.8 0.27 (0.06-1.15) 0.076 0.29 (0.07-1.26) 0.098 0.18 (0.03-1.34) 0.095 
 High N/S, low para, OST 0.9 0.1 0.26 (0.08-0.89) 0.031 0.28 (0.08-0.98) 0.046 0.02 (0.01-0.09) <0.001 
 High N/S, high para, no OST 0.8 0.5 0.22 (0.03-1.65) 0.141 0.25 (0.03-1.90) 0.180 0.16 (0.02-1.25) 0.081 
 High N/S, high para, OST 0.8 0.2 0.21 (0.06-0.71) 0.012 0.28 (0.08-0.97) 0.044 0.07 (0.01-0.35) 0.001 
  Did not inject, OST 1.4 1.4 0.38 (0.16-0.90) 0.028 0.60 (0.24-1.54) 0.292 0.59 (0.20-1.75) 0.343 
N/S: needle(s)/syringe(s); para: paraphernalia 
aAll models adjusted for survey year, homelessness in last six months, stimulant injection in last six months and time since onset of injecting  
bRestricted to those who reported injecting in the last six months; see methods for definition of high and low coverage 
cParaphernalia refers to spoons and filters  
dWhere ‘no OST/OST’ refers to no current/current receipt of OST, ‘low’ refers to low coverage and ‘high’ refers to high coverage 
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Table 6-16. Results of sensitivity analysis of varying parameters in model (v) 
  
Main effects modela,b 
Survey year included as a 
continuous variablea,c 
Time since onset of injecting as a 
categorical variablea Different duplicates excludeda,d 
  AOR 95% CI p-value AOR 95% CI p-value AOR 95% CI p-value AOR 95% CI p-value 
N/S coverage, 
paraphernalia coverage 
and OST combined 
Low N/S, low para, no OST 1   1   1   1   
Low N/S, low para, OST 0.55 0.27-1.11 0.095 0.60 0.30-1.20 0.149 0.60 0.30-1.21 0.154 0.64 0.30-1.39 0.263 
Low N/S, high para, no OST - - - - - - - - -    
 Low N/S, high para, OST - - - - - - - - -    
 High N/S, low para, no OST 0.29 0.07-1.26 0.098 0.28 0.06-1.24 0.093 0.29 0.07-1.27 0.100 0.37 0.08-1.65 0.193 
 High N/S, low para, OST 0.28 0.08-0.98 0.046 0.32 0.09-1.11 0.073 0.33 0.10-1.13 0.076 0.43 0.12-1.51 0.187 
 High N/S, high para, no OST 0.25 0.03-1.90 0.180 0.25 0.03-1.86 0.173 0.24 0.03-1.84 0.170 0.30 0.04-2.28 0.242 
 High N/S, high para, OST 0.28 0.08-0.97 0.044 0.31 0.09-1.08 0.066 0.31 0.09-1.07 0.064 0.36 0.10-1.28 0.114 
 Did not inject, OST 0.60 0.24-1.54 0.292 0.84 0.33-2.13 0.713 0.84 0.33-2.13 0.709 0.89 0.2-2.48 0.825 
N/S: needle(s)/syringe(s); para: paraphernalia 
aAll models adjusted for survey year, homelessness in last six months (binary), stimulant injection in last six months (binary) and time since onset of injecting  
bIn main effects model, survey year is categorical and time since onset of injecting is continuous 
cA continuous variable was created with the first interview conducted in 2008-09 serving as the baseline (time zero) and taking on values equivalent to the days since 
baseline that the respective interviews were carried out 
dWhere a respondent had participated in multiple surveys, the last interview was retained for analysis (as opposed to the first, as was done in the main effects model) 
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Table 6-17. Estimated number of new infections and new chronic infections per calendar year 2008-2012 based on derived incidence rates 
 
Estimated incidence per 100 
PY (95% CI) 
Proportion anti-HCV negative 
(95% CI) 
No. new infections (95% 
CI) 
No. new chronic 
infections (95% CI)a 
2008 13.6 (8.1-20.1) 0.48 (0.46-0.50) 1063 (591-1682) 787 (441-1248) 
2009 13.6 (8.1-20.1) 0.48 (0.46-0.50) 1063 (591-1682) 787 (441-1248) 
2010 9.6 (5.1-15.5) 0.45 (0.43-0.47) 697 (336-1240) 516 (251-908) 
2011 7.3 (3.0-12.9) 0.47 (0.44-0.49) 566 (205-1039) 419 (152-774) 
2012 7.3 (3.0-12.9) 0.47 (0.44-0.49) 566 (205-1039) 419 (152-774) 
Number of PWID assumed to be stable during 2008-2012 at 16,000 (95% CI 11,782-20,334)  
a26% (95% CI 22-29%) were assumed to spontaneously clear acute infection (Micallef, Kaldor, and Dore, 2006) 
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7 Summary and future work 
7.1 Summary of chapter findings in relation to thesis 
objectives 
To recap, the overall aim of this thesis was to investigate the impact of harm reduction 
interventions on the transmission of HCV among PWID in Scotland. The sections in this 
chapter present a summary of the findings in relation to this overall aim, as well as the 
secondary objectives of the thesis, which were: 
i. To review the international literature on the effectiveness of IEP and OST in 
preventing HCV transmission among PWID;  
ii. To determine the association between self-reported sharing of needles/syringes and 
incident/prevalent HCV infection among PWID; 
iii. To determine the association between sharing non-needle/syringe injecting 
paraphernalia and incident HCV infection among PWID in Scotland;  
iv. To determine the incidence of HCV among PWID in Scotland; and 
v. To determine the association between self-reported uptake of harm reduction 
interventions (IEP and OST) and incident HCV infection among PWID in Scotland.  
7.1.1 International evidence for the effectiveness of IEP and OST 
in preventing HCV transmission among people who inject 
drugs: a review of reviews 
Chapter 2 addressed the first objective of reviewing the international literature for evidence 
of effectiveness of OST and IEP in the prevention of HCV transmission. The outcomes 
were also expanded to include HIV and IRB, yielding important insights with regard to 
differences in the evidence base for the respective outcomes. Applying a review of reviews 
approach, the findings with regard to NSP were: insufficient evidence for an impact on 
HCV, tentative evidence for an impact on HIV and sufficient evidence for an impact on 
IRB. For OST, there was insufficient evidence for an impact on HCV and sufficient 
evidence for an impact on both HIV and IRB. For the remaining IEP interventions 
(pharmacy NSP, vending machines, outreach NSP, sterile injecting paraphernalia 
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provision) there was generally no or insufficient evidence with respect to any of the 
outcomes.  
The review of reviews was updated to include reviews published until March 2011 
(Macarthur et al., 2014) (the original work for Chapter 2 included reviews published up 
until March 2007). Only four evidence statements were changed as a result of additional 
evidence identified. The evidence statement for the effectiveness of outreach NSP with 
respect to HIV was upgraded from none to insufficient, as was the evidence statement for 
injecting paraphernalia with respect to HCV. Additionally, the evidence statement for the 
effectiveness of injecting paraphernalia with regard to IRB was upgraded from insufficient 
to tentative; as was the evidence for OST with regard to HCV. Thus, despite updating the 
evidence base with an additional four years of published literature, many interventions are 
still lacking evidence.  
It is, however, important to emphasise that lack of evidence does not equal evidence for 
lack of effectiveness. For the interventions other than NSP and OST, this lack of evidence 
resulted from an absence of reviews that had been undertaken and likely reflects a 
corresponding lack of primary studies investigating these interventions. For NSP and OST, 
the limitations of the primary studies that investigated these interventions may have played 
a role where there was less than sufficient evidence. RCTs were generally absent from the 
evidence base, with the exception of a few that had been undertaken to examine OST. The 
next most robust design in the evidence hierarchy, for the purposes of this review, was the 
longitudinal cohort study; most of the studies employing this design had negative findings 
(i.e. a change in the outcome in the opposite direction of the intended effect) or showed no 
association. Ecological studies were more likely to report positive findings (i.e a reduction 
in the outcome associated with the intervention) than individual-level studies, but were 
accorded less importance in the framework for deriving evidence statements (because 
ecological studies generally did not control for confounding, there was a high risk that any 
changes in the outcome observed could have been a result of other factors). The lack of 
positive findings in cohort studies may have been partly attributable to limitations and/or 
bias in the measurement of exposure to the intervention, as a result of selection bias, lack 
of distinction between exposed and unexposed groups and not measuring intervention 
intensity or ‘coverage’.  
In comparing the relative levels of evidence for the different outcomes, the evidence was 
slightly stronger for HIV than for HCV, but it was particularly notable that it was much 
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stronger for IRB than either of HIV or HCV. In other words, there was better evidence for 
behavioural, than for biological, outcomes. Explanations for this observation are 
potentially three-fold: (i) the limitations of the self-reported nature of IRB, (ii) that IRB is 
more prevalent and therefore studies had more power to detect any differences (as 
compared with HIV or HCV, for which one generally requires a substantial duration of 
follow-up and/or a large sample size in order to observe seroconversions) and (iii) that 
there is a non-linear relationship between IRB and HIV/HCV (i.e. a reduction in IRB does 
not necessarily lead to a proportional reduction in BBV transmission).  
7.1.2 Systematic review and meta-analysis of the association 
between self-reported sharing of needles/syringes and HCV 
prevalence and incidence  
Following on from the finding of apparent inconsistencies between self-reported 
needle/syringe-sharing and biological markers of HCV infection observed in Chapter 2, 
Chapter 3 summarised and explored factors that could explain the variation in the measure 
of association between self-reported sharing of needles/syringes and HCV 
prevalence/incidence (addressing the second thesis objective). A systematic review and 
meta-analysis of European studies published from January 1990 through September 2011 
was undertaken. The pooled prevalence of HCV was 59% among PWID who reported 
never sharing needles/syringes and the pooled incidence of HCV was 11% among PWID 
who reported not recently sharing needles/syringes. Random effects meta-analysis 
generated a pooled OR of 3.3 (95% CI 2.4-4.6), comparing HCV infection among those 
who ever (or recently) shared needles/syringes with HCV infection among those who 
reported never (or not recently) sharing. There was substantial heterogeneity between the 
study effect sizes (I2=72.8%). Differences in pooled ORs were found when studies were 
stratified by recruitment setting (prison vs. drug treatment sites), recruitment method 
(outreach vs. non-outreach), sample HCV prevalence and sample mean/median time since 
onset of injecting. This analysis found high incidence/prevalence rates of HCV among 
those who did not report sharing needles/syringes during the risk period, which may be 
attributable to a combination of unmeasured risk factors (for example, sharing injecting 
paraphernalia) and reporting bias. It was concluded that study design and population are 
likely to be important modifiers of the size and strength of association between HCV and 
needle/syringe-sharing.  
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7.1.3 Association between sharing injecting paraphernalia and 
recent HCV infection 
Chapter 4 addressed the third objective of determining the association between sharing 
injecting paraphernalia (spoons, filters and water) and incident HCV infection using data 
from the 2008-09 and 2010 sweeps of the NESI survey. Logistic regression was applied to 
examine the association between recent HCV infection (individuals in the pre-
seroconversion window period, i.e. anti-HCV negative and HCV-RNA positive) and self-
reported measures of injecting equipment sharing in the six months preceding the 
interview. Twelve percent of the sample reported sharing needles/syringes and 40% 
reported sharing paraphernalia in the previous six months. The AORs for sharing 
needles/syringes (with or without paraphernalia) and sharing only paraphernalia in the last 
six months were 6.7 (95% CI 2.6-17.1) and 3.0 (95% CI 1.2-7.5), respectively. Among 
those who reported not sharing needles/syringes, sharing spoons and sharing filters in the 
last six months were both significantly associated with recent HCV infection (AOR 3.1, 
95% CI 1.3-7.8 and 3.1, 95% CI 1.3-7.5, respectively); sharing water was not. This study is 
the first to apply a cross-sectional approach to the analysis of the association between 
sharing paraphernalia and incident HCV infection and demonstrates consistent results with 
previous longitudinal studies. The prevalence of paraphernalia-sharing in the study 
population is high, representing significant potential for HCV transmission. 
7.1.4 Determining HCV incidence and measuring the association 
between harm reduction intervention uptake and recent HCV 
infection 
The fourth and fifth thesis objectives were addressed in Chapters 5 and 6. Chapter 5 used 
data from the 2008-09 sweep of NESI: twenty-four recent HCV infections were detected. 
By extrapolating from the estimated duration of the window period, incidence rate 
estimates ranging from 10.8-21.9 per 100 person-years were derived. Logistic regression 
analysis of the association between self-reported needle/syringe coverage and recent 
infection illustrated that, after adjustment for confounders, those with high coverage 
(defined as at least two sterile needles/syringes per injection) had reduced odds of recent 
infection, with an AOR of 0.32 (95% CI 0.10-1.00, p=0.050). With regard to OST and 
recent HCV infection, the overall effect size for Scotland was not statistically significant. 
In the Greater Glasgow and Clyde region, however, there was a reduced odds of recent 
infection among those currently receiving OST, relative to those on OST in the last six 
months but not currently (AOR 0.04, 95% CI 0.001-1.07, p=0.055). The effect of 
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combined uptake of OST and high needle/syringe coverage was only significant in 
unadjusted analyses (OR 0.34, 95% CI 0.12-0.97, p=0.043; AOR 0.48, 95% CI 0.16-1.48, 
p=0.203).  
Chapter 6 addressed the same objectives of determining HCV incidence and the 
association between uptake of harm reduction interventions and recent HCV infection; 
however, the analysis involved data generated from three sweeps of the NESI survey, 
undertaken in 2008-09, 2010 and 2011-12. The analyses in Chapter 5 were used to inform 
and refine the analytical strategy; the additional two surveys allowed the examination of 
trends over this time period. A framework to triangulate the different types of evidence – 
‘group-level/ecological’ and ‘individual-level’ – was created and applied. Most of the 
evidence to populate the framework was derived from the cross-sectional surveys; they 
were supplemented with service data on the provision of injecting equipment and OST. 
Ecological analyses examined changes in intervention provision, self-reported intervention 
uptake, self-reported risk behaviour and HCV incidence across the surveys; individual-
level analyses investigated relationships within the pooled survey data. The approach to 
deriving estimates for incidence, and associated uncertainty ranges, was modified from that 
in Chapter 5.  
A decline in HCV incidence, per 100 person-years, from 13.6 (95% CI 8.1-20.1) in 2008-
09 to 7.3 (95% CI 3.0-12.9) in 2011-12 was observed, a period during which increases in 
the coverage of OST and IEP, and decreases in the frequency of injecting and sharing of 
injecting equipment, were also seen. 
 Individual-level evidence demonstrated that combined high coverage of needles/syringes 
and OST were associated with reduced risk of recent HCV in analyses that were 
unweighted (AOR 0.29, 95% CI 0.11-0.74) and weighted for frequency of injecting 
(AORw 0.05, 95% CI 0.01-0.18). There was no additional effect found for high 
paraphernalia coverage. The number of new HCV infections and new chronic HCV 
infections that may have been averted between 2008 and 2012 as a result of the 
combination of harm reduction interventions was estimated to be 1,400 and 1,000, 
respectively. 
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7.2 Considering the thesis findings within the historical 
context of HCV prevention in Scotland 
In analysing the impact of harm reduction interventions in Scotland, this thesis considers 
the relatively narrow period from 2008 to 2012; however, it is important to recall that the 
scale-up of harm reduction interventions had been happening since the late 1980s/early 
1990s (see section 1.4.4 and Figures 1-3 and 1-4). It is only since the introduction of DBS 
collection/testing and the pre-seroconversion window period method of determining 
incidence that it has really been possible to examine the impact of interventions on HCV 
incidence.  
Historically, data on HCV prevalence in Scotland were derived from the UAT system, as 
described in section 1.3.2. This system covered the four largest Health Board areas and 
showed declines in HCV prevalence among all PWID and among PWID aged <25 in three 
of these four areas during the 1990s (see Figures 1-1 and 1-2). Although the data from 
UAT were comparable across years due to the consistent approach applied, the samples 
were associated with limited epidemiological information (only age, gender and NHS 
Board) and it was not known whether they related to people who were currently injecting 
or had injected in the past.  
Another source of historical data on HCV prevalence was a series of cross-sectional 
community surveys of PWID that began in 1990, although they covered only Glasgow, and 
inconsistent inclusion criteria across the different surveys make the data less comparable. 
Nevertheless, overall HCV prevalence in these surveys ranged between 66% and 79%6 
during 1990 to 1996 (Taylor et al., 2000); these figures compare with 64% to 68% during 
2008 to 2012 in Greater Glasgow and Clyde (from the NESI data), suggesting that HCV 
prevalence among all PWID has not changed greatly (certainly, in this NHS Board) after 
approximately two decades of harm reduction.  
Examining trends in disease prevalence as an indicator of the effectiveness of interventions 
is not as simple as examining incidence, since prevalent infections could have been 
acquired at any time in the past. Ecological trends in HCV prevalence are difficult to 
interpret because there are a large number of potentially contributing factors, including the 
initiation and cessation of injecting drug use. Studies nevertheless attributed the early 
                                                 
6
 These figures have been adjusted for the 85% sensitivity of the saliva test in detecting HCV 
antibodies. 
Chapter 7  195 
 
reductions in HCV prevalence (seen in the UAT data during the early to mid-1990s) to the 
initial scale-up of interventions (Hutchinson et al., 2002). It could be that the latter 
reductions were achieved because interventions were increasing from virtually nothing and 
therefore any increase was bound to have an impact. It has been suggested that the 
subsequent plateau in HCV prevalence (seen in both the UAT and community survey data 
in the late 1990s/early 2000s) may indicate that coverage of interventions had to surpass a 
threshold in order to make further inroads (Hutchinson et al., 2002).  
By contrast, HCV prevalence among those with <5 years since onset of injecting was 70% 
in 1990 (Glasgow community surveys, unpublished data) as compared with the respective 
figures of 25 to 40% derived from the recent NESI surveys. Given that HCV prevalence 
among people who recently started injecting could be considered a proxy for incidence, the 
decline in prevalence among recent initiates to injecting would suggest that incidence has 
declined. The changes in IRB over time are also consistent with declining incidence: 27% 
to 43% of Glasgow PWID interviewed in community surveys during 1990 through 1999 
reported injecting with a previously used needle/syringe in the last six months (Taylor et 
al., 2001) as compared with 8% to 15% observed during 2008 through 2012 from NESI; 
and 70% to 90% of Glasgow PWID (1990 through 1996) reported injecting drugs at least 
daily (Taylor et al., 2000) as compared with 49% to 63% during 2008 to 2012. 
What explains the consistently high overall HCV prevalence among PWID, given the 
evidence above? One potential explanation might be that there has been an increase in 
incidence in longer term injectors. While there is no direct evidence to verify this 
possibility historically, there is no evidence to support it if one compares the proportion of 
recent infections across the NESI surveys among those with shorter vs. longer injecting 
careers (in fact, the data seem to suggest the opposite, although statistical power is an 
issue7). Possibly, a more likely explanation is related to the evidence suggesting that PWID 
in Scotland are an ageing cohort: this is supported by data from NESI (see Table 6-2) and 
earlier community surveys of Glasgow PWID indicating that the average age and time 
since onset of injecting of the sample have been increasing over time (Taylor et al., 2000). 
Recent onset injectors, therefore, seem to be forming an ever-decreasing proportion of the 
PWID population. Further evidence from capture-recapture modelling suggests a decline in 
the size of the PWID population between 2006 and 2009 (see Table 1-5). Hypothetically, 
                                                 
7
 For example, the proportion recently infected declined from 2.7% to 2.3% during 2008-09 and 
2011-12 among those with <3 years since onset of injecting, as compared with 1.9% to 0.5%, 
respectively, among those with ≥3 years since onset of injecting 
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supposing there had been no changes in HCV incidence, one might expect HCV 
prevalence to increase if fewer new (uninfected) PWID were entering the population (i.e. 
diluting the existing HCV prevalence among longer term injectors, assuming that those 
leaving the population through cessation or death are equally likely to be anti-HCV 
positive or negative). Thus, in the scenario of declining HCV incidence that has been 
observed in Scotland, one could potentially expect HCV prevalence to remain stable (i.e. 
fewer new uninfected PWID entering the population, but declining incidence among 
existing PWID to counterbalance this).  
A mathematical modelling study suggested that, in a scenario of 40% prevalence of 
chronic infection (which is approximately the situation in Scotland), 60% coverage of both 
OST and high coverage NSP (i.e. 60% of the PWID population receiving OST and 60% of 
the population receiving at least one sterile needle/syringe per injection) would need to be 
sustained for a 15-year period in order to reduce prevalence by a third (Vickerman et al., 
2012). The most recent NESI figures suggest that OST and needle/syringe coverage are 
approximately 65% and 75%, respectively, and that the 60% ‘threshold’ for both 
interventions may have been surpassed only in 2010 (depending on the measure of 
needle/syringe coverage used). Thus, it may be the case that it will take many years of a 
sustained reduction in HCV transmission before any changes in overall HCV prevalence 
are observed. 
7.3 Policy and practice implications 
7.3.1 Influence on current policy and guidelines  
Because the work for this thesis was undertaken over a period of years, some of the 
chapters – the review of reviews (Chapter 2), primarily – have already influenced policy 
within Scotland and elsewhere.  
7.3.1.1 Local 
The review of reviews was a key document that informed the evidence base for Phase II of 
the Hepatitis C Action Plan for Scotland (Scottish Government, 2008a). During Phase I 
(2006-2008) of the Action Plan, working groups relating to three areas (testing, treatment 
and care; education, training and awareness-raising and; prevention) were established. 
Their mandate included the generation of evidence and the translation of evidence into 
proposed ‘issues’ and ‘actions’. A workshop of the Prevention Working Group was 
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convened, at which the results of the review of reviews, among other evidence, were 
presented. The Prevention Working Group developed a series of issues and actions; these 
were shared with various stakeholders, who were given an opportunity to comment, 
primarily through the forum of a consultation event attended by nearly 200 individuals. 
The issues and actions that resulted from this process have been described in section 1.5.1. 
Principally, the review of reviews informed the evidence base that led to the derivation of 
Action 15 (Services providing injection equipment will be improved in accordance with 
the Guidelines). The review of reviews also informed the need to develop ‘Information 
Generating Initiatives to Monitor the Performance of Actions’, specifically: the 
development of a data collection system to monitor the provision of injection equipment 
and national annual surveys of HCV prevalence and incidence among PWID (i.e. the 
Needle Exchange Surveillance Initiative).  
Concurrently with the development of the Action Plan Phase II, the Advisory Council on 
the Misuse of Drugs produced a report to advise the UK government entitled ‘The Primary 
Prevention of Hepatitis C among Injecting Drug Users’, which cited the review of reviews 
among its sources of evidence, and which made recommendations to increase NSP 
coverage, to ensure the implementation of combination interventions (i.e NSP and OST) 
and to undertake studies to directly test the effectiveness of NSP and OST in reducing 
HCV incidence (Advisory Council on the Misuse of Drugs, 2009).  
7.3.1.2 International 
The updated review of reviews (described in section 2.4.1, although covering a wider range 
of interventions than are discussed here) (European Centre for Disease Prevention and 
Control and European Monitoring Centre for Drugs and Drug Addiction, 2011a; Macarthur 
et al., 2014) was commissioned to provide evidence to inform guidance on preventing 
infectious diseases among PWID in Europe (European Centre for Disease Prevention and 
Control, 2011). 
7.3.2 Policy recommendations 
In contrast to clinical interventions, public health interventions have, historically, required 
much less of an evidence base prior to implementation. This implementation despite a lack 
of evidence has been true of IEP interventions: for example, Chapter 2 found that the 
evidence was weak for many interventions that had already been implemented. Another 
example is the Hepatitis C Action Plan for Scotland, which advocated the scale-up of 
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interventions, including the distribution of injecting paraphernalia, despite a weak evidence 
base. A certain level of pragmatism regarding the epidemiological evidence required to 
underpin decision-making, given the difficulties in designing and undertaking studies of 
this nature, is therefore required. With these difficulties in mind, it is important to 
recognise that this thesis, and the existing body of literature to which it adds, is the best 
and strongest evidence that has existed to date on the effectiveness of interventions in 
preventing HCV transmission. Although the study designs used to generate the evidence in 
this thesis could be criticised from a purist epidemiological viewpoint, the evidence is 
nevertheless sufficiently compelling to justify, at least, the maintenance of current harm 
reduction services and certainly the consideration of further scale-up, given that promising 
signs in the direction of movement of HCV incidence have been observed and it is likely 
that the level of interventions will need to be sustained for a number of years before any 
changes in HCV prevalence are seen.   
Although this thesis did not consider the cost-effectiveness of the prevention investment, a 
‘back-of-the-envelope’ calculation indicates that the prevention investment could be much 
less than the potential costs of treating the infections that would otherwise have occurred. 
The costs of the direct-acting antivirals that will be available from 2015 have yet to be 
confirmed, but have been estimated to be in the region of £30,000 to £80,000 per treatment 
course (Sharon Hutchinson, Glasgow Caledonian University, personal communication). If 
the prevention interventions are estimated to have averted 1,000 chronic infections during 
the period 2008 through 2012 (Chapter 6), and if even half of them had gone on to receive 
therapy, then this would result in saved treatment costs of £15 million to £40 million. 
These potential savings compare to the Scottish Government prevention investment of 
approximately £11 million during 2008 to 2012 (£8 million over the course of the Action 
Plan Phase II (Scottish Government, 2008a) and a further £3 million in the first year of the 
Sexual Health and Blood Borne Virus Framework (Nicola Rowan, Health Protection 
Scotland, personal communication)).  
The further scale-up of interventions, however, may not simply be a political decision (i.e. 
securing funding), because there are issues surrounding the saturation of interventions. In 
Scotland, services have attained very high coverage of both OST and IEP (although there 
is perhaps more scope to increase the provision of injecting paraphernalia). There have 
been anecdotal reports from services that PWID do not want to take away any more 
equipment than the amount they are currently getting (John Campbell, Glasgow Addiction 
Services, personal communication). It could be that the ‘easy-to-reach’ PWID are now 
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covered by existing interventions and that increasing the coverage of interventions will 
require innovative ways to target and reach the more ‘hard-to-reach’ PWID. Getting these 
individuals into treatment, maintaining them in treatment and ensuring that they use a 
sterile set of equipment for every injection, remain a challenge.  
Modelling studies have examined the impact of HCV therapy as a preventive intervention, 
(Martin et al., 2013a; Martin et al., 2013b). These studies suggest that scaling up HCV 
therapy (in addition to the existing harm reduction interventions) is necessary if substantial 
reductions in HCV prevalence over the next decade or two are to be made. It has been 
suggested that the new direct-acting antivirals have the potential for much higher rates of 
uptake because of their improved effectiveness, lower toxicity and reduced treatment times 
(Martin et al., 2013c); however, the cost of direct-acting antivirals may prohibit scaling up 
HCV treatment even among high-income countries, let alone low- to middle-income 
countries (Anonymous, 2014). Nevertheless, the future of HCV therapies may have 
implications for HCV prevention in the long term: the patents for many of the direct-acting 
antivirals will run out by 2030 and there are therefore cheaper drugs on the horizon (David 
Goldberg, Health Protection Scotland, personal communication). Some might argue that 
the widespread access to affordable therapy would obviate the need for preventive 
interventions such as IEP. However, widespread therapy would first require a number of 
challenges to be overcome, including increasing the uptake of therapy among PWID 
(which involves the challenges of both case finding, and educating clinicians and the health 
workforce to offer testing and treatment to active PWID). In the meantime, given that this 
scenario of inexpensive HCV therapy is probably at least 15 years away, the need for OST 
and IEP remains (and the speed with which HCV can spread in the absence of harm 
reduction interventions should not be forgotten).  
It merits mention that, with regard to harm reduction interventions, there are policy 
considerations beyond just HCV prevention. While OST has other obvious benefits – 
reduced risk of overdose, reduced criminal activity and increased employment potential 
(Bell and Zador, 2000) – policymakers also need to take a holistic view of IEP services. 
Although chiefly aimed at preventing BBVs, other benefits of IEP that have not been 
considered in this thesis should be taken into account: for example, the prevention of 
bacterial infections. In many cases, IEP services often serve as a first point of contact for 
someone who has recently commenced injecting, therefore providing an opportunity to 
‘capture’ PWID and refer them onto other services, such as treatment for their addiction.  
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A further consideration with regard to harm reduction interventions, particularly IEP, is the 
potential evolution of a new virus. The past epidemics of BBVs among PWID in Scotland 
were not discovered until very large proportions of the population had become infected. 
HIV and HCV found a suitable niche among PWID because of the prevalence of risk 
behaviours in this population group that permitted their efficient transmission given that, at 
the time, preventive interventions did not exist, or existed only at very low levels of 
coverage. Thus, there is a strong argument for maintaining harm reduction to prevent 
future, as-yet-unknown outbreaks of infection among PWID.   
7.4 Recommendations for future research 
The next sections address pertinent outstanding questions and suggest methods through 
which answers might be generated. 
7.4.1 Are there other ways to measure recent HCV infection using 
cross-sectional designs? 
Given that HCV among PWID has not yet been controlled, it will remain important to 
continue to monitor HCV transmission in this population. As described earlier, although 
the ‘pre-seronversion window period’ approach to measuring HCV incidence has benefits 
over a traditional cohort approach, one of its limitations is that large sample sizes are 
required in order to detect relatively few recent infections.  
Another measure of recent infection, involving the avidity of anti-HCV, has been under 
development. Avidity is a term that is used to refer to the affinity or binding capacity of an 
antibody for an antigen (Abbas, Lichtman, and Pillai, 2014; Shepherd et al., 2013): in this 
case, the affinity of anti-HCV Immunoglobulin G for the HCV virus. Briefly, the assay 
involves treating a sample with a dissociation agent (which removes antibodies that are 
weakly bound to antigens) and comparing the treated sample with an untreated sample. 
The comparison generates an avidity index: the higher the index value, the greater the 
affinity or binding of the antibody.  
It has been demonstrated that avidity increases with the time elapsed since infection – 
reflecting that the affinity of an antibody for a particular antigen ‘matures’ over time 
(Shepherd et al., 2013) – and several studies have shown distinct differences in the average 
avidity index between samples taken from individuals with new/acute infection as 
compared with current/chronic infection (Gaudy-Graffin et al., 2010; Kanno and 
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Kazuyama, 2002; Klimashevskaya et al., 2007). One study found that, when using an 
avidity threshold of 43, the assay distinguished new from current/chronic infections with 
98% sensitivity and 100% specificity (Gaudy-Graffin et al., 2010). Another study used a 
threshold of 42 and found that all avidity index values for new/acute infections and 
current/chronic infections were lower and higher, respectively, than this threshold 
(Klimashevskaya et al., 2007). Studies have also demonstrated that, although avidity 
among people with past/cleared infection is (on average) lower than those with 
current/chronic infection and higher than those with new/acute infection, the index values 
can fall below the threshold that might be used to distinguish new/acute and 
current/chronic infection. Thus, the avidity index, alone, has been shown to be insufficient 
to distinguish between a new infection and a past/cleared infection; the individual’s HCV-
RNA status would also need to be known in order to make this distinction 
(Klimashevskaya et al., 2007). 
While the development of the avidity test may have been driven by clinical considerations, 
there are promising epidemiological applications. Work in Scotland has been undertaken to 
validate an avidity assay on plasma and DBS: this study demonstrated that avidity index 
results on DBS samples (that had been mocked up from plasma) were generally lower than 
the corresponding avidity index results on plasma. They derived an algorithm, which 
included HCV-RNA status, that generated 100% sensitivity (95% CI 73.5-100%) and 
98.3% specificity (95% CI 93.9-99.8%) from DBSs (a combination of mocked up and 
‘real’ samples), but this was based on only 12 new/acute infections (Shepherd et al., 2013). 
Being able to undertake the avidity test on DBSs would open up epidemiological 
possibilities, because sero-surveillance studies among PWID are increasingly utilising 
DBSs for their ease and relative cost as compared with venepuncture (Hope et al., 2011). It 
is important to remember, however, that, because the avidity assay is possible only on 
individuals who have anti-HCV, it does not capture all recent infections (as it will miss 
those in the pre-seroconversion window period). Epidemiological studies might consider 
applying both avidity and window period approaches in order to maximise the number of 
recent infections detected, and consequently maximise statistical power. 
For most HCV-infected individuals, the avidity index will increase from the date of 
infection, although not necessarily in a linear fashion. Thus, the avidity index in itself 
cannot be used as a measure of time since infection. The Scottish work indicates that a low 
avidity result suggests the infection has occurred within the previous four to five months 
(Shepherd et al., 2013); however, the duration of this state needs to be better elucidated, 
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particularly if the intention is to use avidity to estimate incidence per 100 person-years, 
using a similar approach to that applied in Chapters 4 and 6.  
7.4.2 Are there alternatives to self-reported information when 
measuring harm reduction intervention uptake? 
The reliance on self-reported information is a recurring limitation in this thesis. In Chapters 
5 and 6, the exposure to the intervention was based on self-report. Although most 
published studies of harm reduction interventions have used self-reported information to 
determine exposure status, there have been a few instances where this was not the case. For 
example, follow-up studies of PWID in treatment have recorded the dosage of OST 
administered to participants; however, these studies have mostly been conducted in clinical 
settings. Additionally, a few studies have assigned exposure status based on whether a 
participant had attended a needle exchange (or not) during a defined time period; however, 
this approach has limitations that were discussed in Chapter 2.  
In Scotland, data on the provision of IEP have been routinely reported and collated 
centrally since 2007 (Information Services Division, 2009). While these data were 
originally collected by means of a survey sent out to the NHS Boards to complete and 
return, recent steps have been taken to implement an electronic system, which will have 
nearly universal coverage across the NHS Boards in Scotland (Boards are currently in 
different stages of implementation). Data are collected in the service at the point of 
transaction with a client. At a minimum, the type and amount of injecting equipment given 
to the client are recorded. The identifying items of information collected from clients are 
initials, date of birth and sex, permitting the linkage of records both within the injecting 
equipment database itself and to external databases. This future national repository of data 
on injecting equipment provision presents the opportunity to undertake data linkage with 
the NESI data in order: (i) to compare provision data with self-reported data on the uptake 
of sterile injecting equipment in order to validate the self-reported data, and (ii) to examine 
the association between uptake of sterile injecting equipment using provision data and 
HCV infection status.  
7.4.3 What is the relationship between needle/syringe coverage 
and HCV incidence?  
In this thesis, the threshold defining high coverage of IEP was set at 200% (i.e. two sterile 
needles/syringes for every injection) for analysis purposes; however, there were indications 
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that PWID had overestimated the amount of equipment that they obtained from services, 
and thus the threshold might not be accurate. Although it has been suggested that the 
relationship between IEP and HCV incidence is not a dose-response relationship (Chapter 
2), further work to determine the nature of this relationship – for example, to elucidate the 
actual coverage ‘threshold’ above which reductions in HCV incidence are realised – would 
be helpful to inform policy and practice. Statistical power to examine this threshold may 
present a challenge, given that the current analysis had only just enough power to examine 
two coverage groups (<200% and ≥200%), by the time other confounding variables were 
taken into account. A potential method to overcome this issue of power is through a pooled 
analysis. The pooling of data can be a useful tool when multiple studies examining the 
same intervention(s) and outcome(s) have been undertaken and when the variables are 
sufficiently similar to combine. Pooled analysis is generally preferable to meta-analysis 
when the data from these studies can be accessed. A pooled analysis of UK studies has 
already been undertaken and was able to demonstrate the combined impact of 
interventions, when individual studies had been unable to do so (Turner et al., 2011).  
7.4.4 To what extent do PWID transition into and out of high 
coverage of interventions?  
While the evidence presented here gives a cross-sectional ‘snapshot’ of the proportion of 
PWID on OST or with high coverage of needles/syringes, it is known that PWID do not 
remain consistently in these categories – for example, individuals’ methadone dosages are 
often adjusted and it is well known that individuals in receipt of OST can drop out of 
treatment (Peters and Reid, 1998). What is not known is the frequency with which they 
transition into and out of high coverage of interventions. As stated in Chapter 6, more than 
1,000 individuals participated two or more times across the three NESI surveys. Data 
linkage across these datasets would therefore offer the opportunity: (i) to examine how 
individuals change intervention ‘states’ over time, and (ii) to examine the factors that are 
associated with sustained high coverage of interventions.   
7.4.5 Can the specific contributions of harm reduction 
interventions to the HCV prevalence and incidence landscape be 
elucidated? 
There is a wealth of historical data available (mainly for Glasgow) on HCV prevalence, 
IRB and uptake of harm reduction interventions from community surveys of PWID 
undertaken regularly since 1990. To understand which interventions contributed to the 
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observed reduction in HCV incidence, a mathematical modelling study is planned, that will 
model the changes in OST, IEP and antiviral therapy over time to explore whether these 
models are consistent in generating the levels of HCV prevalence and incidence that have 
been observed in Scotland. The findings from these models would support or refute the 
evidence for a reduction in HCV transmission associated with the changes in coverage of 
interventions as a result of the Hepatitis C Action Plan. The projected impact of various 
scenarios of future harm reduction intervention coverage in Scotland will also be 
examined: for example, maintaining current coverage levels, further scale-up, or a decline 
in existing coverage. This study will help to identify the combinations of interventions that 
are needed to reduce HCV transmission effectively. 
7.4.6 Can harm reduction interventions be further scaled up?  
Can harm reduction interventions be scaled up or has a saturation point been reached? The 
answer to this question is likely dependent on the local context. In Scotland as a whole, the 
numbers of needles/syringes distributed has more or less reached a plateau; however the 
picture differs if separate NHS Board areas are examined (Information Services Division, 
2013). There also appears to be more scope for scaling up paraphernalia distribution, 
which has not yet reached levels on a par with needle/syringe distribution in certain areas. 
As mentioned above, anecdotally, service providers have said that PWID already feel they 
are taking enough equipment for their needs (John Campbell, Glasgow Addiction Services, 
personal communication). Qualitative research would be helpful to identify reasons why 
PWID take away as much equipment as they do: for example, do they feel it is sufficient 
for their needs? Is it too much to carry? Do other barriers to taking away injecting 
equipment exist? Shedding light on these issues may help to tailor interventions if the 
intention is to bolster existing levels of IEP coverage.   
7.5 Conclusions 
The body of work in this thesis represents a novel contribution to the evidence base: it was 
the first large-scale, national application of a method designed to determine incidence of 
HCV using a cross-sectional design, and the first study to apply a framework to triangulate 
the evidence from different designs in order to investigate the association between harm 
reduction interventions and HCV transmission. This thesis does not propose to be able to 
establish a definitive causal link between IEP/OST and the prevention of HCV 
transmission. It does, however, provide sufficiently plausible evidence that the scale-up of 
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a combination of harm reduction interventions in Scotland between 2008 and 2012 
contributed to the reduction in HCV incidence observed. Components of the thesis have 
already influenced existing policy and practice in Scotland and internationally. Regarding 
future policy in this area, the evidence generated and presented here supports, at least, the 
maintenance of the HCV prevention investment in Scotland, and certainly the 
consideration of further scale-up.  
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Appendix A: Review of reviews of opioid 
substitution treatment 
OST is the provision of agonist pharmacotherapy for the treatment of opioid dependence. 
OST prevents withdrawal symptoms, reduces cravings associated with illicit opioid use 
and diminishes the effects of illicit opioids with a view to reducing both illicit opioid use 
and the frequency of injection. The most commonly prescribed forms of OST are 
methadone maintenance treatment (MMT) and buprenorphine maintenance treatment 
(BMT). In this review we refer primarily to evidence relating to MMT but the findings can 
be largely taken to refer to OST generally. OST is widely prescribed in the UK. 
Three of the core review papers met the critical appraisal criteria related to OST and were 
primarily drawn upon for the evidence of effectiveness of this intervention: 
• Tilson, H., Aramattana, A., Bozzette, S., Celentano, D., Falco, M., Hammett, T., 
Kozlov, A., Lai, S., Mahal, A., Scotthenfeld, R., and Solomon, S., 2007. Preventing 
HIV Infection among Injecting Drug Users in High-Risk Countries: An Assessment 
of the Evidence. Washington D.C.: Institute of Medicine. 
• Gowing, L., Farrell, M., Bornemann, R., and Ali, R., 2004. Substitution treatment 
of injecting opioid users for prevention of HIV infection. The Cochrane Library, 
4(Oct 18). 
• Sorensen, J.L., and Copeland, A.L., 2000. Drug abuse treatment as an HIV 
prevention strategy: A review. Drug Alcohol Depend, 59(1), pp.17-31. 
In the absence of any core review addressing the impact of OST on HCV incidence and 
prevalence, the evidence from one supplementary review paper was also considered: 
• Wright, N.M., and Tompkins, C.N., 2006. A review of the evidence for the 
effectiveness of primary prevention interventions for hepatitis C among injecting 
drug users. Harm Reduct J, 3(6 Sep), p.27. 
Supplementary reviews on the effectiveness of OST in prisons and young people are also 
referred to:  
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• World Health Organization, UNAIDS, and United Nations Office on Drugs and 
Crime, 2007. Effectiveness of interventions to manage HIV in prisons - Opioid 
substitution therapies and other drug dependence treatment. Geneva: World Health 
Organization. 
• Hopfer, C.J., Khuri, E., Crowley, T.J., and Hooks, S., 2002. Adolescent heroin use: 
a review of the descriptive and treatment literature. J Subst Abuse Treat, 23(3), 
pp.231-7. 
Finally, one review which examined the cost-effectiveness of OST and a key modelling 
study on the cost-effectiveness of OST in preventing HIV and HCV, were identified: 
• Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R.J., Fry-
Smith, A., Day, E., Lintzeris, N., Roberts, T., Burls, A., and Taylor, R.S., 2007. 
Methadone and buprenorphine for the management of opioid dependence: a 
systematic review and economic evaluation. Health Technol Assess, 11(9), pp.1-
171. 
 
• Pollack, H.A. and Heimer, R., 2004. The impact and cost-effectiveness of 
methadone maintenance treatment in preventing HIV and hepatitis C. In: J. Jager, 
W. Limburg, M. Kretzschmar, M. Postma, and L. Wiessing., eds. Hepatitis C and 
injecting drug use: impact costs and policy options. Luxembourg: European 
Monitoring Centre for Drugs and Drug Addiction. 
A summary of the papers described above can be found in Table A-1.  
A1.1 Effects on HCV Incidence/Prevalence 
The supplementary review by Wright and Tompkins (2006) refers to the results of five8 
studies which examined the relationship between OST and HCV incidence (Tables A-2 
and A-3a). A nested case-control study and a prospective cohort study found lower but 
statistically non-significant HCV incidence among those in OST compared to those who 
are not in treatment (Rezza et al., 1996) or those who have left treatment (Thiede, Hagan, 
and Murrill, 2000), respectively. Another cohort study found OST (in combination with 
                                                 
8
 One study is erroneously quoted by Wright et al. as comparing HCV incidence between those in 
MMT/not in MMT, but the study in fact compared HCV with HIV and HBV incidence, and is 
therefore not included in the latter table (Chamot et al., 1992). 
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NSP) was not associated with any decreases in annual HCV incidence over four years (van 
Ameijden et al., 1993). Finally, two cohort studies did not find any significant differences 
in HCV incidence between those in OST and those not in OST (Crofts et al., 1997; Selvey, 
Denton, and Plant, 1997). The findings of these studies are summarised in Table A-3. 
Based on the available evidence Wright and Tompkins (2006) concluded that: “As regards 
methadone maintenance therapy, whilst it has been successful in reducing the incidence of 
HIV, the evidence for its effectiveness in reducing HCV incidence is less convincing.” 
(p.5) 
The findings from primary studies examining OST and HCV incidence published since the 
Wright and Tompkins review are mixed (Table A-3b). Two community-based OST studies 
suggested a positive impact of OST: HCV incidence was considerably (although non-
significantly) lower among those in continuous OST compared with those with interrupted 
OST (Hallinan et al., 2004); and OST in the past six months was protective against 
HIV/HCV infection among mono-infected or non-infected IDUs (Miller et al., 2004). 
While Maher et al. (2006), albeit using a less categorical measure of exposure to OST, 
found no difference in risk of HCV seroconversion among IDUs recruited from OST 
clinics and IDUs recruited from NSP sites. From two linked prison-based OST studies, 
Dolan and colleagues found no difference in HCV incidence between the prison OST and 
waitlist control groups at five month follow-up (Dolan et al., 2003); however, in a 
subsequent four year follow-up, retention in OST was associated with reduced HCV 
infection, while short OST episodes (less than five months) were significantly associated 
with greater risk of HCV (Dolan et al., 2005). Finally, in addition, a prospective cohort 
study of IDUs in South Wales showed that, at 12-month follow-up, HCV incidence was 
similar among individuals who were not in OST during follow-up or in OST for up to six 
months, but was lower amongst individuals in treatment for seven to 12 months. Moreover, 
among homeless IDUs, HCV incidence of those not in OST was more than twice that of 
those in OST (Craine et al., 2009). 
Drawing on Wright and Tompkins (2006) and the above-mentioned primary studies, we 
see: three studies have shown a significant positive association between retention in OST 
and reduced HCV incidence (all cohort studies); and eight have reported no association 
(one RCT, one case-control and six cohort studies).  
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We conclude that the level of evidence is insufficient, given the absence of a statement 
from a core review and inconclusive evidence from multiple robust studies (showing a few 
positive associations, but predominantly no association).   
Evidence statement: There is insufficient review-level evidence to either support or 
discount the effectiveness in reducing HCV transmission among PWID. 
A1.2 Effects on HIV Incidence/Prevalence 
All of three of the core OST reviews assessed the evidence with respect to HIV incidence 
outcomes (Gowing et al., 2004; Sorensen and Copeland, 2000; Tilson et al., 2007). The 
focus is primarily on the Tilson et al. (2007) and Gowing et al. (2004) reviews as these are 
the most recent and rigorous (note: Tilson et al. draws heavily on Gowing et al.). In total 
the three reviews draw on seven primary studies which relate to the impact of OST on HIV 
incidence or prevalence and there was high overlap between studies included in the 
reviews (Table A-2). These comprised one RCT (Dolan et al., 2003), four cohort studies 
(Hartel and Schoenbaum, 1998; Metzger et al., 1993; Moss et al., 1994; Williams et al., 
1992); one case-control study (Serpelloni et al., 1994) and one cross –sectional study 
(Novick et al., 1990).  
The odds of HIV seroconversion were found to be many times greater for untreated 
individuals or those with interrupted OST compared to those who remained continuously 
in OST (Metzger et al., 1993; Moss et al., 1994; Williams et al., 1992), although the latter 
study was statistically non-significant. Lower daily dose and more time out of OST was 
also associated with higher risk of HIV seroconversion (Hartel and Schoenbaum, 1998; 
Serpelloni et al., 1994). Dolan and colleagues’ RCT of OST in prison found no difference 
in HIV incidence between those in OST and waitlist controls; however, this was in the 
context a short period of follow-up and low prevalence of HIV and reduced injection 
prevalence (Dolan et al., 2003). The findings from these studies are summarised in Table 
A-4. 
The conclusions from all three core reviews allowed that continuous OST is associated 
with lower rates of HIV seroconversion but that self selection bias, that is patients who 
resist treatment or engage in risky behaviours may leave treatment while those with fewer 
HIV risk behaviours may stay in treatment longer, cannot be ruled out: 
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Tilson et al. (2007) concluded that: 
“Modest evidence from prospective cohort and case-control studies shows that continuous 
opioid agonist maintenance treatment is associated with protection against HIV 
seroconversion. This association persists after controlling for many confounders. These 
studies also show that the risk of HIV seroconversion is inversely related to length of time 
in treatment. However the possibility of bias in these findings from self selection cannot be 
ruled out.” (p.92)  
Gowing et al. (2004) concluded that:  
“Few data and variability in the means of reporting limit the conclusiveness of any 
analysis, but these studies consistently indicate lower rates of [HIV] seroconversion 
associated with substitution treatment. This suggests that reductions in risk behaviour do 
translate into actual reduction in cases of HIV infection.” (p. 16)  
Finally, Sorensen and Copeland (2000) concluded that: 
“Four out of the six studies reviewed…provided firm evidence for the protective effect of 
OST against HIV seroconversion. These findings are more convincing because they are 
based on biologically verified outcomes rather than participant self-report…[but] nearly all 
the studies are inherently limited by a self-selected treatment sample…in most of the 
studies the in-treatment and out-of treatment groups differ on demographics and that there 
may be other unidentified differences in these groups that may account for the differences 
found in HIV seroconversion”. (p.27) 
Evidence statement: There is sufficient review-level evidence to support the effectiveness 
of continuous OST in reducing HIV incidence but self-selection bias cannot be ruled out. 
A1.3 Effects on injecting risk behaviour 
In total the three core reviews draw on 37 primary studies which relate to IRB, 22 of which 
are included in more than one review (A-2). There was considerable heterogeneity in the 
measurement of IRB in the primary studies. The measurement of IRB can be categorised 
into three domains: prevalence and frequency of injection; sharing of injecting equipment; 
and scores of drug-related risk. The studies are summarised in Table A-5. 
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A1.3.1 Prevalence and frequency of injection 
Tilson et al. (2007) and Gowing et al. (2004) reviewed six studies that reported on 
prevalence of injecting drug use before and after OST (Camacho et al., 1996; Chatham et 
al., 1999; Dolan et al., 2003; Gossop et al., 2000; King et al., 2000; Magura et al., 1991); 
eight studies that reported on frequency of injection at baseline and follow-up (Batki et al., 
1989; Brooner et al., 1998; Camacho et al., 1996; Chatham et al., 1999; Dolan et al., 2003; 
Kwiatkowski and Booth, 2001; Simpson et al., 1995; Strang et al., 2000); and two studies 
that examined both the proportion and frequency of injection (Camacho et al., 1996; 
Chatham et al., 1999). The studies varied in design, follow-up periods (range 3 to 12 
months) and measurement of frequency of injecting, but all studies showed statistically 
significant decreases in IRB from baseline to follow-up (Gowing et al., 2004; Tilson et al., 
2007).  
Additionally, Sorensen and Copeland (2000) refer to a further nine studies with data on 
injection prevalence and frequency: five longitudinal studies of in treatment samples 
showed retention in OST was associated with decreases in injection frequency (Abbott et 
al., 1998; Ball et al., 1988; Iguchi, 1998; Saxon, Calsyn, and Jackson, 1994; Shore et al., 
1996); and four studies comparing those in treatment with non treatment samples found 
OST associated with fewer injections (Baker et al., 1995; Greenfield, Bigelow, and 
Brooner, 1995; Meandzija et al., 1994; Stark et al., 1996b). 
A1.3.2 Sharing of injecting equipment  
Tilson et al. (2007) and Gowing et al. (2004) reviewed seven studies that examined the 
proportion of participants who reported sharing equipment before and after a period of 
OST. Six out of seven (Camacho et al., 1996; Chatham et al., 1999; Dolan et al., 2003; 
Gossop et al., 2000; Grella et al., 1996; Margolin et al., 2003) found a significant reduction 
in sharing between baseline and follow-up. The seventh study (King et al., 2000), found a 
non-significant reduction in reported sharing. 
Sorensen (2000) additionally reported on four longitudinal studies of in-treatment samples 
which showed that retention in OST was associated with decreases in sharing of injecting 
equipment (Camacho et al., 1996; Magura et al., 1991; Rhoades et al., 1998; Saxon, 
Calsyn, and Jackson, 1994) and one study that showed no differences in sharing between 
new treatment entrants and the rest of the sample (Calsyn et al., 1991). Five studies 
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comparing those in treatment with non treatment samples found OST was associated with 
decreased sharing (Caplehorn and Ross, 1995; Greenfield, Bigelow, and Brooner, 1995; 
Klee et al., 1991; Longshore et al., 1993; Stark et al., 1996b) and one study found no 
differences in sharing (Baker et al., 1995). 
A1.3.3  Scores of drug related risk  
Tilson et al. (2007) and Gowing et al. (2004) report on five studies which provided data on 
drug-related HIV risk scores before and after OST (Abbott et al., 1998; Avants et al., 1998; 
Baker et al., 1995; Chatham et al., 1999; Sees et al., 2000). Abbott et al. and Avants et al. 
used the Risk Assessment Battery (Navaline et al., 1994), Baker et al. used the HIV-Risk 
Taking Behaviour Scale (Ward, Darke, and Hall, 1990), Sees et al. used the Risk of AIDS 
Behaviour Scale (Metzger et al., 1992) and Chatham et al. calculated a Risky Needle 
Exposure Index (based on the number of persons with whom injecting equipment had been 
shared pre and post OST). For all of these scales, a higher score indicates higher levels of 
risk behaviour. Three of the five studies (Abbott et al., 1998; Avants et al., 1998; Chatham 
et al., 1999) found significant decreases in drug-related HIV risk behaviour scores before 
and after OST. Sees et al. (2000) found a non-significant reduction in mean risk scores 
between intake and six month follow-up between the methadone maintenance and 
methadone detoxification groups. Finally Baker et al. (1995) compared risk scores for 
cohorts of PWID who currently, previously or never received OST and found the current 
OST group had significantly reduced risk scores compared to the other groups.  
The conclusions from all three reviews were conclusively that OST was associated with 
reductions in self-reported prevalence and frequency of injection, sharing of injecting 
equipment and injecting risk scores: Tilson et al. (2007) concluded that: 
“Moderate to strong evidence from one RCT and a number of observational studies show 
that patients receiving methadone maintenance treatment report reductions in several drug-
related HIV risk behaviours, including frequency of injecting and sharing of injecting 
equipment. These patients also had lower summary scores of drug-related risk behaviour 
compared with pre-treatment levels”. (p.89) 
Gowing et al. (2004) concluded that: 
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“Substitution treatment is associated with a significant decrease in the proportion of 
participants reporting injecting drug use and in the frequency of injection…[and] a 
significant decrease in the sharing of injecting equipment…[drug risk scores] data were 
consistent with the findings in relation to injecting drug use and sharing of injecting 
equipment in that the studies that reported scores also showed a significant reduction is risk 
associated with substitution treatment.” (pp.14-15) 
Finally Sorensen (2000) concluded that: 
“26 out of 28 studies showed positive results in reducing HIV risk behaviours…In this 
review both longitudinal studies of in-treatment samples and studies comparing treatment 
patients with other samples found very strong evidence that drug abuse treatment decreases 
the risk of HIV infection by decreasing needle-use. The evidence is less strong, but still 
substantial, that drug abuse treatment changes the needle use patterns of participants (e.g. 
less needle-sharing, more use of sterile needles).” (pp. 27-28). 
Evidence statement: There is sufficient review-level evidence to support the effectiveness 
of OST in reducing IRB by reducing the frequency of injection, the sharing of injecting 
equipment and injecting risk scores. 
A1.4 Prison  
None of the core reviews specifically examined the impact of prison-based OST on HCV/ 
HIV incidence/prevalence or IRB. We refer to a recent supplementary review of the 
effectiveness of OST to manage HIV in prison (World Health Organization, UNAIDS, and 
United Nations Office on Drugs and Crime, 2007). The evidence was reviewed using the 
Bradford Hill criteria as per other reviews in the World Health Organization (WHO) 
Evidence for Action series (e.g. Wodak and Cooney, 2004). The primary question in this 
review, as relates to the outcomes being examined in this review, was whether prison-
based OST leads to a reduction in illegal drug use and associated risk behaviours in prison. 
This review, however, provided very little detail on individual study quality, characteristics 
or findings.  
A1.4.1 Effects on HCV Incidence/Prevalence 
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Two studies included in the WHO (2007) review examined prison OST and HCV 
incidence and have already been described (Section 8.1). Briefly, in their RCT, Dolan and 
colleagues found no difference in HCV incidence between the prison OST and waitlist 
control groups at five month follow-up (Dolan et al., 2003). However at four year follow-
up, retention in OST was associated with reduced HCV infection, while short OST 
episodes (less than five months) were significantly associated with greater risk of hepatitis 
C (Dolan et al., 2005).  
Evidence statement: There is insufficient review-level evidence to either support or 
discount the effectiveness OST with respect to HCV transmission in prison settings. One 
RCT suggests that retention in OST from prison to community settings is associated with 
reduced HCV incidence. 
A1.4.2 Effects on HIV Incidence/Prevalence 
Only one study included in the WHO (2007) review examined the effects of prison OST on 
HIV incidence. Dolan et al. (2003) found no difference in HIV incidence between 
treatment and control groups. As mentioned earlier, however any impact on HIV incidence 
may not have been detectable given the low prevalence of HIV in the Australian context 
and the short period of follow-up (Dolan et al., 2003). 
Evidence statement: There is insufficient review-level evidence to draw any strong 
conclusions regarding the effectiveness OST with respect to HIV transmission in prison 
settings. Data from one RCT in a jurisdiction with low HIV prevalence found no difference 
in HIV incidence between those receiving OST and controls.  
A1.4.3 Effects on injecting risk behaviour 
WHO (2007) referred to seven studies of prison-based OST programmes (‘four controlled 
trials and three descriptive studies’). On closer examination however, it appears that 
several of these publications are reporting very similar findings from the same data set 
((Heimer et al., 2005; Heimer et al., 2006) and (Dolan, Hall, and Wodak, 1996; Dolan, 
Wodak, and Hall, 1998)). 
They reported that all included studies found that opioid using IDUs who receive OST in 
prison inject significantly less frequently than those not receiving OST (Bayanzadeh, 2004; 
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Boguna, 1997; Dolan, Hall, and Wodak, 1996; Dolan et al., 2003; Dolan, Wodak, and Hall, 
1998; Heimer et al., 2005; Heimer et al., 2006).  
WHO (2007) concluded: 
“Prison-based OST programmes appear to be effective in reducing the frequency of 
injecting drug use and associated sharing of injecting equipment, if a sufficient dosage is 
provided and treatment is provided for longer periods of time. The risk of transmission of 
HIV and other BBVs among prisoners is also likely to be decreased. In addition, there are 
other benefits, both for the health of prisoners participating in the programmes, and for 
prison systems and the community” (p.9) 
Evidence statement: There is tentative review-level evidence to support the effectiveness 
of OST in reducing IRB among IDUs in prison settings by reducing heroin and other 
opioid use.  
A1.5 Young IDUs 
None of the core reviews specifically examined the impact of OST on young people’s 
HCV/ HIV incidence/prevalence or IRB. We refer to one supplementary review of drug 
treatment (including OST) in young people (Hopfer et al., 2002). ‘Young’ was defined as a 
mean age of 21 years or less. We also identified a Scottish systematic literature review of 
services for young problem drug users (aged less than 16 years) but it did not include any 
studies that demonstrated the effects of OST for young drug users (Elliott et al., 2002). 
Clinical guidelines and other advisory material suggest that the decision to prescribe OST 
to under-16s should be a highly unusual occurrence, and that is only undertaken in the 
most extreme circumstances (Effective Interventions Unit, 2003).  
A1.5.1 Effects on HCV Incidence/Prevalence 
We did not identify any reviews that examined the effects of OST on HCV incidence or 
prevalence among young people. 
Evidence statement: There is no review-level evidence to either support or discount the 
effectiveness of OST with respect to HCV transmission among young people.  
A1.5.2 Effects on HIV Incidence/Prevalence 
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We did not identify any reviews that examined the effects of OST on HIV incidence or 
prevalence among young people. 
Evidence statement: There is no review-level evidence to either support or discount the 
effectiveness of OST with respect to HIV transmission among young people.  
A1.5.3 Effects on injecting risk behaviour 
Hopfer et al. (2002) refer to three observational studies of OST and young people which 
examined OST retention. The limited data reported on drug use suggest that, for those 
retained in OST, heroin use decreased (DeAngelis and Lehmann, 1973; Rosenberg and 
Patch, 1972; Sells and Simpson, 1979). 
Evidence statement: There is insufficient review-level evidence to either support or 
discount the effectiveness of OST with respect to injecting-related risk behaviour among 
young people.  
A1.6 Other factors affecting OST outcomes 
Several factors have been shown to impact on OST outcomes: duration of treatment, 
dosage and the provision of adjunctive psycho-social services. 
As highlighted previously, continuous OST is associated with lower HIV incidence than 
interrupted OST or no OST. The impact of treatment duration/continuity of treatment on 
drug use and IRB is addressed by Tilson et al. (2007) and Gowing et al. (2004): 
In relation to duration or length of treatment, Tilson et al. (2007) concluded: 
“Strong evidence from several large randomized clinical trials shows that continuous 
agonist maintenance therapy is associated with longer treatment retention – and reductions 
in illicit opioid use and relapse to opioid dependence – than short term use of these agents. 
Furthermore, modest evidence from quasi-experimental studies also suggests that 
discontinuation of agonist maintenance therapy is associated with higher rates of re-
addiction and criminal behaviour. Agonist maintenance therapies are effective while they 
are provided and no evidence suggests a benefit to early termination. Thus, reasonable 
clinical guidance is to continue such therapies as long as they are associated with positive 
effects” (p.94). 
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In relation to the impact of OST on IRB after cessation of OST, Gowing et al. (2004) 
concluded: 
“The duration of effect of substitution treatment is unclear. Relapse to illicit opioid use is 
common following cessation of substitution treatment but it is not clear to what extent 
injecting risk reduction strategies are practised following cessation of substitution 
treatment” (p.16). 
In relation to dosage, Tilson et al. (2007) concluded: 
“Strong evidence from randomized, double-blind clinical trials, shows that buprenorphine 
and methadone maintenance treatment have greater efficacy at higher doses. Thus 
reasonable clinical guidelines would recommend raising the dose until optimal effects 
occur, rather than setting arbitrary limits. Studies systematically examining dosing show 
greater efficacy up to 100 milligrams per day of methadone, and up to 16 milligrams per 
day of buprenorphine” (p.96). 
Finally, in relation to OST in combination with psycho-social treatment, Tilson et al. 
(2007) concluded: 
“Few studies have specifically examined the impact of adjunctive psychosocial 
interventions on HIV risk behaviour among patients on opioid agonist maintenance 
therapy. Weak evidence from several studies suggests that some psychosocial interventions 
for patients enrolled in such therapy can be effective in reducing sexual and drug-related 
HIV risk behaviour, but more research is needed” (p.100). 
Evidence statement: There is sufficient review-level evidence to support the effectiveness 
of continous and higher dose OST in reducing opioid use and injection frequency. There is 
insufficient review-level evidence to either support or discount the impact of adjunctive 
psycho-social treatment in combination with OST treatment in reducing IRB. 
A1.7 Cost-effectiveness 
Connock et al. (2007) reviewed eleven economic evaluations of OST effectiveness in 
managing opioid dependence (Barnett, 1999; Barnett, Zaric, and Brandeau, 2001; 
Dijkgraaf et al., 2005; Doran et al., 2003; Goldschmidt, 1976; Harris, Gospodarevskaya, 
and Ritter, 2005; Masson et al., 2004; Sheerin, Green, and Sellman, 2004; Sirotnik and 
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Bailey, 1975; Zaric, Barnett, and Brandeau, 2000; Zaric, Brandeau, and Barnett, 2000; 
Zarkin et al., 2005). The economic methods and findings of these studies are summarised 
in Table A1-6. They concluded: 
“With respect to retention in treatment and reductions in opioid use, both flexible-dose 
MMT and BMT are more clinically effective and more cost-effective than no drug therapy 
in opioid-dependent users. In direct comparison, flexible-dose MMT (daily equivalent dose 
from 20 or 30 to 60 or 120 mg) was found to be somewhat more effective in maintaining 
individuals in treatment than BMT (daily equivalent dose from 2 or 4 to 8 or 16 mg) and 
was therefore associated with a slightly higher health gain and lower costs. However, this 
needs to be balanced by the more recent experience of clinicians in the use of 
buprenorphine, the possible risk of higher mortality of MMT and individual opioid-
dependent users’ preferences” (Connock et al., 2007). 
Pollack and Heimer (2004) used a random mixing modelling approach to examine the cost-
effectiveness of OST in preventing HCV and HIV, inputting parameters drawn from the 
US literature (Alter and Moyer, 1998; Centers for Disease Control and Prevention, 1998; 
Kaplan, 1989; Kaplan and Heimer, 1992a; Vlahov et al., 1995; Zaric, Barnett, and 
Brandeau, 2000). They drew five main conclusions:  
“MMT appears to be highly cost-effective as a means of HIV prevention in high risk 
populations. Even if MMT did not bring any improvement in other outcome domains (e.g. 
mental health and physical well-being, criminal offending, social integration), it would 
remain highly cost-effective based solely upon its ability to reduce HIV infection; 
Typical MMT programmes appear less effective and thus less cost-effective in the control 
of HCV. As HCV is so efficiently transmitted MMT has a smaller impact on HCV 
incidence. This highlights the reality that harm reduction interventions effective for HIV 
may be less effective against HCV; 
MMT treatment quality is more important to the success of HCV prevention than to the 
prevention of HIV. Given the efficiency of HCV transmission, the impact and cost-
effectiveness of MMT are especially sensitive to treatment quality. The rate of treatment-
related exits and the proportion of treatment adherent MMT clients play critical roles in the 
impact and cost-effectiveness of MMT; 
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MMT is most cost-effective when applied to a large fraction of active IDUs. Because many 
current and former MMT clients share (or would share if active injectors) syringes with 
other IDUs, broad coverage creates substantial benefits, even for active drug injectors who 
are not currently in treatment. Treatment on request provides substantial protection against 
HIV; 
Effective harm reduction interventions can increase the impact and cost- effectiveness of 
concomitant interventions. Costs per averted injection of MMT are proportional to the 
reproductive rate of infection. Interventions that reduce steady-state prevalence (e.g. bleach 
provision, shortening of drug users careers), augment the cost-effectiveness of MMT. The 
converse also holds, broad availability of MMT to slow the spread of blood-borne disease 
increases the cost-effectiveness of harm reduction interventions.” (p.360) 
Evidence statement: There is sufficient review-level evidence to support the cost-
effectiveness of OST in HIV prevention but insufficient evidence to support its cost-
effectiveness in HCV prevention. There is also sufficient review-level evidence to support 
the cost-effectiveness of OST in reducing illicit opioid use. 
A1.8 Discussion and conclusions 
There is a relatively large body of evidence of reasonable quality in relation to OST 
outcomes. We identified several core reviews which reported largely consistent findings 
that allow us to make confident conclusions about the impact of OST on HIV transmission 
and IRB. However the review-level evidence leaves us uncertain about the impact of OST 
on HCV transmission.   
A1.8.1 What we know 
• The available evidence for the impact of OST on HCV incidence is not compelling. 
We did not identify any core level reviews. The evidence from a supplementary 
review and subsequently published primary studies is mixed and suggests any 
impact will be greatest among those in continuous OST.  
• There is consistent evidence from three core reviews that OST is effective in 
reducing HIV seroconversion, especially among those in continuous treatment. 
However, a key bias highlighted in the evidence base which cannot be discounted is 
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self-selection, whereby those with fewer risk behaviours may be more likely to 
both engage in and be retained in OST. 
• There is consistent evidence from three core reviews that OST reduces frequency of 
drug injection, sharing of injecting equipment and scores of drug related risk.  
• There is evidence from two core reviews that highlights that the impact of OST on 
reduced HIV seroconversion and IRB is associated with continuous treatment and 
is dose dependent.  
• There is good evidence that OST is highly cost-effective in reducing opioid use and 
in HIV prevention but not as cost-effective in HCV prevention.  
A1.8.2 Gaps and inconsistencies in the evidence 
• There was insufficient evidence to make conclusions about the role of adjunctive 
psycho-social treatment on blood borne viral incidence and IRB outcomes. 
• It is not clear from these reviews to what extent the reduction in sharing behaviour 
after entering OST is due to overall reductions in the prevalence of injecting and to 
what extent injecting risk reduction strategies are practised following cessation of 
OST. 
• It is not clear from these reviews to what extent treatment service models and 
quality impact on OST blood borne viral incidence and IRB outcomes.  
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Table A-1. Summary of core and supplementary reviews on OST 
Author and 
date 
Title Dates covered Scope Critical 
assessment 
No. studies 
Tilson et al., 
2007 
Preventing HIV 
infection among 
injecting drug 
users in high-risk 
countries: an 
assessment of the 
evidence 
Up to Jan 2006 OST and NSP Core review 0 HCV 
4 HIV 
21 injecting-
risk 
Gowing et al., 
2004 
Substitution 
treatment of 
injection opioid 
users for 
prevention of HIV 
infection 
Up to July 
2003 
OST Core review 0 HCV 
5 HIV  
24 injecting-
risk 
Sorensen and 
Copeland, 
2000 
Drug abuse 
treatment as an 
HIV prevention 
strategy: a review 
1988-1998 MMT and other 
drug treatments 
(e.g. inpatient, 
outpatient, drug 
free, residential) 
Core review 0 HCV 
6 HIV  
19 injecting-
risk 
Wright and 
Tompkins, 
2006 
A review of the 
evidence for the 
effectiveness of 
primary 
prevention 
interventions for 
Hepatitis C among 
injecting drug 
users 
Up to April 
2003 
MMT, NSP, 
behavioural 
interventions, 
bleach, DCRs 
Supplementary 
review 
6 HCV 
0 HIV 
0 injecting 
risk 
WHO, 2007 Effectiveness of 
Interventions to 
Manage HIV in 
Prisons – Opioid 
substitution 
therapies and other 
drug dependence 
treatment 
Not specified. 
Publication 
dates up to 
2006 
Prison settings: 
OST, 
therapeutic 
communities, 
counselling, 
‘boot camp’. 
Supplementary 
review 
2 HCV 
1 HIV  
8 injecting-
risk 
Hopfer et al., 
2002 
Adolescent heroin 
use: a review of 
the descriptive and 
treatment literature 
Not specified. 
Publication 
dates up to 
1998 
Heroin using 
youth: MMT, 
drug free 
treatment, 
therapeutic 
communities 
Supplementary 
review 
0 HCV 
0 HIV  
3 injecting-
risk 
Connock et al., 
2007 
Methadone and 
buprenorphine for 
the management 
of opioid 
dependence: a 
systematic review 
and economic 
evaluation 
Up to August 
2005 
OST Core review 10 Economic 
  
Pollack and 
Heimer, 2004 
The impact and 
cost-effectiveness 
of methadone 
maintenance 
treatment in 
preventing HIV 
and hepatitis C 
Not specified. 
Publication 
dates up to 
2002 
Modelling 
study 
Supplementary 
economic paper 
NA 
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Table A-2. Primary studies included within the core review papers (OST) 
 
Tilson et al (2007) 
Gowing et al 
(2004) 
Sorensen and 
Copeland (2000) 
Wright and 
Tompkins (2006) 
HCV incidence         
Crofts et al., 1997     
Rezza et al., 1996     
Selvey et al., 1997     
Thiede et al., 2000     
Van Ameijden et 
al., 1993    
 
Total 0 0 0 5 
HIV incidence       
Dolan et al., 2003      
Hartel and 
Schoenbaum, 1998    
 
Metzger et al., 
1993    
 
Moss et al., 1994     
Novick et al., 1990     
Serpelloni et al., 
1994    
 
Williams et al., 
1992    
 
Total 4 5 6 0 
Injecting-risk 
behavioura     
 
Abbott et al., 1998     
Avants et al., 1998     
Baker et al., 1995     
Ball et al., 1998     
Batki et al., 1989     
Bellis 1993     
Britton 1994     
Brooner et al., 
1998    
 
Camacho et al., 
1996    
 
Caplehorn and 
Ross, 1995    
 
Caslyn et al., 1991     
Chatham et al., 
1999    
 
Dolan et al., 2003     
Gossop et al., 2000     
Grella et al., 1996     
Gottheil 1993     
Greenfield et al., 
1995    
 
Iguchi, 1998     
King et al., 2000     
aIncludes prevalence and frequency of injecting, sharing and scores of drug related risk 
Appendix A  223 
 
Table A-2 continued. 
 
Tilson et al (2007) 
Gowing et al 
(2004) 
Sorensen and 
Copeland (2000) 
Wright and 
Tompkins (2006) 
Klee et al., 1991     
Kwiatkowski et al., 
2001    
 
Longshore et al., 
1993    
 
Maddux 1997     
Magura et al., 1991     
Magura et al., 1998     
Margolin et al., 
2003    
 
Meandzija et al., 
1994    
 
Metzger et al., 
1993    
 
Rhoades et al., 
1998    
 
Saxon et al., 1994     
Sees et al., 2000     
Shore et al., 1996     
Simpson et al., 
1995    
 
Stark et al., 1996     
Strang et al., 2000     
Thiede et al., 2000     
Williams et al., 
1992    
 
Total 21 23 19 0 
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Table A-3a. Results of primary studies of the effectiveness of OST with respect to HCV prevalence/ 
incidence 
Author and year Study design and setting Findinga Results 
Crofts et al., 1997 MMT clinic cohort 
Australia 
N=73  
 
No association HCV incidence was 
22/100 py (95%CI 14.2-
34.8). There was no 
significant difference in 
cumulative incidence 
between those in MMT 
(continuous or 
interrupted) and those not 
in MMT (f=.005).  
Rezza et al. 1996 Nested case control study  
Naples, Italy 
N=746 
No association HCV incidence was 
28.6/100py (95% CI 
17.8–43.4). Increased risk 
of seroconversion 
associated with no MMT 
in the previous six months 
of borderline significance 
(AOR 2.9, 95% CI 0.9–
9.7). 
Selvey et al., 1997 Prospective cohort  
Brisbane, Australia 
N=106 
MMT clinic 
No association HCV seroconversion was 
11/100 py (95% CI 2-20). 
Univariately MMT was 
not associated with 
seronconversion (RR and 
CIs not reported).  
Thiede et al., 2000 Prospective cohort 
Seattle, USA 
N=716 
No association No statistically significant 
reduction in HCV 
seroconversion among 
those who continued in 
MMT compared to those 
who left MMT (AOR = 
0.4, 95% CI 0–4.2)  
 
Van Ameijden et al., 
1993 
Prospective cohort  
MMT, NSP and 
information/education/counselling 
Amsterdam, Netherlands 
N=305 
 
No association No statistically significant 
reduction in annual HCV 
incidence rate/100 py over 
the four year study period 
(1986: 16.9; 1987: 4.0; 
1988: 12.5; 1989: 11.2) 
chi-squared test for trend, 
P=0.79) 
aPositive, negative, or no association refers to overall direction of association with HCV 
prevalence/seroconversion. 
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Table A-3b. Results of primary studies of the effectiveness of OST with respect to HCV prevalence/ 
incidence published since Wright and Tompkins (2006) review 
Author and year Study design and setting Findinga Results 
Craine et al., 2009 Prospective cohort  
South Wales, UK 
Positive  At 12-month follow-up, 
HCV incidence was similar 
between those not in OST 
and OST up to six months, 
but wassignificantly lower 
among those in OST for 7 
to 12 months. Among 
homeless IDUs, HCV 
incidence of those not in 
OST was more than twice 
that of those in OST. 
Dolan et al., 2003 RCT 
New South Wales, 
Australia 
N=67 (anti-HCV negatives 
at baseline) 
No association There was no difference in 
HCV incidence between 
heroin-using prisoners 
randomised to receiving 
MMT (24.3 per 100 py, 
95% CI 7-62) vs. the 
waitlist control group (31.7 
per 100 py, 95% CI 9-81) 
Dolan et al., 2005b Prospective cohort 
New South Wales, 
Australia 
N=382 
Positive  4 year follow-up found 
among those in MMT in 
prison, increased risk of 
HCV seroconversion was 
associated with MMT 
episodes less than five 
months [AHR 4.2 (95% CI, 
1.4-12.6; P = 0.01)].  
Hallinan et al., 2004 Retrospective cohort 
Sydney, Australia 
N=54 
No association Overall HCV incidence was 
3.8/100 py (95% CI 1.2-
8.9). Of the five 
seroconversions, four were 
in the interrupted OST 
group (n=20), incidence of 
7.4/100 py (95% CI 2.0-
18.9), compared with one 
seroconversion in the 
continuous OST group 
(n=34), incidence of 
1.3/100 py (95% CI 0.03-
7.3). The difference 
between the groups was not 
statistically significant. 
Maher et al., 2006 Prospective cohort 
Multi-site, Australia 
N=368 (anti-HCV 
negatives at baseline) 
No association Study recruitment from a 
MMT clinic was associated 
with no difference in risk of 
seroconversion [AOR 1.92 
(0.66–5.62)] compared to 
recruitment from NSP sites. 
Miller et al., 2004 Prospective cohort 
Vancouver, Canada 
N=479 community 
recruited young IDUs (<30 
years) 
 
Positive 16% were co infected with 
HIV and HCV at baseline 
and a further 15% became 
co infected during the 
study. MMT in previous six 
months was associated with 
reduced time to HCV 
and/or HIVseroconversion 
(ARR = 0.23, CI 0.09, 
0.59). 
aPositive, negative, or no association refers to overall direction of association with HCV 
prevalence/seroconversion. 
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Table A-4. Results of primary studies of the effectiveness of OST with respect to HIV prevalence/ 
incidence 
Author and year Study design and setting Findingb Results 
Dolan et al., 2003 RCT of MMT 
New South Wales, 
Australia 
N=253 
No association  HIV prevalence was zero at 
both baseline and follow up 
for all subjects. 
Hartel and Shoenbaum, 
1998 
Retrospective and 
prospective cohort 
New York. USA 
N=622 
Positive Reduced risk of HIV 
infection associated with 
MMT dose > = 80 mg 
(AOR = 3.07/yr, 95% CI 
1.23-7.68) and last year 
entered MMT (AOR = 
1.22/yr, 95% CI 1.06-1.41). 
Metzger et al., 1993 Prospective cohort 
Philadelphia, USA 
N=205 
Positive HIV seroconversion greater 
among those not in MMT 
compared to those who 
remained continuously in 
MMT (OR 7.63, 95% CI 
1.99-29.27; p<0.01). 
Moss et al., 1994 Case-control 
San Francisco, USA 
N=681 
 
Positive  HIV seroconversion greater 
among those who spent < 
12 months in MMT 
compared with those who 
spent >= 12 months in 
MMT (AHR 4.0, p<0.002).  
Novick et al., 1990 Cross sectional 
New York, USA 
N=58 
 
Positive Zero HIV prevalence 
among long term stable 
MMT clients (16.9 +/- 0.5 
years MMT) on median 
dose of methadone was 60 
mg (range 5 to 100 mg) 
with history of high risk 
PWIDbefore MMT (10.3 
+/- 1.7 years IDU).  
Rhoades et al., 1998 RCT 
Texas, USA 
N=150 
No association Four groups of 50 or 80 mg 
of MMT and clinic 
attendance two or five days 
per week. HIV infection 
rate at MMT entry was 9%. 
No seroconversions 
between baseline and six 
months.  
Serpelloni et al., 1994 Nested Case-control 
Verona, Italy 
N=952 
Positive HIV seroconversion risk 
increased 1.5 times for 
every three months of the 
last 12 months spent out of 
MMT (OR 1.44, CI 0.89-
2.32 , Wald statistic 1.55) 
and there was an inverse 
association between daily 
MMT dose and HIV 
incidence (OR 0.77, CI 
0.53-1.13, Wald statistic - 
1.39). 
Williams et al., 1992 Prospective cohort 
New Haven, USA 
N=98 
No association The seroconversion rate for 
the continuous MMT group 
was 0.7/100 py (95% CI 
0.1-5.3) and 4.3/100 py 
(95% CI 2.2.-8.6) for the 
interrupted treatment group. 
Controlling for length of 
follow-up, the difference 
between seroconversion 
rates was not significant 
(Z=1.65; p=0.10). 
aPositive, negative, or no association refers to overall direction of association with HIV 
prevalence/seroconversion 
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Table A-5. Results of primary studies of the effectiveness of OST with respect to IRBa 
Author and year Study design and setting Findingb Results 
Abbott et al., 1998 RCT  
USA 
N=151 
Positive MMT with community reinforcement 
vs. standard MMT had significantly 
fewer positive urines at three weeks 
and lower drug use and risk scores 
(Addiction Severity Index) at six 
months.  
Avants et al., 1999 RCT 
USA 
N=307 
Positive Among socially anxious IDUs, 
reductions in drug use and HIV risk 
behaviours and abstinence at end of 
treatment greatest in lower intensity 
MMT vs. intensive MMT day 
program group. 
Baker et al., 1995 Cross-sectional 
Sydney, Australia 
N=260 
Positive MMT group had significantly lower 
injecting risk-taking behaviour scores 
(HIV Risk-taking Behaviour Scale) 
than previous MMT and non-MMT 
groups (p<0.05).  
Ball et al., 1998 Cohort 
Multi-site USA 
N=388 
Positive MMT associated with reduced 
injecting and needle-sharing. Of 
those who remained in MMT for >= 
one year, 71% ceased injecting while 
82 % who left MMT relapsed rapidly 
to injecting.  
Batki et al., 1989 Cohort 
San Francisco, USA 
N=42 
Positive Significant reduction in mean 
number of days injected in past 
month between baseline (27.5) and 
12 month MMT follow-up (6.3) 
Bellis et al., 1993 Cohort  
California, USA 
N=41 
Positive 61% retention of sex working female 
IDUs in free MMT program at 12 
months. Total urinalyses positive for 
non-prescribed drugs decreased from 
80% at baseline to 51% at 12 months. 
Britton et al., 1994 Cohort 
San Francisco, USA 
N=96 
Positive PWIDwho ceased MMT due to 
funding cuts at 12 month follow-up 
had more days of heroin injecting (F 
= 6.63, p = .01) and needle-sharing 
(F =4.41, p = .04 ) in the past six 
months than those who remained in 
MMT. 
Brooner et al., 1998 Cohort 
Baltimore, USA 
N=325 
Positive Drug use was significantly reduced 
between baseline and 3-month MMT 
follow-up.  
Camacho et al., 1996 Cohort 
Texas, USA 
N=327 
Positive IRB significantly reduced between 
baseline and three and six months of 
MMT treatment.  
Caplehorn and Ross, 1995 Cross sectional 
Sydney, Australia 
 
 
Positive  MMT clients half as likely as daily 
heroin users not in MMT to report 
IRB (OR 0.55, 95% CI 0.33 to 0.90).  
Caslyn et al., 1991 Seattle, USA 
N=313 
Not 
stated 
Summary not available 
Chatham et al., 1999 Cohort 
Texas, USA 
N=435 
Positive Reductions in illicit drug use and 
IRBs at one year MMT follow-up.  
Dolan et al., 1996 
 
Cross-sectional 
MMT in prison 
New South Wales, 
Australia 
N=185 
Positive IDUs receiving MMT in prison 
reported significantly fewer 
injections per week (mean 0.16 v 
0.35; P=0.03 Mann-Whitney test) 
than those not in MMT but only 
when dose > 60 mg and MMT 
provided for the entire prison time.  
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Table A-5 (continued). 
Author and year Study design and setting Findingb Results 
Dolan et al., 1998 Cross-sectional 
MMT in prison 
New South Wales, 
Australia 
N=185 
Positive IDUs in prison maintained on MMT reported 
a significantly lower prevalence of heroin 
injection and syringe sharing and scored 
lower on an HIV Risk-taking Behavioural 
Scale than IDUs who received counselling or 
time-limited MMT.  
Dolan et al., 2003 RCT of MMT in prison 
New South Wales, 
Australia 
N=253 
Positive  
 
 
At five month follow-up, heroin use was 
significantly lower among MMT than control 
subjects and MMT subjects reported lower 
levels of drug injection and syringe sharing. 
Gossop et al., 2000 Cohort 
London, UK 
Positive Significant reductions in illicit drug use for 
MMT and methadone reduction groups at one 
year follow-up, 
Grella et al., 1996 Secondary follow up 
analysis of data from RCT 
of MMT 
Los Angeles, USA 
N=500 
Positive At follow-up clients had reduced their drug 
use and HIV-risk behaviours from baseline.  
Gottheil et al.,1993 Cohort 
Philladelphia, USA 
N=229 
Positive Of those in MMT for less than 12 months, 
35% were opioid free for a three month 
period, that value increased 71% for patients 
enrolled for >four years, and 85% for paients 
remaining in treatment for >10 years.  
 
Greenfield et al., 1995 Cohort 
USA 
N=281 
Positive MMT group reported fewer drug injections 
and less needle-sharing and had fewer 
positive urinalyses for opioids and cocaine 
than the no MMT group.  
Heimer et al., 2005 
and  
Heimer et al., 2006 
Follow-up prison MMT 
Puerto Rico 
N=60 
 
Positive Inmates enrolled in MMT reduced their heroin 
use by more than 94%. Good correlation 
between self-report and urine test results.  
Iguchi et al., 1998 Cohort 
New Jersey, USA 
N=51 
Positive Decreases in frequency of opioid drug use 
during MMT. Also reductions in the 
frequency of sharing. 
King et al., 2000 Cohort 
Baltimore, USA 
N=91 
Positive Decreases in overall IRB between baseline 
and six month MMT follow-up.  
Klee et al., 1991 Cross-sectional 
UK 
 
Positive Long term MMT clients (>6 months) less 
likely to pass on needles compared to short 
term (< six months) MMT clients or IDUs not 
in treatment. 
Kwiatkowski and Booth, 
2001 
Prospective cohort 
Denver, USA 
N=316 
Positive 
for 
reduced 
heroin 
use not 
sharing 
Those in MMT for >= 90 days before six 
month follow-up had a significantly greater 
reduction in heroin injections than those who 
did not enter/remain in MMT. No differences 
between groups in sharing needles or other 
injection equipment. 
  
Longshore et al., 1993 Cross-sectional 
Los Angeles, USA 
 
Positive Those who continued to inject while in MMT 
reported less sharing than users not in MMT 
after controlling for injecting frequency and 
background characteristics.  
Maddux et al., 1997 Prospective cohort 
San Antonio, USA 
N=610 
Positive MMT retention was 52% at 12 months. 
Among those in MMT at 12 months, injection 
frequency and sharing had decreased 
signicantly between baseline to 12 months. 
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Table A-5 (continued). 
Author and year Study design and setting Findingb Results 
Magura et al., 1991 Retrospective cohort 
New York City, USA 
N=1206 
Positve Higher MMT dosage and less heroin and 
cocaine use during MMT were associated 
with longer treatment retention.  
Margolin et al., 2003 RCT  
New Haven, USA 
N=90 
Positive HIV+ MMT clients randomised to HIV Harm 
Reduction Program (HHRP+) or a control that 
included harm reduction education, both 
showed reductions in IRB at nine month 
follow-up. The HHRP+ were less likely to use 
illicit opioids and and were less likely to have 
engaged in high risk behaviour.  
Meandzija et al., 1994 Cross-sectional 
New Haven, USA 
N=424 
Positive MMT clients compared to other IDUs 
reported fewer injections in the last 30 days, 
reduced speedball injection frequency and 
reduced total cocaine and injected cocaine 
use.  
Rhoades et al., 1998 RCT 
Texas, USA 
N=150 
Positive IRB declined between baseline and six 
months regardless of group/dose assignment 
(i.e. 50 or 80 mg MMT and clinic two or five 
days per week). Higher proportions of opioid-
positive urines were associated with lower 
MMT dose. (F(Des Jarlais et al., 1998)=4.74).  
Saxon et al., 1994 Cohort 
USA 
N=313 
Positive Among IDUs in MMT at baseline, sharing at 
18 month follow-up was independently 
associated with less time in treatment. 
Sees et al., 2000 Controlled clinical trial 
San Francisco, USA 
N=179 
Positive MMT group had greater treatment retention 
and lower rates of heroin use compared to 
detoxification group. MMT resulted in a 
lower rate of IRB (mean [SD] at 12 months, 
2.17 [3.88] vs. 3.73 [6.86]. 
Shore et al., 1996 Cohort 
USA 
N=277 
Positive Decreases in injection frequency associated 
with consistent MMT enrollment and 
increases in injection frequency associated 
with inconsistent MMT enrollment (p < .01).  
Simpson et al., 1995 Cross sectional 
Texas, USA 
N=557 
Positive Significant improvements in drug use 
behaviours and psychosocial functioning 
between baseline and three months MMT.  
Stark et al., 1996 Cross-sectional 
Berlin, Germany 
N=612 
Positive MMT was protective against borrowing of 
syringes (AOR 0.36, 95% CI 0.2, 0.8) 
Strang et al., 2000 RCT 
London, UK 
Positive The average number of days of illicit drug 
injection reduced from 25.7 to 10.8 days for 
the injectable MMT group and from 20.1 to 
11.9 days for the oral MMT group.  
Thiede et al., 2000 Prospective cohort 
Seattle, USA 
N=716 
 Cessation of injecting at follow up was 
significantly associated with continuing MMT 
(AOR = 0.1, 95% CI 0.1–0.2).  
aIncludes IRB (e.g. prevalence and frequency of injecting, sharing and scores of drug related risk) 
and treatment behaviours (levels of drug use, retention, duration, continuity of treatment).   
bPositive, negative, or no association refers to overall direction of association with IRB or treatment 
behaviours . 
 
 
  
 
Table A-6. Results of primary studies of the cost- effectiveness of OSTa 
Author and year Drug regimen and 
comparator 
Form of 
economic 
analysis 
Perspective Model used Time horizon 
(years) 
Outcome 
measure 
ICERb 
Barnett, 1999 MMT vs. drug free 
treatment 
Cost effectiveness  
 
US Healthcare System  
 
Markov Life-time Cost per life year 
gained 
US$5,250 (£3,904 2004) per life year gained 
Barnett et al., 2001 BMT vs. MMT Cost utility US healthcare system Dynamic 10 Cost per QALYc 
gained 
5% HIV prevalence US$14,00-84,700 
(£9,965-60,289 2004) cost per QALY gained 
40% HIV prevalence US$10,800-66,700 
(£7,687-47,477 2004) cost per QALY gained  
Dijkgraff et al., 2005 MMT vs 
MMT+heroin 
Cost-utility Societal None 1 Cost per QALY 
gained 
MMT+heroin alone dominated 
Doran et al., 2003 BMT vs.MMT Cost effectiveness Australian Health 
Service provider 
None 1 Cost per heroin 
free day 
Cost per heroin fee day MMT dominated 
BPN ICER MMT vs BMT (95% CI):$201 per 
heroin free day (-$2069 to $1809) 
Goldschmidt, 1976 MMT vs. therapeutic 
community 
programme (TCP) 
Cost effectiveness Societal None 1 Cost per 
‘effectiveness 
measure unit’, 
‘Normabider 
cirterion’ 
(successful 
patients) and 
‘heroin-free’ 
patients. 
Cost per successful patient: MMT US$147, 
TCP US$243 Cost per heroin free patient 
MMT US$61, TCP US$122 
Harris et al., 2005 BMT vs MMT Cost effectiveness 
and cost utility 
 
Soceital None NA Cost per heroin-
free day, Cost per 
QALY gained 
Cost per heroin-free day exlcudeding cost 
attributed to crime: MMT dominated BPN. 
Including costs attributed to crime: BMT had 
lower costs and less HFD than MMT. Cost 
per QALY Excluding costs attributed to 
crime: ICER for BMT vs MMT AUS$ 39,404 
(£17,326 2004). Including costs attributed to 
crime: BPN dominated MMT 
Masson et al., 2004 MMT vs MDT Cost effectiveness 
and cost utility 
 
US healthcare system Markov 10 Cost per year of 
life gained and 
QALY gained 
US$16,997 per life year saved 
US$46,217-19,997 per QALY gained 
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Table A-6 (continued). 
Sheerin et al 2004 MMT vs five 
treatment options 
Cost effectiveness New Zealand 
Healthcare system 
Markov 10 Cost per year of 
life saved 
NZ$25,035-25,397 per life year saved 
(£8,737-8,864 2004) 
Sirotnik and Bailey, 
1975 
MMT vs five 
modalities of care 
Cost benefit Societal None 1 Dollar benefit to 
society 
Total dollar benefit to society of US$3.4 
millon 
Zaric et al., 2000a MMT vs four 
populations by HIV 
prevalence 
(5,10,20,40) 
Cost utility US healthcare system Dynamic 10 Cost per life year 
gained and cost 
per QALY gained 
US$9,700–17,200a per life-year gained 
(£6,904–12,243 2004) 
US$6,300–10,900a per QALY gained 
(£4,484–7,759 2004) 
Zaric et al., 2000b MMT vs. Expansion 
of 10% of those in 
MMT within high 
(40%) and low (5%) 
HIV prevalence 
populations 
Costy utility US healthcare system Dynamic 10 Cost per life year 
gained and cost 
per QALY gained 
US$8,200–10,900b per QALY gained 
(£5,837–7,759 2004) 
Zarkin et al., 2005 MMT vs no MMT 
comparison of costs 
(criminal activity, 
earnings, healthcare 
use) within a 
simulated population 
of 1 millon 
Cost-benefit Societal Monte-Carlo Lifetime Cost-benefit ratio Benefit-cost ration (i.e MMT vs no MMT) 
over a lifetime was 37.72 
aBased on Connock et al. (2007)  
bIncremental Cost Effectiveness Ratio  
cQuality Adjusted Life Year 
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Appendix B: Search terms used in the review of 
reviews 
Note that access to the MEDLINE, EMBASE and CINAHL databases was through OVID 
gateway. PsycInfo and IBSS were accessed through WebSPIRS 5. The Cochrane Libarary 
was accessed through Wiley InterScience. 
 
(1) MEDLINE  
1. review.pt. 
2. exp "review [publication type]"/ 
3. "consensus development conference [publication type]"/ 
4. exp "Meta-Analysis [Publication Type]"/ 
5. ((review$ or overview$) and (systematic or methodologic$ or quantitative$ or 
literature$)).ti,ab. 
6. 1 or 2 or 3 or 4 or 5 
7. *Hepatitis C/pc 
8. (hepatitis c or HCV).ti,ab. 
9. *HIV Infections/pc 
10. HIV.ti,ab. 
11. transmission.ti,ab. 
12. seroconver$.ti,ab.  
13. risk behavio?r.ti,ab. 
14. Risk Reduction Behavior/ 
15. Behavior Modification/ 
16. Needle Sharing/ 
17. Risk-taking/ 
18. 7 or (8 and 11) or (8 and 12) or 9 or (10 and 11) or (10 and 12) or 13 or 14 or 15 or 
16 or 17 
19. *Substance Abuse, Intravenous/ 
20. (substance$ or drug$).ti,ab. 
21. (abuse$ or depend$ or use$ or misus$ or addict$).ti,ab. 
22. (inject$ or intravenous).ti,ab. 
23. 19 or (20 and 21) or (20 and 22) 
24. Harm Reduction/ 
25. Intervention Studies/ 
26. Preventive Health Services/   
27. Community Health Services/ 
28. Primary Prevention/ 
29. 24 or 25 or 26 or 27 or 28 
30. (needle$ or syringe$).ti,ab. 
31. exchange$.ti,ab. 
32. Needle-Exchange Programs/ 
33. (30 and 31) or 32 
34. outreach.ti,ab. 
35. mobile.ti,ab. 
36. backpack$.ti,ab. 
37. (vending and machine$).ti,ab. 
38. (30 and 34) or (30 and 35) or 36 or 37 
39. (paraphernalia or equipment).ti,ab. 
40. (distribu$ or provi$).ti,ab. 
41. 39 and 40 
42. *Methadone/ 
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43. *Buprenorphine/ 
44. (substitution or maintenance).ti,ab. 
45. 42 or 43 or 44 or "44".mp. [mp=title, subject heading word, abstract, 
instrumentation] 
46. (bleach and disinfect$).ti,ab. 
47. (needle and disinfect$).ti,ab. 
48. 46 or 47 
49. Health Education/ 
50. Patient Education/ 
51. Counseling/ 
52. Health Knowledge, Attitudes, Practice/ 
53. Health Promotion/ 
54. 49 or 50 or 51 or 52 or 53 
55. outreach.ti,ab. 
56. peer intervention.ti,ab. 
57. peer education.ti,ab. 
58. 55 or 56 or 57 
59. HIV Infections/di 
60. Hepatitis C/di 
61. (HCV test$ or hepatitis c test$ or HIV test$).ti,ab. 
62. Diagnostic Tests, Routine/ 
63. 59 or 60 or 61 or 62 
64. ((HCV or hepatitis c) and treatment).ti,ab. 
65. drug consumption rooms.ti,ab. 
66. (safe$ inject$ and (site or facilit$)).ti,ab. 
67. 65 or 66 
68. (structural and intervention$).ti,ab. 
69. (environment$ and intervention$).ti,ab. 
70. 68 or 69 
71. crack pipe$.ti,ab. 
72. 29 or 33 or 38 or 41 or 45 or 48 or 54 or 58 or 63 or 64 or 67 or 70 or 71 
73. 6 and 18 and 23 and 72 
 
(2) EMBASE  
1. review.pt  
2. metaanalys$.ti,ab. 
3. meta-analys$.ti,ab. 
4. ((review$ or overview$) and (systematic or methodologic$ or quantitative$ or 
literature$)).ti,ab. 
5. 1 or 2 or 3 or 4  
6. *Hepatitis C/pc  
7. (hepatitis c or HCV).ti,ab. 
8. *Human Immunodeficiency Virus Infection/pc 
9. HIV.ti,ab. 
10. transmission.ti,ab. 
11. seroconver$.ti,ab. 
12. risk behavio?r.ti,ab. 
13. ((needle$ or syringe$) and sharing).ti,ab. 
14. Risk Reduction/ 
15. Behavior Modification/ 
16. High Risk Behavior/ 
17. 6 or (7 and 10) or (7 and 11) or 8 or (9 and 10) or (9 and 11) or 12 or 13 or 14 or 15 
or 16 
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18. *Substance Abuse/ 
19. (substance$ or drug$).ti,ab. 
20. (abuse$ or depend$ or use$ or misus$ or addict$).ti,ab. 
21. (inject$ or intravenous).ti,ab. 
22. 18 or (19 and 20) or (19 and 21) 
23. Harm Reduction/ 
24. Intervention Study/ 
25. Preventive Health Service/ 
26. Primary Prevention/ 
27. Infection Prevention/ 
28. 23 or 24 or 25 or 26 or 27 
29. (needle$ or syringe$).ti,ab. 
30. exchange$.ti,ab. 
31. 29 and 30 
32. outreach.ti,ab. 
33. mobile.ti,ab. 
34. backpack$.ti,ab. 
35. (vending and machine$).ti,ab. 
36. (29 and 32) or (29 and 33) or 34 or 35 
37. (paraphernalia or equipment).ti,ab. 
38. (distribu$ or provi$).ti,ab. 
39. 37 and 38 
40. *Methadone/ 
41. *Buprenorphine/ 
42. substitution or maintenance.ti,ab. 
43. 40 or 41 or 42 
44. (bleach and disinfect$).ti,ab. 
45. (needle and disinfect$).ti,ab. 
46. 44 or 45  
47. Health Education/ 
48. Patient Education/ 
49. Counseling/ 
50. Attitude to Health/ 
51. Health Promotion/ 
52. 47 or 48 or 49 50 or 51  
53. outreach.ti,ab. 
54. peer intervention.ti,ab. 
55. peer education.ti,ab. 
56. 53 or 54 or 55  
57. Human Immunodeficiency Virus Infection/di 
58. Hepatitis C/di 
59. (HCV test$ or hepatitis c test$ or HIV test$).ti,ab. 
60. Diagnostic Test/ 
61. 57 or 58 or 59 or 60 
62. ((HCV or hepatitis c) and treatment).ti,ab. 
63. drug consumption rooms.ti,ab. 
64. (safe$ inject$ and (site or facility)).ti,ab. 
65. 63 or 64 
66. (structural and intervention).ti,ab. 
67. (environment$ and intervention$).ti,ab. 
68. 66 or 67 
69. crack pipe.ti,ab . 
70. 28 or 31 or 36 or 39 or 43 or 46 or 52 or 56 or 61 or 62 or 65 or 68 or 69 
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71. 5 and 17 and 22  and 70 
 
(3) CINAHL  
1. "Systematic Review"/ 
2. "Literature Review"/ 
3. “Program Evaluation"/ 
4. "Meta analysis"/ 
5. ((review$ or overview$ or evaluation$) and (systematic or methodologic$ or 
quantitative$ or literature$)).ti,ab. 
6. 1 or 2 or 3 or 4 or 5 
7. "Hepatitis C"/ 
8. (hepatitis c or HCV).ti,ab. 
9. HIV Infections/ 
10. HIV.ti,ab. 
11. transmission.ti,ab. 
12. seroconver$.ti,ab. 
13. Risk Taking Behavior/ 
14. risk behav$.ti,ab. 
15. Health Behavior/ 
16. Needle Sharing/ 
17. 7 or (8 and 11) or (8 and 12) or 9 or (10 and 11) or (10 and 12) or 13 or 14 or 15 or 
16 
18. Substance Abuse, Intravenous/ 
19. Intravenous Drug Users/ 
20. (substance$ or drug$).ti,ab. 
21. (abuse$ or depend$ or use$ or misus$ or addict$).ti,ab. 
22. (inject$ or intravenous).ti,ab. 
23. 18 or 19 or (20 and 21) or (20 and 22) 
24. Harm Reduction/ 
25. Experimental Studies/ 
26. Preventive Health Care/ 
27. Community Health Services/ 
28. 24 or 25 or 26 or 27 
29. (needle$ or syringe$).ti,ab. 
30. exchange$.ti,ab. 
31. Needle Exchange Programs/ 
32. (29 and 30) or 31 
33. outreach.ti,ab. 
34. mobile.ti,ab. 
35. backpack$.ti,ab. 
36. (vending and machine$).ti,ab. 
37. (29 and 33) or (29 and 34) or 35 or 36 
38. (paraphernalia or equipment).ti,ab. 
39. (distribut$ or provi$).ti,ab. 
40. 38 and 39 
41. Methadone/ 
42. BUPRENORPHINE/ 
43. (substitution or maintenance).ti,ab. 
44. 41 or 42 or 43 
45. (bleach and disinfect$).ti,ab. 
46. (needle and disinfect$).ti,ab. 
47. 45 or 46 
48. Health Education/ 
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49. Patient Education/ 
50. Health Promotion/ 
51. Counseling/ 
52. Attitude to Health/ 
53. 48 or 49 or 50 or 51 or 52 
54. outreach.ti,ab. 
55. peer intervention.ti,ab. 
56. peer education.ti,ab. 
57. 54 or 55 or 56 
58. HIV Infections/di [Diagnosis] 
59. Hepatitis C/di [Diagnosis] 
60. (HCV test$ or hepatitis c test$ or HIV test$).ti,ab. 
61. 58 or 59 or 60 
62. ((HCV or hepatitis c) and treatment).ti,ab. 
63. drug consumption room$.ti,ab. 
64. (safe$ and inject$ and (site or facilit$)).ti,ab. 
65. 63 or 64 
66. (structural and intervention$).ti,ab. 
67. (environment$ and intervention$).ti,ab. 
68. 66 or 67 
69. crack pipe$.ti,ab. 
70. 28 or 32 or 37 or 40 or 44 or 47 or 53 or 57 or 61 or 62 or 65 or 68 or 69 
71. 6 and 17 and 23 and 70 
 
(4) PsycInfo 
1. Evidence Based Practice (DE) 
2. Intervention (DE)  
3. Program Evaluation (DE)  
4. Meta analysis (ME) 
5. 1 or 2 or 3 or 4 
6. Intravenous Drug Usage (DE)  
7. Drug abuse (DE) 
8. Drug addiction (DE) 
9. At risk populations (DE) or Developing countries (DE) 
10. 6 or 7 or 8 [or 9] for EU review only 
11. HIV ((KW)  
12. Hepatitis C (KW)  
13. Infectious Disorders (DE) 
14. transmission (KW=) 
15. seroconvert* (KW) 
16. Needle Sharing (DE)  
17. Risk Taking (DE)  
18. Risk Management (DE) 
19. Risk behavio?r (KW) 
20. Treatment outcomes (DE) 
21. Drug overdoses (DE)  
22. Death and dying (DE) 
23. Health care seeking behaviour (DE)  
24.  Health care utilization (DE)  
25. Crime (DE)  
26. Costs and cost analysis 
27. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 20 or 21 or 22 or 23 or 24 or 25 or 
26 
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28. AIDS Prevention (DE)  
29.  Harm reduction (DE) 
30. Preventative Medicine (DE) 
31. 28 or 29 or 30 
32. Needle Exchange Programs (DE) 
33. (needle* or syringe*) (KW) 
34. exchange* (KW) 
35. 32 or (33 and 34)  
36. outreach (KW) 
37. mobile (KW) 
38. backpack* (KW) 
39. (vending and machine*) (KW) 
40. (32 and 36) or (32 and 37) or 38 or 39 
41.  (paraphernalia or equipment) (KW) 
42. (distribu* or provi*) (KW) 
43. 41 and 42 
44. Methadone Maintenance (DE) 
45. Buprenorphine (KW) 
46. substitution or maintenance (KW) 
47. 44 or 45 or 46 
48.  (bleach and disinfect*) (KW) 
49. (needle and disinfect*) (KW) 
50. 48 or 49 
51. Naloxone (DE)  
52. overdose prevention (KW)  
53. (peer or take-home or prescription) (KW) 
54. (51 and 53) or 52 
55. Health Education (DE)  
56. Health Promotion (DE) 
57. Client Education (DE) 
58. Counselling (DE) 
59. Health Knowledge (DE) 
60. 55 or 56 or 57 or 58 or 59 
61. Outreach Programs (DE) 
62. outreach (KW) 
63. peer intervention (KW) 
64. peer education (KW) 
65. 61 or 62 or 63 or 64 
66. HIV testing (DE) 
67. (HCV test* or hepatitis c test* or HIV test*)(KW) 
68. 66 or ((11 or 12) and 67) 
69.  ((HCV or hepatitis c) and treatment) (KW) 
70. Safe* inject* and (site or facilit*) (KW) 
71.  Drug consumption rooms (KW) 
72. 70 or 71 
73.  (structural and intervention) (KW=) 
74. (environment* and intervention) (KW=) 
75. 73 or 74 
76. crack pipe(KW) 
77. 31 or 35 or 40 or 43 or 47 or 50 or  54 or 60 or  65 or  68 or 69 or 72 or 75 or 76 
78. 5 and 10 and 27 and 77 
 
(5) IBSS 
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1. Intervention (DE)  
2. Evaluation (DE)  
3. Meta analysis TI or AB  
4. Literature review (DE) 
5. Systematic review TI or AB  
6. 1 or 2 or 3 or 4 or 5 
7. Drug-users (DE) 
8. Drug-abuse (DE)  
9. Inject* drug use* TI or AB 
10. Drug-addiction (DE) 
11. Developing countries (DE) 
12. 7 or 8 or 9 or 10 or 11 or 12 
13. HIV (DE)  
14. Hepatitis (DE) 
15. Hepatitis C TI or AB  
16. transmission TI or AB 
17. seroconvert* TI or AB 
18. Risk (DE) 
19. Needle Sharing TI or AB 
20. Risk behavio?r TI or AB 
21. Inject* frequency TI or AB 
22. Inject* behavio?r TI or AB 
23. Treatment outcomes TI or AB 
24. Drug-overdose (DE)  
25. Health seeking behaviour TI or AB 
26. Health care utilization TI or AB 
27. Access to health care (DE) 
28. Crime or drug-related crime TI or AB  
29. Cost benefit analysis (DE) 
30. 13 or 14 or 15 or 16 or 17 or 18 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 
28 or 29 
31. Prevention (DE)  
32. Harm reduction TI and AB 
33. Public health (DE) 
34. 31 or 32 or 33 
35. needle and program* TI and AB  
36. (needle* or syringe*) TI and AB 
37. exchange* TI and AB 
38. 35 or (36 and 37)  
39. outreach TI and AB 
40. mobile TI and AB 
41. backpack* TI and AB 
42. (vending and machine*) TI and AB 
43. (38 and 39) or (38 and 40) or 41 or 42 
44.  (paraphernalia or equipment) TI and AB 
45. (distribu* or provi*) TI and AB 
46. 42  and 43 
47. Methadone Maintenance TI and AB 
48. Buprenorphine TI and AB 
49. substitution or maintenance TI and AB 
50. 47 or 48 or 49 
51.  (bleach and disinfect*) TI and AB 
52. (needle and disinfect*) TI and AB 
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53. 51 or 52 
54. Naloxone TI and AB 
55. overdose prevention TI and AB 
56. (peer or take-home or prescription) TI and AB 
57. (54 and 56) or  55 
58. Health Education TI or AB 
59. Health Promotion (DE) 
60. Counseling (DE) 
61. Knowledge (DE) 
62. 58 or 59 or 60 or 61 
63. outreach TI and AB 
64. peer intervention TI and AB 
65. peer education TI and AB 
66. 63 or 64 or 65 
67. (HCV test* or hepatitis c test* or HIV test*) TI and AB 
68. 67or ((13 or 14) and 68) 
69.  ((HCV or hepatitis c) and treatment) TI and AB 
70. Safe* inject* and (site or facilit*) TI and AB 
71.  Drug consumption rooms TI and AB 
72. 71 or 72 
73.  (structural and intervention) TI and AB 
74. (environment* and intervention) TI and AB 
75. 74 or 75 
76. crack pipe TI and AB 
77. 34 or 38 or 43 or 46 or 50 or 53 or 57 or 62 or 66 or 68 or 70 or 73 or 76  
78. 6 and 12 and 30 and 77 
 
(6) Cochrane Library 
1. (HCV):ti,ab,kw or (hepatitis c):ti,ab,kw 
2. (HIV):ti,ab,kw 
3. (risk NEXT behav*):ti,ab,kw  
4. (substance*):ti,ab,kw or (drug*):ti,ab,kw 
5. (inject*):ti,ab,kw or (intravenous):ti,ab,kw 
6. (#1 OR #2 OR #3) 
7. (#4 AND #5)  
8. (#6 AND #7) 
  
Appendix C: Critical appraisal of supplementary reviews 
Table C-1. Summary of critical appraisal of supplementary reviews not included in the evidence basea 
Appraisal criteria 
Bastos et 
al., 2000  
Coffin et 
al., 2000  
Delgado et 
al., 2004 
Dolan et al., 
2005 
Hagan et 
al., 2005 
Hoffmann 
et al., 2006 
Hunt et al., 
2003 
Type of review Narrative Systematic Narrative Systematic Narrative Systematic Narrative 
Does the paper have a clearly focused aim or research question?  Yes Yes No Yes Yes Yes Yes 
Study identification        
Are details given of:        
Databases and years searched  No Yes No No No Yes No 
Grey literature searched  No No No Yes No Yes No 
Search terms used No Yes No No No No No 
Inclusion criteria used No No No Yes No Yes No 
What materials were excluded  No No No No No Yes No 
Critical appraisal        
Do the authors address the quality (rigour) of the included 
studies?  No No No Yes No No No 
Data presentation        
Are sufficient data from individual studies included to mediate 
between data and interpretation/conclusions? No No No Yes No No No 
Synthesis and interpretation        
Does the review make clear what steps have been taken to deal 
with potential bias? No No No No No No No 
Do the authors consider whether the results could be due to 
chance (p-values and confidence intervals)? No No No No No No No 
Do the authors acknowledge any other limitations to the research, 
including weakness in their own approach?   No No No No No Yes No 
Has more than one assessor been involved? Not 
reported No No 
Not 
reported 
Not 
reported 
Not 
reported 
Not 
reported 
For meta analyses:        
Are the studies addressing similar research questions?  N/A N/A N/A N/A N/A N/A N/A 
Are the studies sufficiently similar in design?  N/A N/A N/A N/A N/A N/A N/A 
Are the results similar from study to study (test of 
heterogeneity)?  N/A N/A N/A N/A N/A N/A N/A 
Are the reasons for any variation in the results discussed?  N/A N/A N/A N/A N/A N/A N/A 
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Table C-1 continued. 
Appraisal criteria 
Hunt et al., 
2005 
Ksobiech et 
al., 2003 
Ksobiech et 
al., 2006 
Loxley et 
al., 2004 
Rhodes et 
al., 2004 
Rich et al., 
2000 
Strathdee et 
al., 2006 
Type of review Narrative Meta-
analysis 
Meta-
analysis Systematic Systematic Narrative Narrative 
Does the paper have a clearly focused aim or research question?  Yes Yes Yes Yes Yes Yes Yes 
Study identification        
Are details given of:        
Databases and years searched  No No No Yes Yes No No 
Grey literature searched  No No Yes Yes Yes No No 
Search terms used No No Yes No Yes No No 
Inclusion criteria used No Yes Yes No No No No 
What materials were excluded  No Yes Yes No No No No 
Critical appraisal        
Do the authors address the quality (rigour) of the included 
studies?  No No No Yes No No No 
Data presentation        
Are sufficient data from individual studies included to mediate 
between data and interpretation/conclusions? No No No No No No No 
Synthesis and interpretation        
Does the review make clear what steps have been taken to deal 
with potential bias? No No No Yes No No No 
Do the authors consider whether the results could be due to 
chance (p-values and confidence intervals)? No No No No No No No 
Do the authors acknowledge any other limitations to the research, 
including weakness in their own approach?   No Yes Yes No Yes No No 
Has more than one assessor been involved? Not 
reported Yes Yes Yes 
Not 
reported No 
Not 
reported 
For meta analyses:        
Are the studies addressing similar research questions?  N/A Yes Yes N/A N/A N/A N/A 
Are the studies sufficiently similar in design?  N/A Yes Yes N/A N/A N/A N/A 
Are the results similar from study to study (test of 
heterogeneity)?  N/A No No N/A N/A N/A N/A 
Are the reasons for any variation in the results discussed?  N/A Yes Yes N/A N/A N/A N/A 
aBased on the critical appraisal tool developed by the Health Development Agency 
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Appendix D: Proformas for assessing risk of bias 
and precision in cross-sectional and cohort 
studies 
Adapted from: Viswanathan M, Berkman ND. Development of the RTI item bank on risk 
of bias and precision of observational studies. J Clin Epidemiol 2012; 65(2): 163-78. 
Code each item as high, moderate or low (where high = high risk of bias or low precision). 
If no information is provided, code as high.  
Cross-sectional studies 
Sample definition and selection 
(Selection bias) 
  
  
  
Was the strategy for recruiting 
participants into the study the 
same across study groups? (i.e. 
sharers and non-sharers) 
 
Consider rate of non-response and 
whether those who don't 
participate might be different to 
those recruited 
 
Is the selection of the comparison 
groups appropriate? 
 
Are the individuals selected to 
participate in the study likely to be 
representative of the target 
population? 
 
Measurement of 
Interventions/Exposure 
(Detection/ Information bias) 
  
  
Are exposures assessed using 
valid and reliable measures and 
implemented consistently across 
all study participants? 
 
Are outcomes assessed using valid 
and reliable measures and 
implemented consistently across 
all study participants? 
 
What is the level of detail in 
describing the intervention or 
exposure?  
 
Analysis 
  
Were the important confounding 
and effect modifying variables 
taken into account in analysis (e.g. 
through stratification, interaction 
terms, multivariate analysis, etc)? 
 
Are the statistical methods 
appropriate? 
 
Sample size Was the sample size likely to be 
sufficiently large to detect a 
statistically significant difference 
in the main outcome?  
 
Other comments   
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Cohort studies 
Sample definition and selection 
(Selection bias) 
  
  
Was the strategy for recruiting 
participants into the study the 
same across study groups? (i.e. 
sharers and non-sharers) 
 
Consider rate of non-response and 
whether those who don't 
participate might be different to 
those recruited 
 
Is the selection of the comparison 
groups appropriate? 
 
Are the individuals selected to 
participate in the study likely to be 
representative of the target 
population? 
 
Measurement of 
Interventions/Exposure 
(Detection/ Information bias) 
  
  
Are exposures assessed using 
valid and reliable measures and 
implemented consistently across 
all study participants? 
 
Are outcomes assessed using valid 
and reliable measures and 
implemented consistently across 
all study participants? 
 
How was an incident case 
defined? How was follow-up time 
calculated 
 
What is the level of detail in 
describing the intervention or 
exposure?  
 
Follow-up 
  
  
Is the length of time following the 
exposure sufficient to support the 
evaluation of primary outcomes? 
 
What was the attrition rate?  
Did attrition differ between 
groups by more than 20 percent? 
How did those lost-to-follow-up 
differ from those retained in the 
study? 
 
Analysis 
  
Were the important confounding 
and effect modifying variables 
taken into account in analysis (e.g. 
through stratification, interaction 
terms, multivariate analysis, etc)? 
 
Are the statistical methods 
appropriate? (for the purposes of 
this review) 
 
Sample size Was the sample size likely to be 
sufficiently large to detect a 
statistically significant difference 
in the main outcome?  
 
Other comments    
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Appendix E: Needle Exchange Surveillance 
Initiative 2011-12 questionnaire 
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Appendix F: Odds of recent infection by 
needle/syringe coverage group in the pooled NESI 
data 
 
Figure F-1. Odds of recent infection by needle/syringe coverage group among respondents to the 
NESI survey interviewed in 2008-09, 2010 and 2011-12 (n=2,503) 
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Appendix G: Reproduction of analyses in Chapter 
5 using additional NESI survey data 
Table G-1. Multivariable logistic regression models examining the association between recent HCV 
infection (anti-HCV negative and HCV-RNA positive) and i) OST and needle/syringe coverage as 
separate variables and (ii) combined OST and needle/syringe coveragea 
   2008-09 data  2008-09, 2010 and 2011-12 data 
   AOR 95% CI p-value  AOR 95% CI p-value 
   (n=1,131)   (n=3,059)  
Model 
i) 
Received OST In the last six months  1    1   
Currently 0.29 0.07-1.19 0.086  0.29 0.10-0.79 0.016 
 Not in the last six months 0.28 0.06-1.22 0.089  0.33 0.11-0.93 0.036 
          
 N/S coverageb <200% 1    1   
 >200% 0.32 0.10-1.00 0.050  0.38 0.18-0.81 0.012 
 Did not inject  1.30 0.38-4.43 0.674  0.92 0.41-2.08 0.842 
          
 Combined 
intervention 
coverage (N/S 
coverage and OST) 
 (n=1,107)   (n=2,988)  
Model 
ii) 
Low 1    1   
Medium 0.50 0.18-1.35 0.170  0.49 0.25-0.96 0.038 
 High 0.48 0.16-1.48 0.203  0.44 0.21-0.91 0.028 
         
N/S: needle(s)/syringe(s) 
aUsing the intervention categories and confounders described in Chapter 5. The results in the left-
hand panel (2008-09) are those presented in Table 5-2. The results in the right-hand panel are 
applying the same analyses but including the additional data from the 2010 and 2011-12 NESI 
surveys.   
 
 
   
 
Appendix H: Full models (i.e. including covariates) of the associations between 
intervention uptake and recent HCV infection (Chapter 6) 
Table H-1. Model (i) including covariatesa 
  
No. anti-
HCV 
negatives 
(N) 
No. recent 
infections 
(n) % (n/N) 
Univariable Multivariable (n=2,481) 
Weighted multivariable 
(n=2,481) 
  
OR 95% CI p-value AOR 95% CI p-value AORw 95% CI  p-value 
Needle/syringe coverage Low 1443 34 2.4 1     1   1   
High 1051 9 0.9 0.36 0.17-0.75 0.006 0.39 0.19-0.83 0.014 0.14 0.04-0.48 0.002 
Survey year 2008-09 933 20 2.1 1     1   1   
  2010 907 15 1.7 0.77 0.39-1.51 0.443 0.84 0.42-1.66 0.616 0.96 0.40-2.29 0.919 
  2011-12 669 8 1.2 0.55 0.24-1.26 0.159 0.58 0.25-1.33 0.196 0.31 0.12-0.81 0.017 
Homeless in last six months No  1925 21 1.1 1     1   1   
 Yes 581 22 3.8 3.57 1.95-6.54 <0.001 2.98 1.61-5.51 0.001 2.06 0.94-4.50 0.071 
Injected stimulant in last six 
months 
No  2216 32 1.4 1    1   1   
Yes  293 11 3.8 2.66 1.33-5.34 0.006 2.50 1.22-5.09 0.012 2.03 0.85-4.85 0.112 
Time since onset of injecting (continuous) - - - 0.95 0.89-1.01 0.081 0.96 0.90-1.02 0.155 0.94 0.84-1.04 0.209 
aRestricted to those who reported injecting in the last six months 
263
 
  
 
 
Table H-2. Model (ii) including covariatesa 
  
No. anti-
HCV 
negatives 
(N) 
No. recent 
infections 
(n) % (n/N) 
Univariable Multivariable (n=2,481) 
Weighted multivariable 
(n=2,481) 
  
OR 95% CI p-value AOR 95% CI p-value AORw 95% CI  p-value 
Paraphernalia coverage Low (<200%) 1914 39 2.0 1     1   1   
 High (≥200%) 580 4 0.7 0.33 0.12-0.94 0.037 0.39 0.14-1.12 0.081 0.11 0.03-0.44 0.002 
Survey year 2008-09 933 20 2.1 1     1   1   
  2010 907 15 1.7 0.77 0.39-1.51 0.443 0.94 0.47-1.86 0.851 1.06 0.44-2.55 0.901 
  2011-12 669 8 1.2 0.55 0.24-1.26 0.159 0.68 0.30-1.58 0.374 0.38 0.15-0.97 0.043 
Homeless in last six months No  1925 21 1.1 1     1   1   
 Yes 581 22 3.8 3.57 1.95-6.54 <0.001 3.10 1.68-5.72 <0.001 2.07 0.94-4.56 0.071 
Injected stimulant in last six 
months 
No  2216 32 1.4 1    1   1   
Yes  293 11 3.8 2.66 1.33-5.34 0.006 2.48 1.22-5.06 0.012 1.96 0.83-4.67 0.127 
Time since onset of injecting (continuous) - - - 0.95 0.89-1.01 0.081 0.95 0.90-1.01 0.128 0.93 0.84-1.03 0.170 
aRestricted to those who reported injecting in the last six months 
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Table H-3. Model (iii) including covariatesa 
  
No. anti-
HCV 
negatives 
(N) 
No. recent 
infections 
(n) % (n/N) 
Univariable Multivariable (n=3,008) 
Weighted multivariable 
(n=3,008) 
  
OR 95% CI p-value AOR 95% CI p-value AORw 95% CI  p-value 
OST Not current 928 23 2.5 1     1   1   
  Current 2095 27 1.3 0.51 0.29-0.90 0.020 0.63 0.35-1.12 0.111 0.52 0.23-1.18 0.119 
Survey year 2008-09 1116 23 2.1 1     1   1   
  2010 1130 19 1.7 0.81 0.44-1.50 0.507 0.91 0.49-1.69 0.764 0.72 0.29-1.78 0.481 
  2011-12 778 8 1.0 0.49 0.22-1.11 0.088 0.52 0.23-1.17 0.114 0.33 0.13-0.85 0.021 
Homeless in last six months No  2392 25 1.0 1    1   1   
 Yes 629 25 4.0 3.92 2.24-6.87 <0.001 3.56 2.00-6.31 <0.001 2.08 0.91-4.80 0.086 
Injected stimulant in last six 
months 
No  2731 39 1.4 1     1   1   
Yes  293 11 3.8 2.69 1.36-5.32 0.004 2.18 1.08-4.38 0.029 2.08 0.85-5.10 0.110 
Time since onset of injecting (continuous) - - - 0.99 0.95-1.04 0.703 1.01 0.96-1.06 0.742 0.94 0.85-1.05 0.283 
aExcludes individuals who reported not currently being on OST and also not injecting in the last six months 
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Table H-4. Model (iv) including covariatesa 
  
No. anti-
HCV 
negatives 
(N) 
No. recent 
infections 
(n) % (n/N) 
Univariable Multivariable (n=2,993) 
Weighted multivariable 
(n=2,993) 
  
OR 95% CI p-value AOR 95% CI p-value AORw 95% CI  p-value 
N/S coverage and OST 
combined 
Low N/S, no OST 590 20 3.4 1    1   1   
Low N/S, OST 852 14 1.6 0.48 0.24-0.95 0.035 0.55 0.27-1.11 0.093 0.59 0.26-1.35 0.209 
 High N/S, no OST 334 3 0.9 0.26 0.08-0.88 0.030 0.28 0.08-0.96 0.043 0.18 0.04-0.87 0.034 
 High N/S, OST 717 6 0.8 0.24 0.10-0.60 0.002 0.29 0.11-0.74 0.009 0.05 0.01-0.18 <0.001 
 Did not inject, OST 515 7 1.4 0.39 0.17-0.94 0.035 0.62 0.24-1.59 0.324 0.61 0.21-1.80 0.370 
Survey year 2008-09 1116 23 2.1 1    1   1   
  2010 1130 19 1.7 0.81 0.44-1.50 0.507 0.91 0.49-1.69 0.754 0.96 0.40-2.31 0.934 
  2011-12 778 8 1.0 0.49 0.22-1.11 0.088 0.50 0.22-1.13 0.096 0.33 0.13-0.84 0.020 
Homeless in last six months No  2392 25 1.0 1     1   1   
 Yes 629 25 4.0 3.92 2.24-6.87 <0.001 3.47 1.93-6.22 <0.001 1.96 0.88-4.39 0.098 
Injected stimulant in last six 
months 
No  2731 39 1.4 1    1   1   
Yes  293 11 3.8 2.69 1.36-5.32 0.004 2.27 1.11-4.64 0.025 2.04 0.85-4.89 0.109 
Time since onset of injecting (continuous) - - - 0.99 0.95-1.04 0.703 1.01 0.96-1.06 0.734 0.94 0.85-1.04 0.250 
N/S: needle(s)/syringe(s) 
aExcludes individuals who reported not currently being on OST and also not injecting in the last six months 
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Table H-5. Model (v) including covariatesa 
  
No. anti-
HCV 
negatives 
(N) 
No. recent 
infections 
(n) % (n/N) 
Univariable Multivariable (n=2,992) 
Weighted multivariable 
(n=2,992) 
  
OR 95% CI p-value AOR 95% CI p-value AORw 95% CI  p-value 
N/S coverage, 
paraphernalia coverage 
and OST combined 
Low N/S, low para, no OST 569 20 3.5 1     1   1   
Low N/S, low para, OST 817 14 1.7 0.48 0.24-0.96 0.037 0.55 0.27-1.11 0.095 0.58 0.25-1.34 0.202 
Low N/S, high para, no OST 21 0 0.0 - - - - - - - - - 
 Low N/S, high para, OST 35 0 0.0 - - - - - - - - - 
 High N/S, low para, no OST 208 2 1.0 0.27 0.06-1.15 0.076 0.29 0.07-1.26 0.098 0.18 0.03-1.34 0.095 
 High N/S, low para, OST 318 3 0.9 0.26 0.08-0.89 0.031 0.28 0.08-0.98 0.046 0.02 0.01-0.09 <0.001 
 High N/S, high para, no OST 126 1 0.8 0.22 0.03-1.65 0.141 0.25 0.03-1.90 0.180 0.16 0.02-1.25 0.081 
 High N/S, high para, OST 398 3 0.8 0.21 0.06-0.71 0.012 0.28 0.08-0.97 0.044 0.07 0.01-0.35 0.001 
 Did not inject, OST 515 7 1.4 0.38 0.16-0.90 0.028 0.60 0.24-1.54 0.292 0.59 0.20-1.75 0.343 
Survey year 2008-09 1116 23 2.1 1    1   1   
  2010 1130 19 1.7 0.81 0.44-1.50 0.507 0.93 0.50-1.74 0.814 0.99 0.41-2.39 0.988 
  2011-12 778 8 1.0 0.49 0.22-1.11 0.088 0.53 0.23-1.20 0.127 0.35 0.13-0.89 0.028 
Homeless in last six 
months 
No  2392 25 1.0 1     1   1   
Yes 629 25 4.0 3.92 2.24-6.87 <0.001 3.46 1.93-6.21 <0.001 1.96 0.88-4.40 0.099 
Injected stimulant in last 
six months 
No  2731 39 1.4 1    1   1   
Yes 293 11 3.8 2.69 1.36-5.32 0.004 2.22 1.09-4.55 0.029 2.01 0.84-4.82 0.119 
Time since onset of 
injecting (continuous) - - - 0.99 0.95-1.04 0.703 1.01 0.96-1.06 0.759 0.94 0.85-1.04 0.238 
N/S: needle(s)/syringe(s) 
aExcludes individuals who reported not currently being on OST and also not injecting in the last six months 
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